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Motivation: 
In our highly industrialized era the manufacture of complex products or goods like computers, 
mobile phones or cars does not take place one by one, but simultaneously and automated. 
Advantageously, the target products are build-up along an assembly line attaching the 
corresponding components step by step (Figure 1). Those approaches are especially efficient, 
effective, and less time-consuming. 
 
Figure 1: Production of VW Beetles.1 
Based on an analogue concept nature provides a variety of very complex and highly 
functionalized natural products via biosynthesis starting from simple, non-chiral, and easy 
assessable compounds. One example is the polyketide synthase-mediated macrolactone 
synthesis. Specialized enzymes fulfill prominent roles performing one step both exclusively 
and stereoselectively (Figure 2). On the way to the final molecule the corresponding 
intermediates are passed from one catalytically active unit to the other like in an assembly line 
(Figure 3).[1] 
 
Figure 2: Occurring enzymes. 
                                                 
1 http://www.welt.de/motor/article118641936/VW-Kaefer-eine-Erfolgsgeschichte-mit-Schatten.html 
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Figure 3: Polyketide synthase. 
Since several years, the group of Prof. Peter R. Schreiner is working with peptide-based 
catalysts. These compounds accelerate also a single reaction exclusively.[2] The combination of 
different active units separated via linkers mimics very, very small enzymes. This approach 
enables the performance of a special reaction sequence in an assembly line manner. In this 
context Schreiner et al. introduced the terms multicatalyst and retrocatalysis.[3]  
Based on previous work the main focus of this thesis is on adding an enantioselective 
epoxidation to the well-established reaction steps (acylation and oxidation), especially with 
regard to a new multicatalytic reaction sequence. Therefore, a suitable catalytic moiety has to 
be identified and incorporated in a peptidic environment. After optimizing the conditions for 
the separated reaction, the epoxidation should be used as part of the new multicatalytic 
sequence. Furthermore, starting from generated epoxides a suitable downstream chemistry 
should be investigated. Lastly, synthesized peptide-based catalysts should also be examined in 
the context of additional reactions. But, crucial point for all mentioned project is the epoxidation  
(Figure 4). 
 
Figure 4: Motivation of this thesis.2 
                                                 
2 http://www.nibis.de/~niff/material/bild/kueche/original/teller.html 
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1. Introduction 
1.1. Enzyme Catalysis 
Enzymes as catalysts are not only used by nature to prepare a necessary molecule. In the 
meantime, they also find their way into organic laboratories. Especially, due to their high 
specificity and selectivity they are of high interest for synthetic chemists. In close synergy with 
typical organic synthesis the enzymatic strategy represents a powerful tool for natural product 
total synthesis. Associated with complex molecules the mild reaction conditions are a further 
advantage of this procedure.[4] For example, in 2010 Breit et al. published the total synthesis of 
vittatalactone A1 combining both strategies (Scheme 1).[5] 
 
Scheme 1: Total synthesis of vittatalactone A1. 
In the synthesis of both buildings blocks Breit et al. used an enzyme-catalyzed step. After 
reduction of meso-compound A2 desymmetrization of the formed diol with Lipase AK and 
vinyl acetate yielded monoacylated product A3 in 80%. In three additional steps A3 was 
transferred into bromide A4. The western part of the compound was synthesized via hydrogen 
cyanide addition to crotonaldehyde A5 in the presence of (R)-oxynitrilase. After reaction of the 
formed cyanohydrin with ethanol ethyl ester A6 was isolated with an enantiomeric excess (ee) 
of 96%. Starting from this chiral alcohol protected diol A7 was synthesized in two further steps. 
Copper-catalyzed allylic substitution provided allylic alcohol A8 with a yield of 93%.  
After five additional steps vittatalactone A1 was obtained with a total yield of 18%. 
A variety of different enzymes already find versatile application in their “standard reactions” 
like esterification or carbon-nitrogen bond formation as well as reduction.  
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Besides identification of new enzymes for additional transformations investigations of known 
enzymes in mechanistically related reactions is one of promising aspects for further 
development in this research area.[6] One growing field with an excellent potential are 
biocatalytic oxidations. Regarding the aspect of green chemistry due to usage of oxygen or 
hydrogen peroxide as oxidizing agents this class of reactions can be considered as even more 
environmentally friendly.[7]  
Three different classes of enzymes are capable of epoxidizing carbon-carbon double bonds of 
aliphatic alkenes: lipases, monooxygenases, and peroxidases.[7] Based on the mechanism 
lipases provide only the racemic product.[8, 7] In contrast the other ones enable enantioselective 
reactions. In 1996, Hager et al. reported the synthesis of lactone B1 starting with a  
peroxidase-mediated epoxidation (Scheme 2).[9]   
 
Scheme 2: Synthesis of lactone B1. 
Epoxidation of B2 with 0.014 mol% chloroperoxidase (CPO) yielded epoxide B3 in 67% and 
with an enantiomeric excess of 93%. Afterwards, epoxide opening and reduction provided  
γ-hydroxyl nitrile B5. Finally, after cyclization lactone B1 was isolated with a yield of 83%. B1 
was identified to be an important biosynthetic intermediate (IM) in the synthesis of compounds 
like sterols or terpenes.  
Apart from usage in laboratory scale enzymes are also used in industry. Immobilizing those 
catalysts entails additional advantages like increased stability, recyclability, and continuous 
product formation. But, a variety of parameters must be taken into account and a direct transfer 
from one reaction to another might be not possible in some circumstances.[10] 
In the field of catalysis chemists can learn a lot from nature. For example, charged intermediates 
have to be stabilized or the necessary transition state (TS) must be generated. Therefore, plenty 
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organocatalysts were designed following a model in nature.[11] In 2008, Sakai et al. published 
the trifunctionalized catalyst C1 containing an oxygen anion-coordinating moiety,  
a nucleophilic hydroxyl group, and a pyridine unit as base. Thereby, C1 mimics the active side 
of a serine hydrolase showing a high catalytic activity (Figure 5).[12] 
 
Figure 5: Organocatalyst C1 mimicking a serine protease. 
1.2. Organo-, Peptide and Multicatalysis 
1.2.1. Organocatalysis 
Apart from already mentioned bio/enzyme and metal catalysis the field of organocatalysis 
became the third important branch of asymmetric catalysis.[13] It can be divided more precisely 
by the kind of occurring interactions. Covalent bonds are present, for example, in case of amine 
or N-heterocyclic carbene (NHC) catalysts. On the other hand Brønsted acid or urea species 
form hydrogen bonds and in case of phase transfer catalysts (PTC) ionic interactions are 
dominant.[13a, 13b] The phrase ‘organocatalysis’ was introduced in 2000 by David MacMillan 
and form the beginning of the 21th century on the activity in the area of organocatalysis and its 
application started to increase.[14, 13b] Of course, even before 2000 a variety of reactions were 
performed in the presence of substoichiometric amounts of small organic molecules, which 
could also be considered as examples for organocatalysis. One very popular example is the 
proline-catalyzed Hajos-Parrish-Eder-Sauer-Wiechert reaction (Scheme 3). Proline (Pro) D1 is 
used to perform an intramolecular aldol reaction. The bicyclic product D3 was obtained in 70% 
and with an enantiomeric excess of 97%.[15] 
 
Scheme 3: Hajos-Parrish-Eder-Sauer-Wiechert reaction. 
4 
 
A very important progress was achieved by utilizing organocatalysis in so called domino or 
multicomponent reactions. Starting from were simple building blocks, which were all added at 
the same time, highly complex and diverse molecules can be synthesized without isolation of 
appearing intermediates. Therefore, besides the advantages of organocatalysis  
(e.g. environment-friendly, enantioselective) these procedures are additionally efficient and 
atom-economic.[16] Apart from usage in total synthesis organocatalysis is in principle also of 
interest, for example, for the pharmaceutical industry, because of all the aforementioned 
properties, but applications are rarely reported.[13c] Using a proline-based approach  
Tripathi et al. synthesized several tetrahydropyridines like E1, which have an antimalarial 
activity (Scheme 4).[17] 
 
Scheme 4: Synthesis of antimalarial agent E1. 
One equivalent (equiv) aniline E2 and one equivalent aldehyde E3 form the corresponding 
imine E5. After enamine formation between D1/trifluoroacetic acid (TFA) and E4, reaction 
with aldehyde E3, dehydration, and Knoevenagel reaction with aniline E2 diene E6 is yielded. 
After aza-Diels-Alder reaction of building block E5 and E6 target compound E1 was isolated 
after 18 hours with a yield of 60%. Due to formation of prochiral intermediate E6 E1 is finally 
obtained as trans-configured racemate. In vitro screening against Plasmodium falciparum 
tetrahydropyridine E1 showed a 100% inhibition at a concentration (conc.) of 0.09 µg mL−1. 
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Although, higher amounts of catalysts might still be necessary for some organocatalyzed 
transformations improvements regarding low-loading were already made.[13a] But, especially to 
achieve further progress considering scale-up and industrial applications performing reactions 
in continuous-flow is also an intensively studied aspect in the context of organocatalysis.[18]  
In 2012, Fülöp et al. reported an 1,4-addition of aldehydes like F2 and nitroalkene F3 in the 
presence of immobilized acid catalyst F1 under continuous-flow conditions (Scheme 5).[19] 
 
Scheme 5: Immobilized catalyst F1 in an 1,4-addition utilizing continuous-flow conditions. 
After reaction of aldehyde F2 and olefin F3 catalyzed by immobilized tripeptides F1 under 
continuous-flow-conditions nitro-substituted aldehyde F4 was isolated with a yield of 91% and 
an enantiomeric excess of 93% for the major isomer. A simultaneously performed experiment 
with standard batch conditions produced nearly the same result. 
1.2.2. Peptide Catalysis 
As the last example illustrates, besides amino compounds, Brønsted/Lewis acids and bases, 
PTCs, N-heterocyclic carbene precursors as well as compounds, which can form hydrogen 
bonds,[13a] peptides can also act as organocatalysts owing of a course a closer resemblance to 
enzymes. Especially, flexible and modular synthetic availability in combination with the 
possibility to adopt well-defined secondary structures makes oligopeptides to a potent class of 
organocatalysts. Their typical chain-length are between 2 and 50 monomers.[20] One of the first 
examples was the dipeptide-mediated enantioselective synthesis of cyanohydrin reported by 
Inoue et al. in 1979/1981 (Scheme 6).[21]  
In the presence of diketopiperazine G1 addition of HCN on benzaldehyde G2 takes place.  
After 30 minutes conversion (conv.) of 40% and an enantiomeric excess of 93% were observed 
for primary alcohol G3. But astonishingly, racemization of cyanohydrin G3 occurs over time. 
After 72 hours the conversion increased to 90%, but the enantiomeric excess decreased to only 
12%. 
6 
 
 
Scheme 6: Diketopiperazine-mediated cyanohydrin synthesis. 
Of course, larger systems than dipeptides were considered as well and until now a variety of 
different reaction types were identified being catalyzed by those systems.[20] The usage of 
peptide or peptide-based catalysts was, for example, published for Morita-Baylis-Hillman 
reaction,[22] Friedel-Crafts-type alkylation,[23] and conjugated addition[19, 24] with and without 
an immobilized system. Catalyzed bromination in the presence of H1 reported be Miller et al. 
and [3+2] cycloaddition with dipeptide-derived phosphine H5 described by Lu et al. are 
depicted exemplarily as further possible applications (Scheme 7).[25] 
 
 
Scheme 7: Two possible examples for peptide-based or peptide-derived catalysts. 
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A further very intensively studied example is the peptide-catalyzed acylation of alcohols.  
This is one type of reaction, which will be important for this thesis. In 1998, Miller et al. 
published the kinetic resolution of N-acylated alcohols (Scheme 8).[26] π-Methyl histidine-
functionalized (PMH) tripeptide I1 acts as nucleophilic catalyst. In the same year they reported 
a similar system and proposed the intermediately formed imidazolium species incorporated in 
the chiral peptide backbone is essential for transferring the acetyl group onto the free alcohol 
in a selective way.[27] A selective acylation of alcohols is of great importance for the natural 
product class of carbohydrates regarding the regioselective introduction of protecting groups 
(PG). Miller et al. transferred their approach onto polyols showing first promising results, but 
also emphasizing the challenge as well as possible solutions for those substrates.[28] 
 
Scheme 8: Kinetic resolution of N-acylated alcohol I2. 
In 2008, Schreiner et al. published a catalytic system on basis of PMH, which is able to perform 
the kinetic resolution of trans-cycloalkane-1,2-diols in a highly selective fashion. In contrast to 
Miller’s proline-based catalyst they utilized an γ-adamantyl amino acid (AdGly, for the sake of 
convenience) as core structure. During permutation of the amino acid sequence they identified 
cyclohexylalanine (Cha) as second unnatural building block necessary for their oligopeptide 
catalyst. Based on molecular dynamic considerations they concluded that besides hydrogen 
bonding hydrophobic interactions and a pocket-shaped structure of the oligopeptide are 
essential for a selective acetyl transfer.[2a] One year later Sunoj et al. proofed this observation 
via density functional theory (DFT) calculations.[29] Due to the optimal yield of 50% in case of 
a kinetic resolution Schreiner et al. focused on meso-diols because in case of a 
desymmetrization 100% yield can be achieved. But, they observed that after acylation of J2 
with their already established oligopeptide J1 monoacylated diol J3 racemized during 
purification via intramolecular acetyl transfer. To address this finding they performed an  
add-on oxidation of the remaining hydroxyl group to its corresponding ketone with 
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substoichiometric amounts of 2,2,6,6-tetramethylpiperidin-1-yl)oxyl J4 (TEMPO)  
(Scheme 9).[2b] After purification α-acetoxy ketone J5 was isolated with a yield of 70%. The 
enantiomeric ratio (er) after oxidation was the same for target compound J5 compared with its 
monoacylated non-oxidized derivative J3.[2b] Considering the computations of Sunoj et al. the 
proposed cis-(1R,2S)-2-hydroxycyclohexyl acetate J3 forms preferentially during 
desymmetrization.[29] 
 
Scheme 9: Desymmetrization of meso-cyclohexane-1,2-diol J2 with peptide-catalyst J1. 
Schreiner and co-workers extended the application of their catalytic system. In 2010, they 
published the peptide-mediated Steglich esterification. The necessary anhydride is formed  
in situ from the corresponding carboxylic acid in the presence of a carbodiimide as dehydration 
and activation agent. Due to this approach acyl species can be transferred to an alcohol which 
has no stable or commercially available anhydride.[2c] Six years later they used an analogue 
oligopeptide catalyst in the first enantioselective Dakin-West reaction (Scheme 10).[30] 
 
Scheme 10: First enantioselective Dakin-West reaction. 
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Tripeptide K1 is involved in the acylation of the formed azlactone and the decarboxylative 
protonation, which is mechanistically not yet fully understood, yielding final product K3. The 
best result was obtained for cyclohexylalanine, which can be explained by the important role 
of dispersion interactions between catalytic system and side chain of the amino acid. 
The second type of reactions, which is essential for this thesis besides acylations, are oxidation 
reactions. Epoxidation (Chapter 1.3.) and sulfoxidation (Chapter 5.3.) special types of 
oxidations are introduced separately. Two additional examples in this context are shown in 
scheme 11. 
In 2011, Miller and co-worker reported the selective oxidation of indoles via a peptide catalyst 
L1 containing an aspartic acid as catalytically active moiety.[31] The peptidic system is able to 
oxidize the nitrogen heterocycle L2 in the presence of catalytic amounts of  
4-dimethylaminopyridine (DMAP) both chemo- and enantioselectively (Scheme 11). For years 
later they used the similar system L4 for the asymmetric Baeyer-Villiger oxidation  
(Scheme 11).[32] In this case the introduction of the oxygen proceeded enantio- and 
regioselectively. They observed a parallel kinetic resolution of both possible products L6 and 
L7 as well as the preferred formation of L7, which is the less favored product utilizing  
meta-chloroperoxybenzoic acid (mCPBA) as oxidizing agent. They introduced the strategy of 
carboxylic acid-containing peptides for oxidative reactions firstly in the enantioselective 
epoxidation of cyclohexene derivatives in 2007 (Chapter 1.3.2.1).[33] In this context the showed 
a postulated mechanism based on peracid formation via carbodiimide activation and hydrogen 
peroxide addition and explained the role of DMAP in more detail (Chapter 4.3.1).  
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Scheme 11: Examples for peptide-based oxidation reactions. 
1.2.3. Peptide-Based Multicalatysis 
As shown for the polyketide synthase (Figure 2 and 3)[1] nature can produce complex 
compounds via multistep processes and in a linear manner. Occurring intermediates are passed 
from one catalytic part to the other. Even if atom, redox-, and step economy are not optimal for 
all biosynthetic procedures, for synthetic chemists their efficiency is quite high.  
In 2015, Kirschning et al. reviewed these comparable aspects between nature and organic 
synthesis. They showed, for example, that a domino reaction or a multicatalytic approach are 
useful tools mimicking natural principles in organic laboratories.[34] Already three years before  
Schreiner et al. published a review focusing more on the synthetic application of multicatalysis 
with organocatalysts. After describing different models of multicatalytic teamwork they 
illustrated its potency based on several examples of distinct catalyst combinations. Finally they 
introduced the concepts of a multicatalyst and retrocatalysis (Figure 6).[3c] 
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Figure 6: Multicatalyst and retrocatalysis concept. 
In a multicatalyst all catalytic active moieties or precursors are fixed at one common backbone 
separated by suitable spacers. The catalyst is present from the beginning while the different 
reagents are added stepwise. Staring material A is converted into product P via intermediates 
IM1 and IM2, which are not isolated or purified (Figure 6 (a)). Besides simplified dealing with 
unstable intermediates the multicatalyst approach is also less time and resource-consuming. 
Furthermore, with regard to reuse only one catalyst has to be recovered.[3c] 
A multicatalyst can therefore be considered as an ensemble of single catalysts. Like a target 
molecule can be divided into its necessary starting materials via retrosynthesis the two different 
catalytic species are connected via the concept of retrocatalysis. Both principles can be used in 
parallel to identify potential educts and an appropriate multicatalyst to obtain the desired target 
compound (Figure 6 (b)).[3c] 
Several requirements must be fulfilled for a multicatalyst to achieve an efficient functioning. 
Beside an orthogonal reactivity the utilized catalytic moieties are not allowed to interfere or 
inhibit each other. A suitable spacer and/or backbone have to be identified ensuring a defined 
structure associated with an asymmetric reaction.[3a] 
With a closer look on the desymmetrization-oxidation sequence (Scheme 9) and the “similarity” 
of oligopeptide catalysts and enzymes in mind it was obvious to fix PMH and the TEMPO 
moieties on one common peptide backbone. After catalyst screening they identified 
functionalized peptide M1 as the catalyst of choice (Scheme 12). They found out that separation 
of the distinct moieties by three amino acids via substitution of the methyl ester of J1 (Scheme 
9) with TEMPO amine has no effect on the three-dimensional structure. With the first 
organocatalytic multicatalyst M1 they obtained α-acetoxy ketone J5 with a yield of 70% and 
an enantiomeric ratio of 88:12. Astonishingly, the amount of TEMPO catalyst could be reduced 
from 60 to 5 mol% and only three equivalents of mCPBA were necessary to achieve nearly the 
same result.[3a] 
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In the next years, Schreiner et al. reported three further sequences with a multicatalyst.  
In 2014, they showed that instead of changing the catalytic moieties in retrocatalytic manner 
the involved reaction steps can be inverted. The utilized multicatalyst M1 in an oxidative 
esterification (Scheme 12).[3d] 
 
Scheme 12: Oxidative esterification with multicatalyst M1. 
In the first reaction step mixed anhydride M3 was formed under oxidative conditions starting 
from aldehyde M2 and para-nitrobenzoic acid (pNBA) M3. The smaller part of M3 was finally 
transferred onto trans-diol M5. Monoacylated product M6 was obtained with a conversion of 
41% and an enantiomeric excess of 73%. In line with possible acylium sources beginning with 
anhydride,[2a] acid,[2c] and aldehyde[3d] Schreiner et al. also established an “alcohol cross 
coupling”. In 2016, they published the multicatalytic kinetic resolution of  
trans-cyclohexanediols and the corresponding alcohols in the presence of catalytic system M1. 
Different mono- as well as diols were utilized and good yields and enantioselectivities were 
realized.[35] 
It was also possible to extent the kinetic resolution of trans-1,2-cycloalkanediols to a 
multicatalyst approach. In 2012, Schreiner et al. published an epoxidation-epoxide opening-
acylation sequence. For this three-step procedure they substituted the methyl ester of J1 via a 
homoaspartic acid motif, which is able to epoxidize the carbon-carbon double bond in the first 
step (Scheme 13).[3b] 
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Scheme 13: Kinetic resolution of diol N4 with multicatalyst N1 starting from the corresponding olefin N2. 
Starting form cycloheptene N2 the diacid moiety mediates the epoxidation to oxirane N3 by  
in situ formation of its peracid in the presence of diisopropylcarbodiimide (DIC) and hydrogen 
peroxide. The three-membered ring is opened by the additional catalyst hydrazine sulfate and 
ten equivalents of water. Finally, the temporarily formed trans-diol N4 is selectively acylated 
by PMH as catalytically active species. Best results were obtained for the seven-membered 
system N5 with an S-value of 26. The detailed mechanism was elucidated in 2015 by Schrader 
et al. via MS techniques[36] and the epoxidation part is shown in chapter 4.3.1. in more detail.  
1.3. Epoxidation 
In the last-mentioned multicatalytic sequence the asymmetric information was introduced in 
the acylation step. From a synthetic point of view and considering especially complex target 
compounds, it would be worthwhile to carry out the first step of a sequence in an 
enantioselective manner. Therefore, the focus of this thesis lays on the identification of an 
asymmetric epoxidation strategy based on peptidic platform. 
1.3.1. Occurrence of Epoxides 
Due to their ring structure epoxides are highly reactive species. Therefore, they are used as a 
versatile class of starting materials. Besides finding application in polymer chemistry[37] 
oxiranes can be opened with a variety of different nucleophiles (Nu) using carbon- or 
heteroatom-based reactants. Depending on the nature of the nucleophilic component, for 
example, α-halogenated or α-amidated alcohols can be obtained. Moreover, the potential access 
to two defined stereogenic centers in parallel become important in this regard.[38] In our context 
the epoxide opening mediated by an organocatalysts is of course of peculiar interest.[38c] 
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But, besides being starting material or intermediate in a reaction epoxides are also part of 
different natural products or drugs. Starting from both electron-rich or electron-deficient double 
bonds one of the possible enantiomers is highly relevant for the corresponding target molecule 
(Figure 7). 
 
Figure 7: Examples for oxirane-containing natural products or drugs. 
The acetate of bromoxone O1 was isolated from a marine acorn worm and possesses an 
antitumor activity. Its total synthesis starting from a chiral building block was reported in 2003 
by Kitahara and co-workers.[39] Secondly, the relative and absolute configuration of 
apiosporamide O2 was elucidated by Williams et al. in 2005 after total synthesis. It is described 
that their target compound was isolated from a fungus and is both antifungal as well as 
antibacterial active.[40] Thirdly, Wuts et al. synthesized eplerenone O3 in a chemobiological 
way in 2008. This compound is utilized for the treatment of hypertension and congestive heart 
failure.[41] Macrolactone O4 belongs to a group of similar compounds, which were isolated for 
myxobacteria Sorangium cellulosum. A total synthesis was reported in 2012 by Lin and  
co-workers. Epothilone B is approved for the treatment of breast cancer and further applications 
are still under investigation.[42] 
1.3.2. Organocatalytic-Based Synthesis of Epoxides 
As mentioned in the motivation the main focus of this thesis is on the affiliation of the 
epoxidation as further type of reaction in context of multicatalysis. In combination with our 
peptide-based scaffold an organic precursor or catalytic moiety (CM) is preferred. Very 
prominent strategies are, for example, peptide-, phase-transfer-catalyst-, imine-/enamine-, 
iminium- and, chiral ketone-based organocatalytic variants.[43] Therefore, those  
well-established methods are described based on selected examples. 
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1.3.2.1. Peptide-Based Epoxidation 
The first epoxidation, which was carried out with a peptide, was the Juliá-Colonna epoxidation. 
The polyamino acid-mediated reaction was published in 1982 and is also often denoted as one 
of the first organocatalyzed reactions (Scheme 14).[44] The second example is the oxirane 
formation with a carboxylic acid-containing oligopeptide, like it was already introduced in the 
oxidation of indoles and the Baeyer-Villiger oxidation (Scheme 11). In 2007 Miller et al. 
reported the reaction of substituted olefins to their corresponding oxiranes (Scheme 14).[33]  
 
Scheme 14: Exemplary peptide-based epoxidations. 
In the Juliá-Colonna epoxidation polypeptide P1 catalyzes the reaction of α,β-unsaturated 
ketone P2 to its oxirane P3. The desired product was obtained with a yield of 96% and an 
enantiomeric excess of 96%. In 2004, Colonna et al. showed in mechanistic investigations that 
the catalyst coordinates the formed hydroperoxide enolate. Afterwards, the oxygen atom is 
transferred selectively on the double bond.[45, 43e] In case of aspartic acid-containing peptide 
catalyst P4 dicyclohexylcarbodiimide (DCC) and hydrogen peroxide form the reactive peracid 
in situ. In contrast to addition of the reactive species on electron-deficient substrate P2,[45] the 
carbon-carbon double bond is epoxidized in a concerted manner (Chapter 4.3.1).  
Epoxy cyclohexane derivative P6 was obtained with a yield of 58% and an enantioselective 
excess of 54%. 
1.3.2.2. Phase Transfer Catalysts 
With, for example, hydrogen peroxide as oxidizing agent utilized in a biphasic system in the 
presence of a base the reactive species hydroperoxide enolate has to be transported form the 
aqueous (aq) to the organic phase. This interfering property is the huge advantage of a PTC  
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(Figure 8).[43f] Besides epoxidations they are also used, for example, in alkylations,  
Mannich reactions, and fluorinations.[46] 
 
Figure 8: Schematic depiction of the functionality of a PTC. 
In the aqueous phase sodium hydroxide deprotonates hydrogen peroxide. By replacement of 
the anion the formed hydroperoxide enolate is transported into the organic layer by the PTC.  
In the environment of a chiral cationic counterpart the oxygen is transferred onto the olefin in 
a selective fashion. Four different types of PTCs are depicted in figure 9 utilizing this concept.  
 
Figure 9: Selected examples of PTCs. 
Alkaloid Q1 was firstly used in the epoxidation of α,β-unsaturated alkenes in 1976 by Wynberg 
and co-workers. They showed that the presence of the salt is necessary for the formation of an 
enantiomerically enriched product.[47] Bifunctional catalyst Q2 was reported by  
Nagasawa et al. in 2009. A postulated mechanism bases on the activation and coordination both 
of olefin and reactive species by either guanidinium or urea unit.[48] 
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In 2004, Maruoka et al. introduced a quaternary ammonium-based PTC Q3. They obtained the 
corresponding epoxides with up to 99% yield and an enantiomeric excess of 96%.[49] 
Imidazolium-functionalized polypeptide Q4 was utilized in the Juliá-Colonna epoxidation. 
Based on a simple recovery catalyst Q4 was reused in seven cycles without loss of catalytic 
activity.[50] 
1.3.2.3. Proline-Derived Catalysts 
A third class of catalysts are systems derived from proline. Both unprotected as well as 
protected prolinol derivatives can act as catalysts reacting via different mechanisms  
(Scheme 15).  
In 2005, Lattanzi published the enantioselective epoxidation with commercially available  
α,α-diphenylprolinol R1. In their postulated mechanism prolinol R1 deprotonates  
tert-butyl hydrogen peroxide (TBHP) forming a chiral ion pair with the reactive anion.  
n-Hexane as nonpolar solvent prefers the salt formation additionally. Moreover, the free 
hydroxyl group activates the carbonyl moiety of α,β-unsaturated olefin P2. For epoxy ketone 
P3 they obtained a yield of 72% and an enantiomeric excess of 75%. By release of tert-butanol 
prolinol derivative R1 can enter the next catalytic cycle.[51]  
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Scheme 15: Prolinol and prolinol ether catalyzed epoxidations. 
In contrast prolinol ethers, also known as Jørgensen-Hayashi catalysts,[52] have a different 
mechanism. The first usage in an asymmetric epoxidation of α,β-unsaturated aldehydes was 
published by Jørgensen et al. in 2005 including the postulated mechanism.[53] Herein, amine 
R2 and aldehyde R3 form an iminium species, which is afterwards attacked by hydrogen 
peroxide. Ring closing to the oxirane takes place via attack of the α-carbon of the enamine on 
the oxygen atom. After hydrolysis epoxide R4 was isolated with a yield of 90% and an 
enantiomeric excess of 97%. 
1.3.2.4. Chiral Ketones 
Dioxiranes like dimethyldioxirane are standard reagents for the synthesis of epoxides. But, the 
reactive species can also be generated in situ starting form a ketone and an oxidizing agent like 
Oxone® or hydrogen peroxide. For the corresponding mechanism see chapters 4.4.1. and 4.4.5. 
In case of a chiral carbonyl component the epoxidation can proceed in an enantioselective 
manner. Besides C2-symmetric systems sterically hindered ketones are typical precursors for 
this kind of epoxidation.[43c, 43d, 43f] Two examples are depicted in scheme 16.  
In 1996, Shi et al. published the epoxidation with carbohydrate derivative S1.[54] In the 
following year they also reported a catalytic version of their procedure.[55] After transferring 
one of the dioxirane oxygen atoms onto the carbon-carbon double bond the fructose-derived 
ketone can enter the catalytic cycle again. Also in 1996, Yang and co-workers introduced  
C2-symmetric cyclic ketone S4 for the asymmetric epoxidation of electron-rich alkenes like S2. 
Moderate to good enantiomeric excesses were achieved for trans- as well as trisubstituted 
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alkenes. A prolonged reaction time was necessary in regard to the usage of catalytic amounts 
of precursor S4.[56]  
 
Scheme 16: In situ formation of the active dioxirane species. 
Referring to their carboxylic acid-containing peptide catalyst P4 Miller et al. published an 
oligopeptide functionalized with a trifluoromethyl ketone (TFMK) unit. Oligopeptide T1 was 
synthesized in 10 steps beginning with carbamate T2, propionyl chloride, and allyl bromide.  
It was afterwards successfully tested in the enantioselective epoxidation (Scheme 17).[57] 
 
Scheme 17: TFMK-containing peptide T1 as catalyst in asymmetric epoxidation of T5.  
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Starting from Seebach’s auxiliary T2 aldehyde T3 was obtained after four steps. T3 is the key 
intermediate for the introduction of the trifluoromethyl group. Protected TFMK T4 was 
obtained after three additional steps. Finally, T4 was attached to the N-terminal unprotected 
peptide. Late-stage deprotection and oxidation are the last steps, before the TFMK catalyst T1 
can be used in epoxidation reactions. With 10 mol% of the precursor epoxide T6 was isolated 
with a yield of 88% and an enantiomeric ratio of 90.5:9.5.  
These four selected examples for asymmetric epoxidation reactions with organocatalysts should 
clarify the enormous potency of this concept. In this thesis we want to combine those strategies 
with our multicatalyst concept enabling new multicatalytic sequences. 
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2. Key Step: Acylation 
As mentioned and shown in the introduction previous works of our group indicated the key step 
character of the acylation both in kinetic resolution[2a, 2c, 2d] and desymmetrization (Scheme 9) 
of 1,2-diols[2b, 2d] as well as in multicatalytic reaction sequences (Chapter 1.2.3.).[3a, 3b]  
For examining the acylation more intensively, we first tested an alternative acyl source  
(Chapter 2.1.), a novel application of our catalytic system (Chapter 2.2.), and sulfoximines as a 
new class of substrates (Chapter 2.3.).  
2.1. Alternative Acyl Source 
In former experiments acid anhydrides, acyl chlorides, vinyl acetate, and sulfurous- as well as 
phosphorous-based compounds were tested as electrophiles in combination with peptide 
catalyst (cat.) 1. Acetic acid anhydride showed the best results regarding stereo- as well as 
chemoselectivity.[2d] In 2012, Onomura et al. published a Pd-Sn-catalyzed monoacylation of 
cis-cyclohexane-1,2-diol utilizing allyl acetate as acyl source.[58] Due to the good to excellent 
results based on allyl acetate, peptide catalyst 1 was tested under similar reaction conditions 
while using K2CO3 instead of Cs2CO3 as a base (Scheme 18). 
 
Scheme 18: Allyl acetate as electrophile. 
After nearly one day, no conversion to the desired monoacylated product (see 4 and 5 
Experimental Section) was observed by GC-MS (gas chromatography-mass spectroscopy) both 
in the kinetic resolution of trans-cyclohexane-1,2-diol (±)-2 and in the desymmetrization of 
meso-3. Compared to its vinyl analog, allyl acetate did not show any reactivity in the acylation 
with oligopeptide 1. Therefore, allyl acetate was neglected as acyl source in further 
investigations.  
2.2. Oxidative Esterification 
In the previously mentioned experiments the acyl source was added directly at the beginning of 
the reaction whereas in case of an oxidative esterification the reactive species is rather formed 
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in situ from the corresponding aldehyde and an oxidizing agent. In 2011, Hui et al. established 
a NHC-catalyzed oxidative esterification of aldehydes with oxygen as oxidizer.[59] One year 
later, Takemoto and co-workers utilized the same class of catalysts for the reaction of aldehydes 
and thiols.[60] They identified phenazine 7 as the oxidizer of choice. Combining the strategy of 
Takemoto and our nucleophilic peptide concept could accomplish an oxidative esterification of 
alcohols. tert-Butyloxycarbonyl-protected (Boc) PMH 6 was chosen as test catalyst and 
different kind of alcohols as feasible substrates (Scheme 19). 
 
Scheme 19: Oxidative esterification. 
meso-1,2-Diol 3 as well as a primary, secondary, and tertiary alcohols were tested, but none of 
the corresponding esters was observed via GC-MS. We assume that either alcohols, in contrast 
to thiols, are not feasible substrates under these conditions or that our catalyst or the in situ 
generated acid, respectively, is not reactive enough to form the necessary acylium species.  
Later on, Christine Hofmann was able to perform a peptide-catalyzed oxidative esterification 
utilizing a combination of TEMPO, pNBA, and tert-butyl hypochlorite.[3d] 
2.3. Sulfoximines as Substrates 
Not only reaction conditions were varied in the previously mentioned experiments, but also 
different kinds of starting materials were employed. As a result, 1,2-diols were identified as the 
best substrates in combination with the most promising peptide catalyst 1 regarding, for 
example, reactivity and selectivity.[2d] In collaboration with the group of  
Professor Michael Harmata (University of Missouri, Columbia), sulfoximines were added to 
the existing substrate library utilizing our optimized protocol. Harmata et al. had already 
successfully employed the boric acid-catalyzed N-acylation of this class of compounds.[61] 
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2.3.1. Preparation of Racemic Products 
Before starting the kinetic resolution of the sulfoximines the desired products were synthesized 
in racemic form. A protocol based on DMAP as a nucleophilic catalyst in combination with 
N,N-diisopropylethylamine (DiPEA) was utilized (Table 1).[2a, 62] 
Table 1: Syntheses of racemically acylated sulfoximines 9a, 9b, and 9c. 
 
Product DMAP 
[equiv] 
Ac2O 
[equiv] 
DiPEA 
[equiv] 
t 
[h] 
Yield 
[%] 
9a(a) 0.3 1.2 1.1 28 66 (96)(b) 
9b 0.2 4.0 4.0 24 67 
9c 0.4 3.1 3.1 24 55 (85)(b) 
(a): After 8 h additional 1.1 equiv of Ac2O and DiPEA were added; (b): Yield based on the amount of reisolated 
starting material. 
Acylated sulfoximines 9a, 9b, and 9c could be isolated in preparative yields of up to 67%.  
Yet, increasing the amount of anhydride, base, and DMAP as well as extending reaction times 
did not lead to full conversion. Afterwards, the enantiomers of starting material and obtained 
product were separated via chiral GC. 
2.3.2. Catalyzed Kinetic Resolution 
With the analytical data in hand, several types of catalysts were tested in the kinetic resolution 
of sulfoximines 8a, 8b, and 8c. Apart from peptide catalysts 1, 10,3 and 11 we also used peptide-
based catalysts 123 and 133 established by Miller et al. for the kinetic resolution of N-acylated 
amino alcohols[26] as well as chiral DMAP catalysts 14, 15, and 16 synthesized by Stará et al. 
(Table 2).[63] 
For testing the acylation ability of catalysts 1 and 10-16 starting from sulfoximines 8a, 8b, and 
8c all reactions were carried out under standard conditions optimized for the desymmetrization 
of meso-diol 3. However, due to the slow and incomplete formation of the racemic products, 
screening reactions were run at 0 °C and DiPEA was added (Table 2). Earlier results showed 
                                                 
3 Catalyst was synthesized by Dr. Christian E. Müller. 
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that the reaction proceeds faster and with an increased selectivity in the presence of  
5.3 equivalents of base.[2b] 
Table 2: Screening results. 
 
 
 
Entry Product Cat. t [h] Conv.(a) [%] S-value(a) 
1 9a 1 [2 mol%] 24 1 1.2 
2 9a 1 [4 mol%] 24 13 1.2 
3 9a 10 [2 mol%] 24 1 1.4 
4 9a 11 [2 mol%] 24 25 1.3 
5 9a 12 [4 mol%] 24 traces 1.1 
6 9a 13 [3 mol%] 24 3 1.2 
7 9a 14 [2 mol%] 48 18 1.0 
8 9a 15 [2 mol%] 48 traces 1.2 
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9 9a 16 [2 mol%] 24 3 1.2 
10 9a - 24 2 1.2 
11 9b 1 [2 mol%] 24 7 1.5 
12 9b 11 [2 mol%] 24 1 1.5 
13 9b 12 [3 mol%] 24 27 1.0 
14 9b 14 [2 mol%] 24 11 1.1 
15 9b 15 [3 mol%] 24 5 1.0 
16 9b 16 [2 mol%] 24 1 1.2 
17 9c 1 [2 mol%] 24 8 1.5 
18 9c 11 [2 mol%] 24 8 1.4 
19 9c 12 [2 mol%] 24 65 1.1 
20 9c 14 [2 mol%] 24 49 1.1 
21 9c 15 [2 mol%] 24 53 1.1 
22 9c 16 [2 mol%] 24 48 1.1 
23 9c - 24 43 1.0 
(a): Enantiomeric excess of starting material and product were determined via chiral GC without internal standard. 
Conv. and S-value were calculated using the procedure of Kagan and Fiaud.[64] 
Obtained S-values were in the range of 1.0 to 1.5 with a conversion of up to 65%. The high 
values for the conversion are misleading possibly because the equation of Kagan and Fiaud 
cannot be used for very low differences in enantiomeric excesses of reactants and products. 
Obviously, the used catalysts are not able to resolve the three different starting materials in a 
profitable manner. In most cases reactions were quenched after 24 hours because of very low 
conversion and no enantiomeric excess. Minimal acylation could also be observed in 
simultaneously performed background reactions. Hence, it is not completely clear, if product 
formation results from catalytic activity. Based on these first experimental results, changing 
either the substitution pattern of the sulfoximines or varying the type of catalyst seems to be 
less promising. The results indicate that the tested sulfoximines are not feasible substrates in 
combination with the employed catalysts.  
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3. New Multicatalytic Sequence 
3.1. Combination of Well-Established Procedures  
As explained in the introduction, chemical synthesis using a multicatalyst has several 
advantages. Therefore, one point of interest of this thesis is the development of a further 
multicatalytic sequence. Using well-established protocols in combination with new reactions 
leads to extension of our multicatalytic approach. In this context we designed a new catalytic 
sequence: esterification-epoxidation-epoxide opening (Figure 10).  
 
Figure 10: New multicatalytic sequence. 
The Steglich esterification of unsaturated carboxylic acids and 1,2-cyclohexanediols is the first 
step of the sequence. This kind of reaction is intensively studied and should be extended to 
unsaturated acids under otherwise analogue conditions.[2c] After epoxidation of the unsaturated 
esters the resulting epoxides will be opened with a nucleophile using the diol motif as auxiliary. 
For these two steps, feasible catalytic moieties, necessary reagents, and reaction conditions have 
to be developed. The epoxide opening should be performed following the concept of Tomioka 
and co-workers (Figure 11). In 1997, the Japanese group published the enantioselective ring 
opening of epoxides mediated by chiral diether ligands with excellent yields and moderate 
enantiomeric excesses.[65] One year later, Oguni et al. used chiral Schiff bases and salens also 
based on diol units in the same kind of reaction.[66] 
 
Figure 11: Proposed transition states for the opening of the epoxide based on the results of Tomioka et al. (left). 
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Hydrolysis of the esters results in the formation of carboxylic acids containing two defined 
stereogenic centers and three functional groups (carboxyl and hydroxyl groups as well as the 
corresponding nucleophile) enabling a variety of further transformations (e.g., esterification, 
oxidation). Chiral α-hydroxyl carboxylic acids are, for example, present in drugs or  
natural products.[67] 
Before establishing a multicatalytic approach all reactions have to be tested with separate 
peptide catalysts. Moreover, all intermediates and target compounds have to be synthesized as 
racemates to separate their diastereomers as well as enantiomers for further asymmetric 
investigations. 
3.2. Synthesis of Unsaturated Mono-Esters 
For delivering two stereogenic centers in the product the obvious choice as the simplest 
unsaturated compound was crotonic acid. Based on the modified Steglich protocol utilizing 
DMAP, N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC), and 
triethylamine (TEA) both trans- and cis-cyclohexane-1,2-diol 2 and 3 were converted into the 
corresponding esters 17 and 18 (Table 3).[2c, 68] EDAC was selected as the carbodiimide because 
removing the generated urea is simpler compared to DIC or DCC.[68] But, due to the low yield 
of only up to 25%, crotonic anhydride was also tested as an acylium source. Furthermore, a 
larger amount of DMAP was used and TEA was replaced by pyridine as base.[69] This strategy 
provided the α,β-unsaturated products with a yield of 63% (Table 3).  
Table 3: Synthesis of crotonic acid esters. 
 
Starting materials t [h] Product Yield [%] 
(±)-2 
 
Crotonic acid 24 17(a) 
 
25 
meso-3 
 
Crotonic acid 22 18(a) 
 
24 
(±)-2 
 
Crotonic anhydride 16 17(b) 
 
63 
meso-3 
 
Crotonic anhydride 20 18(b) 
 
63 
(a): Reaction conditions: DMAP (1 mol%), crotonic acid (1.0 equiv), EDAC (1.0 equiv), TEA (1.0 equiv), diol (1.1 
equiv), DCM, r.t.; (b): reaction conditions: DMAP (10-12 mol%), crotonic anhydride (0.9 equiv), diol (1.0 equiv), 
pyridine (6.0 equiv), DCM, r.t.. 
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The low amount of isolated product starting from crotonic acid can be explained by the 
mesomeric stabilization of the α,β-unsaturated reactant and hence the minimized reactivity 
considering the formation of the anhydride in situ. Due to the lower chemical stability of 
anhydrides and the easier access to unsaturated acids, crotonic acid was substituted by its 
homologue.[2c] In 3-pentenoic acid 19a the mesomeric effect was circumvented by a  
methylene-spacer. 
Using the DMAP, EDAC, and TEA based Steglich protocol, the corresponding esters 20a and 
21a were synthesized in yields of up to 71% (Table 4).[2c, 68] 
Table 4: Steglich esterification with 3-pentenoic acid 19a. 
 
Starting materials t [h] Product Yield [%] 
(±)-2 
 
25 20a(a) 
 
71 
meso-3 
 
24 21a(a) 
 
54 
(a): Reaction conditions: DMAP (1-2 mol%), diol (1.0 equiv), 3-pentenoic acid 19a (1.0 equiv), EDAC (1.0 equiv), 
TEA (1.0 equiv), DCM, r.t.. 
With the racemic compounds in hand, the enantiomers of the esters were separated via chiral 
GC or high-pressure liquid chromatography (HPLC). Afterwards, the Steglich esterification 
was tested under catalytic conditions utilizing the well-established protocol and tetrapeptide 1 
or 104 as catalysts (Table 5).[2c] Both kinetic resolution of (±)-2 as well as desymmetrization of 
meso-3 worked very well. As mentioned in literature, the protecting group at the C-terminus of 
the catalyst plays a negligible role comparing oligopeptide 1 and 10.[2d] Because a combination 
of EDAC and TEA showed less promising results in simultaneously performed experiments 
either DIC or DCC are the preferred carbodiimides. Based on these encouraging data, the 
esterification between diol and unsaturated, but not conjugated acid 19a is a feasible first step 
of our new multicatalytic sequence. 
                                                 
4 Catalyst was synthesized by Dr. Christian E. Müller. 
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Table 5: Peptide-catalyzed Steglich esterification. 
 
Starting  
Materials 
t  
[h] 
Carbodiimide 
[equiv] 
Product S-value(b) Conv.(b) 
[%] 
(±)-2 4 DIC (1.2) (R,R)-20a(a) 
 
> 50 51 
 
Starting  
materials 
t  
[h] 
Carbodiimide 
[equiv] 
Product ee(c) 
[%] 
Conv.(c) 
[%] 
meso-3 24 DCC (1.0) (1R,2S)-21a(a,d) 
 
83 55 
(a): Reaction conditions: cat. (2 mol%), diol (1.0 equiv), acid (1.0 equiv), toluene (anhyd., 4.00 mL), 0 °C; (b): ee 
of starting material and product were determined via chiral GC without internal standard. Afterwards, conv. and 
S-value were calculated using the procedure of Kagan and Fiaud;[64] (c): ee and conv. were determined via chiral 
GC or HPLC without internal standard; (d): cat. 10 was used. 
3.3. Synthesis of Epoxides 
Now we moved our attention to the second step of the one-pot reaction sequence. All four 
unsaturated esters were epoxidized racemically including the less promising crotonic acid 
derivatives. Utilizing a mCPBA-based protocol the corresponding oxiranes were isolated in 
yields of up to 87% (Table 6).[70] 
Table 6: Racemic epoxidation of the monoesters. 
 
Unsaturated Ester Epoxide t [h] mCPBA [equiv] Yield [%] 
17 
 
22 
 
20 1.2 61 
18 
 
23 
 
24 1.1 72 
30 
 
20a 
 
24a 
 
22 1.1 69 
21a 
 
25a 
 
7 1.1 87 
 
3.4. Synthesis of Functionalized Carbonic Acid Derivatives 
3.4.1. Michael-Addition 
Simultaneously, for the identification of a possible epoxide opening starting from oxiranes 24a 
and 25a, we also tested the Michael addition for α,β-unsaturated compounds 17 and 18.  
This reaction might also be part of a minimally modified multicatalytic sequence based on an 
asymmetric acylation of the corresponding starting material. Hydrolysis of the intermediately 
formed saturated esters would lead to β-functionalized carboxylic acids. This kind of 
compounds are used, for example, as chiral synthons or as receptor antagonists.[71] Sakai et al. 
already described the 1,4-addition of an in situ formed diphenylcuprate onto enantiomerically 
pure crotonic acid derivative 17 providing the product in 66% yield and a diastereomeric ratio 
of 94:6. The authors assume that coordination of a lithium atom of the dimer by the diol motif 
generates a chiral environment for the attack of a phenyl group to the double bond  
(Figure 12).[69] 
 
Figure 12: Postulated transition state for the Michael addition. 
We tried to reproduce Sakai’s result for monoester 17 and to test 18 as further starting material 
under otherwise identical conditions (Table 7). The necessary Gilman reagent was generated  
in situ starting from copper(I) bromide and phenyllithium. Corresponding Michael addition 
products 26 and 27 were isolated with a yield up to 48% as a mixture of both diastereomers.  
An explanation for the lower yield in case of the cis-derivative 18 might be the mismatched 
configuration of the substituents in the transition state (Figure 12). These results show that the 
1,4-addition of those compounds is principally possible and could be incorporated into a 
multicatalytic sequence. But, because of side product formation, purification problems, and less 
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promising overall yields (Table 3 and 6), no extensive optimization attempts were undertaken 
until now. 
Table 7: Michael addition to crotonic acid derivatives 17 and 18. 
 
Starting materials Product Yield [%] 
17 
 
26 
 
48 
18 
 
27 
 
< 10(a) 
(a): Even after several purification steps via column chromatography, the product was not completely pure. 
3.4.2. Epoxide Opening 
Before performing the epoxidation in an asymmetric and multicatalytic fashion a feasible ring 
opening reaction and a possible catalytic moiety have to be identified. In 2012, Schreiner et al. 
published a multicatalytic sequence involving an epoxide opening to racemic  
trans-1,2-cyclohexanediol using hydrazine bisulfate as catalyst, which was not fixed at the 
peptide backbone.[3b] In this thesis, we focused on different nucleophiles introducing a variety 
of further functional groups. Therefore, several approaches were taken into account (oxirane 
ring opening with trimethylsilyl cyanide (TMSCN), lithium- as well as copper organyls, and 
thiols), starting from a racemic mixture of the corresponding epoxides.  
3.4.2.1. TMSCN 
Epoxide opening based on TMSCN is well studied in literature.[72a, 38a, 72b, 72c] Based on this 
strategy amines, carboxylic acids, nitriles, as well as hydroxyl groups can be installed 
simultaneously in a molecule. Furthermore, this kind of reaction is utilized in the synthesis of 
complex compounds.[73] Besides, for example, titanium, ytterbium, and indium species also 
organic compounds like CBr4 or a thiourea derivative activate the oxygen ring atom favoring 
an epoxide opening reaction.[74, 72b, 72c] One drawback of this silyl species is its reactivity 
towards carbonyl groups. Zhang et al. investigated the addition of TMSCN on aldehydes 
catalyzed by the same thiourea as it was utilized in the ring opening reaction.[75] Considering 
our developed multicatalytic sequence starting from epoxy esters this chemoselectivity could 
lead to a variety of potential products. For examining the effect on the functional groups and 
the catalytic motifs as well as for investigating the reaction conditions more closely, we chose 
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the epoxide of benzylideneacetone as test substrate. Epoxide 28 was previously synthesized in 
53% yield over two steps. After aldol condensation of benzaldehyde and acetone the double 
bond was epoxidized utilizing typical Weitz-Scheffer conditions (Scheme 20).[76] 
Scheme 20: Synthesis of epoxide 28. 
(a): TFA salt 29: morpholine (1.0 equiv), TFA (1.1 equiv), Et2O, 0 °C, 1 h, 94%; (b): the same amount of NaOH 
was added hourly. 
With the test substrate in hand, we performed the TMSCN-mediated epoxide opening, 
theoretically leading to up to five possible products (Scheme 21). Based on the polarization of 
the carbon atoms the nitrile anion should preferentially attack at the β-position. This reactivity 
applies for all further epoxide opening approaches. 
 
Scheme 21: TMSCN addition on epoxy ketone 28. 
After performing the reaction both with different kind of catalysts (InCl3 and CBr4) and as a 
two-step synthesis containing the addition of NaCN followed by protection of the formed 
alcohol with TMSCl, none of the expected products could be observed via nuclear magnetic 
resonance (NMR) or GC-MS.[74b, 77] In 2011, Fraile et al. already described the lower reactivity 
of α,β-epoxy ketones in TMSCN-mediated epoxide opening reactions.[72b] Due to the amount 
and complexity of feasible products as well as the incomplete synthesis of the racemic 
compounds and the failed identification of a suitable catalytic moiety or reaction conditions, 
we decided against putting more effort into this reaction as last step of the multicatalytic 
sequence. 
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3.4.2.2. Metal Organyls 
Ensuing from the arising problems for TMSCN, we chose phenyllithium as an alternate 
nucleophile, which is also able to form a new carbon-carbon bond during epoxide opening 
reactions. As already mentioned, the diol motif of our starting material should coordinate the 
counterion ensuring a preferential trajectory for the attack of the phenyl ion at the epoxide 
(Figure 11).[65-66] Aside from the oxirane, a carbonyl group and several acidic protons (hydroxyl 
group as well as α-protons) are present in the molecule representing possible reactive centers 
for the lithium organyl. Therefore, we used directly epoxides 24a and 25a as substrates instead 
of a further test system. We performed the first experiments based on the conditions of Tomioka 
utilizing two equivalents of the lithium species.[65] The first equivalent should deprotonate the 
hydroxyl group and the second one should open the epoxide providing the desired product after 
aqueous work-up (Table 8). 
Table 8: Epoxide opening with PhLi. 
 
Starting materials t [h] Product Yield [%] 
24a 
 
4 31 
 
14 
25a 
 
2 32 
 
18 
 
During the reactions starting both from trans- as well as cis-derivative 24a and 25a the 
formation of up to nine new compounds was detected via thin-layer chromatography (TLC). 
Beside small traces of the corresponding starting materials and diols, only elimination products 
31 and 32 could be clearly identified via NMR or high resolution-MS (HR-MS) (Table 8).  
These facts and the incorrect mass balance proved the high reactivity of lithium organyls and 
the possibility of several simultaneously running side reactions. 
In contrast to the assumed reaction progress, the second equivalent phenyllithium acts not as 
nucleophile, but as an additional equivalent of base. Deprotonation in α-position followed by a 
concerted epoxide opening leads to α,β-unsaturated γ-hydroxyl ketones 31 and 32. Comparison 
of the postulated TS shows a favored six-membered TS for the formation of allyl alcohols in 
contrast to the more complex situation in case of the epoxide opening (Figure 13).  
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Furthermore, the comparable isolated yields clarify the negligible influence of the 
stereochemistry at the cyclohexyl (Cy) system, because starting from the cis-analog should 
show a better coordination of the lithium cation in case of the epoxide opening. 
 
Figure 13: Postulated TSs for elimination and ring opening, respectively. 
Substitution of the lithium organyl by its copper analog is one way to overcome the elimination 
problem. Based on the “hard and soft acid and base (HSAB) concept”, cuprates are softer 
reagents, compared to their lithium analogs. This property can directly be correlated with the 
basicity and nucleophilicity of these compounds. Moreover, due to an increased reactivity in 
addition reactions, milder conditions can be utilized. Even if copper organyls react 
regioselectively in the presence of esters organic copper species provide allyl alcohols as well 
as ketones as side products.[78] We repeated the test experiments combining the in situ 
generation of lithium diphenylcuprate and its ability in oxirane opening reactions  
(Table 9).[78, 69] 
Table 9: Epoxide opening with Ph2CuLi. 
 
Starting materials Product Yield [%] 
24a 
 
31 
 
15 
25a 
 
32 
 
4 
 
Analogous to phenyllithium a variety of new compounds were observed in the reactions with 
lithium diphenylcuprate via TLC. But, the identification of an epoxide opening product was 
also not successful. However, allyl alcohols 31 and 32 were isolated with comparable yields of 
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up to 15% (Table 8 and 9). Even with the less basic copper species formation of the unsaturated 
system could not be suppressed. 
Therefore, we selected the corresponding 4-pentenoic acid derivatives 24b and 25b as starting 
materials. Starting from those oxiranes an epoxide opening to the conjugated compounds is not 
possible, even if a deprotonation in α-position takes place. The epoxy analogs of 4-penonic acid 
19b were synthesized in a total yield of up to 59% utilizing the established protocol mentioned 
before (Table 10).[2c, 68] To avoid problems with the separation of formed acid only  
0.9 equivalents of mCBPA were utilized.[70] 
Table 10: Synthesis of epoxide 24b and 25b. 
 
Educt Ester Yield [%] Epoxide Yield [%] 
(±)-2 20b 
 
45 24b 
 
59 
meso-3 21b 
 
50 25b 
 
57 
 
With the necessary oxiranes in hand, the lithium- as well as copper-based ring opening reactions 
were performed under otherwise identical conditions. Due to polarization of the alkyl chain, the 
phenyl anion should preferentially attack at the δ-position of the epoxy esters 24b and 25b 
(Scheme 22). 
 
Scheme 22: Organometallic ring opening of terminal epoxides 24b and 25b. 
Carrying out the reaction both with trans- as well as cis-analog 24b and 25b in combination 
with the lithium as well as the copper species did not provide the epoxide opening products. 
Firstly, in all cases a number of new compounds were observable via TLC, but could not be 
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identified clearly via NMR or GC-MS. Secondly, only traces of the corresponding reactants 
could be reisolated. Lastly, a satisfactory mass balance was also not achieved. Introducing a 
further methylene-spacer did not lead to the desired effect neither for the lithium- or the  
copper-based strategy. 
3.4.2.3. Manipulation of Coordinating Effects 
Besides changing the nature of utilized nucleophile and starting material, the coordination 
properties can also play an important role. For mimicking the diether motif of Tomioka more 
closely, we first tried to convert the free hydroxyl group into a methyl ether.[65]  
But astonishingly, neither utilizing a BF3•Et2O or an acetic acid-based protocol lead to the 
methoxy derivative of 20a (Scheme 23).[79] 
 
Scheme 23: Introduction of a methyl ether. 
During the synthesis of monoesters 20a and 21a we also observed the formation of the 
corresponding diesters. In contrast to an ether, an ester moiety has two oxygen atoms, which 
can help to coordinate a cation. Based on these two facts, we decided to synthesize the acetoxy-
protected derivatives 35 and 36 as starting materials for the ring opening reaction.  
After a DMAP-catalyzed acylation the double bond was epoxidized with mCPBA.[2a, 62a, 70b] 
Finally, epoxides 35 and 36 were isolated with a total yield of up to 79% (Table 11).  
Table 11: Synthesis of acetoxy analogs 35 and 36. 
 
Educt Ester t 
[h] 
Yield 
[%] 
Epoxide mCPBA 
[equiv] 
t 
[h] 
Yield 
[%] 
20a 33 
 
31(a) 91 35 
 
1.1 7 87 
21a 34 
 
25(b) 76 36 
 
1.2 7.5 89 
(a): 1.0 equiv Ac2O and DiPEA were added after 5.5 h; (b): 1.0 equiv Ac2O and DiPEA were added after 6 h. 
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Only 1.1 equivalents of the lithium organyl were utilized in the ring opening reactions starting 
from epoxides 35 and 36 in contrast to their hydroxyl derivatives (Scheme 24). Besides the 
omission of the acidic hydroxyl group, reduction of phenyllithium should also minimize  
side-product formation. 
 
Scheme 24: Epoxide opening reaction starting form acetoxy derivatives 35 and 36. 
But, contrary to the assumption, carrying out the reaction with even smaller amounts of the 
lithium species, up to six different fractions were separated via column chromatography.  
Either for the trans- or the cis-analog, epoxide opening or elimination product could be 
identified by NMR- or MS-analysis. Due to this observation we assume protecting the hydroxyl 
group as acyl ester seems to prohibit even deprotonation in the α-position of the epoxide. 
Furthermore, a second carbonyl species and an α-methyl group were incorporated into the 
molecule as potential additional reaction centers. Nevertheless, regarding the final step of the 
multicatalytic sequence we stopped further investigations based on metal-containing 
nucleophiles at this point. Especially, the huge tendency for side reactions, an unpredictable 
chemoselectivity, and imbalanced mass proportion are disadvantages, which have to be 
considered. 
3.4.2.4. Thiols 
Based on the previous results we replaced the copper reagent by a thiol, which should also act 
as soft nucleophile, but with a less basic character (pKa: 11.1
[80]). Epoxide opening reactions 
with sulfur species are widely spread in literature.[81] For example, a combination of thiol and 
base provides the basis for the ring opening protocols described by Lattanzi and Luly.[82]  
Our first experiments with epoxides 24 and 25 were performed utilizing the conditions of  
Luly et al. with a combination of tert-butyl thiol and TEA (Table 12).[82a] Before adding the 
epoxide, tBuSH and TEA were stirred for ten minutes at room temperature (r.t.). 
In case of 3-pentenoic acid analogs 24a and 25a, the potential ring-opened compound was not 
observed, but up to 57% of the elimination products 31 and 32 were isolated. This fact indicates 
that either TEA (pKa: 10.7) or in situ formed tert-butyl thiolate removed one of the  
α-protons, thus forming the α,β-unsaturated products. Starting from 4-pentenoic acid 
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derivatives 24b and 25b also did not provide one of the thioethers, but up to 18% of  
epoxy methyl ester 37 (Figure 14). 
Table 12: Thiolate-mediated epoxide opening. 
 
Starting materials(a) Product Yield [%] 
24a 
 
31 
 
57 
25a 
 
32 
 
48 
(a): Results for 24b and 25b are not included, because they did not lead to any of the expected products. 
Furthermore, in all four reactions the corresponding diols 2 and 3 were identified as side 
products. Based on these observations, we assume that due to the presence of a protic as well 
as nucleophilic solvent a transesterification to the corresponding epoxy methyl ester and diol 
takes place. 
 
Figure 14: Epoxy methyl ester 37. 
3.4.3. Substitution of the Third Step of the Multicatalytic Sequence 
However, even if the desired thioether is not formed, the latter reaction conditions showed a 
minimized tendency for side product formation in contrast to the organometallic-based ring 
opening approaches and resulted in an even higher yield of the elimination products.  
These facts are necessary regarding a multicatalytic procedure. Therefore, considering a 
modified sequence we focused on the optimization of the elimination generating  
α,β-unsaturated γ-hydroxyl ketones 31 and 32, which formed under basic conditions. 
For the first test experiment we substituted methanol by chloroform, due to its comparable 
boiling point. Further reaction parameters were kept constant and were varied afterwards one 
by one (Table 13). 
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Table 13: Base-mediated ring opening. 
 
Starting materials(a) Base T t [h] Product Yield [%] 
24a 
 
Imidazole Reflux 2 31 
 
0 
24a 
 
TEA Reflux 2 31 
 
37 
24a 
 
TEA r.t. 2 31 
 
0 
24a 
 
DBU Reflux 2 31 
 
71 
24a 
 
DBU r.t. 2 31 
 
52 
24a 
 
DBU r.t. 1 31 
 
85 
25a 
 
DBU r.t. 1 32 
 
89 
 
Even at higher temperatures, less basic compounds like imidazole (pKa: 7.0) and TEA lead to 
lower isolated yields. The best results both for trans- as well as cis-derivative 24a and 25a were 
achieved with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (pKa: 12.0) as base. Stirring for one 
hour at room temperature resulted in up to 89% of the elimination product. Besides the 
corresponding diol as result of ester hydrolysis, no further side products were observed.  
Longer reaction times seem to favor the consumption of the target molecule in this subsequent 
step. Therefore, stirring a reaction mixture consisting of a 1:1 ratio of epoxide and DBU in 
chloroform for one hour at room temperature should be the standard conditions for further 
investigations. 
3.4.4. Summary and Outlook  
The previous results and especially the problems with a potential epoxide opening reaction 
suggested a necessary modification of the underlying multicatalytic sequence (Figure 10). 
Moreover, due to an overall yield of 42% for 31 and 32, a minimal tendency for side reactions, 
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and a more practicable reaction control the acylation-epoxidation-elimination route is more 
promising. 
First of all, an one-pot approach starting from diol and unsaturated acid should be tested. 
Therefore, the established individual protocols can be combined directly (Scheme 25).  
Re-optimization concerning, e.g., a consistent solvent or the amount of base for the elimination 
might be necessary. In additions, more acids can be included in these investigations. 
 
Scheme 25: One-pot acylation-epoxidation-elimination sequence. 
Based on the formation of diols 2 and 3 as well as methyl ester 37 (Figure 14) using the  
thiol-based strategy, a hydrolysis/transesterification procedure should be established 
simultaneously utilizing either water or methanol as nucleophile under basic conditions. This 
final step of a four-step sequence would provide free as well as methyl-protected  
α,β-unsaturated γ-hydroxyl carboxylic acids (Scheme 26). These compounds are, for example, 
metabolites of biologically active molecules or could be used as starting materials for 
lactones.[83] Afterwards, this protocol should also be incorporated into the one-pot approach 
leading to a four-step sequence: acylation-epoxidation-elimination-hydrolysis/trans-
esterification. 
 
Scheme 26: Envisaged hydrolysis/transesterification step. 
However, even in case of a stereoselective variant, before release of the acid derivative further 
transformations are possible. Hereof, each intermediate might be a potential starting point for 
an additional functionalization (Scheme 27). 
Starting directly from the epoxide zinc[84] as well as magnesium organyls[85] might be utilized 
as alternatives to their lithium or copper analogs with regard to a higher chemoselectivity 
(Chapter 3.4.2.2.). These types of nucleophilic carbon species have already been used in 
epoxide opening reactions, but due to the aforementioned problems these approaches are less 
promising. 
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Instead of carbon nucleophiles halogens also induce ring-opening reactions. In 2006, Wu et al. 
established an thiophenol-promoted epoxide opening with elemental iodine.[86] Four years later, 
Ducho et al. published a similar reaction with sodium bromide in the presence of  
Amberlyst® 15.[87] Installing these functional groups in the molecule enables further 
transformations such as carbon-carbon bond formation or substitution reactions. 
 
Scheme 27: Further potential functionalization approaches. 
Performing either the epoxidation in a stereoselective fashion or the following elimination with 
a feasible chiral base could provide enantiomerically enriched α,β-unsaturated γ-hydroxyl 
esters. Referring to crotonic acid derivatives 17 and 18, these Michael systems might also react 
in an 1,4-addition. Results of Sakai and of the first experiments (Chapter 3.4.1.) showed the 
potential of this concept, whereas re-optimization and further investigations are necessary.[69] 
Substitution of the allylic hydroxyl group by a bromide, chloride, amine or azide group 
represents a further attractive opportunity. The corresponding (pseudo)halogen derivatives 
would enable a variety of consecutive reactions like, e.g., carbon-carbon bond formation or 
reduction. Introducing, for example, an amine would lead to the synthesis of unsaturated  
γ-amino acids.[88] 
Furthermore, configuration of the hydroxyl group can be inverted either by using the reversible 
configured epoxidation catalyst or base or via a subsequent Mitsunobu reaction. A selective 
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oxidation of the allyl alcohol would provide the corresponding unsaturated  
1,4-dicarbonyl compounds.[89] The previous steps can be performed in an achiral way, because 
the stereo-information gets lost during this reaction anyway. 
Finally, α,β-unsaturated γ-hydroxyl esters can be epoxidized under typical Weitz-Scheffer 
conditions utilizing hydrogen peroxide and sodium hydroxide.[76a] Afterwards, the instantly 
formed three-membered rings can be opened by nucleophiles. Introducing, for example, a 
hydroxyl group would lead to triol-substituted carboxylic acids. Uronic and especially 
glucuronic acid, the C6-analogs, have versatile applications in industry.
[90] In case of an amine 
moiety an access to β-amino acids with two alcohol groups in α- as well as γ-position would be 
possible.[88] 
Several of the aforementioned pathways lead to the introduction of new hydroxyl groups in the 
target molecules. After a possible ring closing reaction via transesterification between one of 
the alcohol moieties and the present ester the auxiliary is released and a lactone is formed. These 
compounds are well known as macrolactones and are intensively utilized as antibiotics.[91] 
It has to be investigated in detail if the necessity regarding a cyclohexanediol ligand is really 
given or if the particular reaction sequence can be performed either with the free acid moiety 
or in the presence of an alternative and simpler protecting group. Yet, highly functionalized and 
flexible structured carboxylic acid derivatives can be synthesized based on this strategy. 
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4. Peptide-Catalyzed Epoxidation 
Epoxidation of a carbon-carbon double bond is the second step of the modified multicatalytic 
sequence as well as of each possible variant (Chapter 3.4.4.). For a multicatalytic approach the 
early introduction of stereoselectivity favors, e.g., formation of only one diastereomer or 
potential substrate control in the subsequent steps. Therefore, identification of a feasible 
catalytic moiety, reaction conditions, and especially an enantioselective version is a further 
challenge of this thesis.  
4.1. Preparatory Work 
4.1.1. Substrate Library 
Due to the formation of diastereomers epoxidizing alkenes 24 and 25 a substrate library 
containing a variety of simpler prochiral compounds was established (Table 14). The epoxides 
were synthesized utilizing typical procedures either with mCPBA (Prileschajew 
epoxidation)[70a] or H2O2/NaOH (Weitz-Scheffer epoxidation)
[76a] (see Experimental 
Section).[76b, 70b, 92]  
Table 14: Substrate library. 
Alkene Epoxide Alkene Epoxide Alkene Epoxide 
      
  
 
 
  
 
 
  
  
    
  
    
  
Alkenes 38, 42, 44, 46, 48, 50, 54, and 56 as well as epoxide 45 are commercially available. 
After purification the epoxides were obtained with a yield of up to 89%. The created substrate 
library includes cyclic and linear compounds, conjugated and isolated double bonds as well as 
electron-rich and electron-deficient alkenes. Moreover, due to the presence of aromatic and 
aliphatic substituents as well as hydrogen bonding acceptors and donors π-π-contacts, 
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dispersion, and hydrogen bonding are later on possible interactions between substrate and 
catalyst.  
We also want to include nitrogen-containing molecules in further investigations. We chose  
α,β-unsaturated alkenes 64, 66, 68, and 70 as further candidates (Table 15). 
Table 15: Unsuccessful epoxidation of nitrogen-containing substrates. 
Alkene Epoxide Alkene Epoxide 
    
    
Alkenes 64, 68, and 70 are commercially available. 
Epoxidation reactions both with sodium hydroxide and hydrogen peroxide as well as mCPBA 
were performed, but none of the desired epoxides was obtained. In literature significantly less 
examples for epoxidation of nitrogen-substituted alkenes can be found compared with their 
nitrogen-free analogs. Whereby, Michael systems seem even harder to be epoxidized in contrast 
to electron-rich systems.[93] We assume that the increased mesomeric delocalization and the 
further reduced electron density, respectively, is responsible for lower reactivity  
(Scheme 28). Therefore, we refrain from incorporating this class of substrates into the existing 
substrate library. 
 
Scheme 28: Comparison of delocalization situations. 
4.1.2. Synthesis of Alkenes 
Since not all of the alkenes are commercially available, the corresponding epoxy precursors had 
to be synthesized previously. Thus, cyclohexyl derivative 40 is accessible via a two-step 
synthesis analogue to its phenyl derivative.[94, 85] After Grignard reaction of cyclohexanone and 
cyclohexyl bromide water is eliminated from alcohol 72 in the presence of sulfuric acid 
(Scheme 29). Alkene 40 was obtained with an overall yield of 14%. 
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Scheme 29: Synthesis of alkene 40. 
Miller et al. utilized carbamate 52a as test substrate in an enantioselective epoxidation with 
peracid-bearing peptide catalysts (Scheme 14). They postulated advantageous hydrogen 
bonding between peptide backbone and the urethane moiety.[33b] Therefore, we used their 
established protocol to synthesize alkene 52a for our library. After reduction of methyl ester 73 
with diisobutylaluminium hydride (DiBAL), the generated allyl alcohol 74 reacted with  
benzyl (Bn) isocyanate to yield carbamate 52a in an overall yield of 83% (Scheme 30).[33a] 
 
Scheme 30: Synthesis of carbamate 52a. 
Benzyl-substituted cyclohexenone 58 was synthesized using the protocol of List and  
co-workers.[95] 3-Ethoxy-2-cyclohexen-1-one reacts with benzylmagnesium bromide providing 
62% of the α,β-unsaturated compound (Scheme 31). The challenging separation of formed 
benzyl alcohol might be simplified by reducing the amount of Grignard species.  
 
Scheme 31: Synthesis of Michael system 58. 
Analogue to alkene 30 (Scheme 20) we also synthesized an even more electron-deficient 
derivative via introducing a nitro group in para-position of the phenyl ring. After aldol 
condensation of para-nitrobenzaldehyde and acetone, substrate 62 was obtained with a yield of 
93% after 48 hours (Scheme 32).[76c] 
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Scheme 32: Synthesis of α,β-unsaturated alkene 62. 
(a): TFA salt 29: morpholine (1.0 equiv), TFA (1.1 equiv), Et2O, 0 °C, 1 h, 94%. 
Simultaneously to the epoxidation of alkene 64 containing a free amine group we protected this 
functional group to avoid its possible interference in the subsequent epoxidation step. For 
protection we selected a carboxybenzyl (Cbz) group. Therefore, amine 64 reacts with  
Cbz chloride in the presence of sodium carbonate as base.[96] After purification the  
Cbz-protected analog was isolated with a yield of 31% (Scheme 33). 
 
Scheme 33: Synthesis of Cbz-protected Michael system 66. 
4.2. Digression I: Access to α-Hydroxyl-Carbonates 
Epoxidizing carbamate 52a with mCPBA obviously yielded to epoxide 53a, but also to an 
unknown side product. After isolation and purification latter compound was examined via 
NMR, infrared (IR), and MS techniques all pointing at carbonate 75 (Scheme 34). The 
formation of carbonates appearing during the mCPBA-mediated epoxidation of (homo)allylic 
alcohols was investigated by Kocovsky et al. in 1990.[97] 
 
Scheme 34: Observation of spiro-carbonate 75. 
As mentioned in literature, especially IR and 13C-NMR analysis are suitable tools showing 
characteristic signals for carbonate species.[98] Therefore, comparing our obtained results with 
data reported in literature showed a good agreement (Table 16). Moreover, a crystal structure 
of carbonate 75 underpinned the additionally formed by-product (see Experimental Section). 
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Table 16: Comparison of IR- and NMR-data. 
 IR (C=O) 13C-NMR (C=O) 
Literature 1800 ± 20 cm−1 152.5 ± 4.5 ppm 
Experiment 1777 cm−1 154.9 ppm 
 
Organic carbonates (OC) like 75 are substituted carbonic acid derivatives appearing in a large 
number of natural products[99, 98] and as intermediates in total syntheses.[100] Based on the 
substituents on the oxygen atoms OCs can be divided in different classes (e.g., hemi-carbonic 
acids and carbonates as well as inorganic and organic, saturated and unsaturated, aliphatic and 
aromatic, linear and cyclic carbonates).[101] Due to their beneficial properties (e.g., high 
stability, high boiling point, high flash point, low toxicity),[102, 98] (cyclic) carbonates are widely 
applied,[101, 103, 102] e.g., as solvents,[104] protecting groups,[103] and synthons for typical organic 
reactions.[103, 102] Besides fixation of carbon dioxide,[105] oxidative carbonylation,[106] and 
carbonate interchange reactions as well as carbonyl building blocks like phosgene or its 
derivatives, metal carbonates, and urea[107] are literature-described strategies for the syntheses 
of OCs.[101, 98] Over the last couple of years organocatalytic approaches were also developed. 
Plasseraud et al. published the carbonate interchange reaction between glycerol and dimethyl 
carbonate utilizing a zwitterion catalyst in 2009.[108] More recently, Lu et al. introduced a 
carboxylative cyclization of propargylic alcohols catalyzed by a N-heterocyclic olefin 
(NHO).[109] 
The aforementioned procedures typically require either high pressure, high temperature or toxic 
starting materials or catalysts. In 1983, Roush et al. published a milder and alternative carbonate 
formation procedure using Lewis acid boron trifluoride diethyl etherate in anhydrous (anhyd.) 
diethyl ether (Scheme 35).[110] Afterwards, Roush’s protocol[100a, 100c] as well as the 
unaccompanied carbamate strategy[111] are common in organic synthesis. 
 
Scheme 35: Carbonate formation reported by Roush. 
Phenyl carbamate substituted allyl epoxides were utilized as starting materials. The significance 
of the neighboring-group effect of this substituent was emphasized by testing various reaction 
conditions and considering molecular models.[110] During their investigations Roush et al. 
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showed that not only Lewis acid BF3•Et2O, but also weak Brønsted acids like acetic acid are 
able to generate OCs.[110] Therefore, we assume that during epoxidation of alkene 52a in situ 
generated meta-chlorobenzoic acid (mCBA) is responsible for the carbonate formation.  
Independently from the mechanism, a strong carbon-nitrogen bond must be cleaved during the 
formation of 75. By substitution of the benzyl group we hope to favor the cyclization to 
carbonate 75. Therefore, further carbamates with both aromatic as well as aliphatic isocyanates 
were synthesized with a yield of up to 71% using the protocol of Miller (Table 17).[33b] Due to 
a conjugated system in case of isocyanate 76b its carbamate 52b was isolated with a yield of 
only 52%. The amount of isolated alkenes 52c-e decreased form ethyl to tert-butyl caused by 
an increased steric hindrance. Adamantyl (Ad) analog 52f was only observed in the NMR 
spectrum of the crude product in traces, but could not be isolated. 
Table 17: Syntheses of carbamates 52a-f. 
 
Compound R Yield of 52 [%] 
a Bn 83 
b Ph 52 
c Et 71 
d iPr 64 
e tBu 14(b) 
f Ad traces(a), (b) 
(a): Remaining starting material reisolated; (b): observed via NMR. 
Testing carbamates 52a-e afterwards in the epoxidation-cyclization sequence, product 75 was 
isolated with a yield of up to 82% (Table 18). In contrast to the synthesis of the epoxide 53a, 
1.6 equivalents of the oxidizer were used for those experiments, because a larger amount of 
present acid should favor the formation of the spiro compound. Furthermore, after detecting 
full conversion to the epoxide via TLC, thiourea catalyst (TUC) 775 was added to activate either 
the carbonyl oxygen or the epoxide for the cyclization step.[74c, 75] Taking the first observation 
of carbonate 75 into account the reaction was stirred for further 48 hours (Scheme 34). 
                                                 
5 Catalyst was synthesized by Dr. Katharina M. Lippert. 
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Table 18: Identification of the most feasible leaving group. 
 
Compound R Yield of 75 [%] 
a Bn 75 
b Ph 59 
c Et 82 
d iPr 82 
e tBu 78 
 
Analogue to its synthesis, phenyl derivative 52b is less reactive due to mesomeric stabilization. 
In case of primary, secondary, and tertiary alkyl species the results are comparable indicating 
minor importance of the generated amine. Ethyl and iso-propyl precursors showed the best 
results. But, we prefer the ethyl derivative for several reasons. Ethyl isocyanate 76c is less toxic 
compared to its phenyl, iso-propyl, and tert-butyl analogs. Furthermore, carbamate 52c was 
synthesized with a preparative yield of 71% (Table 17). Moreover, generated ethyl amine is a 
gas shifting the equilibrium to the product side and simplifying the purification. 
In our optimization experiments starting from carbamate 52c besides thiourea 77 acidic 
additives nitrilotri(methylphosphonic acid) 78 and pNBA were included to cover a broader  
pKa-range. Furthermore, variation of solvent, dilution, reaction time of the epoxidation step, 
and amount of mCBPA were also tested (Table 19). 
The best result was achieved performing the first step with 1.6 equivalents mCPBA for 24 hours 
in DCM and the second step with only 5 mol% of catalyst 77 (Table 19, Entry 18). Removing 
in situ formed mCBA is one of the major challenges. A two-step purification procedure 
containing solvent evaporation and column chromatography on silica gel with diethyl ether and 
0.5% TEA provides 75 with a comparable yield. An increased isolated yield of 11% can be 
observed utilizing both mCPBA/mCBA and 77 (Table 19, Entries 18 and 20). Weil et al. already 
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described a cooperative effect between Brønsted and Lewis acids enabling the accelerated 
formation of the desired product.[74c] Zhang et al. investigated this kind of catalysis more 
detailed using NMR techniques and computational studies.[74c, 75] Both aspects lead to the 
assumption that a similar effect is responsible for the preferred formation of 75 utilizing a 
combination of in situ generated mCBA and catalytic amounts of 77. 
Table 19: Optimization procedure. 
 
Entry Solvent mCPBA 
[equiv] 
t1 
[h] 
Additive Additive 
[equiv] 
Yield of 75 
[%] 
1 DCM 1.1 1 - - 62 
2 DCM 1.1 1 77 0.5 71 
3 DCM 1.1 1 78  0.3 48 
4 DCM 1.1 1 pNBA  1.0 54 
5(a) DCM 1.1 1 - - 45 
6(a) DCM 1.1 1 77 0.5 56 
7(a) DCM 1.1 1 78 0.3 51 
8(a) DCM 1.1 1 pNBA 1.0 58 
9(a) DCM 1.1 8 77 0.5 69 
10(a) DCM 1.1 14 77 0.5 58 
11(a) DCM 1.1 24 77 0.5 69 
12(a) DCM/PhCH3 1.1 8.5 77 0.5 67 
13(a) DCM/CHCl3 1.1 8.5 77 0.5 60 
14(a) DCM/tAmylOH 1.1 8.5 77 0.5 57 
15 DCM 1.6 24 77 0.5 73 
16 DCM 1.6 24 77 0.25 74 
17 DCM 1.6 24 77  0.1 75 
18 DCM 1.6 24 77 0.05 78 
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19 DCM 1.6 24 77 0.01 57 
20 DCM 1.6 24 - - 67 
(a): Epoxidation was performed with a conc. of 1.0 mol L−1 and reaction mixture was diluted after t1. 
To gain a deeper insight into the mechanism of the cyclization, we performed a labeling 
experiment. Therefore, epoxide 52a reacts in the presence of mCBA and H2
18O under otherwise 
standard conditions for the second step to labeled carbonate 75-18O. Afterwards, comparison of 
the IR-spectra of 75 (1792 cm−1) and 75-18O (1766 cm−1) showed unequivocally that the  
18O-atom is located at the carbonyl group (Figure 15). 
 
 
 
 
 
Figure 15: Comparison of the IR-spectra of 75 and 75-18O. 
 
 
 
 
In 2012, Jirgensons et al. published the Lewis acid-catalyzed synthesis of  
N-tosyliminocarbonates starting from allylic trichloroacetimidates. From the educt to the 
desired product they postulated the existence of an ammonium species either by SN1- or  
SN2´-mechanism.
[111b] Combining their considerations and our results from IR-analysis, we 
assume that the in situ formed iminium salt 79 is hydrolyzed by water, which is present form 
the utilized mCPBA providing spiro compound 75 (Scheme 36). 
 
Scheme 36: Postulated mechanism for carbonate formation. 
In the synthesis of bis-spiro tetronate Roush et al. used their protocol to introduce an aldehyde 
and a hydroxyl group in cyclohexene 80 at the same carbon atom (Scheme 37).[100c]  
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This reaction sequence shows a potential application for this type of reaction even for the 
synthesis of more complex compounds. 
 
Scheme 37: Synthesis of geminal hydroxyl aldehyde 80. 
Our established protocol provides an access to a spiro center, a carbonate, and a hydroxyl group 
in one molecule. But before searching for an application, especially the function of thiourea 77 
and its interaction with the Brønsted acid has to be studied more intensively. Furthermore, the 
limitations of this approach have to be identified via extension of the substrate scope  
(Table 20). 
Table 20: Potential substrates. 
Carbamate 
    
Carbonate 
 
   
 
Substitution of the isocyanate by its sulfur analog would furthermore provide an access to 
thiocarbonates. Utilizing an asymmetric epoxidation protocol leading to enantiomerically 
enriched intermediates in combination with the thiourea-based cyclization results in also 
enantiomerically enriched spiro compounds. Like Kocovsky, Miller, and Roush showed, the 
carbamate moiety plays a key role in the epoxidation of this two-step sequence.[110, 97, 33a]  
All the latter aspects illustrate the relevance of this approach. 
4.3. Peracid-Based Catalysts 
One typical procedure for the epoxidation of electron-rich alkenes based on peracids like 
mCPBA. In 1909, Prileschajew mentioned the oxidative ability of peracids for the first time.[70a] 
We already used this procedure for the syntheses of oxiranes 39-53a (Chapter 4.1.1.). Later on 
catalytic amounts of the necessary acid precursor in combination with in situ generation of the 
active peracid were intensively examined. For example, Miller and Schreiner utilized this 
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concept and introduced peptide-based acid catalysts, which are transferred into the reactive 
peracid species and regenerated after the epoxidation of the carbon-carbon double  
bond.[33, 31, 3b] 
4.3.1. Mechanism 
In 2007, Miller et al. published a possible catalytic cycle for the in situ generation of a  
peracid-containing peptide catalyst. They showed that a carbodiimide as activating and water-
removing agent and DMAP as N-oxide equivalent and nucleophilic catalyst are necessary for 
the oxidation of the carboxylic acid (Scheme 38).[33a, 31]  
 
Scheme 38: Epoxidation via in situ generated monoacid peptide catalyst. 
Reaction of the carboxylic acid of C-terminal benzyl-protected amino acid 81 and DIC provides 
active ester 82. The latter intermediate is transferred afterwards into catalytically active peracid 
84 via nucleophilic attack of hydrogen peroxide. A possible side reaction of 84 is the  
DIC-mediated formation of aspartic peracid 85. But, the reaction mixture converts this dimer 
back into peracid 85. Miller and co-workers also showed that N-oxide 83, which is also formed 
in situ via oxidation of DMAP, accelerates the whole process. 
Instead of a monoacid Schreiner et al. utilized a diacid as catalytic moiety.[3b] Based on their 
previously performed test experiments, they concluded that an intermolecular anhydride is the 
key intermediate in their reaction cycle (Scheme 39). 
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Scheme 39: Postulated mechanism for the diacid-based epoxidation. 
Similar to Miller’s mechanism the first step is the formation of an active ester. At this stage it 
does not matter, if intermediate 87 or 87’ is generated. Due to the presence of the second acid 
moiety a cyclization to internal anhydride 88 takes place. Afterwards, the cyclic species is 
opened via hydrogen peroxide, providing peracids 89 and 89’. If both catalytically active 
compounds favor the opposite enantiomer of the epoxide, it has to be guaranteed that the 
opening step should deliver one peracid selectively. Furthermore, activation of the remaining 
carboxylic acid could lead to intramolecular peracid 90, analogue to compound 85  
(Scheme 38). Via ring opening with hydrogen peroxide, diperacid 91 could be generated.  
Both the selective generation of peracids 89 and 89’ as well as the formation of 91 complicates 
the establishment of an asymmetric version based on this concept. 
In 2015, Schrader et al. examined this mechanism in more detail using MS techniques.  
They identified in situ formed peptide species and followed the reaction progress of the 
epoxidation. But firstly, they started from homoaspartic acid as precursor so both possible 
peracids are identical. Secondly, diperacid 91 was not observed during their experiments.[36] 
After formation of the peracid, the oxygen atom is transferred onto the carbon-carbon double 
bond in a concerted way.[112] Simultaneously, the peracid is reduced to the corresponding 
carboxylic acid, which can enter the catalytic cycle again. For the generation of the oxirane two 
different TSs are under discussion (Figure 16). The TSs 92 and 93 differ in orientation and 
55 
 
angle between alkene and peracid. Several theoretical and computational approaches were 
performed, but lead to partly opposed results.[113] The butterfly-like spiro structure 93 is the 
most accepted and commonly depicted TS.[114, 113a] One exception was published by  
Oshima et al. in 2012 examining the epoxidation of a highly crowded fulleroid system. Based 
on a slightly twisted double bond the spiro TS is inhibited.[112] In 2006, Luthman and  
co-workers investigated the influence of different alkene substituents on the stereoselective 
outcome. They observed a huge directing effect of those residues. They also showed that via 
changing the active species the reaction outcome can be inverted.[115] Both examples also 
illustrate a substrate as well as reagent dependence. 
 
Figure 16: TSs for the peracid-based epoxidation. 
4.3.2. Proof of Principle 
For proofing the concept phenylcyclohexene 38 was epoxidized both with a monoacid- as well 
as a diacid test catalyst. Under chosen reaction conditions based on Miller et al. and Schreiner 
et al. aspartic acid 95 is nearly twice as active as phenylalanine (Phe) 94 (Scheme 40).[33a, 3b] 
These observation indicate that either two carboxylic moieties react faster than one or the  
in situ generation of an intramolecular anhydride accelerates the whole reaction process.  
The formation of an activated species was also proofed. In both control experiments without 
DIC as activating agent no reaction took place. 
 
Scheme 40: Proofing the concept with a mono- as well as a diacid catalyst. 
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4.3.3. Peptide Catalysts 
Taking even the latter results into account mono- as well as diacid-containing peptide catalysts 
were synthesized. Furthermore, proline and adamantyl glycine were used as structure-giving 
elements like in the well working systems of Miller and Scheiner.[33, 31, 3b] The synthesis of 
tripeptide 96 is exemplarily depicted in scheme 41. 
 
Scheme 41: Exemplary synthesis of a peptide catalyst. 
Peptide coupling was performed in solution and with 1-hydroxybenzotriazole (HOBt) and 
EDAC as coupling reagents.[68, 3a] The Boc protecting group was removed by hydrogen chloride 
in dioxane.[116, 3a] The benzyl ester was cleaved under reductive conditions in  
tert-butanol.[116, 3a] Methanol was not used as solvent because transesterification was observed 
in previously performed experiments. Finally, tripeptide 96 was isolated with a total yield of 
70% after four steps. 
Utilizing analogue conditions three additional peptides were synthesized (Figure 17).  
The aspartic acid moiety at the C-terminus of peptide 101 was protected as dimethyl ester.  
Both protecting groups were removed simultaneously with a sodium hydroxide/  
N,N-dimethylformamide (DMF) protocol.[117] In the end all peptides were isolated in 
preparative amounts after up to 8 steps. 
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Figure 17: Peptide catalysts 100, 101, and 102. 
4.3.4. Optimization of Reaction Conditions 
For a better comparison all four catalysts were tested utilizing slightly modified reaction 
conditions of Miller.[33a] Therefore, in the presence of DIC, DMAP, and H2O2 cinnamic alcohol 
50 was transferred into its epoxide 51 mediated by a mono- or diacid-containing peptide.  
A reduced amount of 5 mol% catalyst and chloroform instead of dichloromethane (DCM) was 
used (Scheme 42). 
 
Scheme 42: Comparison experiment. 
Comparing the results for 96, 101, and 102 a preference for diacid peptide catalysts was not 
observable. Tetrapeptide 100 showed the lowest conversion after 24 hours. Obviously, based 
on those first ambiguous results further investigations of the reaction conditions were carried 
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out. Therefore, the different parameters, e.g., temperature, catalyst loading, and solvent, were 
varied stepwise. Tripeptide 96 and cinnamic alcohol 50 were chosen as test system. Due to its 
better solubility in organic solvents without additives compared to EDAC and its simpler dosing 
compared to DCC we selected DIC as carbodiimide (Table 21). 
Table 21: Optimization of peracid-based epoxidation. 
 
Entry(a) 96 
[mol%] 
Solvent Oxidizer 
[equiv] 
DIC 
[equiv] 
DMAP 
[mol%] 
T 
[° C] 
t 
[h] 
Yield(d) 
[%] 
1 0 DCM H2O2 (4.0) 1.2 0 r.t. 48 0 
2 2.5 DCM H2O2 (4.0) 1.2 0 r.t. 48 55 
3 5.0 DCM H2O2 (4.0) 1.2 0 r.t. 24 80 
4 10 DCM H2O2 (4.0) 1.2 0 r.t. 24 66 
5 20 DCM H2O2 (4.0) 1.2 0 r.t. 24 36 
6 5.0 DCM H2O2 (4.0) 1.2 10 r.t. 24 61 
7 5.0 PhCH3 H2O2 (4.0) 1.2 0 r.t. 24 67 
8 5.0 CHCl3 H2O2 (4.0) 1.2 0 r.t. 24 80 
9 5.0 CHCl3 H2O2 (2 x 2.0)
(b) 1.2 0 r.t. 24 65 
10 5.0 CHCl3 UHP (4.0) 1.2 0 r.t. 24 13 
11(c) 5.0 CHCl3 H2O2 (2.5) 2.0 10 r.t. 24 81 
12 5.0 CHCl3 H2O2 (2 x 2.0)
(b) 1.2 0 0 24 16 
13(c) 5.0 CHCl3 H2O2 (2.5) 2.0 10 0 24 37 
(a): 0.25 mmol alkene and 2 mL solvent were used; (b): second addition of H2O2 (2.0 equiv) after one hour;  
(c): reaction conditions based on Miller et al.; (d): yield determined via chiral GC without internal standard. 
Varying the catalyst loading showed a maximum yield of epoxide 51 with 5 mol% of tripeptide 
96 (Table 21, Entry 3). As expected, without catalyst no reaction took place (Table 21,  
Entry 1) proofing the necessity for the presence of a carboxylic acid species. For enabling better 
substrate-catalyst interactions and resulting enantiomeric excess toluene was chosen as 
solvent,[2c] which did also not show the expected effect (Table 21, Entry 7).  
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Whereas, chloroform and DCM led to the same results (Table 21, Entries 3 and 8). More polar 
solvents like THF, 1,4-dioxane ant tert-amyl alcohol were also tested, but only traces of the 
product could be detected (not included in Table 21). Regarding the oxidizing agent  
a portionwise addition provided epoxide 51 with a minimal reduced yield (Table 21, Entry 9). 
Whereby, due to its decreased activity urea hydrogen peroxide (UHP) can be neglected as 
oxidizer (Table 21, Entry 10). A decelerated reaction process was also observed lowering the 
temperature. Utilizing the conditions of Miller provide the target compound with a higher yield, 
although the results cannot be compared directly because three parameters differ in these 
experiments (Table 21, Entries 9 and 11-13). We assume that, especially the increased amount 
of DIC is coursing this effect, because we were not able to observe the described DMAP 
dependence utilizing our conditions (Table 21, Entries 3 and 6). Summarizing best results were 
achieved performing the epoxidation with 5 mol% catalyst in either chloroform or DCM 
mediated via 1.2 equivalents DIC and 4.0 equivalents hydrogen peroxide (Table 21, Entries 3 
and 8). 
4.3.5. Substrate Scope 
Even knowing that addition of hydrogen peroxide in one portion (Table 21, Entries 8 and 9) 
and a larger amount of DIC (Table 21, Entries 11 and 13) are favorable for the epoxide 
formation we selected the conditions mentioned in entry 9 for all further experiments. 
Regarding the introduction of a stereoinformation we thought slowing down the reaction rate 
minimally via adding the unstable oxidizer portionwise and reducing the amount of reagents 
present in the reaction mixture are beneficial factors. Hereafter, peptides 96 and 100-102 were 
tested in combination with alkenes 38, 40, 44, and 56 to gain a deeper insight into the  
catalyst-substrate relationship (Table 22). 
As expected for all catalysts completely conjugated alkene 44 (Table 22, Entries 3, 8, 13, and 
18) as well as electron-deficient alkene 56 (Table 22, Entries 5, 10, 15, and 20) showed nearly 
no reactivity. Only catalyst 96 epoxidized cinnamic alcohol 50 with a preparative yield of 77% 
(Table 22, Entry 4), while all further catalyst showed a clearly lower reactivity (Table 22, 
Entries 9, 14, and 19). In contrast substrates 38 (Table 22, Entries 1, 6, 11, and 16) and 40 
(Table 22, Entries 2, 7, 12, and 17) were converted into the corresponding epoxides with good 
to excellent yields. A real catalyst-dependent tendency for the preference of aromatic or 
aliphatic starting materials is not observable. Compared with the proof of principle experiments 
diacid catalysts did not show an accelerated epoxidation compared to the monoacid peptides 
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(Scheme 40). Catalyst 102 containing proline as structure-forming element showed a faster 
formation of the target oxirane compared to its adamantyl analog 101 maybe coursed by the 
lower positive inductive (+I) effect or the smaller steric hindrance (Table 22, Entries 11-12 and 
16-17). But, none of the tested acid-based catalysts led to an enantiomeric excess for one of the 
used alkenes. 
Table 22: Substrate scope for the peracid-mediated epoxidation. 
 
 
Entry(a) Cat. Alkene Epoxide t [h] Yield(d) [%] 
1 96 
  
72 97 
2 96 
  
72 14 
3 96 
 
 
72 6 
4 96 
  
72 77 
5 96 
  
72 0 
6 100 38 39 24 48 
7 100 40 41 24 quant. 
8 100 44 45 48 11 
9 100 50 51 48 0 
10 100 56 57 48 0 
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11 101 38 39 72 24 
12 101 40 41 72 63 
13 101 44 45 72 1 
14 101 50 51 72 33 
15 101 56 57 72 0 
16 102 38 39 24 36 
17 102 40 41 24 68 
18 102 44 45 24 1 
19 102 50 51 24 5 
20 102 56 57 24 0 
(a): 0.25 mmol alkene and 2 mL solvent were used, the second addition was carried out after one hour; (b): yield 
determined via chiral GC without internal standard. 
Comparing the results for alkene 50 based on our (Table 22, Entries 4, 9, 14, and 19) and 
Miller’s conditions (Table 21, Entry 11) showed an obvious preference for the latter ones.  
For all catalysts higher yields were achieved in a shortened reaction time of only 24 hours. 
Therefore, our underlying idea was wrong and for all further experiments Miller’s conditions 
should be used. 
4.3.6. Summary and Outlook 
We synthesized four carboxylic acid peptides containing either mono- or diacids as precursors. 
Afterwards, those catalysts were tested in epoxidation reactions of several alkenes utilizing our 
reaction conditions. Electron-rich but unconjugated compounds are the preferred substrates. 
Even if good to excellent results were achieved very long reaction times were required. 
In future experiments additional starting materials from the substrate library should be included. 
For shortening the reaction time DIC and hydrogen peroxide should be added continuously, for 
example, via syringe pump. Besides further educts and a varied adding procedure, further 
catalyst-related aspects should be taken into consideration (Figure 18). Due to the advantageous 
effect of proline this amino acid should be used as structure-forming element. For shortening 
the distance between peptide backbone and reactive center phthalic acid or 1,2-diamines might 
be used as key building blocks. In this regard C2-symmetric systems are accessible.  
Moreover, these molecules can also help to circumvent the problem of peracid formation.  
After opening of the in situ generated intramolecular anhydride both possible active forms are 
identical. Therefore, based on the aforementioned results in combination with this outlook 
regarding a peracid-catalyzed epoxidation a variety of possible changes are still conceivable. 
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Figure 18: Additional carboxylic acid containing peptide catalysts. 
4.4. Dioxirane-Based Catalysts 
Besides peracids dioxiranes are also widely used to epoxidize electron-rich alkenes.  
The reactive intermediate is normally also formed in situ starting form a carbonyl precursor and 
an oxidizing agent like Oxone®. Considering the carbonyl compound both catalytic as well as 
stoichiometric protocols are described in literature.[118, 43a] The most widely spread 
stoichiometric versions base on acetone and its derivatives.[119] Using a chiral ketone would 
enable an asymmetric epoxidation. The most famous catalytic carbonyl precursor in this regard 
was published by Shi and co-workers (Scheme 16).[54] But, of course there are a variety of 
further chiral ketone-based systems.[120a-c, 43c, 120d, 43d] 
4.4.1. Mechanism 
Due to the fact that dioxiranes are an intensively studied class of compounds both in situ 
formation of the active species as well as oxygen transfer are well examined via theoretical and 
experimental studies.[118, 121, 54, 113a, 55] In 1997, Shi et al. described the in situ formation of the 
dioxirane species based on their famous fructose-derived catalyst. In basic solution Oxone® was 
used a oxidizing agent to form the corresponding cyclic intermediate (Scheme 43).[55] 
Carbonyl precursor 103 is nucleophilically attacked by peroxomonosulfate the reactive species 
of Oxone®. Under basic conditions the formed hydroxyl group of oxidized intermediate 104 is 
deprotonated. Hereafter, generated alkoxide 105 cyclizes under release of one equivalent of 
sulfate. One of the oxygen atoms of dioxirane 106 is afterwards transferred onto the double 
bond providing the corresponding epoxide. Thereby carbonyl species 103 regenerates and is 
available for the next catalytic cycle. 
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Scheme 43: Oxone®-based epoxidation of carbon- carbon double bonds. 
This catalytic cycle helps to understand the presence of electron-withdrawing substituents like 
fluorine or trifluoromethyl next to the carbonyl group. Due to their electronic properties they 
lead to a lower electron density at the carbonyl carbon atom, which is therefore activated for 
the nucleophilic attack of the active species.[119b, 119c, 122a, 120b, 122b, 120c, 57] If there are more 
potential precursors present in a catalyst those residues help to transfer only this specific atom 
into the active species. 
After formation of the three-membered catalytically active intermediate 106 (Scheme 43) one 
of the oxygen atoms is transferred onto the alkene. Analogue to peracids a planar 107 as well 
as a spiro TS 108 are discussed (Figure 19). Both experimental and theoretical investigations 
proof the prioritization of the spiro TS 108 also for the dioxirane-mediated  
epoxidation.[113a, 123, 120c] 
 
Figure 19: TSs for the dioxirane-mediated epoxidation. 
The central quaternary carbon atom of the dioxirane is not chiral because of its two identical 
substituents (see 106 Scheme 43). For an enantiomeric version two possible strategies can be 
followed (Figure 20).[120c, 120d] Firstly, one of the substituents must be really crowded shielding 
one side of the system. Catalysts like Shi’s fructose derivative base on this approach allowing 
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the coordination of the alkene to the catalyst only from the sterically less hindered side  
(Figure 20, left).[55, 123, 120b, 124, 57] Secondly, if the catalyst possesses a C2-symmetry both 
trajectories are identical leading to the same epoxidation product (Figure 20, right).[56, 120a]  
 
Figure 20: Solution approaches for an enantioselective version. 
4.4.2. Identification of a Suitable Moiety 
Following the literature, firstly, a sterically hindered and, secondly, an electron-withdrawing 
substituent at the carbonyl group affects the stereoselective outcome as well as the reactivity of 
a potential catalyst. In our small combinatorial approach the peptide backbone should block one 
side of the generated reactive species. Automated peptide synthesis should help to identify the 
most potential amino acid sequence. However, finding a catalytic moiety is more challenging, 
because several aspects must be fulfilled. Firstly, the precursor should be commercially 
available or easily to be synthesized. Secondly, it must be attachable to the peptide backbone. 
Lastly, carbonyl as well as dioxirane species should show a high reactivity for in situ formation 
of the reactive intermediate and final oxygen transfer. We selected four possible compounds 
containing TFMKs as precursors and an amide, a bromide or a carboxylic acid as linker  
(Figure 21). 
 
Figure 21: Potential catalytic moieties. 
A successful reaction of those motives with a test coupling partner was only observed for acids 
111 and para-112[119c] (Scheme 44). We assume that for 109 and 110 due to the short distance 
between linking group and trifluoromethyl substituent with its high negative inductive 
(–I) effect a reaction with their partners was hampered. 
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Scheme 44: Syntheses of the first test catalysts 114 and 115. 
In case of 111 and 112 the amide bond formation was performed with amine 113 utilizing a 
DMAP/EDAC/TEA protocol.[2c, 68] After isolation compounds 114 and 115 were obtained with 
a yield of up to 59%. The target molecules were characterized via NMR, IR, and MS techniques. 
The structures of 115 was clearly elucidated via NMR, but a difference in mass of 32 units was 
observed using ESI techniques. By chancing the solvent from methanol to ethanol we saw a 
mass different of 46 units. Therefore, we concluded that during these analytic experiments an 
addition of the solvent to the TFMK takes place, which is responsible for the increased mass. 
In case of 114 the trifluoromethyl group is part of an amide. Therefore, due to the presence of 
different functional groups the observation was not made for the TFA derivative 114. We tried 
to proof this assumption with a NMR experiment. In a NMR tube a 1:1 mixture of compound 
115 and methanol in deuterated chloroform was prepared. The spectra measured directly and 
after two days showed only traces of the addition product indicating that this reaction 
accompanied with inactivation of the catalyst plays a negligible role under synthetic condition.  
With test systems 114 and 115 in hand, we performed the epoxidation reaction of 
phenylcyclohexene 38 using catalytic amounts of the synthesized carbonyl species (Table 23). 
As starting point we utilized modified protocols published by Cubillos as well as Shi and 
Marples.[54, 119c, 125] Oxone® was chosen as oxidizing agents and sodium bicarbonate as buffer 
system.[125] In the forefront, we identified tetrabutylammonium bromide (TBABr) (compared 
to, e.g., TBAHSO4 and BnEt3NCl) and DCM (compared to, e.g., toluene) as phase transfer 
catalyst and solvent of choice for a biphasic system. During those experiments we also observed 
that without buffer the formed epoxide is immediately opened to the corresponding diol. 
Our first results illustrated that both catalysts in combination either with mono- or biphasic 
systems are able to generate epoxide 39 in up to 96%. Due to byproduct formation with catalyst 
114 (Table 23, Entry 1) we focused on precursor 115. Furthermore, the amount of TBABr has 
to be reduced because of its own epoxidation ability (Table 23, Entry 3). Utilizing an ultrasonic 
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bath for mixing the biphasic system did not show the expected effect (Table 23, Entry 7). 
Identification of a suitable catalytically active motif was the aim of those first coupling and 
epoxidation experiments. Therefore, based on those encouraging results we could focus on the 
preparation of chiral catalysts. 
Table 23: Test catalysts 114 and 115. 
 
Entry Cat. TBABr 
[mol%] 
Reaction conditions t 
[h] 
Yield(g) 
[%] 
1(a,b) 114 40 Oxon® (2.0 equiv), NaHCO3 (5%), 
DCM 
1 30(h) 
2(a,c) 115 40 Oxon® (2.0 equiv), NaHCO3 (5%), 
DCM 
5 96 
3(a,b,c) - 40 Oxon® (2.0 equiv), NaHCO3 (5%), 
DCM 
24 45 
4(d) 115 20 Na2EDTA (0.2 mmol%); Oxon
® (5.0 
equiv), NaHCO3 (7.8 equiv), 
MeCN/H2O 
24 56 
5(d,e) 115 - Na2EDTA (0.2 mmol%); Oxon
® (5.0 
equiv), NaHCO3 (7.8 equiv), 
MeCN/H2O 
24 47 
6(b,c,e,f) 115 20 Na2EDTA (0.2 mmol%); Oxon
® (3.1 
equiv), NaHCO3 (2.0 equiv), DCM/H2O 
7 70 
7(a,b,c) 115 - Oxon® (2.0 equiv), NaHCO3 (aq.), 
DCM, ultrasonic bath 
7 0 
(a): 1.00 mL DCM was used; (b): NaHCO3 (5%) was added to keep the pH at 7; (c): additional amount of Oxon® was 
added.; (d): MeCN/H2O 1.50 mL/1.00 mL.; (e): mixture of Oxon® and NaHCO3 was added portionwise;  
(f): DCM/NaHCO3 (5%) 1.00 mL/1.50 mL; (g): yield determined via chiral GC without internal standard;  
(h): tendency for byproduct formation. 
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4.4.3. Additional Catalysts 
With working epoxidation protocols in hand we drew our attention to the synthesis of  
peptide-based catalysts to enable a stereoselective version of the epoxidation. Therefore, we 
followed two strategies. Firstly, we synthesized possible derivatives of the already established 
and highly selective acylation PMH system 1.[2d] The catalytic motive PMH has to be replaced 
by functionalized lysine. Secondly, we focused on C2-symmetric precursors because of their 
advantage regarding dioxirane formation.[120c] As key building block we selected a  
C2-symmetric amine, which is known, for example, from corresponding TUC.
[126] 
In our first approach we chose the identical backbone compared to the acylation. The utilized 
system showed the ability to generate a pocket-shape structure and to perform a stereoselective 
reaction.[2a, 2d] Via automated solid phase peptide synthesis (SPPS) we synthesized the 
corresponding fundamental unit. Afterwards, either the N-terminus or the amino group of lysine 
acts as linker for attaching the benzoic acid derivative para-112. After cleavage of the 
tetrapeptide from the resin deprotection of the amine as well as fixation of the catalytic moiety 
were carried out in solution. The synthesis is exemplarily shown for functionalized tetrapeptide 
122 (Scheme 45). 
For SPPS a pre-loaded fluorenylmethyloxycarbonyl (Fmoc)-phenylalanine-Wang-resin 116 
was used. After removing of the Fmoc protecting group with piperidine in  
DMF the coupling of the next Fmoc-protected amino acid was performed via a HOBt/ 
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuoro-phosphate (HBTU) protocol. 
After three coupling steps the tetrapeptide was cleaved from the resin utilizing a mixture of 
tetrahydrofuran (THF), methanol, and TEA.[2a] Afterwards, both hydrogenation as well as 
fixation of the catalytic moiety starting from methyl ester 120 were carried out in solution under 
standard conditions.[116, 2c, 68, 3a] Finally, tetrapeptide 122 was isolated with a yield of 47% after 
nine steps. 
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Scheme 45: Exemplary synthesis of functionalized tetrapeptides 122. 
After cleavage of the Fmoc-group with piperidine (25%) in DMF, the peptide coupling was performed with Fmoc-
amino acid-OH (2 x 2.0 equiv), HOBt (2 x 2.0 equiv), HBTU (2 x 2.0 equiv), and DiPEA (2 x 2.0 equiv) in DMF; 
(1) Fmoc-Cha-OH; (2) Fmoc-AdGly-OH; (3) Boc-Lys(2-Cl-Cbz)-OH. 
Based on this protocol additional catalysts 123 and 124 were obtained with up to 50%  
(Figure 22). Compared to 122 the catalytic moiety was attached at the N-terminus in case of 
peptide 123. Therefore, the Boc group was removed via hydrogen chloride in dioxane before 
functionalization.[116, 3a] Oligopeptide 124 is a multicatalytic system containing two different 
catalytic moieties regarding our novel acylation-epoxidation sequence (Chapter 3.1). The PMH 
moiety is located preferentially at the N-terminus of the peptide like in its acylation analog. 
Hence, the lysine linker as well as the TFMK are incorporated in the middle of the catalyst. 
Reductive cleavage of the Cbz group and functionalization were performed starting from 
oligopeptide 125 (see Experimental Section).[116, 2c, 68, 3a] 
Analogue to oligopeptide 124 we also synthesized two compounds containing the catalytic 
moiety at the C-terminus. For those approaches we selected an EDAC/HOBt protocol and 
performed the peptide coupling in solution (Scheme 41).[116, 68, 3a] In the end phenylalanine 
derivative 126 as well as multicatalytic systems 127 were obtained with a yield of up to 62% 
(Figure 22). 
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Figure 22: Additional catalysts 123, 124, 126, and 127. 
Comparable to the last mentioned syntheses we also prepared C2-symmetric diamine-based 
catalysts 128 and 129 with a yield of up to 47% (Figure 23). In an one-step procedure the 
corresponding diamine reacts with our selected catalytic moiety para-112 under standard 
coupling conditions.[2c, 68] In contrast to the aforementioned catalysts the geometric property 
represents the second possibility for a stereoselective epoxidation compared to the otherwise 
bulky peptide backbone. 
 
Figure 23: C2-symmetric diamine-based catalysts 128 and 129. 
With chiral precursors in hand, we wanted to perform the epoxidation in a stereoselective 
fashion. Therefore, we chose alkene 38 and the Oxon® protocol (Table 23, Entry 2) with only 
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5 mol% TBABr as our test system (Table 24). But, in contrast to the previous experiment, we 
used a tenfold dilution because of the concentration dependence in case of the acylation.[2a] 
Table 24: Catalyzed epoxidation. 
 
Entry Cat. Conc. [mol L−1] t [h] Yield(f) [%] 
1(a,b) 122 0.025 72 traces 
2(a,b) 123 0.025 24 5 
3(a,b) 124 0.025 24 4 
4(a,b) 128 0.025 24 6 
5(a,b) 129 0.025 24 11 
6(a,b) 115 0.025 24 3 
7(a,b,c,d) 128 0.250 7.5 quant. 
8(a,b,e) 126 0.250 24 15 
9(a,b,e) 127 0.250 24 14 
(a): DCM/NaHCO3 (5%) 1.00 mL/1.00 mL; (b): additional amount of Oxone® was added.; (c): NaHCO3 (5%) was 
added to keep the pH at 7; (d): 20 mol% TBABr were used.; (e): 10 mol% cat. were used; (f): yield determined via 
chiral GC without internal standard. 
All reactions carried out in a higher dilution showed a decreased yield of epoxide 39 without 
enantiomeric excess (Table 24, Entries 1-5). For a better comparison we also tested our racemic 
catalyst 115 under analogue conditions. It also provides the desired product with only 3% yield 
(Table 24, Entry 6). Subsequently, we used C2-symmetric diamine 128 exemplarily under 
aforementioned conditions with a higher concentration. In this case a quantitative yield of 
oxirane 39 was achieved after 7.5 hours, but also unselectively (Table 24, Entry 7).  
Reducing the amount of catalyst to 10 mol% decelerates the reaction, even with a concentration 
of 0.250 mol L−1 (Table 24, Entries 8-9). 
It is also mentioned in literature that the pH-value is an important factor concerning Oxone® 
decomposition, catalyst reactivity, and occurrence of Baeyer-Villiger oxidation as possible side 
reaction.[55] Therefore, we also performed the epoxidation of alkene 38 with an increased  
pH-value of 8-10. Besides potassium hydroxide or potassium carbonate as base we also varied 
temperature (e.g., r.t., 0 °C), additives (e.g., Na2EDTA, TBABr) or catalysts (e.g., 123, 126, 
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127).[55, 123, 43c] Corresponding to the literature we observed a higher yield of up to 94% after 
four hours, but without enantiomeric excess. The reaction without catalyst is also not negligible. 
4.4.4. Re-Optimization with Chiral Test Catalyst 131 
Based on the missing enantiomeric excess and the observed huge influence of several reaction 
parameters, we took one step back and synthesized a second, chiral, and more peptide-like test 
catalyst (Scheme 46).  
 
Scheme 46: Chiral test catalyst 131. 
To prevent racemization, which was observed for two of the previously synthesized catalysts, 
we utilized the EDAC/HOBt-based protocol instead of using a DMAP-mediated one.[68, 3a] 
Finally, test catalyst 131 was isolated with a yield of 89%. This compound was used afterwards 
for re-optimization of the catalytic epoxidation instead of the more valuable tetrapeptides. 
Parameters like catalyst loading and concentration were varied stepwise  
(Table 25).[123, 119c, 43c, 125] 
Table 25: Re-optimization with functionalized amino acid 131. 
 
Entry 131 
[mol%] 
TBABr 
[mol%] 
Oxone®/NaHCO3 (s) 
[equiv/equiv] 
Conc.(h) 
[mol L−1] 
t 
[h] 
Yield(i) 
[%] 
1(a,b,c) 20 40 2.0/0.0 0.250 7 94 
2(a,b,d) 15 15 2.0/0.0 0.250 7 35 
3(a,b) 11 11 2.0/0.0 0.250 5 17 
4(a,b) - 20 2.0/0.0 0.250 7 8 
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5(e,f) 19 39 3.0/37 0.167 4 quant. 
6(e,f) 20 39 1.5/4.7 0.167 2 quant. 
7(e,f) 20 38 1.0/3.0 0.167 2 81 
8(e,f) - 41 1.5/4.7 0.167 3 quant. 
9(e,f) - 5 1.6/4.7 0.167 24 17 
10(e,f) - - 1.6/4.7 0.167 24 8 
11(e,f) 20 - 1.5/4.9 0.167 25 25 
12(e,f) 20 5 1.5/5.0 0.167 25 23 
13(f,g) 20 20 3.0/4.6 0.250 5 95 
14(f,g) 20 17 3.0/4.6 0.250 5 71 
15(f,g) 20 10 3.0/4.7 0.250 5 41 
16(f,g) 21 5 3.0/4.7 0.250 5 34 
(a): DCM/NaHCO3 (5%) 1.00 mL/1.00 mL; (b): additional amount of Oxon® was added.; (c): NaHCO3 (5%) was 
added to keep the pH at 7; (d): a mixture of NaHCO3/Na2CO3 was used to keep the pH at 7; (e): MeCN/H2O 1.50 
mL/1.00 mL, Na2EDTA were used; (f): mixture of Oxone®/NaHCO3 (s) was added over around 35 min;  
(g): DCM/H2O 1.00 mL/1.00 mL were used; (h): with respect to the volume of organic sovent; (i): yield determined 
via chiral GC without internal standard. 
Based on the last results with the peptide catalysts (Table 24) we started our re-optimization. 
But, for an increased transport of the reactive species we utilized 40 mol% of TBABr as PTC 
at the beginning. 94% of the desired epoxide 39 were obtained after five hours (Table 25,  
Entry 1). The whole system is quite sensitive because reducing the amount of catalyst slowed 
down the reaction distinctly (Table 25, Entries 2 and 3). The background reaction showed that 
the presence of precursor 131 is necessary (Table 25, Entry 4). Keeping the reaction ongoing 
and the pH value constant is quite difficult with the aforementioned procedure. Therefore, we 
decided to mix oxidizing agent and base in solid form beforehand and add the mixture 
portionwise. We tested a mono- and biphasic system yielding epoxide 39 with up to quantitative 
yields (Table 25, Entries 5-16). However, the side-reaction of TBABr could not be suppressed 
and an enantiomeric excess was not observable. We tried to address both problems via changing 
the utilized solvents (e.g., toluene, DMF), but without success. Even with a well-working 
system in hand (Table 25, Entry 13) we stopped our attempts at this point and draw our attention 
to a PTC-free approach. 
4.4.5. tert-Amyl Alcohol and Hydrogen Peroxide Approach 
Especially, because of the PTC-mediated background reaction we proceed to a hydrogen 
peroxide-based protocol form Shi et al. published in 2007. Thereby, we want to realize a  
PTC-free and practically simplified version of our peptide-catalyzed procedure.  
73 
 
Besides dioxirane precursor and oxidizing agent a nitrile source is also required. In their 
postulated mechanism they showed the in situ generation of two reactive intermediates 
(Scheme 47).[124] 
 
Scheme 47: Postulated reaction mechanism including reactive species 106 and 133. 
Shi et al. assume that hydrogen peroxide and nitrile 132 form the reactive peroxyimidic acid 
133. This in situ generated species reacts analogously to peroxomonosulfate to peroxy 
intermediate 104’. With release of primary amide 134 dioxirane 106 is formed enabling the 
already mentioned final steps (Scheme 43). 
A similar strategy with a peptide-like catalyst was successfully applied by Miller et al. in 2012 
(Scheme 17).[57] Instead of n-butanol they used tert-amyl alcohol in combination with water as 
solvent mixture. Based on those promising results for a comparable system we tested 
functionalized phenylalanine 131 under analogue conditions (Table 26). 
Performing the epoxidation of cyclohexene 38 at room temperature with Miller’s reaction 
conditions provided product 39 with 63% yield, but no enantiomeric excess (Table 26, Entry 
1). Via omission of either peptide 131 or acetonitrile we get the hints that both components are 
essential for the formation of the dioxirane (Table 26, Entries 2 and 3). For our system a 
stepwise addition of hydrogen peroxide and minimizing the equivalents of acetonitrile showed 
less effect on the reaction outcome compared to lower catalyst loading and concentration  
(Table 26, Entries 4-8). Utilizing a higher dilution did not only slow the reaction down, but also 
favored the occurrence of side-reaction (Table 26, Entry 8). Exemplarily GC-determined and 
isolated yield were compared (Table 26, Entry 4). 
74 
 
Table 26: Hydrogen peroxide-based epoxidation. 
 
Entry 131 
[mol%] 
K2CO3 
[equiv] 
H2O2 
[equiv] 
MeCN 
[equiv] 
Conc.(f) 
[mol L−1] 
t  
[h] 
Yield(g) 
[%] 
1(a) 10 1.9 8.1 8.0 0.327 5 63 
2(a) - 1.9 8.9 8.0 0.327 25 13 
3(a,b) 10 1.8 8.1 - 0.327 23 7 
4(a,b) 10 1.8 2.0 8.0 0.327 1 99(d) 
5(a,b) 11 1.8 6.0 2.0 0.327 3 quant. 
6(a,c) 10 1.8 3.0 2.0 0.327 3 54 
7(a,c) 5 1.8 3.0 2.0 0.327 3 18 
8(c,e) 11 2.0 4.0 8.0 0.164 4 18 
(a): 38 (0.628 mmol, 1.0 equiv), Na2EDTA (0.1 mol%), 131, K2CO3, MeCN, H2O2, tamyl alcohol/H2O 1.92 mL/1.92 
mL; (b): 2.0 equiv H2O2 were added hourly; (c): 1.0 equiv H2O2 were added hourly; (d): 93% isolated yield; (e): 0.314 
mmol (1.0 equiv) 38, 0.2 mol% Na2EDTA, 131, K2CO3, MeCN, H2O2, tamyl alcohol/H2O 1.92 mL/1.92 mL 
 (f): with respect to the volume of organic solvent; (g): yield determined via chiral GC without internal standard. 
4.4.6. Comparison 
As a short summary the best conditions both for Oxone® and H2O2/MeCN are summarized in 
table 27. The most important advantages and disadvantages are included as well. 
Table 27: Comparison of reaction conditions for the catalytic epoxidation. 
Oxone/NaHCO3 H2O2/MeCN 
20 mol% 131 10 mol% 131 
Oxone (3.0 equiv) H2O2 (3 x 2.0 equiv),  
MeCN (2.0 equiv) 
NaHCO3 (4.6 equiv) K2CO3 (1.8 equiv), 
20 mol% TBABr, CH2Cl2/H2O 
(1:1) 
Na2EDTA (10−4 mol L−1), 
tAmylOH/H
2
O (1:1) 
0.250 mol L−1 0.327 mol L−1 
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r.t. r.t. 
96% conversion (5 h) Quant. conversion (3 h) 
 Extremely pH-dependent 
 Mixing Oxone/NaHCO3 and 
adding portionwise 
 Fast background reaction  
 PTC necessary 
 H2O2 added in portions 
 MeCN necessary 
 Less catalyst: slower reaction, but 
more side reactions 
 Very slow background reaction 
 No PTC necessary 
 
The major differences are catalyst loading, necessity of a PTC, pH-influence, background 
reaction, and rate of epoxide formation. Based on those observations we used the  
H2O2/MeCN-protocol for testing the peptide catalysts. 
4.4.7. Testing of the H2O2/MeCN-Protocol 
For those experiments we selected peptide-based and C2-symmetric catalysts 126 and 128 
exemplarily. Those dioxirane precursors showed the best results with the Oxone®-based 
protocol (Table 24, Entries 7 and 8). We chose alkene 48 for catalyst 126 and cinnamic alcohol 
50 for catalyst 128 as substrate building on dispersion and π-π interactions, respectively, as 
beneficial factors. Due to the negligible effect of the volume of acetonitrile eight equivalents 
were used. For a direct comparison both reactions were performed with test catalyst 131 
simultaneously (Table 28). 
Table 28: Epoxidation with catalysts 126 and 128 utilizing the H2O2/MeCN-protocol. 
 
 
Entry Cat. Alkene Epoxide H2O2(c) 
[equiv] 
t 
[h] 
Yield(d) 
[%] 
1(a) 126 
  
8.0 7 25 
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2(b) 128 
  
2.0 1 quant. 
3(a) 131 48 49 8.0 7 19 
4(b) 131 50 51 6.0 3 quant. 
(a): Alkene (0.165 mmol, 1.0 equiv), Na2EDTA (0.1 mol%), cat. (10 mol%), K2CO3 (1.8 equiv), MeCN (8.0 equiv), 
H2O2 (8.0 equiv), tamyl alcohol/H2O 0.500 mL/0.500 mL; (b): alkene (0.628 mmol, 1.0 equiv), Na2EDTA  
(0.1 mol%), cat. (10 mol%), K2CO3 (1.8 equiv), MeCN (8.0 equiv), H2O2 (8.0 equiv), tamyl alcohol/H2O  
1.92 mL/1.92 mL; (c): 2.0 equiv H2O2 were added hourly; (d): yield determined via chiral GC without internal 
standard. 
4.4.8. More Efficient Synthetic Procedure 
In case of the already shown peptide catalysts the backbone was synthesized initially and 
functionalized in the last steps. From a synthetic point of view it would be more favorable to 
have a complete building block in hand enabling a straight forward peptide coupling afterwards. 
Therefore, we established a three-step process yielding lysine derivative 137 (Scheme 48).  
 
Scheme 48: Synthesis of functionalized lysine 137. 
The well-working methyl ester introduction based on thionyl chloride is not possible[127] 
because the Boc group of orthogonal protected starting material 135 would be cleaved 
immediately by the in situ generated hydrogen chloride. Therefore, we utilized a typically 
DMAP-mediated esterification protocol with methanol.[2c, 68] Completely protected lysine 136 
was isolated with a yield of only 27%. After reductive cleavage of the carbamate group and 
functionalization of the free amine target compound 137 was finally isolated with a yield of 
28% after two steps.[116, 2c, 68, 3a] Purification of the completely protected intermediate and the 
target product 137 is quite difficult and causes the low overall yield of only 8%.  
Conclusively, the synthesis of the functionalized building block, which can be utilized in 
peptide coupling in solution after re-movement of the Boc group, is possible, but for a larger 
scale not really practicable. In addition to the missing enantiomeric excess, which might be 
caused by the very flexible alkyl chain, further optimization attempts were stopped. 
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4.4.9. Missing Enantiomeric Excess 
In all catalyzed epoxidation reactions hitherto no enantiomeric excess was observed.  
For peptide catalyst 123, C2-symmetric amines 128 and 129 as well as phenylalanine 131 we 
assume that the distance between in situ generated dioxirane and first chiral center is too large. 
For further oligopeptides the flexible alkyl chain additionally complicates the formation of a 
fixed transition state. Therefore, we developed three possible strategies to address these 
problems. Firstly, we wanted to shorten the linker by utilizing 2,3-diaminopropionic acid (Dap) 
instead of lysine (Chapter 4.4.9.1.). Secondly, the substitution pattern of the aromatic ring of 
the catalytic moiety should be changed (Chapter 4.4.9.2.). Finally, an amino acid containing the 
dioxirane precursor should be synthesized (Chapter 4.4.9.5.). 
4.4.9.1. Variation of the Linking Amino Acid 
Our first idea to achieve a stereoselective epoxidation based on minimizing the flexibility by 
reducing the number of CH2-units between catalytic moiety and peptide backbone. With the 
already established synthetic route and an orthogonal protecting group strategy in mind we 
wanted to synthesize the corresponding Cbz-protected Dap derivative 139, which can 
afterwards be included in the established SPPS functionalization pipeline (Scheme 49). 
 
Scheme 49: SPPS of Dap-containing tripeptide 142. 
After cleavage of the Fmoc-group with piperidine (25%) in DMF, the peptide coupling was performed with (1) 
139 (1.0 equiv), HOBt (3.0 equiv), HBTU (3.0 equiv), and DiPEA (3.0 equiv) in DMF and (2) Boc-AdGly-OH (2 
x 2.0 equiv), HOBt (2 x 2.0 equiv), HBTU (2 x 2.0 equiv), and DiPEA (2 x 2.0 equiv) in DMF. 
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The Cbz protection of Fmoc-Dap 138 was performed with disodium carbonate as base and 
building block 139 was isolated with a yield of 68%.[96] By analogy with peptide catalyst 124 
we synthesized tripeptide 142 under SPPS conditions with 23% yield after three steps.[2a]  
In combination with a modified catalytic moiety the concept of a shorter linker should enable 
access to a potent catalytic system. 
4.4.9.2. Substitution Pattern of the Aromatic Ring 
As already mentioned we assume that beside the influence of the flexible alkyl chain combined 
with the distance between first chiral center and reactive species the substitution pattern of the 
catalytic moiety plays an important role. Hence, we focused on synthesizing ortho- as well as 
meta-substituted derivatives of our identified aromatic catalytic moiety para-112 (Table 29).  
In the first place we tried to introduce the TFMK while the starting material already contains 
the necessary linker.[128] Firstly, based on the protocol of Tuominen et al. we performed a 
Grignard reaction with protected bromide 143 and Weinreb amide 144 to obtain  
ortho-substituted benzoic acid derivative 145 (Table 29, Entry 1).[129] But, during the reaction 
a reduction took place independently from solvent, temperature as well as inert atmosphere.  
In contrast to the literature we utilized a substituent with a negative mesomeric (–M) effect, 
which might have an influence on the reactivity of the aromatic system. 
Table 29: Attempts for introducing a TFMKs. 
Entry Conditions 
1 
 
2 
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3 
 
4 
 
 
Secondly, utilizing Ruppert-Prakash reagent (TMSCF3),
[130] which is a further well-established 
CF3-source,
[131] in combination with the procedure published by Miller et al. we chose 
carboxybenzaldehyde 146 as educt (Table 29, Entry 2).[57] But, under the selected conditions 
we could not observe the desired product ortho-112 (Chapter 4.4.9.3). 
In 2012, Leadbeeater et al. showed that Weinreb amides can also be converted into the TFMKs 
via TMSCF3.
[132] Referring to this strategy we thirdly synthesized the Weinreb amide of 
isophthalic acid, which was coupled with phenylalanine in the forefront (see 149 Experimental 
Section). Final conversion to the TFMK 150 would directly provide meta-analog of 131  
(Table 29, Entry 3). We performed the final two-step transformation as published both under 
standard heating as well as microwave conditions, but we only reisolated the Weinreb amide. 
Lastly, also testing phthalic acid anhydride 151 with the conditions of the previous experiment 
does not lead to the corresponding ortho-substituted product (Table 29, Entry 4). 
Due to the failed aforementioned approaches different starting materials in combination with 
variation of the reaction conditions could be tested additionally. As further alternative strategy 
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the DMAP-mediated acylation of aromatic systems with trifluoroacetic anhydride published by 
Simchen et al. in 1996 could be transferred to our starting materials.[133] 
As a consequence of the first functionalization attempts we turned our strategy around.  
We selected trifluoroacetophenone 152 as commercially available starting material and wanted 
to convert the monosubstituted aromatic system under Vilsmeier conditions to corresponding 
aldehyde 153, which should be oxidized finally to the carboxylic acid 112, which acts 
afterwards as linking unit (Scheme 50). 
 
Scheme 50: Vilsmeier reaction. 
The reaction was performed both with DMF as well as N-methylfomanilide as formylation 
reagent.[85] But, these typical Vilsmeier conditions did not work for our aromatic system 152 
and after aqueous work-up only starting material was reisolated.  
Due to the abortive attachment of both a TFMK as well as a carboxylic acid we chose an amino 
group as potential linker. This functional group should also be introduced via an electrophilic 
aromatic substitution in a two-step sequence of nitration followed by reduction (Scheme 51). 
The nitration of trifluoroacetophenone 152 worked excellent under standard conditions with an 
isolated yield of 94%.[85] It was also possible to separate the majority of both isomers via column 
chromatography. But afterwards, we were not able to reduce the amino group selectively in the 
presence of the carbonyl with palladium as catalyst under a hydrogen atmosphere even via 
variation of the reaction conditions.[85, 134] We isolated completely reduced amino alcohols 155 
with an average yield of 93%. 
In 2008, Bonesi et al. published the photoreduction of aromatic nitro compounds.[135]  
Mild conditions and a high functional group tolerance are two advantages of their described 
protocol. We reisolated quantitative amounts of the starting material after irradiation of our 
substrate for six hours. 
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Scheme 51: Synthetic routes for the synthesis of CF3-derivatives 155 and 159. 
Therefore, we decided to protect the carbonyl before reducing the nitro group. Removing the 
protecting group would result in attachable amine 159. We tried to introduce cyclic as well as 
acyclic acetals even by utilizing different protocols,[116, 136] but we only reisolated or observed 
unreacted starting material 154. So we stopped all further attempts to synthesize catalytic 
moieties 159 at this point. 
But, on the other hand we were able to isolate amino alcohols 155 after two steps with a total 
yield of 87% regarding both isomers. After peptide coupling with phenylalanine 94 and  
late-stage oxidation these initially unintended compounds would give us ortho- and  
meta-substituted analogs of peptide catalyst 131 (Scheme 52). 
The formation of the amide bond was performed with the already described  
HOBt/EDAC-mediated protocol.[68, 3a] Amides 160 were isolated with a yield of up to 32%. 
One explanation for the reduced amount of product is the disubstituted species, which was 
separated and identified via ESI-MS in case of ortho-155. Protection of the free hydroxyl group 
in the forefront could prevent this problem in further experiments. The late-stage oxidation was 
carried out with TEMPO as catalyst and mCPBA as oxidizing agent.[137] The reaction took place 
successfully for meta-161, while only starting material was isolated in case of its  
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ortho-derivative. The higher steric hindrance of ortho-160 might complicate the formation of 
the necessary intermediate and thereby prohibit the oxidation. But, with meta-161 in hand a 
comparison between para- and meta-substitution pattern in the catalytic epoxidation is possible. 
If the results show a preference for the meta-derivative further optimization efforts will be 
invested in the synthesis of the corresponding ortho-analog. 
 
Scheme 52: Syntheses of ortho- and meta-substituted analogs of peptide derivative 131. 
Conditions for the amide bond formation: ortho-160: 94 (1.2 equiv), HOBt (1.3 equiv), EDAC (1.3 equiv), and 
TEA (0.9 equiv) for 13 h; meta-160: 94 (1.1 equiv), HOBt (1.1 equiv), EDAC (1.1 equiv), and TEA (1.1 equiv) 
for 23 h. 
4.4.9.3. Digression II: Asymmetric Synthesis of α-Keto Acetals 
As mentioned above it was not possible to convert carboxybenzaldehyde 146 into the desired 
ortho-substituted TFMK 112 (Table 29, Entry 2). But, we were able to isolate and characterize 
α-keto acetal 162a after work-up with ethyl acetate (Scheme 53).  
 
Scheme 53: Observation of the formation of α-keto acetals 162a. 
Firstly, we assume that there must exist a hemiacetal form of starting material 146 in solution. 
Secondly, the organic solvent is hydrolyzed by hydrochloric acid during extraction of the 
aqueous layer. Afterwards, the cyclic species is acid-mediately transferred into acetal 162a via 
reaction with formed ethanol.  
Already in 1957, Wheeler et al. investigated the open and closed form of carboxybenzaldehyde 
146 via IR. They reported that both species exist depending on solvent and temperature. 
Furthermore, it is mentioned that carboxybenzaldehyde 146 possess a reactivity comparable to 
83 
 
an acid chloride or anhydride and a variety of possible reactions were described including the 
formation of 162a.[138] For gaining a deeper insight into the real situation in solid state and 
solution we repeated the IR experiments and performed additional NMR measurements  
(Table 30). 
Table 30: IR and NMR experiments. 
 
 KBr Solution in CHCl3 
 
C=O (cm−1) 1741 
1761 
 
1767 
 
Solvent 1H 13C Ratio or 146:163 
 
DMSO-d6 
6.68 
10.48 
98.3 and 168.5 
167.6 and 192.9 
 
1:10 
CDCl3 6.66 98.0 and 169.7 0:1
 
 
Two bands in the IR spectrum showed the presence of carboxybenzaldehyde 146 in the solid 
state. In contrast all experiments in solution confirmed clearly the closed form 163. Only in 
dimethyl sulfoxide (DMSO)-d6 small traces of the open form were observable. Therefore, a 
reaction of hemiacetal 163, which is formed directly during solvation, is possible.  
Simultaneously, we performed some test reactions to proof our hydrolysis-acetalization 
hypothesis. Therefore, we mixed ethyl acetate, diluted hydrochloric acid, and 
carboxybenzaldehyde 146. After stirring 17.5 hours we isolated 26% of the ethylated species 
162a. Without acid no reaction took place.  
With those information in hand, we postulated that it should be possible to deprotonate 
generated hemiacetal 163 in situ and scavenge the alkoxide subsequently with a suitable 
electrophile (E+). Utilizing a chiral base (B*) like an alkaloid should result in chiral intermediate 
164, which should provide target product 162 in a chiral form after reaction with the electrophile 
(Scheme 54). 
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Scheme 54: Postulated sequence for the synthesis of enantiomerically enriched α-keto acetals 162. 
As test system we chose cinchonine 165 as base and acetic anhydride as electrophile referring 
to our acylation concept. To facilitate the formation of polar intermediate 164 in a defined 
orientation we selected toluene as solvent, which is also favorable concerning our  
PMH-mediated acylation (Table 31).[2c] 
Table 31: Cinchonine-mediated asymmetric synthesis of enantiomerically enriched α-keto acetals 162b. 
 
Entry(a) 165 
[equiv] 
Ac2O 
[equiv] 
T2 
[°C] 
t1 
[h] 
T2 
[°C] 
t2 
[h] 
Yield 
[%] 
ee(b) 
[%] 
1 1.0 1.0 r.t. 18 r.t. 6 67 28 
2 2.0 1.0 r.t. 18 r.t. 6 79 28 
3 1.0 2.0 r.t. 18 r.t. 6 83 28 
4 2.0 2.0 r.t. 18 r.t. 6 96 28 
5 2.0 2.0 0 24 0 8 88 32 
(a): 0.300 mmol (1.0 equiv) 146, 165, and 4.00 mL PhMe than Ac2O; (b): ee determined via chiral GC without 
internal standard. 
Performing deprotonation and protection of hemiacetal 163 with one equivalent base as well as 
electrophile at room temperature yielded in 67% of acetal 162b with an enantiomeric excess of 
28% (Table 31, Entry 1). Astonishingly, variation of temperature as well as equivalents of base 
and electrophile did not play such an important role. Yields are always in a good to excellent 
range and the enantiomeric excess is around 30% (Table 31, Entries 2-5). 
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In 2008, Yamada et al. reported the first catalytic dynamic kinetic resolution for hemiaminals 
with a very similar structure compared to 163.[139] With 0.1 to 10 mol% of chiral DMAP 
catalysts and isobutyric anhydride they obtained excellent yields and good selectivities for the 
acylated compounds. Utilizing the same procedure they isolated the product of hemiacetal 163 
with a nearly quantitative yield and an enantiomeric excess of 40%. But moreover, only a few 
racemic protocols are described regarding the synthesis of acetate 162b requiring carbon 
monoxide and catalytic amounts of a palladium species as well as high temperatures.[140] 
Taking this into account and based on only a few very simple experiments we conclude that our 
approach for the synthesis of α-keto acetals is very promising. Further optimization of the 
procedure, e.g., catalyst screening, use of additives, different electrophiles, and solvent 
variation in combination with the substrate scope, is easily possible.  
Afterwards, enantiomerically enriched compound 162a can be used as starting material in the 
synthesis of 3-(heteroaryl)phthalides[140c] or the protocol can help to synthesize chiral esters like 
the racemic one reported in the biological evaluation of monocyclic β-lactams.[141]  
4.4.9.4. Effect on Epoxidation Outcome 
At the end of chapter 4.4.9.2. we showed the successful synthesis of the meta-substituted TFMK 
161. With this catalyst and functionalized phenylalanine 131 in hand, it is possible to compare 
reactivity as well as selectivity of those different substitution pattern. Due to the described 
synthetic problems the orientation of the amide bond is inverted, which should not play a very 
important role. In parallel, we wanted to test also the cyclohexylalanine derivative of 131. 166 
was synthesized analogue to 131 (Schema 46; see 166 Experimental Section).  
Different substituted alkenes were epoxidized in the presence of those three catalysts utilizing 
the established H2O2/MeCN protocol (Table 32). 
Based on those results we conclude, changing the substitution pattern of the aromatic ring from 
para to meta did not lead to an enantioselectively enriched product formation. But, apart from 
alkenes 40 and 54 (Table 32, Entries 7 and 11) the further epoxides are formed slower with 
meta-161. Maybe the increased steric hindrance hampers the generation of the dioxirane in case 
of meta-161.  
Substitution of phenyl with cyclohexyl did not show a real tendency for either dispersion or  
π-π-interactions driven reactions. For example, phenylcyclohexene 38 is converted faster by 
131 (Table 32, Entries 1 and 12), whereas its cyclohexyl derivative 40 is transferred in an equal 
manner from both catalysts (Table 32, Entries 2 and 13). Flexible epoxide 49 forms slowly 
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utilizing all three catalysts (Table 28, Entry 3; Table 32, Entries 9 and 15), but  
Michael systems 54 and 56 can be epoxidized astonishingly well (Table 32, Entries 4, 5, 11, 
and 17). The last experiments have to be reproduced and investigated in more detail. 
Table 32: Investigation of interaction and substitution pattern. 
 
Entry Cat. Alkene Epoxide H2O2(c) 
[equiv] 
t 
[h] 
Yield(d) 
[%] 
1(a) 131 
  
2.0 1 99 
2(a) 131 
  
2.0 
 
1 quant. 
3(b) 131 
 
 
8.0 
 
7 63 
4(b) 131 
  
8.0 
 
7 98 
5(a) 131 
  
8.0 24 36 
6(b) meta-161 38 39 8.0 6 23 
7(b) meta-161 40 41 2.0 1 quant. 
8(b) meta-161 44 45 8.0 7 51 
9(b) meta-161 
  
8.0 7 16 
10(b) meta-161 
 
 
8.0 
 
6 50 
11(b) meta-161 54 55 8.0 7 98 
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12(a) 166 38 39 8.0 6 55 
13(a) 166 40 41 2.0 1 quant. 
14(b) 166 44 45 4.0 2 42 
15(b) 166 48 49 8.0 24 14 
16(b) 166 50 51 8.0 24 20 
17(a) 166 56 57 8.0 24 34 
(a): Alkene (0.628 mmol, 1.0 equiv), Na2EDTA (0.1 mol%), cat. (10 mol%), K2CO3 (1.8 equiv), MeCN (8.0 equiv), 
H2O2 (8.0 equiv), tamyl alcohol/H2O 1.92 mL/1.92 mL; (b): alkene (0.165 mmol, 1.0 equiv), Na2EDTA (0.1 mol%), 
cat. (10 mol%), K2CO3 (1.8 equiv), MeCN (8.0 equiv), H2O2 (8.0 equiv), tamyl alcohol/H2O 0.500 mL/0.500 mL; 
(c): 2.0 equiv H2O2 were added hourly; (d): yield determined via chiral GC without internal standard. 
Due to the still absent enantiomeric excess even by varying the substituents at the aromatic ring 
of the catalytic moiety, we stopped our approach of synthesizing a catalytic moiety before 
fixation on a peptidic system at this point. Combining the aspect of a shorter linker with a 
TFMK lead to the synthesis of a functionalized amino acid, which can act as building block in 
peptide synthesis. 
4.4.9.5. TFMK-Based Amino Acid 
As starting point we wanted to synthesize the TFMK derivative from aspartic acid. To obtain 
target compound 169 we linked the procedures of synthesized amino acid 139 (Scheme 49) and 
the Weinreb amid strategy (Table 29, Entry 3).[132] Finally, we would end up with an 
orthogonally protected and functionalized amino acid, which contains only one  
CH2-linker and can be used directly in SPPS (Scheme 55). 
 
Scheme 55: Synthetic approach for amino acid 169. 
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The synthesis of Weinreb amid 168 was performed utilizing the EDAC/HOBt-mediated 
protocol.[68, 3a] After reaction of orthogonal protected carboxylic acid 167 with hydrochloride 
148 the target compound was isolated with a yield of 68%. But, the transformation of  
Weinreb amide 168 to its TFMK analog 169 did not take place and only starting material 168 
was reisolated.  
Due to the fact that the synthesis of TFMKs via their Weinreb amides failed both for substrate 
150 (Table 29, Entry 3) as well as for 168 (Scheme 55) we suggest a route starting from an 
aldehyde. Whereas, the aldehyde of serine is prone to racemize its aspartic acid-derived analog 
would be our first choice.[142] Two potential approaches are depicted in scheme 56.  
 
Scheme 56: Future approaches for the synthesis of TFMK containing amino acids. 
(a): (1) LAH and (2) DMP; (b): (1) 173, Zn, DMF, −20 °C and (2) DMP; (c): (1) TMSCF3, TBAF, THF, 0 °C and (2) 
Ac2O, DMAP, DCM r.t.; (d): deprotection and peptide coupling; (e): (1) LiBr, DBU, MeOH and (2) DMP. 
Starting material 170 is commercially available or should be synthesizable in a two-step 
sequence form aspartic acid 171.[85] Afterwards, we would firstly utilize the procedure included 
in the patent of Napper and colleagues6. They described the synthesis of 172 via addition of 
trifluoroiodomethane 173 to aldehyde 170 followed by oxidation of the intermediately formed 
alcohol with Dess-Martin periodinane (DMP). Secondly, we would transfer the strategy 
established by Miller et al. for synthesizing their TFMK containing peptide catalyst to aldehyde 
170.[57] In the first step in situ formed trifluoromethyl-substituted alcohol is transferred to 
acetate derivative 174. This protected intermediate can be used in the following deprotection 
                                                 
6 A. D. Napper, R.C. Titmas, M. T. Martin, W. inventors; IGEN International, Inc., assignee. Catalytic antibodies 
which hydrolyze primary amides and methods for eliciting such antibodies. US 5900237. 1999 May 4. 
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and coupling steps. After completion of desired target peptide 175 the protecting group has to 
be removed. Finally, after late-stage oxidation catalyst 176 can be used in epoxidation reactions. 
4.4.10. Outlook 
After identification of suitable catalytic moiety 112 (Chapter 4.4.2.) we synthesized several 
peptide-based and C2-symmetric catalysts containing this dioxirane precursor (Chapter 4.4.3.). 
For the catalyzed epoxidation we optimized an Oxone®- as well as a H2O2/MeCN protocol with 
less complex chiral test catalyst 131 (Chapter 4.4.6.). To simplify the synthetic procedure of 
our catalytic systems we prepared functionalized lysine derivative 137 (Chapter 4.4.8.). 
Unfortunately, none of the performed catalyzed epoxidation reactions provided an 
enantiomerically enriched product. Therefore, we developed three strategies to address this 
aspect (Chapter 4.4.9.). While the synthesis of the Dap derivative 139 (Chapter 4.4.9.1.) and 
meta-substituted TFMK 161 worked (Chapter 4.4.9.2.), we were not able to prepare 
functionalized amino acid 169 yet (Chapter 4.4.9.5.). But, because of synthetic problems 
concerning the synthesis of catalytic moiety and the still missing enantiomeric excess in the 
epoxidation (Chapter 4.4.9.4.), we deem it appropriate and the most promising approach to put 
more effort in the synthesis of amino acid building blocks like 176 and 177 (Scheme 57). 
 
Scheme 57: Potential building blocks 176 and 177. 
In addition to possible synthetic strategies for 176 (Chapter 4.4.9.5) functionalized 
phenylalanine 177 might be assessable via Friedel-Crafts acylation of protected phenylalanine 
with trifluoroacetic anhydride. The DMAP-mediated synthesis of such aromatic species was 
published by Simchen et al. in 1999.[133] The synthesis of its para-substituted analog was 
described by Hashimoto et al. in 2015 utilizing another aromatic substitution approach.  
After halogen-metal exchange they introduced the TFMK via ethyl trifluoroacetate.[143]  
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The identification of a new and maybe selective catalysts is the key step in this project.  
While, re-optimization of the established protocols and extending the substrate scope via testing 
the whole substrate library is straight forward. 
Furthermore, during the attempt to synthesize ortho-112 starting form carboxybenzaldehyde 
146 we isolated α-keto acetal 162a (Chapter 4.4.9.3.). Based on this observation we established 
an alkaloid-mediated asymmetric synthesis of acylated analog 162b. After only a few reactions 
we were able to isolate the target compound with 96% yield and an enantiomeric excess of 
28%. A variety of parameters like catalyst, temperature or solvent should be varied to refine 
this very promising approach. 
4.5. Peptide-Based Phase Transfer Catalysts 
During the first test reactions with catalysts 114 and 115 we saw that TBABr itself is also able 
to transfer alkene 38 under the chosen reaction conditions in its oxirane (Table 23, Entry 3).  
Of course a variety of protocols based on the PTC concept for a variety of different reactions 
in an asymmetric fashion are already described in literature.[46, 43f] Two typical representatives 
are alkaloid- as well as binaphtyl-based PTCs (Figure 9). The enantioselective epoxidation of  
electron-deficient alkenes is one intensively studied reactions in the context.[144, 46]  
Ensuing from our observations and by combining the PTC approach with our peptide concept 
we wanted to develop a peptide-based PTC, which can be used as third class of catalytically 
active compounds in epoxidation reactions. 
4.5.1. Preliminary Considerations  
In first place, we had to find a suitable building block, which could be both incorporated into a 
peptidic structure and be alkylated in the final step to yield the active species. Based on the 
good experiences with amide bond formation to connect catalytic moiety and peptide we were 
looking for carboxylic acid or amine derivatives as potential precursors (Figure 24). 
 
Figure 24: Potential PTC precursors. 
Diamine 178 and diacid 179 were selected to incorporate the PTC precursor in the peptide 
backbone. Thereby, C2-symmetric or asymmetric peptides can be obtained. Primary amines 180 
and 181 can connected to the C-terminus of the peptide or to a carboxylic acid side chain of 
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aspartic or glutamic acid. In case of 178, 179, and 180 we would end up with a pyridine or 
quinolone-based salt, in which the nitrogen atom is sp2-hydridized. In contrast, diamine 181 
would provide a quaternary ammonium species, which is the typical motif in the already known 
and established PTCs. 
4.5.2. Synthesis of the First Peptide-Based PTC 
Our preliminary experiments with 178, 179, and 180 showed that formation of an amide bond 
was indeed only possible for diacid 179 and quinolone derivative 180,[68, 3a] but the salification 
did not occur for both species under the selected conditions.[145] Due to its weaker  
s-character the sp3-hybridized nitrogen atom of tertiary amine 181 reacts faster in an alkylation 
than a comparable aromatic sp2-analog. For example, alkylation of alkaloid 217  
(Chapter 5.3.5.3) containing a nitrogen aromatic compound in the presence of a tertiary amine 
yielded quaternary ammonium salt 218 with 90% utilizing the conditions of Meng.[146]  
Based on those observation and with the typical used quaternary ammonium salts in mind we 
focused on tertiary amine 181. Initial experiments showed that synthesizing the peptide in the 
typically fashion from C- to N-terminus starting with diamine 181 lead to purification problems, 
which were solved by synthesizing the peptide beforehand and attaching the primary amine as 
last monomer to the final peptide. Due to bad solubility of starting material 181 we also had to 
change the conditions for its coupling reaction with a C-terminal unprotected amino acid.  
After variation of solvent and addition of base, we were oriented by the conditions of Rogers 
and co-workers.[147] They reported a procedure with O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium-hexafluorphosphat (HATU) and three equivalents DiPEA. Instead of 
HATU we used HBTU. After late-stage alkylation of the tertiary amine we obtained the desired 
PTC. The modified synthetic procedure is exemplarily depicted for PTC 182 (Scheme 58). 
After peptide coupling utilizing the EDAC/HOBt protocol[68, 3a] the methyl ester was cleaved 
with lithium hydroxide in 1,4-dioxane.[116] After acidification with hydrochloric acid  
C-terminal unprotected dipeptide 183 was isolated with a yield of 80% after two steps.  
Based on the HBTU/DiPEA protocol we isolated tripeptide 184 with a yield of 85% after  
20 hours.[147] Alkylation with benzyl bromide provided target ammonium salt 182 with a yield 
of 41%.[145] In the end we obtained PTC 182 with an overall yield of 28% after four steps. 
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Scheme 58: Adapted peptide synthesis for PTC 182. 
Besides the adapted synthetic procedure we included foreknowledge from our initial 
experiments for designing catalyst 182. Solubility of the PTC and a faster reaction of the alkene 
in the afterwards performed epoxidation can be increased by a higher lipophilicity of the 
catalyst. Therefore, we synthesized a dipeptide consisting of leucine (Leu) and phenylalanine. 
Furthermore, even if free hydroxyl groups are favorable for an enantioselective  
epoxidation[49, 148] we refrained from incorporation of unprotected threonine. The free hydroxyl 
group complicated the purification of the peptides. Of course, one logical alternative would be 
the use of protected threonine and its deprotection directly before alkylation. 
4.5.3. PTC-Based Epoxidation 
For investigation of the reaction conditions for the catalytic epoxidation we used enone 58 and 
10 mol% PTC 185 (see Experimental Section). Due to better solubility properties considering 
ammonium salt 185 chloroform was chosen as solvent at the beginning. Oxygen sources were 
selected with respect to literature-known protocols.[49, 148, 76b] Afterwards, the best conditions 
were directly transferred to further substrates and PTC 182 (Table 33). 
Due to a faster reaction in toluene chloroform was substituted in further experiments  
(Table 33, Entries 3 and 6). In contrast to sodium hypochlorite epoxidation ability of hydrogen 
peroxide and TBHP are comparable (Table 33, Entries 1, 6, and 8). Increasing the amount of 
base has no effect on epoxide formation (Table 33, Entries 3 and 4). Based on those results we 
used toluene in combination with two equivalents of base and ten equivalents hydrogen 
peroxide for further investigations (Table 33, Entry 6). The background reaction can only be 
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neglected for alkene 60 (Table 33, Entry 11). Both utilized PTCs showed similar results, but no 
enantiomeric excess.  
Table 33: PTC-based epoxidation of enones. 
 
Entry(a) Cat. Alkene Epoxide Solvent t [h] Yield(f) [%] 
1(b) 185 
  
CHCl3 23 traces 
2(c) - 58 59 CHCl3 48 10 
3(c) 185 58 59 CHCl3 23 20 
4(d) 185 58 59 CHCl3 24 20 
5(c) - 58 59 PhCH3 23 28 
6(c) 185 58 59 PhCH3 24 87 
7(e) - 58 59 PhCH3 25 4 
8(c) 185 58 59 PhCH3 24 71 
9(c) - 
  
PhCH3 24 50 
10(c) 185 56 57 PhCH3 23 52 
11(c) - 
  
PhCH3 23 4 
12(c) 185 60 61 PhCH3 23 53 
13(c) 182 56 57 PhCH3 23 72 
14(c) 182 58 59 PhCH3 23 81 
15(c) 182 60 61 PhCH3 23 58 
(a): Enone (0.080 mmol, 1.0 equiv), cat. (0.008 mmol, 0.1 equiv, 10 mol%), 1.00 mL solvent; (b): NaOCl (13%) 
(0.160 mmol, 2.0 equiv); (c): NaOHaq (2%) (0.160 mmol, 2.0 equiv) and H2O2 (30%) (0.800 mmol, 10.0 equiv);  
(d): NaOHaq (6%) (0.480 mmol, 6.0 equiv) and H2O2 (30%) (0.800 mmol, 10.0 equiv); (e): NaOHaq (2%) (0.160 
mmol, 2.0 equiv) and TBHP (5 M in n-decane) (0.800 mmol, 10.0 equiv); (f): yield determined via chiral GC or 
HPLC without internal standard. 
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In contrast, for example, to the catalysts of Nagasawa, Maruoka, and Tang our two catalytic 
systems are inferior considering the epoxidation of olefin 60.[49-50, 48] 
4.5.4. Summary and Outlook 
During this project we gained a deeper inside in the field of phase transfer catalysis.  
After identification of a suitable key building block we were able to synthesize, to the best of 
our knowledge, the first peptide-based PTCs. Arising problems were solved via adaption of the 
synthetic protocol. As most important aspect we recognized the use of lipophilic amino acids 
in regard to solubility and epoxidation ability. With those catalysts in hand we tested a protocol 
starting form literature-known procedures, with which several alkenes were transferred 
successfully into the corresponding epoxides. But, due to the missing enantiomeric excess, the 
still difficult synthetic procedure, and especially the excellent working and already published 
catalysts we stopped further investigations in this direction at this point. 
4.6. Prolinol-Based Peptide Catalysts 
Besides PTCs α,α-diaryl prolinols are also suitable and well-examined catalysts for the 
epoxidation of α,β-unsaturated carbonyl compounds. In 2005, Lattanzi et al. published the first 
prolinol-based enantioselective version of this reaction (Scheme 15).[51] Several years later, 
Maltsev and Alza described the attachment of hydroxyl prolinol to an ionic liquid and to a 
polymer, respectively.[149] By containing a linker and a catalytic moiety this prolinol derivative 
is a perfect motif for our peptide-based approach. Therefore, we wanted to develop this strategy 
combined with our peptide concept as forth epoxidation procedure.  
4.6.1. Synthesis of an Attachable Hydroxyl Prolinol Derivative 
Compared to the two last described epoxidation strategies (Chapters 4.4. and 4.5.) we did not 
have to identify a catalytic moiety in this case because hydroxyl prolinol was already used as 
catalytic system. Thus, after synthesis and successful coupling with a peptide backbone our 
preconditions look promising to obtain a functionalized, active, and hopefully selective peptide. 
For preparation of catalytically active amino acid derivative 188 we oriented ourselves towards 
the procedures of Maltsev and Alza.[149] Considering a peptide synthesis we selected benzyl as 
protecting group for the secondary amine. Independently, if SPPS or a peptide synthesis in 
solution is performed, the benzyl group is orthogonal to the Fmoc and Boc protecting group, 
respectively. To mimic adamantyl-based catalysts 1 a dipeptide of phenylalanine and adamantyl 
glycine were bound via ester to hydroxyl prolinol 188. Finally, reductive cleavage of the benzyl 
group would yield peptide catalyst 192 (Scheme 59). 
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Scheme 59: Synthesis of prolinol-derived peptide catalyst 192. 
Utilizing standard conditions for methyl and benzyl protection of acid as well as amine proline 
derivative 187 was obtained with a quantitative yield.[127, 149b] The following Grignard reaction 
was performed in a solvent mixture of THF and diethyl ether, because of solubility problems 
of the starting materials.[149a] But, tertiary alcohol 188 was only isolated with a yield of 48% as 
the corresponding hydrochloride. Its presence was elucidated via utilizing different solvents for 
NMR measurements. But, this ionic species was not disadvantageous for the next reaction step 
and add-on DMAP-mediated coupling yielded functionalized amino acid 189 with 92%.[149a, 68] 
After removing the Boc group under acidic conditions adamantyl carboxylic acid was 
coupled.[116, 68, 3a] Even trying to purify product 191 utilizing different procedures could not 
remove unreacted acid completely (yields in brackets). The mixture of dipeptide and adamantyl 
carboxylic acid was reduced anyway.[116, 3a] The final step needed a lot of optimization efforts 
due to incomplete conversion. 27 mol% of Pd/C were necessary to overcome the  
literature-known catalyst inactivation caused by inhibitors.[150] Unprotected amine 192 
contaminated with around 20% carboxylic acid were finally obtained. 
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4.6.2. Catalysis and Comparison 
It is mentioned in literature that the presence of an acid leads to inhibition of the amine 
catalyst.[151] Protonation of the amine hampers its participation in the catalytic cycle  
(Scheme 15). Although peptide-bound prolinol 192 still contained adamantyl carboxylic acid, 
we wanted to perform a proof of principle reaction with this successfully synthesized catalyst. 
For direct comparison with examples from the literature we used the optimized condition 
published by Lattanzi (Table 34).[51] 
Table 34: Proof of principle experiment with prolinol-based peptide 192. 
 
Entry Cat. Amount of cat. 
[mol] 
TBHP 
[equiv] 
t 
[h] 
Yield 
[%] 
ee 
[%] 
1 192 25 1.2 94 4(a) 66(a) 
2 193 30 1.2 94 72 75 
3 194 30 1.3 144 32 80 
(a): Yield and enantiomeric excess were determined via chiral HPLC without internal standard. 
A yield of 72% and an enantiomeric excess of 75% for epoxide 61 are reported for unsubstituted 
prolinol 193 after 94 hours (Table 34, Entry 2).[51] Such long reaction times in combination with 
a comparable high catalyst loading are typical for those epoxidation reactions. Introducing a 
large substituent like a para-nitrobenzyl ether in four position of the cyclic system leads to a 
decreased activity by an unchanged selectivity (194: Table 34, Entry 3).[152] As expected, due 
to inhibition, caused by the still present acid, our catalyst 192 formed epoxide 61 very slowly. 
Substitution of the pyrrolidine ring decreased the activity additionally. Hence, it is very 
astonishing that a catalyst loading much lower than 25 mol% generated oxirane 61 with an 
enantiomeric excess of 66% (Table 34, Entry 1). 
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4.6.3. Summary and Outlook 
We were able to synthesize a prolinol-functionalized peptide mimicking highly selective 
acylation catalyst 1. Afterwards, 192 was directly tested successfully in a proof of principle 
epoxidation under optimized conditions form literature. Especially, in regard to a possible 
multicatalytic sequence with very flexibly applicable prolinol catalysts further optimizations of 
the synthetic procedure are useful. After establishing a smoothly working purification 
procedure acid-free catalysts have to be synthesized and tested in combination with additional 
substrates to get impression of their real epoxidation ability. Furthermore, a new multicatalytic 
sequence consisting of epoxidation-epoxide opening-acylation can be investigated. 
Multicatalyst 195 in combination with hydrazine sulfate[3b] could be used to synthesize acylated 
α-keto diols (Scheme 60). 
 
Scheme 60: New mutlicatalytic sequence with prolinol-catalyzed epoxidation. 
4.7. Summary and Outlook 
Considering the second step of our new postulated multicatalytic sequence (Chapter 3.) we 
created a substrate library containing 14 alkenes and their corresponding epoxides (Chapter 
4.1.1.). These less complex unsaturated compounds mimicking the unsaturated esters should 
facilitate the identification of an asymmetric epoxidation procedure based on  
peracid- (Chapter 4.3.), dioxirane- (Chapter 4.4.), PTC- (Chapter 4.5.) or prolinol-based 
catalytic systems (Chapter 4.6.). For dioxirane- and PTC-based strategies we were able to 
identify a suitable catalytic moiety. After synthesis of peptide-based catalysts containing 
precursors or catalytic active moieties themselves for all four approaches epoxidation protocols 
were successfully established. Except for the prolinol-based variant a racemic reaction process 
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was observed. Although, especially for dioxirane-based systems besides variation of the peptide 
backbone a lot of effort was invested to synthesize a selective precursor (see Chapter 4.4.9.). 
Due to the excellent working PTCs our peptide-based analogs are the less promising approach. 
On the other hand particularly C2-symmetric diacid catalysts (Chapter 4.3.6.) and peptides 
containing a TFMK functionalized amino acid appear to be encouraging (Chapter 4.4.9.5.). 
The most potent strategy is the prolinol-mediated procedure. A well-working system with 
intensively studied reaction conditions are optimal requirements. After identification of a 
suitable peptide backbone in combination with the first promising results this approach should 
be investigated in more detail. 
The last mentioned example illustrates that an alternative to synthesis of catalytic moieties is 
the use of already discovered ones with optimized reaction conditions and focus on the 
identification of appropriate peptide backbones in the future examinations. Finding and 
synthesizing new precursors is very challenging and time-consuming and no warranty is given 
that they will be active and selective in the end. Therefore, we suggest that, for example, 
catalytic motifs like Shi’s catalysts or alkaloids should be incorporated in peptidic structures 
providing catalysts like 196 or 197 (Figure 25). 
 
Figure 25: Potential peptide-based systems. 
During the synthesis of olefins and modifying TFMK-substituted aromatic systems we 
discovered both spiro carbonate 75 (Chapter 4.2.) as well as α-keto acetals 162a  
(Chapter 4.4.9.3). For the spiro compound the cooperative effect and the substrate scope of the 
protocol should be investigated in more detail. Considering the α-keto acetals further 
optimization of the synthetic procedure is necessary to increase the enantioselectivity and 
include additional substrates and electrophiles in the study. 
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5. Further Applications for the Available Peptide Catalysts 
Besides epoxidation, there are a variety of further reactions, which can be catalyzed, especially 
by dioxirane- and peracid-based species. Therefore, it is quite obvious to examine the already 
available catalysts simultaneously starting from literature-known procedures. In this context we 
tested the oxidative lactam opening (Chapter 5.1.), the synthesis of oxaziridines (Chapter 5.2.), 
and sulfoxidation (Chapter 5.3.). 
5.1. Oxidative Lactam Opening 
In 2013, Fusco et al. published the oxidative cleavage of lactams. In an aqueous solution 
trifluoromethyl acetone mediates the ring opening of cyclic amides and provides the 
corresponding nitro-substituted carboxylic acids in excellent yield. In case of 2-pyrrolidinone 
198 Fusco and co-workers isolated over 99% of carboxylic acid 199 after 90 minutes at 0 °C.[153] 
Based on this observation and with optimized conditions for the dioxirane formation regarding 
the epoxidation in hand, we tried to combine these strategies. Amide 115 was chosen as the test 
dioxirane precursor and 2-pyrrolidinone 198 as the substrate (Scheme 61). 
 
Scheme 61: Oxidative lactam opening. 
The reaction was performed in a 0.526 mmol scale with 6.00 mL of solvent; addition of H2O2 was split into four 
portions of 2.0 equiv each, added in 1 hour intervals; reaction progress was monitored by GC-MS. 
After a reaction time of 24 hours, no evidence for the formation of carboxylic acid 199 could 
be found, neither by GS-MS nor NMR analysis. Instead, catalyst 115 and small amounts of 
lactam 198 were reisolated. Due to the fact that large amounts of starting material 198 are 
missing we assume that the quite polar byproduct 199, if formed, might remain in the aqueous 
phase during work-up. The usage of rather nonpolar starting materials is a possibility to prove 
this circumstances. However, judging from the less promising test experiment, this reaction was 
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not studied in more detail, even if a kinetic resolution or desymmetrization of corresponding 
lactams should be possible using chiral peptide catalyst. 
5.2. Synthesis of Oxaziridines 
Based on the same starting material we also examined the synthesis of oxaziridine 200 
containing an additional quaternary carbon atom. In a two-step sequence, the conjectured 
intermediary formed α-acetoxy imine 201 should be directly epoxidized by the in situ generated 
dioxirane species (Scheme 62). Two papers dealing with one of the reaction steps have already 
been published. Blanton and co-workers described the synthesis of a comparable acylated 
compound in 1982,[154] whereas Aue et al. established a peracid-based epoxidation protocol of 
imino ethers in 1973.[155] 
 
Scheme 62: Synthetic approach for oxaziridine 200. 
The reaction was performed in a 0.526 mmol scale with 3.00 mL tAmylOH and 3.00 mL water; addition of H2O2 
was split into four portions of 2.0 equiv each, added in 1 hour intervals; reaction progress was monitored by  
GC-MS. 
Formation of intermediate 201 was not observable via GC-MS. Hence, it was hardly surprising 
that we reisolated 51% of starting material 198 instead of desired product 200. Due to the fact 
that the first step limits the sequence, no further attempts regarding the epoxidation  
(e.g., use of peracid-based catalysts) were undertaken. 
5.3. Sulfoxidation 
Comparing nitrogen and sulfur organic compounds of the latter can be chiral. In combination 
with oxidative conditions suitable catalysts may lead directly to sulfoxidation. 
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5.3.1. Introduction 
In contrast to sulfides 202 and sulfones 203, sulfoxides 204 can be chiral if they are substituted 
with two different residues. Besides the oxygen atom and the two aliphatic and/or aromatic 
groups, the remaining electron pair counts as the forth substituent (Scheme 63). 
 
Scheme 63: Oxidation states of sulfur. 
One approach for synthesizing sulfoxides is, for example, a titanium- or vanadium-based 
oxidation via combination of bi-, tri, and tetradendate ligands and a feasible oxidizer.[156] In the 
mid 1980s, Kagan and Modena independently established protocols for the enantioselective 
sulfoxidation based on the epoxidation concept of Sharpless.[157] Afterwards, several papers 
were published using different kind of ligands, oxidizing agents, as well as metals.[156]  
Metal-free methods have also been studied intensively during the last years.  
Besides hypervalent iodine, iminium, and oxaziridine compounds as well as hydroperoxide 
organocatalysts can be utilized to generate sulfoxides.[158] A combination of a catalyst and a 
conveniently accessible oxidizer, e.g., Oxone®, oxygen or hydrogen peroxide is favored instead 
of using stoichiometric amounts of a chiral organic oxidizer, which has to be synthesized 
beforehand. In 2003, Murahashi et al. published the oxidation of sulfides and amines with flavin 
205 in an oxygen atmosphere. Water and nitrogen are formed as non-toxic byproducts, 
thermodynamically favoring the overall process (Scheme 64).[159] 
 
Scheme 64: Flavin-catalyzed sulfoxidation. 
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Secondly, Lattanzi et al. introduced the activation of TBHP via TUC 77. Under these 
conditions, a variety of sulfides were transferred into their corresponding sulfoxides in good 
yields and selectivities with a catalyst loading of only 1 mol% (Scheme 65).[160] 
 
Scheme 65: Sulfoxidation via hydrogen bond activation of TBHP. 
Amino acids like N-protected proline 206 can also act as catalyst in sulfide oxidations. 
Tsogoeva and co-workers established a protocol providing sulfoxides in good yields up to 97% 
(Scheme 66). In their postulated mechanistic model, catalyst 206 activates hydrogen peroxide 
for the nucleophilic attack of the starting material.[161] 
 
Scheme 66: Proline-catalyzed oxidation of sulfides. 
Lastly, Colonna and co-workers described the asymmetric sulfoxidation of disulfides with 
fructose derivative 207 known from the Shi epoxidation. Besides a solvent mixture of 
acetonitrile and dimethoxymethane (DMM), a 1:1 ratio of starting material, oxidizing agent, 
and catalyst were chosen providing excellent conversion and good stereoselectivity  
(Scheme 67).[162] 
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Scheme 67: Sulfoxidation of disulfides. 
The stereoselective mono-oxidation of sulfides catalyzed by metals as well as enzymes plays a 
key role in the synthesis of biologically active sulfoxides (Figure 26), some of which are already 
produced on an industrial scale. [163] Esomeprazole 208, the S-enantiomer of omeprazole, a 
proton-pump inhibitor is used for acid-related diseases.[164] Sulfoxide 209, derived from the 
Hantzsch ester, showed good activity as a calcium channel antagonist for the treatment of heart 
diseases.[165] 
 
Figure 26: Biologically active sulfoxides. 
Furthermore, chiral sulfoxides fulfill a variety of tasks. Over the last years, these compounds 
have been established as chiral auxiliaries. Owing to their electronic structure as well as flexible 
substitution pattern, they stabilize TSs of a variety of asymmetric reactions, e.g., carbon-carbon 
bond formation and cycloadditions, yielding enantiomerically pure products (Scheme 68).[166] 
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Scheme 68: Sulfoxides as auxiliaries in asymmetric reactions. 
Based on their coordinating ability and simple access, sulfoxides are also used as ligands in 
metal-catalyzed reactions, e.g., 1,2- and 1,4-addition reactions.[167] They provide an alternative 
to diene as well as phosphane- and amino-olefin ligands. Some examples are depicted in  
figure 27.[168, 167]  
 
Figure 27: Sulfoxide-olefin ligands. 
Substituting an oxygen atom with a sulfinyl moiety in carbohydrates delivers glycosulfoxides. 
These compounds play a key role as glycosylation donors or as natural carbohydrate mimics, 
influencing the stability of these molecules (Figure 28).[169] Moreover, glycosulfoxides are 
pharmaceutically active species for the treatment of , e.g., infectious diseases or cancer.[169d]  
 
Figure 28: Sulfinyl groups in glycosulfoxides. 
Due to the versatility of racemic and especially enantiomerically-enriched sulfoxides we try to 
establish an organocatalytic and stereoselective synthetic strategy, thus enabling access to this 
class of compounds. 
Based on the successful application of TUC 77 (Scheme 65), proline derivative 206  
(Scheme 66), and dioxiranes precursor 207 (Scheme 67) as catalysts in sulfide oxidation 
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reactions, we tested our peptide-based analogs as well as the cooperative catalysis concept of 
joint phase transfer and thiourea catalysis. 
5.3.2. Synthesis of the Racemic Products 
Before screening the catalytic reactions, the corresponding products were synthesized  
as racemic mixtures starting from substituted methyl phenyl sulfides 211a-c.  
Both electron-donating as well as electron-withdrawing groups were examined. A procedure 
based on trimetylsilyl chloride (TMSCl) and hydrogen peroxide in acetonitrile was used leading 
to the sulfoxides in good to optimal yields (Table 35).[170] The enantiomers were separated 
afterwards via chiral GC. 
Table 35: Racemic synthesis of the corresponding sulfoxides. 
 
Product t [h] Yield [%] 
212a 17 61 
212b 7 86 
212c 6.5 85 
 
Methyl phenyl sulfide 211d was selected as test substrate for the first experiments. The starting 
material as well as sulfoxide 212d were commercially available. However, to determine a 
possible overoxidation, methyl phenyl sulfone 213d was also synthesized utilizing a mCPBA 
protocol (Scheme 69). Starting with 1.1 equivalents of the oxidizing agent quantitative 
conversion to the corresponding sulfoxide was observed via GC after one hour. With further 
1.1 equivalents of mCPBA sulfone 213d was isolated in 85%.[171] 
 
Scheme 69: Synthesis of sulfone 213d. 
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5.3.3. Dioxirane-Based Sulfoxidation 
It is known that sulfoxides can be synthesized via in situ generated dioxiranes starting from 
Oxone® and acetone or a carbonyl containing compound.[162, 172] With TFMK catalysts in hand, 
it is obvious to test them in the mono-oxidation of sulfides as well using the same strategy as 
for the epoxidation reactions. 
With regard to the paper of Yu et al. Oxone® was neglected as an oxidizer, because potassium 
peroxomonosulfate, a feasible oxidizing agent to generate the active species in situ, requires the 
addition of water to prevent solubility problems in most organic solvents. However, Yu et al. 
described that water can activate Oxone®, which transfers an oxygen atom onto sulfides without 
a further catalyst (Scheme 70).[172] Tugnoli et al. used acetone and Oxone to synthesize 
sulfoxides.[171] These compounds lead to the formation of dimethyldioxirane immediately.  
We assume that an in situ formed dioxirane species transfer one of the oxygen atoms onto the 
sulfur in a quite comparable manner (Scheme 71). 
 
Scheme 70: Water-based activation of peroxomonosulfate. 
 
Scheme 71: Postulated dioxirane-based mechanism. 
5.3.3.1. Proof of Principle 
Consequently, in analogy to the epoxidation the protocol with TFMK precursor, acetonitrile, 
and hydrogen peroxide was tested in the oxidation of sulfides (Chapter 4.4.). As mentioned in 
chapter 4.4.5. solvent and oxidizer generate the peroxyimidic acid, which is able to transfer the 
carbonyl group into the active dioxirane species. For the initial experiments methyl phenyl 
sulfide 211d was chosen as substrate and functionalized phenylalanine 131 as well as 
oligopeptide 214 as catalysts. Both dioxirane precursors led to sulfoxide 212d in excellent 
conversions (Table 36). The simultaneously performed background reaction showed  
only 8% conversion to the product after 24 hours. This approach demonstrates the feasibility to 
obtain sulfoxides via in situ generated dioxirane peptide catalysts. 
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Table 36: Activity of dioxirane-based catalysts in sulfoxidation reactions. 
 
Cat. 212d(a) [%] 213d(a) [%] 
131 87 traces 
214 97 traces 
- 8(b) 0 
(a): Conv. was determined using chiral GC without internal standard; (b): 24 hours reaction time. 
5.3.3.2. Optimization Process 
Concerning a possible enantioselective oxygen transfer catalyst 214 was used for further 
optimization. Table 37 summarizes the results regarding the variation of catalyst loading, 
temperature, concentration, and solvent. 
Table 37: Optimization of the sulfoxidation. 
 
Entry 214 
[mol%] 
MeCN 
[mL] 
Toluene 
[mL] 
T  
[°C] 
t 
[h] 
212d(a) 
[%] 
213d(a) 
[%] 
1 7.5 1.60 - r.t. 24 89 traces 
2 10 1.60 - r.t. 24 93 1 
3 10 3.20 - r.t. 49 98 traces 
4 10 0.800 - r.t. 24 95 5 
5 10 1.60 - 0 46 32 1 
6 10 0.800 0.800 r.t. 24 96 2 
7 10 0.100(b) 1.50 r.t. 48 85 15 
(a): Conv. was determined using chiral GC without internal standard; (b): corresponds to 5.0 equiv of MeCN. 
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Increasing the amount of catalyst accelerates the reaction and comparable results were achieved 
after only 24 hours (Table 37, Entries 1 and 2). We refrained from performing the reaction with 
a smaller amount of catalyst expecting a much longer and unpractical reaction time.  
Altering the concentration by using 3.20 mL acetonitrile slowed the reaction. A faster reaction 
was observed in case of 0.800 mL of solvent. One explanation is the necessary encounter of 
four different compounds to transfer the oxygen atom onto sulfide 211d  
(Table 37, Entries 3 and 4). With respect to the missing enantiomeric excess two strategies were 
examined. Decreasing the temperature to 0 °C did not show the desired result.  
Obviously, sulfoxide 212d forms much slower at this temperature and, hence, lower 
temperatures were not tested (Table 37, Entry 5). Secondly, toluene as nonpolar solvent was 
added to enable interactions between peptide catalyst and substrate.[2a] Neither a 1:1-solvent 
ratio nor the addition of 5.0 equivalents of acetonitrile in toluene showed any influence on the 
reaction outcome (Table 37, Entries 6 and 7). 
The variation of parameters had to be performed carefully as overoxidation to the corresponding 
sulfone 213d was also observed (Table 37, Entries 5 and 7). Consequently, using 10 mol% 
catalyst and 1.60 mL of acetonitrile at ambient temperature were selected as the best reaction 
conditions for further investigations. 
5.3.3.3. Substrate Scope 
After optimization sulfides 211a-c with a methyl, methoxy or nitrile substituent in  
para-position were oxidized via the established protocol to investigate the influence of  
electron-donating as well as electron-withdrawing groups (Table 38). 
Table 38: Testing of further substrates with peptide catalyst 214. 
 
R t [h] 212(a) [%] 213(a) [%] 
Me 24 >99 traces 
OMe 24 >99 traces 
CN 48 80 traces 
(a): Conv. was determined using chiral GC without internal standard. 
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All substrates were converted into the corresponding products with good to excellent 
conversions. Substituents in para-position with either a +I or a positive mesomeric (+M) effect 
in conjunction with a −I effect accelerate the formation of sulfides. The nitrile analog reacts 
more slowly, because the −M effect withdraws electron density from the sulfur atom and 
decreases its nucleophilic character. The protocol can be carried out with further sulfides, but 
introducing a residue in para-position on the phenyl ring did not lead to an enantiomerically 
enriched product. 
5.3.3.4. Additional Catalysts 
Before synthesizing and testing further peptide catalysts a more qualified catalytic moiety has 
to be found. As mentioned in chapter 4.4.9. two methods have already been tested to obtain a 
TFMK, which is able to perform a reaction in an enantioselective fashion. Firstly, the 
substitution pattern of the phenyl ring of the basic moiety was varied from para to meta.  
Then, the synthesis of an amino acid containing the dioxirane precursor was studied.  
After solving this problem, especially via the latter approach, further peptide catalysts have to 
be examined. 
5.3.3.5. Outlook 
Three different strategies for an enantioselective version of the sulfoxidation based on in situ 
generated dioxiranes are feasible. Further catalysts have to be synthesized and investigated 
under analogue conditions. Moreover, additional sulfides have to be tested as starting materials. 
Finally, a combinatorial approach examining catalysts and starting material has to be 
established to identify a matching-pair. 
5.3.4. Peracid-Based Sulfoxidation 
Another access to sulfoxides is based on an oxidation procedure with peracids,[171] as it was 
published by Barbarella et al. and observed during the synthesis of sulfone 213d. Peracids can 
be generated in situ via a carboxylic acid, hydrogen peroxide, and a carbodiimide as, for 
example, Miller and Schreiner et al. already showed (Chapter 4.3.1.).[33a, 31, 3b] Hence, our 
carboxylic acid containing peptides should be feasible catalysts for sulfoxidation. 
Mechanistically a similar pathway should be followed as mentioned in scheme 70 (Scheme 72). 
The sulfur atom attacks one of the oxygen atoms of the peracid. Electron transfer provides 
sulfoxide and acid, which can be transferred into the active species for the next oxidation step. 
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Scheme 72: Postulated mechanism using peracids. 
5.3.4.1. Proof of Principle 
The synthesis of terephthalic acid analog to peptide catalyst 214 in preparative amounts was 
troublesome because of solubility problems of the starting material in the reaction mixture and 
formation of side products involving the two acid moieties. Therefore, the concept was tested 
utilizing mono- and diacids in combination with hydrogen peroxide and DIC as precursors. 
Simultaneously, oxidation with mCPBA and investigation of a possible background reaction 
were performed (Table 39). 
Table 39: Test experiments for peracid-catalyzed sulfoxidation. 
 
Entry(a) Cat. 
 
Oxidizer 
 
DIC 
[equiv] 
t  
[h] 
212d(d) 
[%] 
213d(d) 
[%] 
1(b) - mCPBA  - 1 94 6 
2(b) benzoic acid H2O2 1.1 48 30 0 
3(b) mCBA H2O2 1.1 48 25 0 
4(b) phthalic acid H2O2 1.1 48 90 0 
5(c) phthalic acid H2O2 1.1 24 98 2 
6(c) phthalic acid H2O2 2.5 4 98 traces 
7(c) phthalic acid H2O2 5.0 3 95 3 
8(b) - H2O2 1.1 48 6 0 
(a): The reaction was performed in 1.60 mL solvent; (b): DCM; (c): chloroform; (d): conv. was determined using chiral 
GC without internal standard. 
In order to prove the concept the reaction was performed with mCPBA as the oxidizer. 
Sulfoxide 212d formed quantitatively, but an overoxidation was also observed via GC (Table 
39, Entry 1). Comparing the dioxirane and the peracid-based sulfoxidation 10 mol% of catalyst 
and 5.0 equivalents of hydrogen peroxide were used as the initial conditions (Table 37).  
Benzoic acid as well as mCBA in correlation to mCPBA were tested and showed a conversion 
of up to 30% (Table 39, Entries 2 and 3). With phthalic acid as catalyst 90% conversion was 
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observed (Table 39, Entry 4). In case of monoacids DIC helps to generate an active ester, which 
is transferred into the reactive species.[33b] Starting from a vicinal diacids, DIC leads to an 
intramolecular anhydride, which is opened to the peracid via hydrogen peroxide  
(Chapter 4.3.1.).[3b] Upon changing the solvent from DCM to chloroform the procedure of 
Tugnoli et al. accelerates the reaction and a nearly quantitative conversion was observed after 
24 hours (Table 39, Entry 5).[171] Increasing the amount of carbodiimide leads to an even faster 
oxidation (Table 39, Entries 6 and 7). The background reaction is negligible as only 6% of the 
sulfoxide 212d formed after 48 hours under the same conditions. Chloroform as solvent and 
2.5 equivalents of DIC were utilized for further experiments. 
5.3.4.2. Optimization Studies 
Peptide catalyst 102 containing proline as structure-forming element and aspartic acid as 
catalytically active precursor was used for testing the concept and further optimizations. 
Afterwards, both kind and amount of the solvent, catalyst loading, and temperature were 
changed (Table 40). 
Table 40: Optimization using peptide catalyst 102. 
 
Entry 102 
[mol%] 
Solvent 
[mL] 
t 
[h] 
T 
[°C] 
212d(a) 
[%] 
213d(a) 
[%] 
1 10 CHCl3 (1.6) 3 r.t. 96 4 
2 10 CHCl3 (1.6) 4 0 96 2 
3 10 PhCH3 (1.6) 7 r.t. 76 15 
4 10 PhCH3 (1.6) 25 0 68 13 
5 5 CHCl3 (1.6) 1 r.t. 97 2 
6 2.5 CHCl3 (1.6) 2 r.t. 97 1 
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7 1 CHCl3 (1.6) 5 r.t. 89 0 
8 - CHCl3 (1.6) 5 r.t. 2 0 
9 2.5 CHCl3 (0.8) 2 r.t. 95 traces 
10 2.5 CHCl3 (3.2) 8 r.t. 97 2 
(a): Conv. was determined using chiral GC without internal standard. 
Decreasing the temperature did not slow the reaction rate in case of chloroform as solvent. 
(Table 40, Entries 1 and 2). Replacing chloroform by toluene to promote interactions between 
substrate and catalyst led to a slower sulfoxidation and favored the formation of sulfone 213d 
(Table 40, Entry 3). When performing the reaction at 0 °C a reaction time of 25 hours was 
necessary to achieve comparable results (Table 40, Entry 4). Yet, an enantiomeric excess was 
not observed. The catalyst loading could be reduced to 2.5 mol% without influencing the 
catalytic activity (Table 40, Entries 5-7). The background reaction was very slow and delivered 
sulfoxide 212d with a conversion of only 2% after five hours, thereby confirming the need of 
an acid catalyst (Table 40, Entry 8). While decreasing the amount of solvent did not have a 
huge influence on the reaction process utilizing a higher dilution delayed the oxidation  
(Table 40, Entries 9 and 10). The data showed variation of catalyst loading and solvent volume 
are tunable parameters, whereas temperature seems to have a negligible effect.  
Hence, 2.5 mol% of catalyst and 1.6 mL of chloroform were used as standard parameters.  
5.3.4.3. Substrate Scope 
With optimized conditions in hand, substrates 211a-c were tested to study the effect of the 
substituents located at the phenyl ring (Table 41). 
Table 41: Scope of the reaction. 
 
Sulfide t [h] 212(a) [%] 213(a) [%] 
Me 1 >99 traces 
OMe 2 >99 traces 
CN 24 67 traces 
(a): Conv. was determined using chiral GC without internal standard. 
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In comparison to sulfide 211d, its para-methyl and para-methoxy derivatives react faster and 
its para-nitrile congener reacts more slowly in comparison to their sulfoxides 212a-c. The first 
mentioned substituents possess either a +I- or a +M/−I-effect, thereby increasing the electron 
density on the phenyl ring and hence on the sulfur atom. These two sulfides are more active 
regarding the attack on the peracid (Scheme 72). The nitrile group removes electron density 
from the phenyl ring and the sulfur atom, thus decreasing the overall nucleophilic reactivity. 
The same observations were made utilizing the TFMK peptide catalyst 214 (Table 38).  
5.3.4.4. Additional Catalysts 
Several feasible acid-containing peptides synthesized for the asymmetric epoxidation are 
available to examine their sulfoxidation ability. The reaction was performed by using optimized 
conditions and monoacid as well as diacid catalysts (Table 42). 
Table 42: Testing further acid peptide catalysts. 
 
 
Entry Cat. t [h] 212d(a) [%] 213d(a)[%] 
1 96 24 16 traces 
2 100 24 31 0 
3 101 7 94 traces 
4 215 24 20 0 
(a): Conv. was determined using chiral GC without internal standard. 
The results of the pre-optimization with benzoic as well as phthalic acid (Table 39) already 
illustrated that diacid catalysts react faster than monoacids. This observation was confirmed 
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with the peptide-based species (Table 42, Entries 1, 2, and 4 as well as 3).  
Astonishingly, tetrapeptide 100 is more active compared to tripeptides 96 and 215, even if the 
steric hindrance seems to be larger (Table 42, Entries 1, 2, and 4). 2.5 mol% of satalyst 215, the 
acid analog of TFMK peptide 214, provide sulfide 212d with a conversion of 20%  
(Table 42, Entry 4). Aspartic acid catalyst 101 generated 94% of the product after seven hours 
(Table 42, Entry 3). But, as depicted in the catalytic cycle (Chapter 4.3.1.) and in contrast to 
C2-symmetric diacid catalysts in case of a system like 101 two different catalytically active 
species can be generated preventing a possible stereoselective reaction outcome. 
5.3.4.5. Outlook 
The optimization procedure demonstrates that sulfoxidations can be carried out via in situ 
generated peracid species and that diacid catalysts are superior to monoacids. Regarding a 
stereoselective oxidation the employed catalysts and starting materials did not lead to the 
desired results. Further experiments have to ensure that either one carboxylic acid is transferred 
selectively into the catalytically active peracid or that either the catalyst or the precursor 
possesses C2-symmetry. Besides already synthesized oligopeptides, β-aspartic acids described 
in the publication of Schreiner et al. should be incorporated in catalysts.[3b] A short distance 
between the two carboxylic acid moieties is necessary for a fast process. Furthermore, the 
existing library of starting materials should be extended and tested utilizing all peptides to 
identify a suitable combination of catalyst and substrate as well as attractive types of interaction. 
5.3.5. Cooperative Thiourea and Phase Transfer Catalysis 
5.3.5.1. Concept 
Considering the activation model of water and Oxone® a TUC should also be able to activate 
HSO5
−. The reaction must be performed in a dry organic solvent to prevent the simultaneous 
activation by water. The reactive species of the oxidizer should be solved in the organic medium 
using a PTC. Afterwards, the TUC coordinates and activates the anion before the oxygen atom 
is transferred onto the sulfide (Figure 29). 
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Figure 29: Sulfoxidation using cooperative catalysis. 
5.3.5.2. Test Experiments 
Using a chiral TUC should enable a stereoselective oxidation. Hence, Nagasawa thiourea 2167 
and TBABr or tetrabutylammonium iodide (TBAI) as a catalytic system and sulfide 211d as 
test substrate were chosen for the first experiments (Table 43). 
Table 43: Test experiments utilizing cooperative catalysis. 
 
Entry 216 
[mol%] 
TBABr 
[mol%] 
TBAI 
[mol%] 
t  
[h] 
212d(a) 
[%] 
1 0.2 0.2 - 24 0 
                                                 
7 Catalyst was synthesized by Dr. Katharina M. Lippert. 
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2 0.2 - 0.2 23 0 
3 0.2 - - 25 2 
4 - 0.2 - 26 16 
5 - - 0.2 24 0 
6 - - - 27 6 
(a): Conv. was determined using chiral GC without internal standard. 
But, reactions involving thiourea 216 did not lead to the desired product (Table 43,  
Entries 1-3). In contrast oxidation with only TBABr as catalyst led to a conversion of 16% after 
24 hours (Table 43, Entry 4). A simultaneously performed background reaction provided 6% 
of sulfoxide 212d after 27 hours (Table 43, Entry 6) illustrating that a catalytic intervention of 
TBABr is not insignificant. The final product is not formed, if bromide is substituted with iodide 
(Table 43, Entry 5). These experiments confirm the assumption that 216 inhibits the oxidation 
and that bromide is the preferred counter ion of the PTC. 
Based on these first results, 216 was replaced by a more active catalyst to examine the general 
oxidative ability of TUC. Achiral thiourea 778 possesses two 3,5-bis(trifluoromethyl)phenyl 
substituents decreasing the electron density of the nitrogen-hydrogen bond. This effect favors 
the coordination of 77 to HSO5
−. Furthermore, in the following experiments the influence of 
the solvent as well as the subsequently added water was investigated (Table 44). 
Table 44: Variation of reaction conditions. 
 
 
 
                                                 
8 Catalyst was synthesized by Dr. Katharina M. Lippert. 
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Solvent(s) Product 77/TBABr 77 TBABr Without 
catalyst 
tAmylOH(a) 212d 
8% (24 h) 34% (24 h) 
37% (48 h) 
44% (24 h) 
56% (48 h) 
37% (24 h) 
48% (48 h) 
PhCH3/water
(b) 
212d 
213d 
15% (24 h) 
10% (24 h) 
15% (24 h) 
26% (24 h) 
19% (23 h) 
19% (23 h) 
traces (25 h) 
30% (25 h) 
tAmylOH/water(b) 212d 61% (4 h) 48% (26 h) 60% (1 h) 62% (25 h) 
Conv. determined using chiral GC without internal standard; reaction time in parentheses; (a): reaction performed 
under argon atmosphere; (b): 1:1-mixture of solvent and water. 
To increase the formation of sulfoxide 212d two different strategies were developed. At first, 
toluene was replaced by the more polar solvent tert-amyl alcohol, due to an increased solubility 
of the oxidizer (Table 44, Line 2). Reactions with separated as well as a combination of catalysts 
showed better conversions in comparison to the ones performed in toluene (Table 43).  
The background reaction proceeds quite fast, but the presence of TBABr accelerates the 
sulfoxidation. Secondly, a biphasic system consisting of toluene and water was tested to enable 
a liquid-liquid phase transfer catalysis (Table 44, Line 3). The background reaction provided 
only traces of sulfoxide 212d after 25 hours. Product 212d was formed in catalyzed oxidation 
reactions with a conversion of up to 19%, but the synthesis of sulfone 213d was even more 
favored in all experiments. These facts illustrate the catalytically active role of both phase 
transfer and thiourea species. Substituting toluene with tAmylOH in the biphasic system 
necessitates the use of TBABr as PTC (Table 44, Line 4). A fine suspension results from 
stirring. Even without TUC 77 the product 212d is formed with a conversion of 62%, thereby 
decreasing the benefit from this strategy. 
It is noticeable that in all cases using a phase transfer catalyst accelerates and a thiourea catalyst 
inhibits the sulfoxidation compared with the background reaction (Table 43, Entries 1, 3, 4, and 
6; Table 44). 
5.3.5.3. Single Phase Transfer Catalysis 
With all these information in hand, compound 218 was synthesized to test a chiral phase transfer 
catalyst instead of TBABr. The alkylation of quinine 217 with benzyl bromide yielded PTC 218 
in 90% (Scheme 73).[146] Regarding our peptide-based PTCs alkaloid-derived system 218 
should be utilized as test system in the forefront. 
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Scheme 73: Synthesis of chiral PTC 218. 
In the following experiments 218 was tested as the chiral version of TBABr. Due to the not 
promising results of the cooperative catalysis concept, combination with a thiourea catalyst was 
neglected (Table 45). 
Table 45: Chiral PTC 218 in the sulfoxidation of sulfide 211d. 
 
Solvent(s) Product 218 TBABr TBAI Without 
catalyst 
PhCH3
(a) 212d 0% (25 h) 16% (26 h) 0% (24 h) 6% (27 h) 
PhCH3/water
(b) 
212d 
213d 
9% (25 h) 
21% (25 h) 
19% (23 h) 
19% (23 h) 
- 
traces (25 h) 
30% (25 h) 
tAmylOH(a) 212d traces (25 h) 
44% (24 h) 
56% (48 h) 
42% (23 
h) 
37% (24 h) 
48% (48 h) 
tAmylOH/water(b) 212d 78% (25 h) 60% (1 h) - 62% (25 h) 
Conv. determined using chiral GC without internal standard; reaction time in parentheses; (a): reaction performed 
under argon atmosphere; (b): 1:1-mixture of solvent and water. 
Quinine-based bromide 218 was tested utilizing all four different solvent combinations. 
Conversions of up to 78% were obtained, but no enantiomeric excess was achieved.  
In comparison with TBABr and TBAI catalyst 218 seems to be less reactive except utilizing 
tAmylOH. The results concerning the solvents are comparable. tAmylOH is inferior to toluene 
and the use of water results in even higher conversion due to the literature-known  
water-activation of Oxone®.[172] 
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5.3.5.4. Thiourea-Catalyzed Sulfoxidation 
Based on the paper of Lattanzi et al. TUC 77 was tested separately in the sulfoxidation.  
This kind of compound is able to activate TBHP affording oxygen transfer on sulfides  
(Figure 30).[160] 
 
Figure 30: Activation of TBHP via thiourea 77. 
At the beginning, the reaction parameters used by Lattanzi and co-workers were chosen to 
reproduce the results mentioned in the paper. Due to substitution of 77 with 216 under otherwise 
constant conditions an enantioselective variant of this process should be investigated  
(Table 46). 
Table 46: Sulfoxidation via thiourea catalysts 77 and 216. 
 
 
Entry R Cat. Solvent t [h] 212(a) [%] 213(a) [%] 
1 Me 77 DCM 53 93 7(b) 
2 Me 216 DCM 54 91 9(b) 
3 OMe 216 DCM 52 97 3(b) 
4 CN 216 DCM 51 91 6(b) 
5 H 216 DCM 51 99 1(b) 
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6 Me 216 PhCH3 48 79 2
(b) 
7 Me 216 CHCl3 26 73 27
(b) 
8 Me - DCM 50 38 traces(b) 
(a): Conv. was determined using chiral GC without internal standard; (b): identification of the sulfones 213 via GC-
MS. 
First of all, we repeated the experiment of Lattanzi et al. with catalyst 77. But, in contrast to the 
results mentioned in the original report we needed nearly twice as long to obtain equal amounts 
of sulfoxide 212a (Table 46, Entry 1). Furthermore, both the overoxidation to sulfone 213a as 
well as the background reaction without catalyst were not negligible (Table 46,  
Entries 1 and 8). By replacing TUC 77 with 216 we were able to generate mono-oxygenated 
product 212a and di-oxygenated by-product 213a in comparable amounts, but without 
enantiomeric excess (Table 46, Entry 2). Similar results were observed for starting materials 
211b-d (Table 46, Entries 3-5). Carrying out the reaction in toluene had not a significant 
influence on the outcome (Table 46, Entry 6), but using chloroform instead accelerated the 
oxidative process and favored the formation of 213a (Table 46, Entry 7). 
5.3.5.5. Outlook 
Combining phase transfer and thiourea catalysis in a cooperative manner does not provide 
preparative amounts of the sulfoxides. The same observations were made utilizing only a PTC 
and an oxidizer. However, we were able to reproduce the thiourea-catalyzed protocol 
established by Lattanzi and co-workers with some discrepancies (formation of sulfone and 
background reaction), but development of an enantiomeric variant based on Nagasawa’s 
catalyst was not successful. Hence, extending the substrate library and testing further TCUs are 
the most promising aspects in future experiments beginning with these results. 
5.3.6. Summary and Outlook 
While carrying out this work, we were able to identify three possible strategies to generate 
sulfoxides starting from sulfides. Apart from the already established thiourea-based protocol 
(Chapter 5.3.5.4.), we optimized a dioxirane- (Chapter 5.3.3.) and a peracid-based 
(Chapter 5.3.4.) sulfoxidation concept (Table 47). 
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Table 47: Optimized conditions. 
 Dioxirane-based Ox.  Peracid-based Ox. Thiourea-based Ox.[160] 
Catalyst loading 10 mol% 2.5 mol% 1 mol% 
Solvent MeCN (1.6 mL) CHCl3 (1.6 mL) DCM (0.400 mL) 
Oxidizer H2O2 (5.0 equiv) H2O2 (5.0 equiv) TBHP (1.2 equiv) 
Temperature r.t. r.t. r.t. 
Additive - DIC (2.5 equiv) - 
For dioxirane-based catalysts a more suitable TFMK moiety has to be identified  
(Chapter 4.4.10.). Afterwards, oligopeptides including this group have to be synthesized 
utilizing an automated platform, and these new compounds have to be tested under the 
optimized conditions (Table 47). 
Regarding the peracid strategy, we could show that the focus has to lie on C2-symmetric diacid 
catalysts with a short acid-acid distance favoring the formation of an intermolecular anhydride. 
Therefore, further oligopeptides based on these concepts must be synthesized (Chapter 4.3.6) 
and examined using the aforementioned protocol (Table 47). 
TCUs are an intensively studied class of compounds. A variety of catalysts are easily accessible 
and can be tested afterwards utilizing Lattanzi’s protocol (Table 47).  
For all three cases further sulfoxides must be synthesized to extent the substrate library, to 
examine the influence of the substitution pattern, and to get a deeper insight into the interactions 
between catalyst and sulfide (Figure 31). 
 
Figure 31: Further possible substrates. 
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6. Summary and Outlook 
6.1. Summary 
The aim of this thesis was the establishment of an enantioselective epoxidation in the context 
of our multicatalysis approach in combination with the already utilized acylation and/or 
oxidation. As starting point we designed a new sequence consisting of acylation, epoxidation, 
and epoxide opening (Chapter 3.1.). After epoxidation of the unsaturated side chain the 
cyclohexanediol moiety should coordinate the nucleophile and enable a selective epoxide 
opening. After hydrolysis of the auxiliary a carboxylic acid with two stereogenic centers will 
be yielded. 
Considering the already optimized and established enantioselective acylation allyl acetate was 
tested as further acyl source (Chapter 2.1.). Furthermore, based on phenazine 7 we examined a 
possible oxidative esterification (Chapter 2.2.) and with sulfoximines 8 we wanted to extent the 
substrate scope (Chapter 2.3.). But, all three attempts did not show the desired result. 
For examination of the single steps of the new multicatalytic sequence we synthesized the 
racemic products of acylation (Chapter 3.2.) and epoxidation (Chapter 3.3.). Due to synthetic 
reasons we selected pentenoic acid derivatives as unsaturated components. Promisingly, we 
were able to obtain the products of trans-3-pentenoic acid after both kinetic resolution as well 
as desymmetrization with the corresponding cyclohexanediol with high selectivities utilizing 
the Steglich procedure. As alternative to the epoxidation of the crotonic acid monoesters 17 and 
18 we tested the Michael addition successfully as potential second step (Chapter 3.4.1.).  
Both carbon nucleophiles as well as a thiol were used for the possible epoxide opening reaction 
starting with monoesters 24a and 25a. But, independently from the chosen conditions we 
obtained α,β-unsaturated and γ-hydroxylated esters 31 and 32. Either protection of the free 
hydroxyl group or the usage of 4-pentenoic acid led to the desired epoxide opening  
(Chapter 3.4.2.). After optimization using only DBU as base nearly 90% yield could be 
achieved for 31 and 32. Therefore, this step should be included in the multicatalytic sequence 
enabling a variety of possible transformations based on olefin or alcohol subsequently  
(Chapter 3.4.3. and 3.4.4.). 
For identification and optimization of a feasible epoxidation procedure a substrate library of  
14 epoxides was established (Chapter 4.1.1.), because using alkenes 24 and 25 might yield 
enantiomers as well as diastereomers. A diacid- (Chapter 4.3.), a TFMK- (Chapter 4.4.),  
a PTC- (Chapter 4.5.), and a prolinol-based epoxidation approach (Chapter 4.6.) were 
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investigated. Both catalyst synthesis and development of well-working and optimized 
epoxidation protocols were possible for all four concepts. Generation of an enantiomeric excess 
was only observable in case of prolinol-based system 192. Especially, the synthesis of a 
selective TFMK-derived catalyst was studied very intensively and finally several potential 
strategies for the synthesis of a directly functionalized amino acid were illustrated  
(Chapter 4.4.8 and 4.4.9.). 
Besides epoxidation dioxirane- (Chapter 5.3.3.) and peracid-based systems (Chapter 5.3.4.) 
were also tested successfully in the oxidation of sulfides. Starting materials reacted 
chemoselectively, but not stereoselectively to the corresponding sulfoxides in the presence of 
both types of catalyst. Simultaneously, a PTC- (Chapter 5.3.5.) and thiourea-based procedure 
(Chapter 5.3.5.4.) were also studied and an optimized protocol was established for the latter one 
in regard to further experiments. 
During dealing with the main topic of this thesis the formation of spiro carbonate 75  
(Chapter 4.2.) and α-keto acetal 162a (Chapter 4.4.9.3.) were observed. For spiro carbonate 75 
reaction conditions were optimized starting from carbamate 52c to obtain the desired product 
with a yield of 78%. We assume that a cooperative catalysis based on in situ generated mCBA 
and TCU 77 takes place. For α-keto acetal 162b we were able to develop an asymmetric access 
based on literature research and mechanistic considerations. After investigation of the existence 
of closed form 163 of carboxybenzaldehyde 146 in solution via IR and NMR an alkaloid-based 
procedure was studied. With only a few experiments we found a strategy yielding acylated 
derivative 162b with nearly quantitative yield and an enantiomeric excess of up to 32%.  
Both projects have a huge potency to be investigated in more detail. 
6.2. Zusammenfassung 
Im Rahmen dieser Arbeit sollte die Epoxidierung als weiterer Reaktionsschritt neben 
Acylierung und Oxidation für die Multikatalyse zugänglich gemacht werden. Daher wurde eine 
neue Multikatalysesequenz bestehend aus Acylierung, Epoxidierung und Epoxidöffnung 
entwickelt (Kapitel 3.1.). Nach Epoxidierung der ungesättigten Ester sollte das 
Cyclohexandiolmotiv als Auxiliar fungieren und das Nucleophil während der abschließenden 
Reaktion koordinieren. Nach Esterhydrolyse könnten auf diese Weise Carbonsäurederivate mit 
zwei stereogenen Zentren erhalten werden. 
Für die bereits optimierte und etablierte enantioselektive Acylierung wurde mit Allylacetat eine 
weitere Acetylquelle (Kapitel 2.1.), unter Verwendung von Phenazin 7 eine oxidative Strategie 
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(Kapitel 2.2.) und mit den Sulfoximinen 8 weitere Substrate getestet (Kapitel 2.3.).  
Jedoch konnte in keinem der Fälle das gewünschte Resultat erzielt werden.   
Zur genauen Untersuchung der jeweiligen Einzelschritte der neuen Multikatalysesequenz 
wurden die notwendigen racemischen Acylierungs- (Kapitel 3.2.) und Epoxidierungsprodukte 
(Kapitel 3.3.) dargestellt. Aus synthetischen Gründen wurden Pentensäurederivate gewählt. 
Diesbezüglich war es sehr vielversprechend, dass die enantiomerenangereicherten Produkte der 
trans-Pent-3-encarbonsäure sowohl nach kinetischer Racematspaltung, als auch 
Desymmetrisierung des jeweiligen Cyclohexandiols unter Steglich-Bedingungen in sehr guten 
Selektivitäten erhalten werden konnten. Als Alternative zur Epoxidierung wurde die  
Michael-Addition an Crotonsäurederivaten 17 und 18 erfolgreich als möglicher zweiter 
Sequenzschritt getestet (Kapitel 3.4.1.). Zur Öffnung racemischer Epoxide der ungesättigten 
Monoester 24a und 25a wurden sowohl Kohlenstoffnucleophile, wie auch ein Thiol untersucht. 
Allerdings wurde jeweils die Eliminierung zu den α,β-ungesättigten und γ-hydroxylierten 
Estern 31 und 32 beobachtet. Sowohl Schützung der freien Alkoholfunktion, wie auch 
Verwendung der Pent-4-encarbonsäure führte nicht zur gewünschten Epoxidöffnung  
(Kapitel 3.4.2.). Nach Optimierung und nur unter Verwendung von DBU war eine Umsetzung 
zu 31 und 32 mit fast 90% Ausbeute möglich. Dieser Reaktionsschritt sollte als dritter Schritt 
in die Multikatalysesequenz eingebaut werden, da sowohl mit Doppelbindung, wie auch 
Hydroxyfunktion vielfältige Folgechemie möglich ist (Kapitel 3.4.3. und 3.4.4.). 
Zur Identifizierung und Optimierung der asymmetrischen Epoxidierung wurde eine 
Substratbibliothek mit 14 prochiralen Epoxiden aufgebaut, da im Falle von Epoxiden 24 und 
25 jeweils vier Stereoisomere möglich wären (Kapitel 4.1.1.). Für die katalysierte Epoxidierung 
wurden Disäure- (Kapitel 4.3.), Trifluormethylketon- (Kapitel 4.4.), PTC- (Kapitel 4.5.) und 
Prolinol-basierende Strategien (Kapitel 4.6.) untersucht. Katalysatorsynthese mit 
anschließender Optimierung von gut funktionierenden Epoxidierungsprotokollen wurde 
realisiert. Dabei wurde allerdings nur mit Prolinol-basierendem Peptide 192 
enantiomerenangereichertes Epoxid erhalten. Gerade für die Trifluoromethylketone wurden 
eine Vielzahl von Synthesestrategien untersucht und am Ende mögliche Syntheserouten 
aufgezeigt, die zu direkt funktionalisierten Aminosäuren führen sollten (Kapitel 4.4.8 und 
4.4.9.). 
Neben der Epoxidierung wurden Trifluormethylketon- (Kapitel 5.3.3.) und Carbonsäure-
basierende Systeme (Kapitel 5.3.4.) auch erfolgreich in Sulfoxidationen getestet. Diese verlief 
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zwar chemoselektiv zu den entsprechenden Sulfoxiden, aber ohne jegliche Stereoselektivität. 
Zusätzlich wurden noch PTC- (Kapitel 5.3.5.) und Thioharnstoff-katalysierte Sulfoxidationen 
(Kapitel 5.3.5.4.) untersucht und für letztgenannten Ansatz ein optimiertes Protokoll für weitere 
Experimente erarbeitet. 
Im Laufe der Arbeit wurde zudem noch die Bildung von Spirocarbonat 75 (Kapitel 4.2.) und  
α-Ketoacetal 162a (Kapitel 4.4.9.3.) beobachtet. Für Spirocarbonat 75 wurden die 
Reaktionsbedingungen soweit optimiert, dass in einem Zweistufenprozess ausgehend von 
Carbamat 52c 78% des Carbonats isoliert werden konnten. Es wird dabei eine kooperative 
Katalyse zwischen in situ erzeugter mCBA und Thioharnstoff 77 vermutet. Für Ketal 162b 
konnte basierend auf Literaturrecherche und mechanistischen Überlegungen ausgehend von 
Hemiacetal 163, welches zuvor mittels IR und NMR als in Lösung vorliegende Form 
identifiziert werden konnte, ein asymmetrischer Zugang entwickelt werden. Auf Basis weniger 
Experimente wurde eine Alkaloid-basierende Variante erarbeitet, mit der acyliertes Hemiacetal 
162b mit fast quantitativer Ausbeute und einem Enantiomerenüberschuss von bis zu 32% 
isoliert wurde. In beiden Fällen gibt es noch vielfältige Möglichkeiten, den jeweiligen Ansatz 
intensiver zu untersuchen. 
6.3. Synthesized Compounds 
6.3.1. Peptide Catalysts 
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6.3.2. (Towards) TFMKs 
 
 
6.3.3. (Mono-)Acylated Compounds 
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6.3.4. Epoxides and Alkenes 
 
6.3.5. Epoxide Opening Products 
 
6.3.6. ‘Digression’ Compounds 
 
6.4. Outlook 
With this thesis we gained a deeper insight into the field of multicatalysis identifying 
challenges, but also possibilities of this approach regarding further developments.  
Especially, formation of α,β-unsaturated and γ-hydroxylated esters 31 and 32 enables a very 
flexible add-on chemistry, which can easily be included in a multicatalytic sequence  
(Chapter 3.4.4.). Besides synthesis of C2-symmetric diacids catalysts (Chapter 4.3.6.), we 
consider the synthetic approach towards directly TFMK-functionalized amino acids  
(Chapter 4.4.9.5. and 4.4.10.) as most potential regarding an asymmetric epoxidation. 
Furthermore, utilizing synthesized catalysts in the sulfoxidation showed that it is obvious to test 
corresponding systems directly in further possible reactions. Via investigation of different 
reaction types in combination with synthesizing new oligopeptides and establishing thereby a 
catalyst library increases the probability to find an active catalytic system, which acts as starting 
point for modification. With the optimized protocols for epoxidation and sulfoxidation in hand 
testing and re-optimizing can be done very quickly. One possible reaction type, which can be 
included in this context, is the Baeyer-Villiger oxidation referring to the work of Miller and  
co-workers.[32] 
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With regard to a new multicatalytic sequence we think it is more promising not to synthesize 
motifs catalyzing steps of a beforehand determined sequence de novo, but to pursue an 
alternative approach, especially with the results of the prolinol-based epoxidation in mind 
(Chapter 4.6.2). Based on literature-known catalytically active systems, for which optimized 
reaction procedures are already reported, a multicatalytic sequence should be developed and 
the necessary moieties should be combined in a peptide-based catalyst afterwards, because 
finding a suitable structure-forming element incorporated in a peptidic backbone is challenging 
enough. Additionally to quoted examples of organocatalysts (e.g., F1 Scheme 5, 77 and 216 
Table 43) and the mentioned motifs 196 and 197 (Chapter 4.7.) additional well-established 
systems are depicted in figure 32. They were taken from the review of Rüping et al. 
summarizing the progress of organocatalytic-based flow-systems,[18] because substitution of the 
solid support via a peptide would directly yield an functionalized oligopeptidic catalyst. 
 
Figure 32: Potential catalytic motifs for functionalization of peptides. 
But, besides chiral organocatalysts also achiral ones (e.g., 77) can be utilized because the 
peptidic backbone is responsible for generation of a chiral environment. Based on the huge 
number of systems enabling a variety of different reactions a wide range of multicatalytic 
sequences can be realized. One further example additionally to the ones given in chapters 3.4.4. 
and 4.6.3. is depicted in scheme 74. After epoxidation of olefin 222 with a moiety derived from 
Shi’s catalyst the formed oxirane could be transferred into α,β-unsaturated and  
γ-hydroxylated ketone 223 via addition of DBU.[54] In the presence of a MacMillan-type motif 
a Diels-Alder reaction with cyclopentadiene 224 would provide bicyclic product 225.[14] 
Besides three stereogenic centers both carbon-carbon double bond as well as ketone or hydroxyl 
group of the norbornene system can be utilized for further chemical transformations. 
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Scheme 74: Further postulated multicatalytic sequence. 
A combination of a Fmoc protecting group strategy with automated peptide synthesis would be 
the method of choice for preparation of a larger amount of distinct peptidic backbones.  
The azide derivative 226 could be a possible alternative for the typically utilized amino acid 
adamantyl glycine (Figure 33). Firstly, an orthogonal attachment of both functionalized and 
previously synthesized peptide chains can be achieved via azide and carboxylic acid moiety, 
respectively. Secondly, the via click chemistry introduced triazole ring can participate in the 
interactions between catalyst and substrate in a different way than the replaced amide bond.  
 
Figure 33: Potential structure-forming unit. 
As mentioned in the introduction for enzymes as well as organocatalysts an immobilization 
approach with peptide and/or multicatalysts should be tested. This strategy implemented in 
batch or flow conditions would result in a reusable catalytic system. 
Apart from the multicatalysis project the synthesis of spiro carbonate 75 can also be investigated 
further. Especially, synergy of TCU 77 and generated mCBA as well as the substrate scope are 
aspects, which should be considered (Chapter 4.2.). 
In case of α-keto acetals 162 first of all the reaction conditions have to be optimized.  
Therefore, parameters like additional chiral bases (e.g. further alkaloids), different electrophiles 
(E+: like further anhydrides or alkylation agent), solvents or temperatures have to be tested. 
With optimized conditions in hand the substrate scope has to be elucidated. In this regard the 
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aldehyde moiety can be substituted via a ketone, the acid group via a primary amide and 
intramolecular systems via intermolecular reaction partners (Scheme 75). 
 
Scheme 75: Possible substrates. 
Subsequently, from a multicatalytic as well as synthetic point of view the gained knowledge 
can lead to further projects or can help to develop approaches in the right direction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
7. Abbreviations 
±I effect 
 
Positive or negative inductive 
effect 
LD 
 
Loading didomain 
 
±M effect 
 
Positive or negative mesomeric 
effect 
LDA 
 
Lithium diisopropylamide 
 
anhyd. Anhydrous Leu Leucine 
Ac Acetyl lit. Literature 
Ad Adamantyl m Multiplet (NMR); medium (IR) 
AdGly 
 
γ-Adamantyl amino acid (for 
the sake of convenience) 
M 
 
mol L−1 
 
aq Aqueous m.p. Melting point 
Ar Argon mCBA meta-Chlorobenzoic acid 
B* Chiral base mCPBA meta-Chloroperbenzoic acid 
Bn Benzyl Me Methyl 
Boc tert-Butyloxycarbonyl  MHz Megahertz 
bs Broad signal mL Millilitre 
calc. Calculated MS Mass spectrometry 
cat. Catalyst MTBE Methyl tert-butyl ether 
Cbz Carboxybenzyl NBS N-Bromosuccinimide 
Cha Cyclohexylalanine   NHC N-Heterocyclic carbene 
CM Catalytic moiety NHO N-Heterocyclic olefin 
conc. Concentration NMR Nuclear magnetic resonance 
conv. 
 
Conversion 
 
NOESY 
 
Nuclear Overhauser effect 
spectroscopy 
COSY Correlation spectroscopy Nu Nucleophile 
CPO Chloroperoxidase OC Organic carbonate 
Cy 
 
Cyclohexyl 
 
o-DPPB 
 
o-Diphenylphosphinobenzoic 
acid 
d Doublet PG Protecting group 
Dap 2,3-Diaminopropionic acid Ph Phenyl 
DBU 
 
1,8-Diazabicyclo[5.4.0]undec-
7-ene 
Phe 
 
Phenylalanine 
 
DCC N,N-Dicyclohexylcarbodiimide PMH π-Methyl histidine  
DCM Dichloromethane pNBA para-Nitrobenzoic acid  
DEPT 
 
Distortionless enhancement by 
polarization transfer  
ppm 
 
Parts per million 
 
DFT Density functional theory  Pr Propyl 
DiBAL Diisobutylaluminium hydride Pro Proline 
DIC N,N-Diisopropylcarbodiimide PTC Phase transfer catalyst/catalysis 
DiPEA N,N-Diisopropylethylamine  pTSA para-Toluenesulfonic acid 
DMAP 4-Dimethylaminopyridine  q Quartet 
DMF N,N-Dimethylformamide quant. Quantitative 
DMM Dimethoxymethane R Organic group 
DMP Dess-Martin periodinane  r.t. Room temperature 
DMSO Dimethyl sulfoxide resp. Respectively 
E+ Electrophile Rt Retention time 
EDAC 
 
 
 N-Ethyl-N′-(3-
dimethylaminopropyl)carbo-
diimide hydrochloride 
s 
 
 
Singlet (NMR); strong (IR) 
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EDTA Ethylenediaminetetraacetate sat. Saturated 
ee Enantiomeric excess SPPS Solid phase peptide synthesis 
EI Electron ionization t Time; triplet 
equiv Equivalent(s) T Temperature 
er Enantiomeric ratio tAmyl tert-Amyl 
ESI Electron spray ionization TBA Tetrabutylammonium 
Et Ethyl TBDPS tert-Butyldiphenylsilyl 
et al. And others TBHP tert-Butyl hydroperoxide 
eV Electronvolt TBS tert-Butyldimethylsilyl 
FID Flame-ionization detector tBu tert-Butyl 
Fmoc Fluorenylmethyloxycarbonyl TE Thioesterase 
GC Gas chromatography TEA Triethylamine 
GP 
 
General procedure 
 
TEMPO 
 
(2,2,6,6-Tetramethylpiperidin-
1-yl)oxy  
h Hour(s) TFA Trifluoroacetic acid 
HATU 
 
 
O-(7-Azabenzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium-
hexafluorphosphat 
TFMK 
 
 
Trifluoromethyl ketone 
 
 
HBTU 
 
 
2-(1H-Benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium 
hexaﬂuorophosphate 
THF 
 
 
Tetrahydrofuran 
 
 
HMBC 
 
Heteronuclear multiple-bond 
correlation spectroscopy  
TLC 
 
Thin-layer chromatography 
 
HOBt 
 
1-Hydroxybenzotriazole 
 
TMS 
 
Trimethylsilyl; 
tetramethylsilane 
HPLC 
 
High-pressure liquid 
chromatography 
TS 
 
Transition state 
 
HR High resolution TUC Thiourea catalyst 
HSAB Hard and soft acid and base UHP Urea hydrogen peroxide 
HSQC 
 
Heteronuclear single quantum 
coherence 
UV 
 
Ultraviolet 
 
Hz Hertz Val Valine 
IM Intermediate vs Very strong 
iPr iso-Propyl vw Very weak 
IR Infrared w Weak 
J Coupling constant  wt% Weigth percent 
LAH Lithium aluminum hydride δ Chemical shift 
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9. Experimental Section 
9.1. General Information 
Chemicals were purchased from Alfa Aesar, Acros Organics, Fluka, Fluorochem, Merck, 
Novabiochem, Roth, Sigma Aldrich, and TCI used without further purification. Solvents for 
column chromatography, extractions, filtrations, and recrystallizations were distilled prior use. 
After drying anhyd. solvents using standard procedures they were stored under Ar and over 
activated molecular sieves (3 Å or 4 Å) or sodium. Column chromatography was carried out 
with silica gel 60 M (Macherey-Nagel; 0.040 – 0.063 mm, 230 – 400 mesh ASTM). TLC was 
performed using precoated Machery-Nagel plastic sheets Polygram® SIL G/UV254 (Macherey-
Nagel; 0.2 mm silica gel layer with fluorescent indicator). For visualization ultraviolet (UV) 
light (254 nm) or staining solutions (2,4-dinitrophenylhydrazine: 1.0 g hydrazine, 5 mL 
concentrated H2SO4, 8 mL H2O, 237 mL EtOH; KMnO4: 2.5 g KMnO4, 8.3 g K2CO3, 250 mL 
H2O; ninhydrin: 0.2 weight percent (wt%) in ethanol; phosphomolybdic acid: 5 wt% in ethanol) 
were utilized.  
All NMR spectra were recorded on Bruker AV 200, AV 400 or AV 600 spectrometers. 
Chemical shifts (δ) are reported in parts per million (ppm) using either tetramethylsilane (TMS) 
or the corresponding residual solvent signal as internal standard.[173] Structural assignments 
were made employing distortionless enhancement by polarization transfer (DEPT) and  
2D-NMR spectra (correlation spectroscopy (COSY), heteronuclear multiple-bond correlation 
spectroscopy (HMBC), heteronuclear single quantum coherence (HSQC), nuclear Overhauser 
effect spectroscopy (NOESY)). Data are reported as follows: δ, multiplicity (bs: broad signal, 
s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet, or combinations thereof), integration, 
coupling constant (J) in hertz (Hz), assignment. IR spectra were measured on a Bruker IFS25 
spectrometer. ESI-MS was performed employing a Finnigan LCQ-Duo spectrometer. HR-MS 
was performed employing either a Thermo Scientific LTQ FT Ultra (ESI) or a Finnigan MAT95 
sectorfield spectrometer (EI). For ESI measurements a methanol solution of the corresponding 
compound was used. Reaction progress and product formation was monitored by GC-MS 
analysis with a Hewlett Packard 5890 gas chromatograph with flame-ionization detector (FID) 
and a Quadropol-MS Hewlett Packard MSD 5971 detector (EI, 70 eV) and a DB-5MS column 
(30 m x 0.250 mm) was used. Either chiral stationary phase GC analyses on Hewlett Packard 
5890 or 6890 gas chromatographs or chiral stationary phase HPLC with a Dionex system 
(Dionex P680 HPLC pump, Shodex RI-101 detector) were used to monitor enantioselective 
product formation. Analytic HPLC was performed using a Spectra SP 8700 system and 
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preparative HPLC utilizing a Knauer system (Knauer HPLC Pump 64, Knauer 2151 Variable 
Wavelength Monitor). For measurement of melting points (m.p.) a Krüss KSP1N capillary 
melting point apparatus was utilized. X-ray crystal structures were obtained using either a 
Bruker/Nonius FR591 rotating anode (Mo-Kα, λ = 0.71073 Å) equipped with a graphite 
monochromator, a Kappa CCD area detector, and an Oxford Cryostream 600 low temperature 
unit or a Bruker D8 Venture with dual a Mo/Cu IµS microfocus source  
(Mo-Kα, λ = 0.71073 Å; Cu-Kα, λ = 1.54178 Å) and a graphite monochromator, equipped with 
an Oxford Cryostream 700 low temperature unit.  
9.2. Racemic Synthesis of Mono-Acylated Compounds 
9.2.1. Acyl Derivatives 
General Procedure (GP-1):  
Catalytic amounts DMAP and 1.0 equiv alcohol were dissolved in DCM. Afterwards 1.0 equiv 
freshly distilled Ac2O and 1.0 equiv DiPEA were added in one portion and the resulting mixture 
was stirred at r.t.. At the end of the reaction the solvent was evaporated and the crude product 
was purified utilizing column chromatography. 
trans-2-Acetoxycyclohexan-1-ol 4: (GP-1) 
The reaction was performed with 0.011 g (0.090 mmol, 5 mol%) DMAP,  
0.200 g (1.72 mmol, 1.0 equiv) diol 2, 0.163 mL (0.176 g, 1.72 mmol, 1.0 equiv) 
Ac2O, 0.292 mL (0.222 g, 1.72 mmol, 1.0 equiv) DiPEA, and 9 mL DCM.  
The resulting mixture was stirred for 19 h. After purification via column chromatography 
(EtOAc) 0.133 g (0.841 mmol, 49%) 4 were isolated as colorless oil. 
Rf: 0.50 (EtOAc). 
1H-NMR (200 MHz, CDCl3): δ = 4.61–4.49 (m, 1 H); 3.59–3.47 (m, 1 H); 2.56 (bs, 1 H); 2.11–
1.91 (m, 5 H); 1.77–1.61 (m, 2 H); 1.45–1.11 (m, 4 H) ppm.  
13C-NMR (50 MHz, CDCl3): δ = 171.5; 78.3; 72.8; 33.2; 30.1; 23.8; 24.0; 21.5 ppm. 
Analytic data are identical to those reported in literature.[174] 
Chiral GC analysis: 
Enantiomers of 4 were separated by chiral GC employing a 30 m FS-Hydrodex γ-DiMOM 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: initial temperature: 100 °C; initial time: 45 min. 
Retention times: Rt1 = 42.0 min; Rt2 = 43.5 min. 
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cis-2-Acetoxycyclohexan-1-ol 5: (GP-1) 
The reaction was performed with 0.011 g (0.090 mmol, 5 mol%) DMAP,  
0.200 g (1.72 mmol, 1.0 equiv) diol 3, 0.163 mL (0.176 g, 1.72 mmol, 1.0 equiv) 
Ac2O, 0.292 mL (0.222 g, 1.72 mmol, 1.0 equiv) DiPEA, and 9 mL DCM.  
The resulting mixture was stirred for 19 h. After purification via column chromatography 
(EtOAc) 0.178 g (1.13 mmol, 65%) 5 were isolated as colorless oil. 
Rf: 0.52 (EtOAc). 
1H-NMR (400 MHz, CDCl3): δ = 4.90 (dt, 1 H, J = 8.1 Hz, J = 2.8 Hz); 3.88–3.85 (m, 1 H); 
2.08 (s, 3 H); 1.94 (bs, 1 H); 1.87–1.73 (m, 2 H); 1.67–1.54 (m, 4 H); 1.41–1.33 (m, 2 H) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 170.9; 74.4; 69.2; 30.4; 27.0; 22.2; 21.4; 21.0 ppm. 
Analytic data are identical to those reported in literature.[2b]  
Chiral GC analysis: 
Enantiomers of 5 were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Condition: initial temperature: 100 °C; final temperature:  
140 °C; rate: 2.00 °C/min. Retention Times: Rt1 = 14.3 min; Rt2 = 15.2 min. 
trans-2-Acetoxycyclohexyl (E)-3-pentenoate 33: (GP-1) 
The reaction was performed with 0.003 g (0.020 mmol, 8 mol%) DMAP, 
0.050 g (0.252 mmol, 1.0 equiv) monoester 20a, 24.0 µL  
(25.9 mg, 0.254 mmol, 1.0 equiv) Ac2O, 43.0 µL (32.7 mg, 0.253 mmol, 
1.0 equiv) DiPEA, and 2 mL DCM. Based on TLC further 24.0 µL (25.9 mg, 0.254 mmol,  
1.0 equiv) Ac2O and 43.0 µL (32.7 mg, 0.253 mmol, 1.0 equiv) DiPEA were added after 5.5 h. 
The reaction mixture was stirred 31 h. After purification via column chromatography  
(n-hexane:EtOAc 4:1 to 2:1) 0.055 g (0.229 mmol, 91%) 33 were isolated as colorless oil. 
Rf: 0.49 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.61–5.45 (m, 2 H, CHCH); 4.84–4.76 (m, 2 H, CHCO); 2.97 
(d, 2 H, 3J = 6.3 Hz, CH2CHCH); 2.06–2.00 (m, 2 H, HCy); 2.00 (s, 3 H, CH3); 1.76–1.70 (m, 2 
H, HCy); 1.69–1.67 (m, 3 H, CHCH3); 1.44–1.29 (m, 4 H, HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 171.7 (CO); 170.6 (CO); 129.5 (CH2CH); 122.8 (CHCH); 
73.9 (CHO); 73.8 (CHO); 38.5 (CH2CH); 30.3 (CH2CHO); 30.2 (CH2CHO); 23.57 
(CH2CH2CH); 23.56 (CH2CH2CH); 21.2 (CH3); 18.1 (CHCH3) ppm. 
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cis-2-Acetoxycyclohexyl (E)-3-pentenoate 34: (GP-1) 
The reaction was performed with 0.003 g (0.020 mmol, 8 mol%) DMAP, 
0.049 g (0.247 mmol, 1.0 equiv) monoester 21a, 24.0 µL  
(25.9 mg, 0.254 mmol, 1.0 equiv) Ac2O, 43.0 µL (32.7 mg, 0.253 mmol, 
1.0 equiv) DiPEA, and 2 mL DCM. Based on TLC further 24.0 µL (25.9 mg, 0.254 mmol,  
1.0 equiv) Ac2O and 43.0 µL (32.7 mg, 0.253 mmol, 1.0 equiv) DiPEA were added after 6 h. 
The reaction mixture was stirred 25 h. After purification via column chromatography  
(n-hexane:EtOAc 4:1) 0.045 g (0.187 mmol, 76%) 34 were isolated as colorless oil. 
Rf: 0.50 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.64–5.48 (m, 2 H, CHCH); 5.04–5.02 (m, 1 H, CHCO); 
5.00–4.97 (m, 1 H, CHCO); 3.00–3.01 (m, 2 H, CH2CHCH); 2.02 (s, 3 H, CH3); 1.88–1.77 (m, 
2 H, HCy); 1.68 (d, 3 H, 
3J = 5.0 Hz, CHCH3); 1.66–1.58 (m, 4 H, HCy); 1.51–1.35 (m, 2 H, HCy) 
ppm.  
13C-NMR (101 MHz, CDCl3): δ = 171.6 (CO); 170.5 (CO); 129.4 (CH2CH); 122.9 (CHCH); 
71.2 (CHO); 71.0 (CHO); 38.3 (CH2CH); 27.8 (CH2CHO); 27.6 (CH2CHO); 22.0; 21.6; 21.2; 
18.1 (CHCH3) ppm. 
9.2.2. Unsaturated Esters 
General procedure for the esterification using anhydrides (GP-2):  
DMAP and diol were dissolved in DCM. Afterwards pyridine and anhydride were added in one 
portion. The resulting mixture was stirred at r.t. and the reaction progress was monitored via 
TLC. At the end of the reaction 10 mL of a brine were added. After phase separation, extraction 
with either DCM or EtOAc (three times 10 mL), and drying over Na2SO4 the solvent was 
evaporated. The crude product was purified utilizing column chromatography. 
General procedure using the Steglich protocol (GP-3):  
DMAP, EDAC, diol, and solid acids were solved in DCM. Afterwards TEA and liquid acids 
were added in one portion. The resulting mixture was stirred at r.t. and the reaction progress 
was monitored via TLC. At the end of the reaction sat. NaHCO3 was added. After phase 
separation, extraction of the aqueous layer with DCM, and drying over Na2SO4 the solvent was 
evaporated. The crude product was purified utilizing column chromatography. 
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trans-2-Hydroxycyclohexyl crotonate 17: (GP-2) 
The reaction mixture containing 0.021 g (0.172 mmol, 10 mol%) DMAP, 
0.242 mL (0.252 g, 1.63 mmol, 0.9 equiv) crotonic anhydride, 0.202 g  
(1.74 mmol, 1.0 equiv) diol 2, 0.840 mL (0.822 g, 10.4 mmol, 6.0 equiv) 
pyridine, and 4 mL DCM was stirred for 16 h. EtOAc was used for the extraction.  
After purification via column chromatography (n-hexane:EtOAc 4:1 to 0:1) 0.188 g  
(1.02 mmol, 63%) 17 were isolated as colorless oil. 
Rf: 0.27 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 6.98 (dq, 1 H, 3J = 15.5 Hz, 3J = 6.9 Hz, CHCH3); 5.84 (dq, 
1 H, 3J = 15.5 Hz, 4J = 1.7 Hz, COCH); 4.63–4.58 (m, 1 H, CHOCO); 3.59–3.53 (m, 1 H, 
CHOH); 2.44 (bs, 1 H, OH); 2.07–2.00 (m, 2 H, HCy); 1.86 (dd, 3 H, 3J = 6.9 Hz, 4J = 1.7 Hz, 
CH3); 1.72–1.64 (m, 2 H, HCy); 1.39–1.18 (m, 4 H, HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 166.9; 145.2; 122.8; 78.0; 72.9; 33.1; 30.1; 24.0; 23.8; 18.1 
ppm. 
IR (Film): ṽ = 3449 (vw); 2939 (w); 2863 (vw); 1718 (w); 1187 (w); 1029 (w); 853 (vw) cm−1. 
HR-MS (ESI): m/z: 207.0997 [M + Na]+ (cal. 207.0992); 391.2086 [2M + Na]+ (cal. 391.2091). 
Analytic data are identical to those reported in literature.[69] 
cis-2-Hydroxycyclohexyl crotonate 18: (GP-2) 
The reaction mixture containing 0.013 g (0.106 mmol, 12 mol%) DMAP, 
0.121 mL (0.126 g, 0.816 mmol, 0.9 equiv) crotonic anhydride, 0.101 g 
(0.869 mmol, 1.0 equiv) diol 3, 0.420 mL (0.411 g, 5.12 mmol, 5.9 equiv) 
pyridine, and 3 mL DCM was stirred for 20 h. DCM was used for the extraction.  
After purification via column chromatography (n-hexane:EtOAc 4:1 to 1:1) 0.095 g  
(0.516 mmol, 63%) 18 were isolated as colorless oil. 
Rf: 0.29 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.00 (dq, 1 H, 3J = 15.5 Hz, 3J = 6.9 Hz, CHCH3); 5.88 (dq, 
1 H, 3J = 15.5 Hz, 4J = 1.6 Hz, COCH); 4.98 (dt, 1 H, 3J = 7.9 Hz, 3J = 2.7 Hz, CHCO); 3.93–
3.85 (m, 1 H, CHOH); 1.92–1.86 (m, 4 H, CH3 and HCy); 1.82–1.73 (m, 1 H, HCy); 1.72–1.54 
(m, 4 H, HCy); 1.45–1.30 (m, 2 H, HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 166.3; 145.3; 122.9; 74.0; 69.5; 30.5; 27.2; 22.1; 21.3; 18.1 
ppm. 
IR (Film): ṽ = 3443 (w); 2941 (m); 2866 (m); 1717 (s); 1185 (m); 972 (m); 850 (w) cm−1. 
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HR-MS (ESI): m/z: 207.1002 [M + Na]+ (cal. 207.0992); 391.2092 [2M + Na]+ (cal. 391.2091). 
Chiral GC analysis: 
Enantiomers of 18 were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: initial temperature: 130 °C; initial time: 55 min. 
Retention times: Rt1 = 31.5 min; Rt2 = 32.2 min. 
trans-2-Hydroxycyclohexyl (E)-3-pentenoate 20a: (GP-3) 
The reaction mixture containing 2.60 mg (0.021 mmol, 2 mol%) DMAP, 
0.101 g (0.869 mmol, 1.0 equiv) diol 2, 0.087 mL (0.086 g, 0.857 mmol, 
1.0 equiv) 3-pentonic acid 19a, 0.165 g (0.861 mmol, 1.0 equiv) EDAC, 
0.120 mL (0.087 g, 0.861 mmol, 1.0 equiv) TEA, and 5 mL DCM was stirred for 25 h.  
The reaction was quenched with 10 mL sat. NaHCO3 and the aqueous layer was extracted with 
DCM (three times 10 mL). After purification via column chromatography (n-hexane:EtOAc 
3:1 to 0:1) 0.120 g (0.605 mmol, 71%) 20a were isolated as colorless oil. 
Rf: 0.23 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.64–5.49 (m, 2 H, CHCH); 4.60–4.54 (m, 1 H, CHOC); 
3.60–3.53 (m, 1 H, CHOH); 3.09–3.00 (m, 2 H, COCH2); 2.13 (d, 1 H, 3J = 3.9 Hz, OH); 2.08–
1.97 (m, 2 H, HCy); 1.75–1.63 (m, 5 H, CH3 and HCy); 1.40–1.18 (m, 4 H, HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 172.6 (CO); 129.7 (CH2CH); 122.8 (CHCH); 78.6 
(CHOCO); 72.9 (CHOH); 38.4 (CH2CH); 33.1 (CH2CHOH); 30.1 (CH2CHOCO); 24.0 
(CH2CH2CHOCO); 23.9 (CH2CH2CHOH); 18.1 (CH3) ppm. 
IR (Film): ṽ = 3429 (s); 2939 (s); 2865 (s); 1722 (s); 1261 (s); 854 (m); 574 (w) cm−1. 
HR-MS (EI): m/z: 198.1239 (cal. 198.1256). 
MS (ESI): m/z: 221.1 [M + Na]+ (cal. 221.1); 237.1 [M + K]+ (cal. 237.1); 418.9 [2M + Na]+ 
(cal. 419.2). 
Chiral HPLC analysis: 
Enantiomers of 20a were separated by chiral HPLC employing a 25 cm 
Chiralpak IA column (4.6 mm ID, Daicel) in combination with an UV-detector (220 nm). Flow 
= 0.700 mL/min. Solvent mixture: n-hexane:isopropanol 90:10. Retention times: Rt1 = 11.7 
min; Rt2 = 17.7 min. 
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trans-2-Hydroxycyclohexyl 4-pentenoate 20b: (GP-3) 
The reaction mixture containing 0.021 g (0.172 mmol, 1 mol%) DMAP, 
2.00 g (17.2 mmol, 1.0 equiv) diol 2, 1.74 mL (1.71 g, 17.0 mmol,  
1.0 equiv) 4-pentonic acid 19b, 3.32 g (17.3 mmol, 1.0 equiv) EDAC,  
2.40 mL (1.74 g, 17.2 mmol, 1.0 equiv) TEA, and 80 mL DCM was stirred for 42 h. The reaction 
was quenched with 80 mL sat. NaHCO3 and the aqueous layer was extracted with DCM  
(three times 10 mL). After purification via column chromatography (n-hexane:EtOAc 2:1)  
1.51 g (7.62 mmol, 45%) 20b were isolated as colorless oil. 
Rf: 0.32 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.83 (ddt, 1 H, 3J = 16.4 Hz, 3J = 10.3 Hz, 3J = 6.2 Hz, 
CHCH2); 5.09–5.04 (m, 1 H, CHCH2); 5.03–5.00 (m, 1 H, CHCH2); 4.61–4.55 (m, 1 H, 
CHOC); 3.57–3.51 (m, 1 H, CHOH); 2.47–2.43 (m, 2 H, COCH2CH2CH); 2.41–2.35 (m, 2 H, 
CH2CHCH2); 2.15 (bs, 1 H, OH); 2.07–1.97 (m, 2 H, HCy); 1.74–1.64 (m, 2 H, HCy); 1.39–1.19 
(m, 4 H, HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 173.4 (CO); 136.9 (CHCH2); 115.8 (CHCH2); 78.4 
(CHOCO); 72.9 (CHOH); 34.0 (CH2CH2CH); 33.1 (CH2CHOH); 30.1 (CH2CHOCO); 29.2 
(CH2CH2CH); 24.0 CH2CH2CHOCO); 23.9 (CH2CH2CHOH) ppm.
  
IR (Film): ṽ = 3445 (m); 2940 (vs); 2863 (s); 1733 (vs); 1179 (vs); 852 (w); 568 (vw) cm−1. 
HR-MS (EI): m/z: 198.1227 (cal. 198.1256). 
Chiral HPLC analysis: 
Enantiomers of 20b were separated by chiral HPLC employing a 25 cm 
Chiralpak IA column (4.6 mm ID, Daicel) in combination with an UV-detector (254 nm). Flow 
= 1.00 mL/min. Solvent mixture: n-hexane:isopropanol 95:5. Retention times: Rt1 = 13.4 min; 
Rt2 = 14.7 min. 
cis-2-Hydroxycyclohexyl (E)-3-pentenoate 21a: (GP-3) 
The reaction mixture containing 1.05 mg (0.009 mmol, 1 mol%) DMAP, 
0.103 g (0.887 mmol, 1.0 equiv) diol 3, 0.089 mL (0.088 g, 0.876 mmol, 
1.0 equiv) 3-pentonic acid 19a, 0.165 g (0.861 mmol, 1.0 equiv) EDAC, 
0.120 mL (0.087 g, 0.861 mmol, 1.0 equiv) TEA, and 4 mL DCM was stirred for 24 h.  
The reaction was quenched with 10 mL sat. NaHCO3 and the aq layer was extracted with DCM 
(three times 10 mL). After purification via column chromatography (n-hexane:EtOAc 2:1 to 
0:1) 0.093 g (0.469 mmol, 54%) 21a were isolated as colorless oil. 
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Rf: 0.24 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.63–5.50 (m, 2 H, CHCH); 4.92 (dt, 1 H, 3J = 8.1 Hz, 3J = 
2.8 Hz, CHOC); 3.88–3.83 (m, 1 H, CHOH); 3.06–3.04 (m, 2 H, COCH2); 1.92 (bs, 1 H, OH); 
1.88–1.81 (m, 1 H, HCy); 1.79–1.72 (m, 1 H, HCy); 1.71–1.68 (m, 3 H, CH3); 1.65–1.54 (m, 4 
H, HCy); 1.42–1.31 (m, 2 H, HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 172.0 (CO); 129.7 (CH2CH); 122.8 (CHCH); 74.4 
(CHOCO); 69.3 (CHOH); 38.4 (CH2CH); 30.4 (CH2CHOH); 27.0 (CH2CHOCO); 22.1 
(CH2CH2CHOCO); 21.2 (CH2CH2CHOH); 18.1 (CH3) ppm.
  
IR (Film): ṽ = 3433 (vs); 2940 (s); 2866 (s); 1719 (vs); 1182 (vs); 887 (m); 596 (w) cm−1. 
HR-MS (EI): m/z: 198.1240 (cal. 198.1256). 
MS (ESI): m/z: 221.0 [M + Na]+ (cal. 221.1); 237.1 [M + K]+ (cal. 237.1); 418.9 [2M + Na]+ 
(cal. 419.2). 
Chiral GC analysis: 
Enantiomers of 21a were separated by chiral GC employing a 30 m Chiraldex G-TA column 
(Astech). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. Precolumn pressure = 0.8 
bar. Conditions: Initial temperature: 80 °C; Final temperature: 150 °C; Rate: 1.00 °C/min. 
Retention times: Rt1 = 56.5 min; Rt2 = 57.5 min. 
cis-2-Hydroxycyclohexyl 4-pentenoate 21b: 
The reaction mixture containing 0.022 g (0.180 mmol, 1 mol%) DMAP, 
2.00 g (17.2 mmol, 1.0 equiv) diol 3, 1.80 mL (1.77 g, 17.6 mmol,  
1.0 equiv) 4-pentonic acid 19b, 3.32 g (17.3 mmol, 1.0 equiv) EDAC, 
2.40 mL (1.74 g, 17.2 mmol, 1.0 equiv) TEA, and 80 mL DCM was stirred for 43 h. The reaction 
was quenched with 80 mL sat. NaHCO3 and the aq layer was extracted with DCM (three times 
10 mL). After purification via column chromatography (n-hexane:EtOAc 2:1) 1.69 g (8.52 
mmol, 50%) 21b were isolated as colorless oil. 
Rf: 0.36 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.84 (ddt, 1 H, 3J = 16.3 Hz, 3J = 10.3 Hz, 3J = 6.1 Hz, 
CHCH2); 5.10–5.05 (m, 1 H, CHCH2); 5.03–5.00 (m, 1 H, CHCH2); 4.94 (dt, 1 H, 3J = 8.2 Hz, 
3J = 3.0 Hz, CHOC); 3.88–3.83 (m, 1 H, CHOH); 2.48–2.45 (m, 2 H, COCH2CH2CH); 2.43–
2.36 (m, 2 H, CH2CHCH2); 1.89 (d, 1 H, 
3J = 4.0 Hz, OH); 1.85–1.70 (m, 2 H, HCy); 1.68–1.54 
(m, 4 H, HCy); 1.43–1.30 (m, 2 H, HCy) ppm.  
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13C-NMR (101 MHz, CDCl3): δ = 172.8 (CO); 136.9 (CHCH2); 115.8 (CHCH2); 74.3 
(CHOCO); 69.3 (CHOH); 33.9 (CH2CH2CH); 30.5 (CH2CHOH); 29.1 (CH2CH2CH); 27.1 
(CH2CHOCO); 22.1 CH2CH2CHOCO); 21.2 (CH2CH2CHOH) ppm.
  
IR (Film): ṽ = 3455 (w); 2940 (m); 2863 (w); 1732 (m); 1177 (m); 850 (vw); 601 (vw) cm−1. 
HR-MS (ESI): m/z: 221.1158 [M + Na]+ (cal. 221.1148); 419.2411 [2M + Na]+ (cal. 419.2404). 
Chiral HPLC analysis: 
Enantiomers of 21b were separated by chiral HPLC employing a 25 cm 
Chiralpak IA column (4.6 mm ID, Daicel) in combination with an UV-Vis-detector (220 nm). 
Flow = 1.00 mL/min. Solvent mixture: n-hexane:iso-propanol 97:3. Retention times: Rt1 = 13.9 
min; Rt2 = 15.5 min. 
9.2.3. N-Acylated Sulfoximines 
General Procedure (GP-4):  
Catalytic amounts DMAP and the corresponding sulfoximine were dissolved in 2 mL DCM. 
Afterwards, freshly distilled Ac2O and DiPEA were added in one portion. The resulting mixture 
was stirred at r.t. and the reaction progress was monitored via TLC. At the end of the reaction 
10 mL sat. NaHCO3 were added. After phase separation, washing with DCM, and drying over 
Na2SO4 the solvent was evaporated. The crude product was purified utilizing column 
chromatography. 
1-(o-Fluorophenylmethylthioamino)-1-ethanone 9a: (GP-4) 
A reaction mixture containing 4.10 mg (0.034 mmol, 27 mol%) DMAP, 
22.0 mg (0.127 mmol, 1.0 equiv) sulfoximine 8a, 0.014 mL (15.1 mg, 
0.148 mmol, 1.2 equiv) Ac2O, and 0.024 mL (18.2 mg, 0.141 mmol,  
1.1 equiv) DiPEA was stirred for 28 h. After 8 h further 1.1 equiv Ac2O 
and DiPEA were added. After purification via column chromatography (n-hexane:EtOAc 1:2 
to 1:3) 18.0 mg (0.084 mmol, 66%) 9a were isolated as colorless oil. 
Rf: 0.26 (n-hexane:EtOAc 1:2). 
1H-NMR (19F) (400 MHz, CDCl3): δ = 8.05 (dd, 1 H, 3J = 8.0 Hz, 4J = 1.4 Hz, H6); 7.68–7.64 
(m, 1 H, H5); 7.39 (t, 1 H, 3J = 7.7 Hz, H4); 7.25 (d, 1 H, 3J = 8.6 Hz, H3); 3.42 (s, 3 H, SCH3); 
2.11 (s, 3 H, COCH3) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 180.0 (CO); 158.4 (C8, 1JCF = 254.8 Hz); 136.3 (C7, 3JCF = 
8.5 Hz); 130.9 (C6); 126.4 (C5, 2JCF = 14.0 Hz); 125.2 (C
4, 4JCF = 3.7 Hz); 117.4 (C
3, 2JCF = 
21.3 Hz); 43.4 (SCH3, 
4JCF = 3.5 Hz); 26.6 (COCH3) ppm. 
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IR (Film): ṽ = 3019 (vw); 2929 (vw); 2090 (vw); 1858 (vw); 1641 (s); 1475 (m); 1263 (s); 
1231 (s); 1037 (m); 826 (m); 765 (m) ; 483 (m) cm−1. 
HR-MS (ESI): m/z: 216.0498 [M + H]+ (cal. 216.0489); 238.0314 [M + Na]+ (cal. 238.0308); 
453.0725 [2M + Na]+ (cal. 453.0725). 
MS (ESI): m/z: 238.1 [M + Na]+ (cal. 238.0); 452.9 [2M + Na]+ (cal. 453.1). 
Chiral GC analysis: 
Enantiomers of 9a were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 140 °C; Final temperature:  
250 °C; Rate: 2.00 °C/min. Retention times: Rt1 = 34.0 min; Rt2 = 35.8 min. 
1-(o-Chlorophenylmethylthioamino)-1-ethanone 9b: (GP-4) 
A reaction mixture containing 4.10 mg (0.019 mmol, 21 mol%) DMAP, 
17.0 mg (0.090 mmol, 1.0 equiv) sulfoximine 8b, 34.2 µL (36.9 mg,  
0.362 mmol, 4.0 equiv) Ac2O, and 61.5 µL (46.7 mg, 0.362 mmol,  
4.0 equiv) DiPEA was stirred for 24 h. After purification via column 
chromatography (n-hexane:EtOAc 1:2) 14.0 mg (0.060 mmol, 67%) 9b were isolated as 
colorless oil. 
Rf: 0.29 (n-hexane:EtOAc 1:2). 
1H-NMR (400 MHz, CDCl3): δ = 8.24–8.22 (m, 1 H, H4); 7.61–7.51 (m, 3 H, H3); 3.43 (s, 3 
H, SCH3); 2.11 (s, 3 H, COCH3) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 179.7 (CO); 136.2 (C8); 134.8 (CH); 132.2 (CH); 131.8 (C5); 
131.1 (C4); 128.0 (CH); 42.0 (SCH3); 26.4 (COCH3) ppm. 
IR (KBr): ṽ = 3014 (m); 2931 (m); 2087 (vw); 1948 (vw); 1860 (vw); 1634 (vs); 1475 (m); 
1268 (vs); 1213 (vs); 1051 (vs); 969 (vs); 824 (s); 761 (vs); 510 (vs); 465 (s) cm−1. 
HR-MS (ESI): m/z: 254.0017 [M + Na]+ (cal. 254.0013); 485.0133 [2M + Na]+ (cal. 485.0134). 
MS (ESI): m/z: 254.0 [M + Na]+ (cal. 254.0); 485.4 [2M + Na]+ (cal. 485.0). 
Chiral GC analysis: 
Enantiomers of 9b were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 140 °C; Final temperature:  
250 °C; Rate: 2.00 °C/min. Retention times: Rt1 = 37.7 min; Rt2 = 38.8 min. 
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1-(o-Bromophenylmethylthioamino)-1-ethanone 9c: (GP-4) 
A reaction mixture containing 3.30 mg (0.027 mmol, 37 mol%) DMAP, 
17.0 mg (0.073 mmol, 1.0 equiv) sulfoximine 8c, 0.021 mL (22.7 mg,  
0.222 mmol, 3.1 equiv) Ac2O, and 0.038 mL (28.8 mg, 0.223 mmol,  
3.1 equiv) DiPEA was stirred for 24 h. After purification via column 
chromatography (n-hexane:EtOAc 1:2) 11.0 mg (0.040 mmol, 55%) 9c were isolated as 
colorless oil. 
Rf: 0.29 (n-hexane:EtOAc 1:2). 
1H-NMR (400 MHz, CDCl3): δ = 8.27 (dd, 1 H, 3J = 8.0 Hz, 4J = 1.7 Hz, H6); 7.76 (dd, 1 H, 3J 
= 7.9 Hz, 4J = 1.2 Hz, H5); 7.58 (dt, 1 H, 3J = 7.7 Hz, 4J = 1.2 Hz, H4); 7.48 (dt, 1 H, 3J = 7.7 
Hz, 4J = 1.7 Hz, H3); 3.45 (s, 3 H, SCH3); 2.12 (s, 3 H, COCH3) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 179.7 (CO); 137.9 (C8); 135.8 (C7); 134.8 (C6); 132.0 (C5); 
128.6 (C4); 119.3 (C3); 41.8 (SCH3); 26.4 (COCH3) ppm. 
IR (KBr): ṽ = 3002 (m); 2922 (s); 2090 (vw); 1871 (vw); 1635 (vs); 1367 (s); 1264 (vs); 1211 
(vs); 1045 (vs); 959 (s); 831 (s); 758 (s); 507 (s); 456 (s) cm−1. 
HR-MS (ESI): m/z: 297.9514 [M + Na]+ (cal. 297.9508). 
MS (ESI): m/z: 297.9 [M + Na]+ (cal. 298.0). 
Chiral GC analysis: 
Enantiomers of 9c were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 140 °C; Final temperature:  
250 °C; Rate: 2.00 °C/min. Retention times: Rt1 = 42.3 min; Rt2 = 43.1 min. 
9.3. Catalytic Acylation  
9.3.1. Peptide-Based Steglich Esterification of Pentonic Acids and Diols  
For the kinetic resolution the reaction vessel was charged with 1.0 equiv diol (±)-2. Dissolved 
cat. 1 (toluene, 2 mol%), 1.2 equiv DIC, and 2.0 equiv pentenoic acid 19a were rinsed into the 
reaction vial using 4.40 mL anhyd. toluene. The resulting mixture was cooled to 0 °C.  
Samples of 0.5 mL were taken, quenched with MeOH, and analyzed directly via chiral GC or 
HPLC. 
For the desymmetrization the reaction vessel was charged with 2 mol% cat. 11, 1.0 equiv DCC, 
and 1.0 equiv meso-3. 2.0 equiv pentenoic acid 19a were rinsed into the reaction vial using  
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4.00 mL anhyd. toluene. The resulting mixture was cooled to 0 °C. Samples of 0.5 mL were 
taken, quenched with MeOH, and analyzed directly via chiral GC. 
9.3.2. Sulfoximines 
The reaction vessel was charged with sulfoximine. Freshly distilled Ac2O, DiPEA as well as 
the corresponding volume of a stock solution containing the cat. were rinsed into the reaction 
vial using anhyd. toluene. In total 4.00 mL anhyd. toluene were used. The resulting mixture 
was cooled to 0 °C. Samples of 0.5 mL were taken, quenched with MeOH, and analyzed directly 
via chiral GC. 
9.4. Synthesis of Peptide Catalysts 
9.4.1. Peptide Synthesis in Solution 
Methyl ester protection/Boc deprotection (GP-5):  
1.0 equiv of the Boc-protected amino acid was dissolved in MeOH. The resulting mixture was 
cooled to 0 °C and afterwards SOCl2 was added carefully. After removing the ice bath the 
solution was stirred for 24 h at r.t.. The solvent was removed under reduced pressure and the 
crude hydrochloride was used without further purification. 
Peptide coupling (GP-6): 
1.0 equiv of the C-terminal unprotected compound, 1.0 equiv of the hydrochloride, 1.1 equiv 
HOBt, and 1.1 equiv EDAC were dissolved in DCM. Finally, 1.1 equiv TEA were added and 
the resulting reaction mixture was stirred at r.t.. The organic layer was diluted with EtOAc, 
washed three times with citric acid (0.5 M), three times with sat. NaHCO3, and dried over either 
MgSO4 or Na2SO4. Finally, the solvent was removed under reduced pressure and co-evaporated 
afterwards several times with DCM. 
For Boc-PMH-OH 2.0 equiv of EDAC, HOBt, and TEA were utilized. 
Removal of the Bzl-/Cbz-/(2-Cl-Cbz)-PG (GP-7): 
1.0 equiv of the protected compound was dissolved. After adding catalytic amounts of Pd/C the 
resulting suspension was stirred at r.t. under a hydrogen atmosphere. After 24 h the reaction 
mixture was filtered over Celite® and the deprotected product was used directly either for 
catalytic test reactions or further coupling steps after evaporation of the solvent. 
Removal of the Boc-PG (GP-8): 
0.500 mmol of the Boc-protected compound were dissolved in 1.00 mL of HCl in 1,4-dioxane  
(4 M). The vessel was closed with a septum and the generated gas was purged periodically. 
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After 1 h remaining HCl was removed in an Ar flow. Finally, the solvent was removed under 
reduced pressure and co-evaporated afterwards several times with DCM. 
Those procedures were repeated until the desired oligopeptide was synthesized. The target 
compound was purified via column chromatography or HPLC. 
Removal of the methylester (GP-9): 
The methylester derivative was dissolved in DMF and NaOHaq (15%) was added. The resulting 
reaction mixture was stirred at r.t. for 24 h. Diluted HCl was added to obtain pH 5. The aq layer 
was extracted with EtOAc. After drying over Na2SO4 the solvent was removed under reduced 
pressure. Remaining DMF was removed under high vacuum.  
Boc-PMH-AdGly-Cha-Phe-OMe 1: 
The synthesis of ClH3N-Phe-OMe 130 was 
performed with 2.07 g (7.80 mmol, 1.0 equiv)  
Boc-Phe-OH 94, 1.80 mL (2.95 g, 24.8 mmol,  
3.2 equiv) SOCl2, and 20 mL MeOH utilizing GP-5. 
1.69 g (7.84 mmol, quant.) hydrochloride 130 were 
obtained as colorless solid. 
MS (ESI): m/z: 180.0 [M + H]+ (cal. 180.1). 
The synthesis of Boc-Cha-Phe-OMe was performed with 0.610 g (2.83 mmol, 1.0 equiv) 
hydrochloride 130, 1.28 g (2.83 mmol, 1.0 equiv) Boc-Cha-OH•DCHA, 0.605 g (3.16 mmol, 
1.1 equiv) EDAC, 0.434 g (3.21 mmol, 1.1 equiv) HOBt, 0.432 mL (0.315 g, 3.11 mmol,  
1.1 equiv) TEA, and 30 mL DCM utilizing GP-6. After 21 h the reaction mixture was diluted 
with 300 mL EtOAc. For washing a volume of 25 mL was used. The organic layer was washed 
additionally with 25 mL brine. 1.18 g (2.73 mmol, 96%) dipeptide were obtained as colorless 
solid. 
1H-NMR (400 MHz, CDCl3): δ = 7.25–7.13 (m, 3 H and CHCl3); 7.07–7.01 (m, 2 H); 6.48–
6.40 (m, 1 H); 4.82–4.71 (m, 2 H); 4.10–4.00 (m, 1 H); 3.64 (s, 3 H); 3.08 (dd, 1 H, 2J = 13.8 
Hz, 3J = 5.9 Hz); 3.01 (dd, 1 H, 2J = 13.8 Hz, 3J = 5.9 Hz); 1.70–1.50 (m, 7 H); 1.37 (s, 9 H); 
1.27–1.01 (m, 4 H); 0.94–0.74 (m, 2 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 172.4; 171.8; 155.6; 135.9; 129.4; 128.7; 127.2; 80.2; 53.3; 
52.6; 52.4; 40.0; 38.1; 34.1; 33.7; 32.7; 28.4; 26.5; 26.3; 26.1 ppm. 
MS (ESI): m/z: 455.2 [M + Na]+ (cal. 455.3); 887.1 [2M + Na]+ (cal. 887.5). 
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The synthesis of ClH3N-Cha-Phe-OMe was performed with 1.16 g (2.68 mmol, 1.0 equiv)  
Boc-Cha-Phe-OH and 6.00 mL HCl in 1,4-dioxane (4 M) utilizing GP-8. 1.11 g (3.00 mmol, 
quant.)9 hydrochloride were obtained as colorless solid. 
MS (ESI): m/z: 333.1 [M + H]+ (cal. 333.2); 355.2 [M + Na]+ (cal. 355.2); 687.1 [2M + Na]+ 
(cal. 687.4). 
The synthesis of Boc-AdGly-Cha-Phe-OMe was performed with 0.989 g (2.68 mmol,  
1.0 equiv) hydrochloride, 0.793 g (2.68 mmol, 1.0 equiv) Boc-AdGly-OH, 0.576 g (3.00 mmol, 
1.1 equiv) EDAC, 0.412 g (3.05 mmol, 1.1 equiv) HOBt, 0.409 mL (0.298 g, 2.95 mmol,  
1.1 equiv) TEA, and 30 mL DCM utilizing GP-6. After 18 h the reaction mixture was diluted 
with 200 mL EtOAc. For washing a volume of 25 mL was used. The organic layer was washed 
additionally with 25 mL brine. 1.82 g (2.98 mmol, quant.)9 tripeptide were obtained as slightly 
yellowish solid. 
MS (ESI): m/z: 610.2 [M + H]+ (cal. 610.4); 632.4 [M + Na]+ (cal. 632.4); 1241.4 [2M + Na]+ 
(cal. 1241.7). 
The synthesis of ClH3N-AdGly-Cha-Phe-OMe was performed with 1.57 g (2.57 mmol,  
1.0 equiv) Boc-Cha-Phe-OH and 5.80 mL HCl in 1,4-dioxane (4 M) utilizing GP-8. 1.80 g 
 (3.30 mmol, quant.)9 hydrochloride were obtained as slightly yellowish solid. 
MS (ESI): m/z: 510.2 [M + H]+ (cal. 510.3); 1019.5 [2M + H]+ (cal. 1019.7) ; 1041.3 [2M + 
Na]+ (cal. 1041.6). 
The synthesis of Boc-PMH-AdGly-Cha-Phe-OMe 1 was performed with 0.411 g (2.58 mmol, 
1.0 equiv) hydrochloride, 0.695 g Boc-PMH-OH (2.58 mmol, 1.0 equiv), 0.999 g (5.21 mmol, 
2.0 equiv) EDAC, 0.706 g (5.22 mmol, 2.0 equiv) HOBt, 0.717 mL (0.523 g, 5.17 mmol,  
2.0 equiv) TEA, and 30 mL DCM utilizing GP-6. After 21 h the reaction mixture was diluted 
with 200 mL EtOAc. For washing a volume of 25 mL was used. The organic layer was washed 
additionally with 25 mL brine. Afterwards the aq layer was extracted with 100 mL EtOAc. 
0.699 g (0.919 mmol, 36%) tetrapeptide 1 were obtained as slightly brownish solid. 
1H-NMR (400 MHz, CDCl3): δ = 7.57–7.52 (m, 1 H); 7.31–7.21 (m, 3 H and CHCl3); 7.11–
7.09 (m, 2 H); 6.86 (s, 1 H); 6.54 (d, 1 H, 3J = 7.7 Hz); 6.02 (d, 1 H, 3J = 7.9 Hz); 5.95 (s, 1 H); 
5.24 (d, 1 H, 3J = 8.3 Hz); 4.82–4.77 (m, 1 H); 4.46–4.40 (m, 1 H); 4.25–4.14 (m, 1 H); 3.70 
(s, 3 H); 3.62 (s, 3 H); 3.15–3.04 (m, 2 H); 3.00–2.98 (m, 2 H); 2.19 (bs, 2 H); 1.99–1.87 (m, 6 
                                                 
9 Contains traces of solvent. 
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H); 1.72–1.60 (m, 13 H); 1.52–1.46 (m, 1 H); 1.43 (s, 9 H); 1.27–1.07 (m, 4 H); 0.99–0.76 (m, 
1 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 176.5; 172.0; 171.8; 169.7; 155.5; 138.1; 135.9; 129.4; 
128.8; 127.7; 127.5; 127.4; 127.3; 80.7; 53.4; 52.52; 52.48; 50.8; 42.7; 42.3; 40.5; 40.4; 39.6; 
38.3; 38.2; 38.0; 35.3; 34.3, 33.6; 32.8; 31.9; 29.22; 29.19; 28.4; 27.1; 26.5; 26.3; 26.2 ppm. 
MS (ESI): m/z: 761.5 [M + H]+ (cal. 761.5), 783.5 [M + Na]+ (cal. 783.4); 1521.3 [2M + H]+ 
(cal. 1521.9); 1543.2 [2M + Na]+ (cal. 1543.9). 
For tetrapeptide 1 the analytic data are identical to those reported in literature.[2a] 
Boc-Asp(OH)-AdGly-Cha-OMe 96: 
The synthesis of Boc-AdGly-Cha-OMe 98 was performed 
with 1.33 g (6.00 mmol, 1.0 equiv) ClH3N-Cha-OMe 97, 
1.78 g (6.03 mmol, 1.0 equiv) Boc-AdGly-OH, 1.27 g  
(6.62 mmol, 1.1 equiv) EDAC, 0.890 g (6.59 mmol,  
1.1 equiv) HOBt, 0.920 mL (0.671 g, 6.63 mmol, 1.1 equiv) 
TEA, and 30 mL DCM utilizing GP-6. After 24 h the reaction mixture was diluted with  
200 mL EtOAc. For washing a volume of 25 mL was used. 2.63 g (5.68 mmol, 95%) dipeptide 
98 were obtained as yellowish solid. 
1H-NMR (400 MHz, CDCl3): δ = 5.93 (d, 1 H, 3J = 8.1 Hz); 4.64 (td, 1 H, 3J = 8.7 Hz, 3J = 5.5 
Hz); 4.43 (bs, 1 H); 3.71 (s, 3 H); 2.24–2.18 (m, 2 H); 1.96–1.86 (m, 5 H); 1.80–1.75 (m, 6 H); 
1.70–1.61 (m, 9 H); 1.54–1.47 (m, 1 H); 1.42 (s, 9 H); 1.20–1.11 (m, 2 H); 0.98–0.84 (m, 2 H) 
ppm. 
13C-NMR (101 MHz, CDCl3): δ = 176.3; 173.8; 52.2; 50.8; 49.8; 42.9; 42.6; 40.9; 40.1; 38.2; 
35.3; 34.3; 33.4; 32.6; 29.2; 28.4; 26.3; 26.1; 26.0; 14.2 ppm. 
The synthesis of ClH3N-AdGly-Cha-OMe was performed with 2.63 g (5.68 mmol, 1.0 equiv) 
Boc-AdGly-Cha-OMe 98 and 11.5 mL HCl in 1,4-dioxane (4 M) utilizing GP-8. The crude 
product was obtained as yellowish solid and used directly without further purification. 
The synthesis of Boc-Asp(OBzl)-AdGly-Cha-OMe 99 was performed with the crude product 
of the hydrochloride, 1.83 g (5.66 mmol, 1.0 equiv) Boc-Asp(OBzl)-OH, 1.20 g (6.26 mmol, 
1.1 equiv) EDAC, 0.850 g (6.29 mmol, 1.1 equiv) HOBt, 0.870 mL (0.634 g, 6.27 mmol,  
1.1 equiv) TEA, and 30 mL DCM utilizing GP-6. After 24 h the reaction mixture was diluted 
with 200 mL EtOAc. For washing a volume of 25 mL was used. After purification via column 
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chromatography (DCM:MeOH 30:1) 2.90 g (4.34 mmol, 77%) tripeptide 99 were isolated as 
colorless solid. 
Rf: 0.40 (DCM:MeOH 30:1). 
MS (ESI): m/z: 568.3 [M – Boc + H]+ (cal. 568.3); 690.3 [M + Na]+ (cal. 690.4); 1357.0 [2M 
+ Na]+ (cal. 1357.8). 
The synthesis of carboxylic acid-containing tripeptide 96 was performed with 0.207 g  
(0.310 mmol, 1.0 equiv) Bzl-protected compound 99, 0.066 g (0.007 mmol, 20 mol%) Pd/C 
(10%), and 25 mL tBuOH. 0.170 g (0.294 mmol, 95%) tripeptides 96 were obtained as colorless 
solid. (GP-7) 
1H-NMR (400 MHz, CDCl3): δ = 6.49 (bs, 1 H); 6.16 (d, 1 H, J = 8.0 Hz); 5.74 (d, 1 H, J = 7.1 
Hz); 4.63 (td, 1 H, J = 8.6 Hz, J = 5.5 Hz); 4.40 (bs, 1 H); 3.72 (s, 3 H); 2.94 (dd, 1 H, J = 17.0 
Hz, J = 3.9 Hz); 2.67 (dd, 1 H, J = 16.5 Hz, J = 6.4 Hz); 2.26–2.19 (m, 2 H); 2.13–2.06 (m, 2 
H); 2.06–1.89 (m, 5 H); 1.88–1.74 (m, 5 H); 1.73–1.58 (m, 8 H); 1.55–1.48 (m, 2 H); 1.45 (s, 
9 H); 1.25–1.09 (m, 2 H); 1.00–0.80 (m, 1 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 179.0; 176.9; 174.0; 170.5; 155.9; 69.6; 52.51; 52.48; 50.1; 
42.7; 42.2; 40.5; 40.3; 40.1; 38.28; 38.25; 36.4; 35.3; 34.4; 33.6; 32.7; 31.3; 29.3; 28.4; 26.5; 
26.3; 26.2 ppm. 
IR (KBr): ṽ = 3367 (s); 2922 (vs); 2853 (s); 1659 (vs); 1525 (s); 1450 (m); 1367 (m); 1252 
(w); 1169 (m); 1051 (vw); 1025 (vw); 620 (vw) cm−1. 
HR-MS (ESI): m/z: 600.3261 [M + Na]+ (cal. 600.3255). 
MS (ESI): m/z: 600.3 [M + Na]+ (cal. 600.3); 1177.2 [2M + Na]+ (cal. 1177.7). 
Boc-Phe-AdGly-Asp(OH)-Phe-OMe 100: 
The synthesis of Boc-Asp(OBzl)-Phe-OMe was 
performed with 0.647 g (3.01 mmol, 1.0 equiv) 
ClH3N-Phe-OMe 130, 0.970 g (3.00 mmol,  
1.0 equiv) Boc-Asp(OBzl)-OH, 0.633 g (3.30 mmol, 
1.1 equiv) EDAC, 0.509 g (3.76 mmol, 1.3 equiv) 
HOBt, 0.460 mL (0.335 g, 3.31 mmol, 1.1 equiv) TEA, and 30 mL DCM utilizing GP-6.  
After 24 h the reaction mixture was diluted with 200 mL EtOAc. For washing a volume of  
25 mL was used. 1.31 g (2.71 mmol, 90%) dipeptide were obtained as yellowish oil. 
MS (ESI): m/z: 507.1 [M + Na]+ (cal. 507.2). 
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The synthesis of ClH3N-Asp(OBzl)-Phe-OMe was performed with 1.31 g (2.71 mmol,  
1.0 equiv) Boc-Asp(OBzl)-Phe-OMe and 6.00 mL HCl in 1,4-dioxane (4 M) utilizing GP-8. 
The crude product was obtained as colorless solid and used directly without further purification. 
The synthesis of Boc-AdGly-Asp(OBzl)-Phe-OMe was performed with the crude product of 
the hydrochloride, 0.796 g (2.69 mmol, 1.0 equiv) Boc-AdGly-OH, 0.568 g (2.96 mmol,  
1.1 equiv) EDAC, 0.456 g (3.37 mmol, 1.3 equiv) HOBt, 0.413 mL (0.301 g, 2.98 mmol,  
1.1 equiv) TEA, and 30 mL DCM utilizing GP-6. After 24 h the reaction mixture was diluted 
with 200 mL EtOAc. For washing a volume of 25 mL was used. 1.64 g (2.48 mmol, 92%) 
tripeptide were obtained as yellowish solid. 
MS (ESI): m/z: 684.3 [M + Na]+ (cal. 684.3). 
The synthesis of ClH3N-AdGly-Asp(OBzl)-Phe-OMe was performed with 1.64 g (2.48 mmol, 
1.0 equiv) Boc-AdGly-Asp(OBzl)-Phe-OMe and 6.00 mL HCl in 1,4-dioxane (4 M) utilizing 
GP-8. The crude product was obtained as colorless solid and used directly without further 
purification. The synthesis of Boc-Phe-AdGly-Asp(OBzl)-Phe-OMe was performed with the 
crude product of the hydrochloride, 0.657 g (2.48 mmol, 1.0 equiv) Boc-Phe-OH 94, 0.522 g  
(2.72 mmol, 1.1 equiv) EDAC, 0.420 g (3.11 mmol, 1.3 equiv) HOBt, 0.380 mL (0.277 g,  
2.74 mmol, 1.1 equiv) TEA, and 30 mL DCM utilizing GP-6. After 24 h the reaction mixture 
was diluted with 200 mL EtOAc. For washing a volume of 25 mL was used. After purification 
via column chromatography (DCM:MeOH 40:1) 1.28 g (1.58 mmol, 64%) tetrapeptide were 
isolated as colorless solid. 
MS (ESI): m/z: 831.4 [M + Na]+ (cal. 831.4); 1639.0 [2M + Na]+ (cal. 1639.8). 
The synthesis of carboxylic acid-containing tetrapeptide 100 was performed with 1.27 g  
(1.57 mmol, 1.0 equiv) Bzl-protected tetrapeptide, 0.336 g (0.316 mmol, 20 mol%) Pd/C (10%), 
and 25 mL tBuOH. 0.935 g (1.30 mmol, 83%) tetrapeptide 100 were obtained as colorless solid. 
Rf: 0.23 (DCM:MeOH 20:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.28–7.10 (m, 10 H and CHCl3); 7.07–7.03 (m, 2 H); 7.00 
(d, 1 H, 3J = 7.4 Hz); 5.55 (bs, 1 H); 4.76–4.68 (m, 2 H); 4.18–4.07 (m, 1 H); 3.60 (s, 3 H); 3.06 
(dd, 1 H, 2J = 13.9 Hz, 3J = 5.6 Hz); 3.00–2.85 (m, 4 H); 2.61 (dd, 1 H, 2J = 17.0 Hz, 3J = 6.1 
Hz); 2.10–2.02 (m, 2 H); 1.84–1.67 (m, 6 H); 1.62–1.46 (m, 6 H); 1.33 (s, 9 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 177.1; 174.3; 171.7; 170.7; 155.7; 137.0; 135.9; 129.6; 
129.4; 128.8; 128.7; 127.2; 127.1; 80.4; 56.6; 53.7; 53.6; 52.5; 52.4; 49.2; 42.6; 42.0; 40.2; 
39.0; 37.9; 37.7; 35.6; 35.1; 31.3; 29.11; 29.09; 28.4 ppm. 
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IR (KBr): ṽ = 3329 (m); 3063 (m); 2914 (m); 2853 (s); 1664 (s); 1522 (s); 1455 (m); 1367 (m); 
1250 (m); 1170 (s); 1050 (vw); 1022 (vw); 744 (w); 701 (m); 590 (vw); 534 (vw) cm−1. 
HR-MS (ESI): m/z: 741.3475 [M + Na]+ (cal. 741.3470). 
MS (ESI): m/z: 641.3 [M – Boc + Na]+ (cal. 641.3); 717.2 [M – H]– (cal. 717.4); 741.3 [M + 
Na]+ (cal. 741.3). 
Boc-Cha-AdGly-Asp(OH)-OH 101: 
The synthesis of ClH3N-Asp(OMe)-OMe was performed 
with 1.34 g (6.00 mmol, 1.0 equiv) H-Asp(OBzl)-OH,  
1.50 mL (2.46 g, 20.7 mmol, 3.4 equiv) SOCl2, and 15 mL 
MeOH utilizing GP-5. After adding SOCl2 to methanol the 
amino acid was added portionwise. The reaction mixture was 
stirred for 48 h. After evaporation of the solvent the crude product was used directly without 
purification. The synthesis of Boc-AdGly-Asp(OMe)-OMe was performed with the crude 
product of the hydrochloride, 1.77 g (5.99 mmol, 1.0 equiv) Boc-AdGly-OH, 1.27 g  
(6.62 mmol, 1.1 equiv) EDAC, 1.02 g (7.54 mmol, 1.3 equiv) HOBt, 0.920 mL (0.671 g,  
6.63 mmol, 1.1 equiv) TEA, and 30 mL DCM utilizing GP-6. After 24 h the reaction mixture 
was diluted with 200 mL EtOAc. For washing a volume of 25 mL was used. 2.66 g (6.07 mmol, 
quant. over two steps) dipeptide were obtained as yellowish solid. 
MS (ESI): m/z: 439.0 [M + H]+ (cal. 439.2); 461.1 [M + Na]+ (cal. 461.2). 
The synthesis of ClH3N-AdGly-Asp(OMe)-OMe was performed with 2.63 g (5.99 mmol,  
1.0 equiv) Boc-AdGly-Asp(OMe)-OMe and 12 mL HCl in 1,4-dioxane (4 M) utilizing GP-8. 
The crude product was obtained as colorless solid and used directly without further purification. 
The synthesis of Boc-Cha-AdGly-Asp(OMe)-OMe was performed with the crude product of 
the hydrochloride, 2.71 g (5.99 mmol, 1.0 equiv) Boc-Cha-OH•DCHA, 1.27 g (6.62 mmol,  
1.1 equiv) EDAC, 1.01 g (7.47 mmol, 1.2 equiv) HOBt, 0.920 mL (0.671 g, 6.63 mmol,  
1.1 equiv) TEA, and 30 mL DCM utilizing GP-6. After 24 h the reaction mixture was diluted 
with 200 mL EtOAc. For washing a volume of 25 mL was used. 3.14 g (5.31 mmol, 89%) 
tripeptide were obtained as colorless solid. 
MS (ESI): m/z: 614.3 [M + Na]+ (cal. 614.3); 1205.0 [2M + Na]+ (cal. 1205.7). 
The synthesis of carboxylic acid-containing tripeptide 101 was performed with 2.89 g  
(4.88 mmol, 1.0 equiv) of the dimethylester, 55 mL NaOHaq (15%), and 80 mL DMF (GP-9). 
For extraction EtOAc (three times 150 mL) was used. After purification via column 
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chromatography (DCM:MeOH 30:1 to 10:1) 2.17 g (3.85 mmol, 79%) tetrapeptide 101 were 
isolated as colorless solid. 
Rf: 0.41 (DCM:MeOH 10:1). 
1H-NMR and 13C-NMR not meaningful. 
IR (KBr): ṽ = 3337 (m); 2922 (vs); 2853 (s); 1651 (s); 1519 (s); 1449 (m); 1366 (m); 1249 (w); 
1169 (m); 1046 (vw); 1022 (vw); 575 (vw) cm−1. 
HR-MS (ESI): m/z: 586.3097 [M + Na]+ (cal. 586.3099). 
MS (ESI): m/z: 462.2 [M – Boc – H]– (cal. 462.3); 486.3 [M – Boc + Na]+ (cal. 486.3); 562.2 
[M – H]– (cal. 562.3); 586.2 [M + Na]+ (cal. 586.3); 1149.1 [2M + Na]+ (cal. 1149.6). 
Boc-Val-Pro-Asp(OH)-OH 102: 
The synthesis of Boc-Asp(OBzl)-OBzl was performed with 1.94 g 
(6.00 mmol, 1.0 equiv) Boc-Asp(OBzl)-OH, 0.624 mL (0.671 g, 
6.62 mmol, 1.0 equiv) BnOH, 1.26 g (6.57 mmol, 1.1 equiv) 
EDAC, 0.890 g (6.59 mmol, 1.1 equiv) HOBt, 0.915 mL (0.667 g, 
6.59 mmol, 1.1 equiv) TEA, and 30 mL DCM utilizing GP-6. After 24 h the reaction mixture 
was diluted with 300 mL EtOAc. For washing a volume of 25 mL was used. 1.54 g (3.72 mmol, 
62%) completely protected amino acid were obtained as yellowish oil. 
MS (ESI): m/z: 436.1 [M + Na]+ (cal. 436.2). 
The synthesis of ClH3N-Asp(OBzl)-OBzl was performed with 1.49 g (3.60 mmol, 1.0 equiv) 
Boc-Asp(OBzl)-OBzl and 5 mL HCl in 1,4-dioxane (4 M) utilizing GP-8. The crude product 
was obtained as slightly yellowish solid and used without further purification. The synthesis of 
Boc-Pro-Asp(OBzl)-OBzl was performed with the crude product of the hydrochloride, 0.960 g 
(4.37 mmol, 1.2 equiv) Boc-Pro-OH, 0.940 g (4.90 mmol, 1.4 equiv) EDAC, 0.650 g  
(4.81 mmol, 1.3 equiv) HOBt, 0.677 mL (0.494 g, 4.88 mmol, 1.4 equiv) TEA, and 30 mL 
DCM utilizing GP-6. After 22 h the reaction mixture was diluted with 300 mL EtOAc.  
For washing a volume of 25 mL was used. 1.15 g (2.25 mmol, 63%) dipeptide were obtained 
as yellowish oil. 
MS (ESI): m/z: 533.1 [M + Na]+ (cal. 533.2); 549.0 [M + K]+ (cal. 549.2). 
The synthesis of ClH3N-Pro-Asp(OBzl)-OBzl was performed with 1.15 g (2.25 mmol,  
1.0 equiv) Boc-Pro-Asp(OBzl)-OBzl and 4.5 mL HCl in 1,4-dioxane (4 M) utilizing GP-8.  
The crude product was obtained as yellowish solid and used without further purification.  
The synthesis of Boc-Val-Pro-Asp(OBzl)-OBzl was performed with the crude product of the 
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hydrochloride, 0.490 g (2.26 mmol, 1.0 equiv) Boc-Val-OH, 0.470 g (2.45 mmol, 1.1 equiv) 
EDAC, 0.330 g (2.44 mmol, 1.1 equiv) HOBt, 0.341 mL (0.249 g, 2.46 mmol, 1.1 equiv) TEA, 
and 30 mL DCM utilizing GP-6. After 15 h the reaction mixture was diluted with 300 mL 
EtOAc. For washing a volume of 25 mL was used. 1.27 g (2.08 mmol, 92%) tripeptide were 
obtained as yellowish oil. 
1H-NMR (400 MHz, CDCl3): δ = 7.40–7.27 (m, 10 H); 5.17 (d, 1 H, 3J = 9.4 Hz); 5.11 (s, 2 
H); 5.06 (s, 2 H); 4.86 (dt, 1 H, 3J = 9.0 Hz, 3J = 4.7 Hz); 4.54–4.52 (m, 1 H); 4.25 (dd, 1 H, 3J 
= 9.3 Hz, 3J = 6.0 Hz); 4.54–4.52 (m, 1 H); 3.70–3.64 (m, 1 H); 3.53–3.48 (m, 1 H); 3.05 (dd, 
1 H, 2J = 17.2 Hz, 3J = 4.7 Hz); 2.85 (dd, 1 H, 2J = 17.2 Hz, 3J = 4.8 Hz); 2.25–2.18 (m, 1 H); 
2.00–1.85 (m, 4 H); 1.43 (s, 9 H); 0.95 (d, 3 H, 3J = 6.8 Hz); 0.86 (d, 3 H, 3J = 6.7 Hz) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 172.4; 171.2; 170.7; 170.4; 156.0; 135.5; 135.3; 128.72; 
128.69; 128.56; 128.55; 128.49; 79.7; 67.6; 67.0; 60.0; 56.9; 48.8; 47.6; 36.4; 31.5; 28.5; 27.7; 
25.2; 19.6; 17.4; 14.4 ppm. 
MS (ESI): m/z: 632.2 [M + Na]+ (cal. 632.3). 
The synthesis of carboxylic acid-containing tripeptide 102 was performed with 1.27 g  
(2.08 mmol, 1.0 equiv) of the Bzl-protected compound, 0.320 g (0.301 mmol, 14 mol%)  
Pd/C (10%), and 17.0 mL tBuOH (GP-7). The reaction mixture was stirred for 90 h. 0.780 g  
(1.82 mmol, 88%) tripeptide 102 were obtained as colorless solid. 
1H-NMR (200 MHz, CDCl3): δ = 7.69 (d, 1 H, 3J = 8.3 Hz); 7.43 (bs, 2 H); 5.64 (d, 1 H, 3J = 
9.2 Hz); 4.88–4.72 (m, 1 H); 4.70–4.53 (m, 1 H); 4.28–4.20 (m, 1 H); 3.89–3.56 (m, 2 H); 3.12–
2.96 (m, 1 H); 2.90–2.67 (m, 1 H); 2.27–1.82 (m, 5 H); 1.41 (s, 9 H); 0.97–0.88 (m, 6 H) ppm. 
13C-NMR (151 MHz, CDCl3): δ = 174.5; 174.1; 173.1; 171.6; 156.2; 79.9; 60.4; 57.4; 48.6; 
48.2; 36.2; 31.2; 28.5; 25.2; 19.4; 17.9 ppm. 
HR-MS (ESI): m/z: 452.2026 [M + Na]+ (cal. 452.2003). 
MS (ESI): m/z: 452.1 [M + Na]+ (cal. 452.2). 
2,2,2-Trifluoro-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-1-ethanone 114: 
The synthesis of amide 114 was performed with 0.146 mL (0.150 g,  
1.02 mmol, 1.0 equiv) amine 113, 1.70 mg (0.014 mmol, 1 mol%) DMAP, 
0.150 mL (0.230 g, 2.02 mmol, 2.0 equiv) TFA 111, 0.383 g (2.00 mmol,  
2.0 equiv) EDAC, 0.279 mL (0.203 g, 2.00 mmol, 2.0 equiv) TEA, and 6 mL 
DCM. After stirring for 24 h at r.t. the reaction was quenched with  
sat. NaHCO3. The aq layer was extracted with DCM (three times 10 mL). After drying over 
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Na2SO4 the solvent was evaporated under reduced pressure. After purification via column 
chromatography (n-hexane:EtOAc 7:1 to 0:1) 0.148 g (0.599 mmol, 59%) 114 were isolated as 
slightly yellowish solid. 
Rf: 0.33 (n-hexane:EtOAc 5:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.25–7.19 (m, 3 H, HAr); 7.15–7.13 (m, 1 H, HAr); 6.51 (bs, 
1 H, NH); 5.23–5.18 (m, 1 H, NHCH); 2.90–2.74 (m, 2 H, CHCH2CH2CH2); 2.15–2.06 (m, 1 
H, CHCH2); 1.95–1.79 (m, 3 H, CHCH2CH2 and CHCH2) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 159.6 (q, 2JCF = 36.9 Hz, COCF3); 137.9 (quart., CAr); 134.5 
(quart., CAr); 129.7 (CAr); 128.7 (CAr); 128.2 (CAr); 126.8 (CAr); 116.0 (q, 
1JCF = 288.2 Hz, CF3); 
48.5 (CH); 29.6 (CHCH2); 29.1 (CHCH2CH2CH2); 19.8 (CHCH2CH2) ppm. 
19F-NMR (376 MHz, CDCl3): δ = –75.8 ppm. 
IR (KBr): ṽ = 3283 (m); 2944 (w); 2090 (vw); 1697 (s); 1183 (s); 746 (m) ; 700 (w) cm−1. 
HR-MS (ESI): m/z: 266.0755 [M + Na]+ (cal. 266.0763). 
MS (ESI): m/z: 266.0 [M + Na]+ (cal. 266.1). 
2,2,2-Trifluoro-1-(p-((1,2,3,4-tetrahydronaphth-1-ylamino)carbonyl)phenyl)-1-ethanone 
115: 
The synthesis of amide 115 was performed with 0.220 g (1.01 mmol, 
1.0 equiv) acid para-112, 0.146 mL (0.150 g, 1.02 mmol, 1.0 equiv) 
amine 113, 2.88 mg (0.024 mmol, 2 mol%) DMAP, 0.385 g  
(2.00 mmol, 2.0 equiv) EDAC, 0.279 mL (0.203 g, 2.00 mmol,  
2.0 equiv) TEA, and 6 mL DCM. After stirring for 23 h at r.t. the 
reaction was quenched with sat. NaHCO3. The aq layer was extracted with DCM (three times 
10 mL). After drying over Na2SO4 the solvent was evaporated under reduced pressure.  
After purification via column chromatography (n-hexane:EtOAc 7:1 to 1:5) 0.148 g (0.426 
mmol, 42%) 115 were isolated as slightly yellowish solid. 
Rf: 0.73 (n-hexane:EtOAc 1:5). 
1H-NMR (400 MHz, CDCl3): δ = 8.07 (m, 2 H, CHCCOCF3); 7.90 (m, 2 H, NHCOCCH); 
7.30–7.27 (m, 1 H, HAr); 7.22–7.15 (m, 2 H, HAr); 7.12–7.10 (m, 1 H, HAr); 6.77 (bs, 1 H, NH); 
5.34 (dd, 1 H, 3J = 13.1 Hz, 3J = 6.2 Hz, NHCH); 2.85–2.77 (m, 2 H, CHCH2CH2CH2); 2.16–
2.09 (m, 1 H, CHCH2); 1.97–1.84 (m, 3 H, CHCH2CH2 and CHCH2) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 180.1 (q, 2JCF = 35.7 Hz, COCF3); 165.3 (CO); 140.8 (quart., 
CAr); 137.8 (quart., CAr); 136.1 (quart., CAr); 131.9 (quart., CAr); 130.4 (2 C, CAr); 129.5 (CAr); 
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128.7 (CAr); 127.8 (2 C, CAr); 127.7 (CAr); 126.5 (CAr); 116.5 (q, 
1JCF = 291.2 Hz, CF3); 48.5 
(CH); 30.1 (CHCH2); 29.3 (CHCH2CH2CH2); 20.1 (CHCH2CH2) ppm. 
19F-NMR (376 MHz, CDCl3): δ = –71.6 ppm. 
IR (KBr): ṽ = 3296 (vs); 2933 (m); 1941 (vw); 1723 (s); 1628 (vs); 1536 (vs); 1147 (vs); 1057 
(s); 754 (s); 563 (s) cm−1. 
HR-MS (ESI): m/z: 402.1296 [M + MeOH + Na]+ (cal. 402.1287); 781.2692 [2M + MeOH + 
Na]+ (cal. 781.2683). 
MS (ESI): m/z: 402.3 [M + MeOH + Na]+ (cal. 402.1); 780.9 [2M + 2MeOH + Na]+ (cal. 781.3) 
and 416.1 [M + EtOH + Na]+ (cal. 416.1); 808.9 [2M + 2EtOH + Na]+ (cal. 809.3), respectively. 
Boc-Lys(CM)-AdGly-Cha-Phe-OMe 122: 
The synthesis of amine 121 was performed with 
0.089 g (0.098 mmol, 1.0 equiv) (2-Cl-Cbz)-
protected compound 120, 23.3 mg (0.022 mmol,  
22 mol%) Pd/C (10%), and 3 mL MeOH (GP-7). 
The reaction mixture was stirred for 17 h. 0.071 g 
(0.096 mmol, 98%) free amine 121 were obtained as 
colorless solid. 
MS (ESI): m/z: 638.5 [M – Boc + H]+ (cal. 638.4); 738.4 [M + H]+ (cal. 738.5). 
The synthesis of Boc-Lys(CM)-AdGly-Cha-Phe-OMe 122 was performed with 0.071 g  
(0.096 mmol, 1.0 equiv) amine 121, 27.3 mg (0.125 mmol, 1.3 equiv) acid para-112, 2.00 mg 
(0.016 mmol, 17 mol%) DMAP, 0.040 g (0.209 mmol, 2.2 equiv) EDAC, 28.8 µL (21.0 mg, 
0.207 mmol, 2.2 equiv) TEA, and 3 mL DCM utilizing GP-3. After 24 h the reaction was 
quenched with NaHCO3 and the organic layer was extracted with DCM (three times). 
After purification via column chromatography (EtOAc) 0.059 g (0.063 mmol, 65%) 122 were 
isolated as colorless solid. 
Rf: 0.50 (EtOAc). 
1H-NMR (400 MHz, CDCl3): δ = 8.12 (d, 2 H, 3J = 8.0 Hz); 8.00–7.97 (m, 2 H); 7.29–7.20 (m, 
5 H + CHCl3); 7.10–7.08 (m, 2 H); 6.84 (bs, 1 H); 6.50 (bs, 1 H); 6.03–5.99 (m, 2 H); 5.17–
5.08 (m, 1 H); 4.81–4.76 (m, 1 H); 4.46–4.40 (m, 1 H); 4.02–3.91 (m, 1 H); 3.70 (s, 3 H); 3.56–
3.43 (m, 2 H); 3.14–3.03 (m, 2 H); 2.22–2.15 (m, 2 H); 2.06–2.01 (m, 1 H + EtOAc); 1.98–1.93 
(m, 4 H); 1.87–1.77 (m, 2 H); 1.75–1.71 (m, 4 H); 1.70–1.59 (m, 13 H); 1.41 (s, 9 H); 1.20–
1.07 (m, 3 H); 0.95–0.79 (m, 2 H) ppm.  
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13C-NMR (101 MHz, CDCl3): δ = 180.2 (COCF3); 176.6; 172.0; 171.7; 171.4; 166.2; 156.1; 
140.8; 135.8; 131.9; 130.4; 129.4; 128.8; 128.0; 127.3; 116.6 (CF3); 80.4; 53.4; 52.5; 52.4; 
50.8; 42.7; 42.5; 40.6; 40.5; 39.63; 39.57; 38.3; 38.2; 37.9; 35.3; 34.3; 33.6; 32.9; 31.7; 29.2; 
28.7; 28.4; 26.5; 26.3; 26.2; 22.7 ppm. 
19F-NMR (376 MHz, CDCl3): δ = –71.6 ppm. 
HR-MS (ESI): m/z: 992.4972 [M + MeOH + Na]+ (cal. 992.4967). 
MS (ESI): m/z: 892.4 [M – Boc + MeOH + Na]+ (cal. 892.4); 992.3 [M + MeOH + Na]+ (cal. 
992.5). 
CM-Lys(2-Cl-Cbz)-AdGly-Cha-Phe-OMe 123: 
The synthesis of ClH3N-Lys(2-Cl-Cbz)-
AdGly-Cha-Phe-OMe was performed 
with 0.137 g (0.151 mmol,  
1.0 equiv) Boc-Lys(2-Cl-Cbz)-AdGly-
Cha-Phe-OMe 120 and 2 mL HCl in  
1,4-dioxane (4 M) utilizing GP-8.  
The reaction mixture was stirred for 22.5 h. The crude product was obtained as yellowish solid 
and used without further purification. The synthesis of CM-Lys(2-Cl-Cbz)-AdGly-Cha-Phe-
OMe 123 was performed with the crude product of the hydrochloride, 0.038 g (0.174 mmol,  
1.2 equiv) acid para-112, 2.30 mg (0.019 mmol, 13 mol%) DMAP, 0.054 g (0.282 mmol,  
1.9 equiv) EDAC, 58.0 µL (42.3 mg, 0.418 mmol, 2.8 equiv) TEA, and 4 mL DCM utilizing 
GP-3. After 18 h the reaction was quenched with 15 mL NaHCO3 and the organic layer was 
extracted with DCM (three times 10 mL). After purification via column chromatography  
(n-hexane:EtOAc 1:5) 0.104 g (0.103 mmol, 68%) 123 were isolated as colorless oil. 
Rf: 0.51 (n-hexane:EtOAc 1:5). 
1H-NMR and 13C-NMR not meaningful. 
HR-MS (ESI): m/z: 1060.4424 [M + MeOH + Na]+ (cal. 1060.4421). 
MS (ESI): m/z: 1028.5 [M + Na]+ (cal. 1028.4); 1060.5 [M + MeOH + Na]+ (cal. 1060.4). 
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Boc-PMH-AdGly-Lys(CM)-Phe-OMe 124: 
The synthesis of the free amine was performed with 
0.095 g (0.109 mmol, 1.0 equiv) Cbz-protected 
compound 125, 24.5 mg (0.023 mmol, 21 mol%) 
Pd/C (10%), and 5 mL MeOH (GP-7). The reaction 
mixture was stirred for 19 h. 0.072 g (0.098 mmol, 
90%) of the free amine were obtained as yellowish 
solid. 
MS (ESI): m/z: 636.4 [M – Boc + H]+ (cal. 636.4); 736.4 [M + H]+ (cal. 736.4); 758.4 [M + 
Na]+ (cal. 758.4). 
The synthesis of Boc-PMH-AdGly-Lys(CM)-Phe-OMe 124 was performed with 0.072 g  
(0.098 mmol, 1.0 equiv) of the free amine, 26.0 mg (0.119 mmol, 1.2 equiv) acid para-112, 
2.10 mg (0.017 mmol, 17 mol%) DMAP, 0.039 g (0.203 mmol, 2.1 equiv) EDAC, 27.0 µL 
(19.7 mg, 0.195 mmol, 2.0 equiv) TEA, and 3 mL DCM utilizing GP-3. After 16 h the reaction 
was quenched with 15 mL NaHCO3 and the organic layer was extracted with DCM (three times  
10 mL). After purification via column chromatography (CHCl3:MeOH 9:1 to 5:1) 0.060 g 
(0.064 mmol, 65%) 124 were isolated as colorless solid. 
Rf: 0.35 (CHCl3:MeOH 9:1). 
1H-NMR10 shows traces of racemization and was therefore not evaluable. 
13C-NMR (101 MHz, CDCl3):
10 δ = 180.1 (COCF3); 176.7; 171.9; 171.7; 169.6; 166.1; 155.4; 
140.9; 137.9; 135.7; 131.5; 130.1; 130.1; 129.1; 128.7; 128.0; 127.5; 127.2; 114.3 (CF3); 80.4; 
54.4; 53.5; 52.4; 52.2; 52.1; 42.5; 42.1; 40.3; 40.1; 39.7; 38.0; 37.8; 37.5; 35.0; 32.1; 31.6; 29.7; 
29.0; 28.3; 26.9; 22.3 ppm. 
HR-MS (ESI): m/z: 495.7326 [M + MeOH + H + Na]2+ (cal. 495.7316); 990.4566 [M + MeOH 
+ Na]+ (cal. 990.4559). 
MS (ESI): m/z: 958.4 [M + Na]+ (cal. 958.4); 968.4 [M + MeOH + H]+ (cal. 968.5); 990.3 [M 
+ MeOH + Na]+ (cal. 990.5); 1006.3 [M + MeOH + K]+ (cal. 1006.4). 
 
 
 
 
                                                 
10 Racemization observable. 
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Boc-Phe-AdGly-Phe-Lys(CM)-OMe 126: 
The synthesis of ClH3N-Lys(2-Cl-Cbz)-OMe was 
performed with 0.402 g (0.969 mmol, 1.0 equiv) 
Boc-Lys(2-Cl-Cbz)-OH, 0.250 mL (0.410 g,  
3.45 mmol, 3.6 equiv) SOCl2, and 6 mL MeOH 
utilizing GP-5. 0.365 g (0.999 mmol, quant.) 
hydrochloride were obtained as yellow solid. 
The synthesis of Boc-Phe-Lys(2-Cl-Cbz)-OMe was performed with the crude product of the 
hydrochloride, 0.265 g (0.999 mmol, 1.0 equiv) Boc-Phe-OH 94, 0.215 g (1.12 mmol,  
1.2 equiv) EDAC, 0.153 g (1.13 mmol, 1.2 equiv) HOBt, 0.153 mL (0.112 g, 1.10 mmol,  
1.1 equiv) TEA, and 5 mL DCM utilizing GP-6. After 24 h the reaction mixture was diluted 
with EtOAc. For washing a volume of 20 mL was used. The organic layer was washed 
additionally with 15 mL brine. 0.549 g (0.953 mmol, 98%) dipeptide were obtained as colorless 
solid. 
1H-NMR (400 MHz, CDCl3): δ = 7.44–7.40 (m, 1 H); 7.38–7.34 (m, 1 H); 7.28–7.21 (m, 6 H 
and CHCl3); 7.18–7.16 (m, 3 H); 6.64 (bs, 1 H); 5.28–5.10 (m, 4 H); 4.57–4.49 (m, 1 H); 4.45–
4.33 (m, 1 H); 3.69 (s, 3 H); 3.24–3.12 (m, 2 H); 3.11–2.97 (m, 2 H); 1.85–1.74 (m, 1 H); 1.70–
1.58 (m, 1 H); 1.52–1.46 (m, 1 H); 1.38 (s, 9 H); 1.30–1.20 (m, 1 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 172.3; 171.5; 156.5; 155.7; 136.7; 134.5; 133.6; 129.8; 
129.6; 129.4; 128.7; 127.0; 80.4; 64.0, 55.9; 52.5; 52.0; 40.7; 38.2; 32.0; 29.3; 28.4; 22.3 ppm. 
MS (ESI): m/z: 498.3 [M – Boc + Na]+ (cal. 498.2); 598.2 [M + Na]+ (cal. 598.2). 
The synthesis of ClH3N-Phe-Lys(2-Cl-Cbz)-OMe was performed with 0.549 g (0.953 mmol, 
1.0 equiv) Boc-Phe-Lys(2-Cl-Cbz)-OMe and 2.5 mL HCl in 1,4-dioxane (4 M) utilizing GP-8. 
The crude product was obtained as colorless solid and used without further purification.  
The synthesis of Boc-AdGly-Phe-Lys(2-Cl-Cbz)-OMe was performed with the crude product 
of the hydrochloride, 0.282 g (0.955 mmol, 1.0 equiv) Boc-AdGly-OH, 0.206 g (1.07 mmol, 
1.1 equiv) EDAC, 0.148 g (1.10 mmol, 1.1 equiv) HOBt, 0.145 mL (0.106 g, 1.04 mmol,  
1.1 equiv) TEA, and 7 mL DCM utilizing GP-6. After 24 h the reaction mixture was diluted 
with EtOAc. For washing a volume of 50 mL was used. Additionally 10 mL brine were used 
for washing. 0.669 g (0.888 mmol, 93%) tripeptide were obtained as colorless solid. 
1H-NMR (400 MHz, CDCl3): δ = 7.42–7.40 (m, 1 H); 7.37–7.33 (m, 1 H); 7.29–7.18 (m, 8 H 
and CHCl3); 6.62–6.55 (m, 1 H); 6.18 (d, 1 H, 3J = 6.3 Hz); 5.29 (bs, 1 H); 5.24–5.17 (m, 2 H); 
4.65–4.59 (m, 1 H); 4.53–4.46 (m, 1 H); 3.70 (s, 3 H); 3.23–3.12 (m, 2 H); 3.11–3.01 (m, 2 H); 
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2.20–2.10 (m, 2 H); 1.97–1.92 (m, 2 H); 1.91–1.85 (m, 2 H); 1.84–1.76 (m, 3 H); 1.71–1.48 
(m, 9 H); 1.41 (s, 9 H); 1.31–1.20 (m, 2 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 177.0; 172.2; 171.0; 156.5; 154.3; 136.6; 134.5; 133.6; 
129.8; 129.6; 128.8; 127.1; 127.0; 79.2; 64.0; 54.2; 52.5, 52.2; 50.8; 42.8; 42.7; 41.0; 40.7; 
38.1; 37.7; 35.4; 31.8; 29.3; 29.2; 28.6; 22.2 ppm. 
MS (ESI): m/z: 775.3 [M + Na]+ (cal. 775.3). 
The synthesis of ClH3N-AdGly-Phe-Lys(2-Cl-Cbz)-OMe was performed with 0.669 g  
(0.888 mmol, 1.0 equiv) Boc-AdGly-Phe-Lys(2-Cl-Cbz)-OMe and 2.5 mL HCl in 1,4-dioxane 
(4 M) utilizing GP-8. The crude product was obtained as yellow solid and used without further 
purification. The synthesis of Boc-Phe-AdGly-Phe-Lys(2-Cl-Cbz)-OMe was performed with 
0.326 g (0.473 mmol, 1.0 equiv) hydrochloride, 0.128 g (0.475 mmol, 1.0 equiv) Boc-Phe-OH 
94, 0.103 g (0.537 mmol, 1.1 equiv) EDAC, 0.074 g (0.548 mmol, 1.2 equiv) HOBt, 0.072 mL 
(0.052 g, 0.519 mmol, 1.1 equiv) TEA, and 5 mL DCM utilizing GP-6. After 27 h the reaction 
mixture was diluted with EtOAc. For washing a volume of 50 mL was used.  
Additionally 20 mL brine were used for washing. 0.376 g (0.418 mmol, 88%) tetrapeptide were 
obtained as yellowish solid. 
MS (ESI): m/z: 922.4 [M + Na]+ (cal. 922.4); 938.3 [M + K]+ (cal. 938.4). 
The synthesis of the free amine was performed with 0.376 g (0.418 mmol, 1.0 equiv) of the  
(2-Cl-Cbz)-protected compound, 0.090 g (0.085 mmol, 20 mol%) Pd/C (10%), and 10 mL 
MeOH (GP-7). The reaction mixture was stirred for 22 h. 0.298 g (0.407 mmol, 97%) free 
amine were obtained as colorless solid. 
MS (ESI): m/z: 632.4 [M – Boc + H]+ (cal. 632.4); 732.4 [M + H]+ (cal. 732.4). 
The synthesis of Boc-Phe-AdGly-Phe-Lys(CM)-OMe 126 was performed with 0.298 g  
(0.407 mmol, 1.0 equiv) of the free amine, 0.137 g (0.628 mmol, 1.5 equiv) acid para-112,  
11.5 mg (0.094 mmol, 23 mol%) DMAP, 0.241 g (1.26 mmol, 3.1 equiv) EDAC, 0.171 mL 
(0.125 g, 1.23 mmol, 3.0 equiv) TEA, and 10 mL DCM utilizing GP-3. After 24 h the reaction 
was quenched with 30 mL NaHCO3 and the organic layer was extracted with DCM (two times  
10 mL). After purification via column chromatography (n-hexane:EtOAc 1:5 to 1:7) 0.180 g 
(0.193 mmol, 47%) 126 were isolated as colorless solid. 
Rf: 0.39 (n-hexane:EtOAc 1:5). 
1H-NMR and 13C-NMR not meaningful. 
HR-MS (ESI): m/z: 986.4493 [M + MeOH + Na]+ (cal. 986.4497). 
162 
 
MS (ESI): m/z: 986.3 [M + MeOH + Na]+ (cal. 986.4). 
Boc-PMH-AdGly-Phe-Lys(CM)-OMe 127: 
The synthesis of Boc-PMH-AdGly-Phe-Lys(2-Cl-
Cbz)-OMe was performed with 0.330 g  
(0.478 mmol, 1.0 equiv) of the corresponding 
hydrochloride, 0.131 g (0.486 mmol, 1.0 equiv) 
Boc-PMH-OH, 0.234 g (1.22 mmol, 2.6 equiv) 
EDAC, 0.168 g (1.24 mmol, 2.6 equiv) HOBt,  
0.166 mL (0.121 g, 1.20 mmol, 1.2 equiv) TEA, and 6 mL DCM utilizing GP-6. After 28 h the 
reaction mixture was diluted with EtOAc. For washing a volume of 50 mL was used. 
Additionally 20 mL brine were used for washing. 0.342 g (0.378 mmol, 79%) tetrapeptide were 
obtained as yellowish solid. 
MS (ESI): m/z: 904.4 [M + H]+ (cal. 904.4); 926.3 [M + Na]+ (cal. 926.4). 
The synthesis of the free amine was performed with 0.296 g (0.327 mmol, 1.0 equiv) of the 
(2-Cl-Cbz)-protected compound, 0.074 g (0.070 mmol, 15 mol%) Pd/C (10%), and 10.0 mL 
MeOH (GP-7). The reaction mixture was stirred for 42 h. 0.235 g (0.319 mmol, 98%) of the 
free amine were obtained as colorless solid. 
MS (ESI): m/z: 368.7 [M + 2H]2+ (cal. 368.7); 636.4 [M – Boc + H]+ (cal. 636.4); 736.4 [M + 
H]+ (cal. 736.4). 
The synthesis of Boc-PMH-AdGly-Phe-Lys(CM)-OMe 127 was performed with 0.235 g 
(0.319 mmol, 1.0 equiv) of the free amine, 0.086 g (0.394 mmol, 1.2 equiv) acid para-112,  
2.4 mg (0.020 mmol, 6 mol%) DMAP, 0.127 g (0.662 mmol, 2.1 equiv) EDAC, 0.090 mL 
(0.066 g, 0.648 mmol, 2.0 equiv) TEA, and 10 mL DCM utilizing GP-3. After 24 h the reaction 
was quenched with 10 mL NaHCO3 and the organic layer was extracted with DCM (three times  
10 mL). After purification via column chromatography (CH2Cl2:MeOH 5:1) 0.264 g  
(0.282 mmol, 88%) 127 were isolated as colorless solid. 
Rf: 0.35 (CH2Cl2:MeOH 10:1). 
1H-NMR and 13C-NMR show traces of racemization and are therefore not evaluable. 
HR-MS (ESI): m/z: 495.7310 [M + MeOH + Na + H]2+ (cal. 495.7316); 990.4565 [M + MeOH 
+ Na]+ (cal. 990.4559). 
MS (ESI): m/z: 968.3 [M + MeOH + H]+ (cal. 968.5); 990.3 [M + MeOH + Na]+ (cal. 990.5). 
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1-(p-(((1S,2S)-2-(p-(2,2,2-Trifluoroacetyl)benzoylamino)cyclohexylamino)carbonyl) 
phenyl)-2,2,2-trifluoro-1-ethanone 128: 
The synthesis of C2-symmetric cat. 128 was performed with 0.105 g 
(0.920 mmol, 1.0 equiv) of the corresponding diamine, 0.394 g  
(1.81 mmol, 2.0 equiv) acid para-112, 4.5 mg (0.037 mmol, 4 mol%) 
DMAP, 0.504 g (2.63 mmol, 2.9 equiv) EDAC, 0.365 mL (0.266 g,  
2.63 mmol, 2.9 equiv) TEA, and 8 mL DCM utilizing GP-3. After 47 h 
the reaction was quenched with 30 mL NaHCO3 and the organic layer 
was extracted with DCM (three times 20 mL). After purification via 
column chromatography (EtOAc) 0.174 g (0.338 mmol, 37%) 128 were 
isolated as yellow solid. 
Rf: 0.55 (EtOAc). 
1H-NMR (600 MHz, CDCl3): δ = 8.02 (d, 4 H, 3J = 8.2 Hz); 7.85 (d, 4 H, 3J = 8.4 Hz); 6.95 (d, 
2 H, 3J = 6.3 Hz, NH); 4.11–4.03 (m, 2 H, CHNH); 2.26–2.24 (m, 2 H, HCy); 1.91–1.90 (m, 2 
H, HCy); 1.53–1.44 (m, 4 H, HCy) ppm. 
13C-NMR (151 MHz, CDCl3): δ = 180.0 (q, 2JCF = 35.6 Hz, COCF3); 166.8; 140.1; 132.1; 
130.5; 127.7; 116.5 (q, 1JCF = 291.4 Hz, COCF3); 55.1 (CHNH); 32.3 (CH2CHNH); 24.9 
(CH2CH2CHNH) ppm. 
IR (KBr): ṽ = 3276 (w); 2943 (vw); 1726 (m); 1634 (m); 1541 (m); 1143 (m); 944 (w); 694 
(vw) cm−1. 
HR-MS (ESI): m/z: 601.1747 [M + 2MeOH + Na]+ (cal. 601.1744); 1179.3559 [M + 2MeOH 
+ Na]+ (cal. 1179.3595). 
MS (ESI): m/z: 579.2 [M + 2MeOH + H]+ (cal. 579.2); 601.3 [M + 2MeOH + Na]+ (cal. 601.2); 
1178.9 [2M + 2MeOH + Na]+ (cal. 1179.4). 
1-(p-(((1R,2R)-2-(p-(2,2,2-Trifluoroacetyl)benzoylamino)cyclohexylamino)carbonyl) 
phenyl)-2,2,2-trifluoro-1-ethanone 129: 
The synthesis of C2-symmetric cat. 129 was performed with 0.057 g 
(0.499 mmol, 1.0 equiv) of the corresponding diamine, 0.225 g (1.03 
mmol, 2.1 equiv) acid para-112, 3.2 mg (0.026 mmol, 5 mol%) DMAP, 
0.287 g (1.50 mmol, 3.0 equiv) EDAC, 0.208 mL (0.151 g, 1.50 mmol, 
3.0 equiv) TEA, and 6 mL DCM utilizing GP-3. After 67 h the reaction 
was quenched with 15 mL NaHCO3 and the organic layer was extracted 
with DCM (three times 10 mL). After purification via column 
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chromatography (n-hexane:EtOAc 1:5) 0.120 g (0.233 mmol, 47%) 129 were isolated as 
colorless solid. 
Rf: 0.45 (n-hexane:EtOAc 1:5). 
1H-NMR (400 MHz, CDCl3): δ = 7.80–7.75 (m, 8 H); 7.41 (d, 2 H, 3J = 7.4 Hz, NH); 4.22–
4.12 (m, 2 H, CHNH); 2.26–2.22 (m, 2 H, HCy); 1.95–1.93 (m, 2 H, HCy); 1.67–1.55 (m, 2 H, 
HCy); 1.52–1.41 (m, 2 H, HCy) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 179.7 (q, 2JCF = 35.8 Hz, COCF3); 166.8; 140.0; 131.9; 
130.2; 127.6; 116.4 (q, 1JCF = 291.1 Hz, COCF3); 54.9 (CHNH); 32.2 (CH2CHNH); 25.0 
(CH2CH2CHNH) ppm. 
IR (KBr): ṽ = 3275 (w); 2943 (w); 1726 (m); 1634 (m); 1540 (m); 1143 (m); 944 (w); 693 (w) 
cm−1. 
HR-MS (ESI): m/z: 601.1747 [M + 2MeOH + Na]+ (cal. 601.1744); 1179.3566 [M + 2MeOH 
+ Na]+ (cal. 1179.3595). 
MS (ESI): m/z: 579.2 [M + 2MeOH + H]+ (cal. 579.2); 601.3 [M + 2MeOH + Na]+ (cal. 601.2); 
1178.9 [2M + 2MeOH + Na]+ (cal. 1179.4). 
Methyl (2S)-3-phenyl-2-(p-(2,2,2-trifluoroacetyl)benzoylamino)propionate 131: 
The synthesis of functionalized Phe 131 was performed with 
0.301 g acid para-112 (1.38 mmol, 1.0 equiv), 0.338 g  
(1.57 mmol, 1.1 equiv) ClH3N-Phe-OMe 130, 0.297 g  
(1.54 mmol, 1.1 equiv) EDAC, 0.212 g (1.57 mmol, 1.1 equiv) 
HOBt, 0.210 mL (0.153 g, 1.51 mmol, 1.1 equiv) TEA, and 13 mL DCM utilizing GP-6.  
After 22 h the reaction mixture was diluted with EtOAc. For washing a volume of 33 mL was 
used. Additionally 25 mL brine were used for washing. After purification via column 
chromatography (n-hexane:EtOAc 1:1) 0.466 g (1.23 mmol, 89%) 131 were isolated as 
colorless solid. 
Rf: 0.34 (n-hexane:EtOAc 1:1). 
1H-NMR (400 MHz, CDCl3): δ = 8.04 (d, 2 H, 3J = 8.0 Hz, HAr-COCF3); 7.79–7.77 (m, 2 H, HAr-
COCF3); 7.26–7.17 (m, 3 H, HAr and CHCl3); 7.06–7.04 (m, 2 H, HAr); 6.62 (d, 1 H, 3J = 7.4 Hz, 
NH); 5.02 (dt, 1 H, 3J = 7.5 Hz, 3J = 5.6 Hz, CH); 3.73 (s, 3 H, CH3); 3.25 (dd, 1 H, 
2J = 13.9 
Hz, 3J = 5.7 Hz, CH2); 3.16 (dd, 1 H, 
2J = 13.9 Hz, 3J = 5.5 Hz, CH2) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 180.1 (q, 2JCF = 35.7 Hz, COCF3); 171.9; 165.4; 140.0; 
135.6; 132.3; 130.5; 129.4; 128.9; 127.8; 127.5; 116.6 (q, 1JCF = 291.1 Hz, COCF3); 53.8; 52.8; 
37.8 ppm. 
165 
 
IR (KBr): ṽ = 3300 (m); 2959 (vw); 1755 (m); 1737 (m); 1647 (s); 1546 (s); 1141 (s); 942 (m); 
699 (m) cm−1. 
HR-MS (ESI): m/z: 434.1191 [M + MeOH + Na]+ (cal. 434.1186); 845.2478 [2M + 2MeOH 
+ Na]+ (cal. 845.2479). 
MS (ESI): m/z: 412.1 [M + MeOH + H]+ (cal. 412.1); 434.1 [M + MeOH + Na]+ (cal. 434.1). 
Methyl (2S)-3-cyclohexyl-2-(p-(2,2,2-trifluoroacetyl)benzoylamino)propionate 166: 
The synthesis of functionalized Cha 166 was performed with 
0.300 g acid para-112 (1.38 mmol, 1.0 equiv), 0.339 g  
(1.53 mmol, 1.1 equiv) ClH3N-Cha-OMe, 0.298 g (1.55 mmol,  
1.1 equiv) EDAC, 0.214 g (1.58 mmol, 1.1 equiv) HOBt,  
0.230 mL (0.168 g, 1.66 mmol, 1.1 equiv) TEA, and 12 mL DCM utilizing GP-6. After 27.5 h 
the reaction mixture was diluted with EtOAc. For washing a volume of 45 mL was used.  
0.514 g (1.33 mmol, 97%) 166 were obtained as a yellowish oil. The crude product was used 
without further optimization.11 
Rf: 0.40 (n-hexane:EtOAc 1:1). 
1H-NMR (600 MHz, MeOH-d4): δ = 7.89 (d, 2 H, 3J = 7.9 Hz, HAr-COCF3); 7.72 (d, 2 H, 3J = 
7.9 Hz, HAr-COCF3); 4.71 (dd, 1 H, 
3J = 8.7 Hz, 3J = 6.1 Hz, CHCH2); 3.74 (s, 3 H, CH3); 1.85 
(d, 1 H, J = 12.6 Hz); 1.78–1.70 (m, 5 H); 1.66 (d, 1 H, J = 10.4 Hz); 1.44 (bs, 1 H); 1.32–1.17 
(m, 3 H); 1.02 (q, 1 H, J = 11.8); 0.95 (q, 1 H, J = 11.8) ppm. 
13C-NMR (151 MHz, MeOH-d4):
12 δ = 174.9; 170.0; 139.8; 136.3; 129.5; 128.3; 124.3 (q, 1JCF 
= 287.2 Hz, COCF3); 97.7 (q, 
2JCF = 31.6 Hz, C(OH)2CF3); 52.7; 52.1; 39.7; 35.7; 34.8; 33.2; 
27.5; 27.3; 27.2 ppm. 
HR-MS (ESI): m/z: 440.1655 [M + MeOH + Na]+ (cal. 440.1655); 857.3416 [2M + 2MeOH 
+ Na]+ (cal. 857.3418). 
MS (ESI): m/z: 440.2 [M + MeOH + Na]+ (cal. 440.2); 856.9 [2M + 2MeOH + Na]+ (cal. 
857.3). 
 
 
 
                                                 
11 Decomposition over time to the hydrate observed. 
12 Formation of the hydrate in MeOH-d4 observable. Not observable in MS (ESI). 
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(1S)-1-Benzyl-2-oxo-2-(o-(2,2,2-trifluoro-1-hydroxyethyl)phenylamino)ethylamino-2,2-
dimethyl-propionate ortho-160: 
The synthesis of amino alcohol ortho-155 was performed with 0.335 g 
(1.53 mmol, 1.0 equiv) nitro compound ortho-154, 0.042 g  
(0.039 mmol, 3 mol%) Pd/C (10%), and 7 mL EtOH (GP-7).  
The reaction mixture was stirred for 21 h. The crude product was 
utilized without further purification. 
1H-NMR (400 MHz, CDCl3 and MeOD-d4): δ = 7.17 (d, 1 H, 3J = 7.0 Hz); 7.11 (t, 1 H, 3J = 
7.6 Hz); 6.76–6.67 (m, 2 H); 5.06–4.97 (m, 1 H, CHOHCF3); 3.65 (bs, 3 H, NH and OH) ppm. 
13C-NMR (101 MHz, CDCl3 and MeOD-d4): δ = 145.4; 129.8; 129.5; 125.3 (q, 1JCF = 282.8 
Hz, CHOHCF3); 119.4; 118.8; 117.8; 71.3 (q, 
2JCF = 32.4 Hz, CHOHCF3) ppm. 
IR (ATR): ṽ = 3397 (vw); 3075 (vw); 2289 (vw); 1609 (vw); 1496 (vw); 1294 (vw); 1180 (w); 
1112 (w); 758 (w) cm−1. 
HR-MS (ESI): m/z: 214.0463 [M + Na]+ (cal. 214.0450). 
The synthesis of ortho-160 was performed with 0.139 g (0.727 mmol, 1.0 equiv) ortho-155, 
0.232 g (0.874 mmol, 1.2 equiv) Phe 94, 0.175 g (0.913 mmol, 1.3 equiv) EDAC, 0.127 g  
(0.940 mmol, 1.3 equiv) HOBt, 0.088 mL (0.064 g, 0.634 mmol, 0.9 equiv) TEA, and 10 mL 
DCM utilizing GP-6. The resulting mixture was stirred for 13 h. For washing a volume of 30 
mL was used. After purification via column chromatography (n-hexane:EtOAc 5:1 to 0:1)  
0.072 g (0.164 mmol, 26%) ortho-160 were isolated as colorless solid.  
Rf: 0.57 (n-hexane:EtOAc 1:5). 
IR (ATR): ṽ = 3294 (vw); 2928 (vw); 1669 (vw); 1496 (vw); 1160 (w); 751 (vw); 698 (vw) 
cm−1. 
HR-MS (ESI): m/z: 461.1662 [M + Na]+ (cal. 461.1659); 899.3433 [2M + Na]+ (cal. 
899.3425). 
MS (ESI): m/z: 461.1 [M + Na]+ (cal. 461.2). 
(1S)-2-(m-(2,2,2-Trifluoro-1-hydroxyethyl)phenylamino)-1-benzyl-2-oxoethylamino-2,2-
dimethyl propionate meta-160: 
The synthesis of amino alcohol meta-155 was performed with 
0.194 g (0.885 mmol, 1.0 equiv) nitro compound meta-154,  
17.7 mg (0.017 mmol, 2 mol%) Pd/C (10%), and 4.5 mL EtOH 
(GP-7). The reaction mixture was stirred for 17 h.  
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After purification via column chromatography (n-hexane:EtOAc 2:1 and 0.25% TEA) 0.144 g 
(0.761 mmol, 86%) meta-155 were isolated as yellow oil. 
Rf: 0.46 (n-hexane:EtOAc 1:2). 
1H-NMR (400 MHz, CDCl3): δ = 7.18 (t, 1 H, 3J = 7.8 Hz); 6.84 (d, 1 H, 3J = 7.2 Hz); 6.76 (s, 
1 H, C(CHOHCF3)CHC(NO2)); 6.73–6.67 (m, 1 H); 4.91–4.85 (m, 1 H, CHOHCF3); 3.58 (bs, 
3 H, NH and OH) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 146.6; 135.5; 129.7; 124.4 (q, 1JCF = 281.9 Hz, CHOHCF3); 
118.0; 116.5; 114.0; 73.0 (q, 2JCF = 32.1 Hz, CHOHCF3) ppm. 
IR (ATR): ṽ = 3408 (vw); 3116 (vw); 1614 (vw); 1255 (w); 1101 (m); 791 (w); 706 (m) cm−1. 
HR-MS (ESI): m/z: 214.0453 [M + Na]+ (cal. 214.0450). 
The synthesis of meta-160 was performed with 0.141 g (0.738 mmol, 1.0 equiv) meta-155, 
0.215 g (0.810 mmol, 1.1 equiv) Phe 94, 0.160 g (0.835 mmol, 1.1 equiv) EDAC, 0.114 g  
(0.844 mmol, 1.1 equiv) HOBt, 0.113 mL (0.082 g, 0.814 mmol, 1.1 equiv) TEA, and 10 mL 
DCM utilizing GP-6. The resulting mixture was stirred for 23 h. For washing a volume of  
175 mL was used. After purification via column chromatography (DCM:MeOH 50:1 to 30:1) 
0.104 g (0.237 mmol, 32%) meta-160 were isolated as yellowish foam.  
Rf: 0.23 (DCM:MeOH 30:1). 
HR-MS (ESI): m/z: 461.1668 [M + Na]+ (cal. 461.1659); 899.3450 [2M + Na]+ (cal. 
899.3425). 
MS (ESI): m/z: 461.0 [M + Na]+ (cal. 461.2). 
(1S)-1-Benzyl-2-oxo-2-(m-(2,2,2-trifluoroacetyl)phenylamino)ethylamino-2,2-dimethyl 
propionate meta-161: 
0.086 g (0.196 mmol, 1.0 equiv) alcohol meta-160 and 3.58 mg 
(0.023 mmol, 0.1 equiv, 12 mol%) TEMPO were dissolved in  
10 mL DCM. Afterwards 0.088 g (0.357 mmol, 1.8 equiv) 
mCPBA (70%) were added and the resulting reaction mixture was 
stirred for 20 h at r.t.. The organic layer was washed portionwise with 200 mL sat. NaHCO3 
and dried afterwards over Na2SO4. After purification via column chromatography  
(n-hexane:EtOAc 2:1) 47.2 mg (0.108 mmol, 55%) meta-161 were isolated as yellow oil. 
Rf: 0.23 (n-hexane:EtOAc 2:1). 
1H-NMR (600 MHz, CDCl3): δ = 8.81 (bs, 1 H, NH); 8.02 (s, 1 H, C(COCF3)CHC(NO2)); 
7.77–7.65 (m, 2 H); 7.39–7.31 (m, 1 H); 7.28–7.19 (m, 5 H and CDCl3); 5.41 (d, 1 H, 3J = 7.3 
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Hz, NH); 4.64 (bs, 1 H, CHCH2); 3.19–3.16 (m, 1 H, CHCH2); 3.08 (dd, 1 H, 2J = 13.7 Hz, 3J 
= 7.9 Hz, CHCH2); 1.41 (s, 9 H, C(CH3) 3) ppm. 
13C-NMR (151 MHz, CDCl3): δ = 180.1 (q, 2JCF = 35.2 Hz, COCF3); 170.7 (NHCOCH); 156.5 
(NHCOO C(CH3)3); 138.6 (Cquart.); 136.4 (Cquart.); 130.5 (Cquart.); 129.7; 129.3; 128.9; 127.3; 
126.8; 125.8; 121.0; 119.5; 116.5 (q, 1JCF = 291.2 Hz, COCF3); 81.1 (C(CH3) 3); 56.8 (CHCH2); 
38.5 (CHCH2); 28.4 (C(CH3) 3) ppm. 
MS (ESI): m/z: 491.0 [M + MeOH + Na]+ (cal. 491.2). 
Boc-Leu-Phe-((3S)-N-benzylquinuclidinium) bromide 182: 
The synthesis of Boc-Leu-Phe-OMe was performed with 0.220 g 
(1.02 mmol, 1.0 equiv) hydrochloride 130, 0.250 g (1.08 mmol, 
1.1 equiv) Boc-Leu-OH, 0.210 g (1.12 mmol, 1.1 equiv) EDAC, 
0.150 g (1.11 mmol, 1.1 equiv) HOBt, 0.153 mL (0.112 g,  
1.10 mmol, 1.1 equiv) TEA, and 15 mL DCM utilizing GP-6. 
After 24 h the reaction mixture was diluted with 150 mL EtOAc. For washing a volume of  
30 mL was used. The organic layer was washed additionally with 100 mL brine. 0.350 g  
(0.892 mmol, 87%) dipeptide were obtained as colorless solid. 
After dissolving 0.350 g (0.892 mmol, 1.0 equiv) dipeptide in 15 mL 1,4-dioxane 15 mL LiOHaq 
(1 M) were added. The resulting reaction mixture was stirred for 19 h at r.t. and was acidified 
afterwards with HCl (2 M) until a pH-value of 5 was reached. The unprotected dipeptide was 
dissolved in 100 mL EtOAc. The organic layer was washed with 50 mL brine. This aq layer 
was again extracted with 50 mL EtOAc. After washing the second organic layer with 50 mL 
brine, both organic layers were combined, and dried finally over MgSO4. After evaporation of 
the solvent under reduced pressure 0.310 g (0.819 mmol, 92%) Boc-Leu-Phe-OH 183 were 
obtained as colorless solid. 
To a suspension of 0.310 g (0.819 mmol, 1.0 equiv) unprotected dipeptide 183 in 20 mL DMF 
0.426 mL (0.324 g, 2.50 mmol, 3.1 equiv) DiPEA were added. After stirring the resulting 
solution for 5 min at r.t. 0.170 g (0.858 mmol, 1.0 equiv) 181 • 2 HCl were added. After stirring 
for additional 10 min at r.t. the reaction mixture was cooled to 0 °C and 0.310 g (0.818 mmol, 
1.0 equiv) HBTU were added. After stirring the reaction mixture for 24 h at r.t. the solvent was 
evaporated under reduced pressure. The residue was dissolved in 50 mL CHCl3/MeOH (9:1). 
The organic layer was washed with 30 mL sat. NaHCO3. The aq solution was extracted two 
times with 25 mL CHCl3/MeOH (9:1). The combined organic layers were washed with 30 mL 
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birne and dried over MgSO4. After purification via column chromatography (CHCl3:MeOH 
7:3) 0.340 g (0.696 mmol, 85%) Boc-Leu-Phe-((3S)-N-benzyl-quinuclidine) 184 were isolated 
as colorless solid. 
Rf: 0.34 (CHCl3:MeOH 7:3). 
MS (ESI): m/z: 487.5 [M + H]+ (cal. 487.3). 
To a solution of 0.340 g (0.696 mmol, 1.0 equiv) Boc-Leu-Phe-((3S)-N-benzyl-quinuclidine) 
184 in 10 mL MeCN 0.083 mL (0.119 g, 0.698 mmol, 1.0 equiv) BnBr were added.  
After refluxing the resulting solution for 72 h the solvent was evaporated under reduced 
pressure. The residue was dissolved in 5 mL MeCN and the crude product precipitated by 
addition of Et2O. After filtration and washing with Et2O the crude product was dried over night 
in the desiccator. After purification via column chromatography (CHCl3:MeOH 4:1) 0.190 g 
(0.289 mmol, 41%) 182 were isolated as colorless solid. 
Rf: 0.34 (CHCl3:MeOH 7:3). 
1H-NMR (400 MHz, MeOD-d4): δ = 7.62–7.51 (m, 5 H); 7.24–7.14 (m, 5 H); 4.48–4.37 (m, 3 
H); 4.05–4.00 (m, 2 H); 3.83–3.79 (m, 1 H); 3.64–3.58 (m, 1 H); 3.56–3.37 (m, 3 H); 3.14 (bs, 
1 H); 3.05 (dd, 1 H, 2J = 13.3 Hz, 3J = 6.8 Hz); 2.98–2.89 (m, 1 H); 2.70 (bs, 1 H); 2.11 (bs, 1 
H); 2.03 (bs, 2 H); 1.78 (bs, 2 H); 1.67–1.59 (m, 1 H, CH(CH3)2); 1.50–1.39 (m, 11 H); 1.18 
(td, 2 H, 3J = 7.5 Hz, J = 1.5 Hz); 0.94–0.89 (m, 6 H, CH(CH3)2) ppm. 
13C-NMR (101 MHz, MeOD-d4): δ = 175.5; 173.6; 158.0; 138.1; 134.4; 132.0; 130.5; 129.7; 
128.2; 128.0; 80.7; 68.9; 60.9; 58.3; 55.9; 55.8; 54.9; 54.6; 46.9; 42.0; 39.0; 28.7; 26.0; 25.9; 
23.6; 23.4; 21.9; 19.5; 18.4 ppm. 
MS (ESI): m/z: 577.4 [M]+ (cal. 577.4). 
Boc-Leu-Phe-Thr-((3S)-N-benzylquinuclidinium) bromide 185: 
To a suspension of 1.32 g (6.02 mmol, 1.0 equiv) Boc-Thr-
OH in 20 mL DMF 3.10 mL  
(2.36 g, 18.2 mmol, 3.0 equiv) DiPEA were added.  
After stirring the resulting solution for  
5 min at r.t. 1.20 g (6.06 mmol, 1.0 equiv) 181 • 2 HCl 
were added. After stirring for additional 10 min at r.t. the 
reaction mixture was cooled to 0 °C and 2.28 g (6.01 mmol, 1.0 equiv) HBTU were added. 
After stirring the reaction mixture for 24 h at r.t. the solvent was evaporated under reduced 
pressure. The residue was dissolved in 50 mL CHCl3/MeOH (9:1). The organic layer was 
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washed with 30 mL sat. NaHCO3. The aq solution was extracted two times with 25 mL 
CHCl3/MeOH (9:1). The combined organic layers were washed with 30 mL birne and dried 
over MgSO4. 1.47 g (4.49 mmol, 75%) Boc-Thr-((3S)-N-benzylquinuclidine) were isolated as 
orange oil. The crude product was used without further purification. 
MS (ESI): m/z: 328.1 [M + H]+ (cal. 328.2); 350.1 [M + H]+ (cal. 350.2). 
The synthesis of ClH3N-Thr-((3S)-N-benzylquinuclidinium) chloride was performed with  
1.47 g (4.49 mmol, 1.0 equiv) Boc-Thr-((3S)-N-benzylquinuclidine) and 6.3 mL HCl in  
1,4-dioxane (4 M) utilizing GP-8. The crude product was used without further purification or 
analytics. To a suspension of 0.500 g (1.88 mmol, 1.3 equiv) Boc-Phe-OH 94 in 20 mL DMF 
0.640 mL (0.486 g, 3.76 mmol, 2.5 equiv) DiPEA were added. After stirring the resulting 
solution for 5 min at r.t. 0.450 g (1.50 mmol, 1.0 equiv) ClH3N-Thr-((3S)-N-
benzylquinuclidinium) chloride were added. After stirring for additional 10 min at r.t. the 
reaction mixture was cooled to 0 °C and 0.710 g (1.87 mmol, 1.2 equiv) HBTU were added. 
After stirring the reaction mixture for 24 h at r.t. the solvent was evaporated under reduced 
pressure. The residue was dissolved in 50 mL CHCl3/MeOH (9:1). The organic layer was 
washed with 30 mL sat. NaHCO3. The aq solution was extracted two times with 25 mL 
CHCl3/MeOH (9:1). The combined organic layers were washed with 30 mL birne and dried 
over MgSO4. 0.720 g (1.52 mmol, quant.) Boc-Phe-Thr-((3S)-N-benzylquinuclidine) were 
isolated as orange oil. The crude product was used without further purification. 
MS (ESI): m/z: 475.4 [M + H]+ (cal. 475.4). 
The synthesis of ClH3N-Phe-Thr-((3S)-N-benzylquinuclidinium) chloride was performed with 
0.720 g (1.52 mmol, 1.0 equiv) Boc-Phe-Thr-((3S)-N-benzylquinuclidine) and 2.1 mL HCl in 
1,4-dioxane (4 M) utilizing GP-8. The crude product was used without further purification and 
analytics. To a suspension of 0.400 g (1.73 mmol, 1.3 equiv) Boc-Leu-OH in 20 mL DMF  
0.545 mL (0.414 g, 3.20 mmol, 2.4 equiv) DiPEA were added. After stirring the resulting 
solution for 5 min at r.t. 0.600 g (1.35 mmol, 1.0 equiv) ClH3N-Phe-Thr-((3S)-N-
benzylquinuclidinium) chloride were added. After stirring for additional 10 min at r.t. the 
reaction mixture was cooled to 0 °C and 0.610 g (1.61 mmol, 1.2 equiv) HBTU were added. 
After stirring the reaction mixture for 24 h at r.t. the solvent was evaporated under reduced 
pressure. The residue was dissolved in 50 mL CHCl3/MeOH (9:1). The organic layer was 
washed with 30 mL sat. NaHCO3. The aq solution was extracted two times with 25 mL 
CHCl3/MeOH (9:1). The combined organic layers were washed with 30 mL birne and dried 
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over MgSO4. 0.840 g (1.43 mmol, quant.)
13 Boc-Leu-Phe-Thr-((3S)-N-benzylquinuclidine) 
were isolated as orange oil. The crude product was used without further purification. 
MS (ESI): m/z: 588.4 [M + H]+ (cal. 588.4). 
To a solution of 0.450 g (0.766 mmol, 1.0 equiv) Boc-Leu-Phe-Thr-((3S)-N-
benzylquinuclidine) in 10 mL MeCN 0.092 mL (0.132 g, 0.774 mmol, 1.0 equiv) BnBr were 
added. After refluxing the resulting solution for 72 h the solvent was evaporated under reduced 
pressure. The residue was dissolved in 5 mL MeCN and the crude product precipitated by 
addition of Et2O. After filtration and washing with Et2O the crude product was dried over night 
in the desiccator. After centrifugation and decantation with Et2O 0.180 g (0.237 mmol, 31%) 
185 were isolated as fawn solid. 
1H-NMR (400 MHz, MeOD-d4): δ = 7.70–7.45 (m, 5 H); 7.39–7.17 (m, 5 H); 4.70–4.41 (m, 3 
H); 4.38–4.13 (m, 3 H); 4.11–3.83 (m, 2 H); 3.73–3.46 (m, 5 H); 3.42–3.28 (m, 2 H and MeOH); 
3.27–3.13 (m, 1 H); 3.11–2.96 (m, 1 H); 2.37–2.16 (m, 2 H); 2.15–2.02 (m, 2 H); 2.00–1.87 
(m, 1 H); 1.75–1.54 (m, 1 H); 1.52–1.31 (m, 10 H); 1.27–1.06 (m, 5 H); 1.04–0.81 (m, 6 H, 
CH(CH3)2) ppm. 
13C-NMR (101 MHz, MeOD-d4): δ = 176.4; 173.6; 172.7; 158.0; 138.1; 134.3; 131.8; 130.4; 
129.6; 128.2; 127.9; 80.9 (C(CH3)3); 69.0 (CH2); 68.2; 66.9 (CH2); 60.8 (CH2); 60.3; 56.5; 55.4 
(CH2); 55.3 (CH2); 54.9; 46.9; 41.9 (CH2); 37.9 (CH2); 28.8 (C(CH3)3); 26.2; 25.8; 23.6 (CH2); 
23.3 (CH(CH3)2); 22.0 (CH(CH3)2); 20.5; 19.7 (CH2); 15.5 ppm. 
MS (ESI): m/z: 678.4 [M]+ (cal. 678.4). 
Ad-Phe-((2S,4R)-4-oxy-2-pyrrolidinyl)diphenylmethanol 192: 
0.011 g (0.090 mmol, 0.1 equiv, 9 mol%) DMAP and 0.321 g 
(1.67 mmol, 1.7 equiv) EDAC were dissolved in 56 mL DCM. 
After cooling the reaction mixture to 0 °C 0.400 g (1.01 mmol, 
1.0 equiv) hydrochloride 188 were added over 10 min and the 
resulting mixture was stirred for 1 h at this temperature.  
After addition of 0.444 g (1.67 mmol, 1.7 equiv) Boc-Phe-OH 94 the reaction mixture was 
refluxed for an additional hour. The reaction mixture was washed with citric acid (0.5 M) as 
well as sat. NaHCO3 (three times 56 mL). After drying over Na2SO4 the solvent was removed 
under reduced pressure. After purification via column chromatography (n-hexane:EtOAc 3:1)  
                                                 
13 Contains traces of solvent. 
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0.566 g (0.933 mmol, 92%) Boc-Phe-((2S,4R)-4-oxy-2-pyrrolidinyl)diphenylmethanol 189 
were isolated as colorless foam. 
Rf: 0.52 (n-hexane:EtOAc 3:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.76 (d, 2 H, 3J = 7.5 Hz); 7.57 (d, 2 H, 3J = 7.4 Hz); 7.34–
7.27 (m, 8 H); 7.24–7.15 (m, 7 H); 7.00 (d, 2 H, 3J = 6.4 Hz); 5.02–5.00 (m, 1 H, CO2CH); 4.81 
(s, 1 H, OH); 4.58–4.53 (m, 1 H, CHPhe); 4.20 (t, 1 H, 3J = 8.0 Hz, CHCquart.,OH); 3.30–3.20 (m, 
2 H, CH2,Bn); 3.12–3.02 (m, 3 H, CH2,Phe and CH2NBn); 2.64 (d, 1 H, 2J = 12.3 Hz, CH2NBn); 
1.92–1.85 (m, 1 H, CH2CHCquart.,OH); 1.80–1.75 (m, 1 H, CH2CHCquart.,OH); 1.44 (s, 9 H, 
C(CH3)3) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 171.8 (CO2CH); 155.2 (COC(CH3)3); 147.5 (Cquart.,Ph); 145.7 
(Cquart.,Ph); 139.3(Cquart.,Ph); 136.2 (Cquart.,Ph); 129.4 (CHPh); 128.8 (CHPh); 128.41(CHPh); 128.37 
(CHPh); 128.3 (CHPh); 127.23 (CHPh); 127.18(CHPh); 126.8(CHPh); 126.6 (CHPh); 125.7 (CHPh); 
125.5 (CHPh); 80.2 (C(CH3)3); 76.8 (Cquart.,OH); 75.3 (CO2CH); 70.6 (CHCquart.,OH); 61.2 
(CH2,Bn); 59.1 (CH2NBn); 54.7 (CHPhe); 38.7 (CH2,Phe); 35.5 (CH2CHCquart.,OH); 28.4 (C(CH3)3) 
ppm. 
IR (ATR): ṽ = 3352 (vw); 2978 (vw); 2249 (vw); 1708 (m); 1494 (w); 1162 (m); 729 (s); 697 
(s) cm−1. 
HR-MS (ESI): m/z: 607.3179 [M + H]+ (cal. 607.3166); 629.3003 [M + Na]+ (cal. 629.2986). 
MS (ESI): m/z: 607.4 [M + H]+ (cal. 607.3); 629.4 [M + Na]+ (cal. 629.4). 
The synthesis of hydrochloride 190 was performed with 0.566 g (0.933 mmol, 1.0 equiv)  
Boc-Phe-((2S,4R)-4-Oxy-2-pyrrolidinyl)diphenylmethanol 189 and 1.87 mL HCl in  
1,4-dioxane (4 M) utilizing GP-8. 0.507 g (0.934 mmol, quant.) hydrochloride 190 were 
obtained as orange oil. 
MS (ESI): m/z: 507.3 [M + H]+ (cal. 507.3). 
The synthesis of Bn-protected amine 191 was performed with 0.507 g (0.934 mmol, 1.0 equiv) 
hydrochloride 190, 0.168 g (0.932 mmol, 1.0 equiv) Ad-CO2H, 0.197 g (1.03 mmol, 1.1 equiv) 
EDAC, 0.157 g (1.16 mmol, 1.2 equiv) HOBt, 0.143 mL (0.104 g, 1.03 mmol, 1.1 equiv) TEA, 
and 10 mL DCM (GP-6). After 24 h the reaction mixture was diluted with DCM. For removing 
the unreacted acid the organic layer was washed three times with Na2CO3. After purification 
via column chromatography (n-hexane:EtOAc 3:1) 0.309 g of a redish foam consisting of 191 
and Ad-CO2H (around 20%) were obtained. 
Rf: 0.19 (n-hexane:EtOAc 3:1). 
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MS (ESI): m/z: 669.5 [M + H]+ (cal. 669.4); 691.5 [M + Na]+ (cal. 691.4); 1359.4 [M + 2Na]+ 
(cal. 1359.7). 
The synthesis of Ad-Phe-((2S,4R)-4-oxy-2-pyrrolidinyl)diphenylmethanol 192 was performed 
with 0.092 g of acid-impured Bn-protected amine 191, 0.040 g Pd/C (10%), and 10 mL MeOH 
(GP-7). The reaction mixture was stirred for 2 d. 0.072 g of a colorless solid consisting of 192 
and Ad-CO2H (around 20%) were obtained. 
MS (ESI): m/z: 579.4 [M + H]+ (cal. 579.3); 601.4 [M + Na]+ (cal. 601.3). 
CM-AdGly-Val-Phe-OMe 214: 
The synthesis of Boc-Val-Phe-OMe was 
performed with 0.506 g (2.35 mmol, 1.0 equiv) 
hydrochloride 130, 0.510 g (2.35 mmol,  
1.0 equiv) Boc-Val-OH, 0.504 g (2.63 mmol, 
1.1 equiv) EDAC, 0.359 g (2.66 mmol,  
1.1 equiv) HOBt, 0.360 mL (0.262 g, 2.59 mmol, 1.1 equiv) TEA, and 9 mL DCM utilizing 
GP-6. After 16.5 h the reaction mixture was diluted with EtOAc. For washing a volume of  
20 mL was used. 0.682 g (1.80 mmol, 77%) dipeptide were obtained as colorless solid. 
1H-NMR (200 MHz, CDCl3): δ = 7.27–7.12 (m, 3 H and CHCl3); 7.10–6.99 (m, 2 H); 6.26 (d, 
1 H, 3J = 6.8 Hz, NH); 4.95 (d, 1 H, 3J = 8.3 Hz, NH); 4.80 (dt, 1 H, 3J = 7.8 Hz, 3J = 6.0 Hz); 
3.83 (dd, 1 H, 3J = 8.6 Hz, 3J = 6.2 Hz); 3.64 (s, 3 H, OCH3); 3.08–3.01 (m, 2 H, CHCH2); 
2.15–1.92 (m, 1 H, CH(CH3)2); 1.38 (s, 9 H, C(CH3)3); 0.85 (d, 3 H, 3J = 6.8 Hz, CH(CH3)2); 
0.79 (d, 3 H, 3J = 6.7 Hz, CH(CH3)2) ppm. 
13C-NMR (50 MHz, CDCl3): δ = 171.9; 171.4; 155.8; 135.8; 129.4; 128.8; 127.3; 80.9; 60.0; 
53.2; 52.5; 38.1; 31.0; 28.4; 19.3; 17.8 ppm. 
MS (ESI): m/z: 401.1 [M + Na]+ (cal. 401.2). 
The synthesis of ClH3N-Val-Phe-OMe was performed with 0.661 g (1.75 mmol, 1.0 equiv) 
Boc-Val-Phe-OMe and 3.6 mL HCl in 1,4-dioxane (4 M) utilizing GP-8. The crude product 
was obtained as colorless solid and used without further purification. 
MS (ESI): m/z: 279.0 [M + H]+ (cal. 279.2). 
The synthesis of Boc-AdGly-Val-Phe-OMe was performed with the crude product of  
ClH3N-Val-Phe-OMe, 0.517 g Boc-AdGly-OH (1.75 mmol, 1.0 equiv), 0.372 g (1.94 mmol, 
1.1 equiv) EDAC, 0.268 g (1.98 mmol, 1.1 equiv) HOBt, 0.270 mL (0.197 g, 1.95 mmol,  
1.1 equiv) TEA, and 20 mL DCM utilizing GP-6. After 24.5 h the reaction mixture was diluted 
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with 200 mL EtOAc. For washing a volume of 50 mL was used. After purification via column 
chromatography (DCM:MeOH 30:1 to 20:1) 0.764 g (1.37 mmol, 79% over two steps) 
tripeptides were isolated as colorless solid. 
Rf: 0.22 (DCM:MeOH 30:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.25–7.14 (m, 3 H and CHCl3); 7.05–7.01 (m, 2 H); 6.35–
6.25 (m, 1 H, NH); 6.08 (d, 1 H, 3J = 8.3 Hz, NH); 4.78 (dt, 1 H, 3J = 7.6 Hz, 3J = 6.2 Hz); 4.40 
(d, 1 H, 3J = 5.1 Hz, NH); 4.23–4.16 (m, 1 H); 3.64 (s, 3 H, OCH3); 3.08–2.98 (m, 2 H, CHCH2); 
2.14 (bs, 2 H); 2.04–1.96 (m, 1 H, CH(CH3)2); 1.92 (bs, 2 H); 1.90–1.79 (m, 4 H); 1.74–1.67 
(m, 4 H); 1.61–1.53 (m, 2 H); 1.36 (s, 9 H, C(CH3)3); 0.84–0.80 (m, 6 H, CH(CH3)2) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 176.6; 171.8; 171.1; 154.2; 135.7; 129.3; 128.8; 127.4; 79.1; 
57.9; 53.3; 52.5; 50.9; 43.2; 42.9; 41.0; 38.4; 38.0; 35.4; 31.2; 29.3; 28.6; 19.2; 18.2 ppm. 
MS (ESI): m/z: 556.2 [M + H]+ (cal. 556.3); 578.4 [M + Na]+ (cal. 578.3); 594.3 [M + K]+ (cal. 
594.3). 
The synthesis of ClH3N-AdGly-Val-Phe-OMe was performed with 0.764 g (1.37 mmol,  
1.0 equiv) Boc- AdGly-Val-Phe-OMe and 3 mL HCl in 1,4-dioxane (4 M) utilizing GP-8.  
The crude product was obtained as colorless solid and used without further purification. 
MS (ESI): m/z: 456.1 [M + H]+ (cal. 456.3); 478.3 [M + Na]+ (cal. 478.3); 911.3 [2M + H]+ 
(cal. 911.6). 
The synthesis of CM-AdGly-Val-Phe-OMe 214 was performed with 0.115 g (0.234 mmol,  
1.0 equiv) hydrochloride, 61.9 mg (0.284 mmol, 1.2 equiv) para-112, 51.4 mg (0.268 mmol, 
1.1 equiv) EDAC, 38.3 mg (0.283 mmol, 1.2 equiv) HOBt, 35.6 µL (26.0 mg, 0.256 mmol,  
1.1 equiv) TEA, and 3 mL DCM utilizing GP-6. After 24 h the reaction mixture was diluted 
with 30 mL EtOAc. For washing a volume of 7 mL was used. After purification via column 
chromatography (n-hexane:EtOAc 1:3) 69.8 mg (0.106 mmol, 45%) functionalized tripeptides 
214 were isolated as colorless solid. 
Rf: 0.40 (n-hexane:EtOAc 1:3). 
1H-NMR (600 MHz, CDCl3): δ = 8.04 (d, 2 H, 3J = 8.1 Hz, HAr-COCF3); 7.79 (d, 2 H, 3J = 8.4 
Hz, HAr-COCF3); 7.22–7.20 (m, 2 H and CHCl3, HPh); 7.17–7.15 (m, 1 H, HPh); 7.04–7.03 (m, 2 
H, HPh); 6.45 (d, 1 H, 
3J = 7.8 Hz, NHCHCH2); 6.19 (d, 1 H, 
3J = 8.5 Hz, NHCHCH(CH3)2); 
5.95 (s, 1 H, NHAdGly); 4.78 (dt, 1 H, 3J = 7.9 Hz, 3J = 6.2 Hz, CHCH2); 4.23 (dd, 1 H, 
3J = 
8.4 Hz, 3J = 6.7 Hz, CHCH(CH3)2); 3.63 (s, 3 H, OCH3); 3.06 (dd, 1 H, 
2J = 13.9 Hz, 3J = 6.0 
Hz, CHCH2); 3.01 (dd, 1 H, 
2J = 13.9 Hz, 3J = 6.4 Hz, CHCH2); 2.22 (bs, 2 H, HAd); 2.16–2.11 
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(m, 4 H, HAd); 2.02–1.97 (m, 3 H, HAd and CH(CH3)2); 1.82–1.77 (m, 2 H, HAd); 1.76–1.72 (m, 
2 H, HAd); 1.68 (d, 1 H, J = 12.7 Hz, HAd); 1.60 (d, 1 H, J = 12.6 Hz, HAd); 0.84 (d, 3 H, 
3J = 
6.8 Hz, CH(CH3)2); 0.82 (d, 3 H, 
3J = 6.8 Hz, CH(CH3)2) ppm. 
13C-NMR (151 MHz, CDCl3): δ = 180.1 (q, 2JCF = 35.6 Hz, COCF3); 176.4 (CO); 171.9 (CO); 
171.1 (CO); 165.3 (CO); 141.9 (Cquart.); 135.7 (Cquart.); 131.8 (Cquart.); 130.45 (CHAr-COCF3); 
130.44 (CHAr-COCF3); 129.3 (CHPh); 128.8 (CHPh); 127.7 (CHAr-COCF3); 127.4 (CHPh); 116.6 (q, 
1JCF = 291.1 Hz, COCF3); 57.9 (CHCH(CH3)2; 53.31 (CHCH2); 53.27 (Cquart., Ad); 52.5 (OCH3); 
43.0 (Cquart., Ad); 42.9 (CH2,Ad); 40.5 (CH2,Ad); 38.5 (CH2,Ad); 38.4 (CH2,Ad); 38.0 (CHCH2); 35.3 
(CH2,Ad); 31.4 (CHCH(CH3)2; 29.4 (CHAd); 19.2 (CH(CH3)2); 18.2 (CH(CH3)2) ppm. 
HR-MS (ESI): m/z: 710.3027 [M + MeOH + Na]+ (cal. 710.3024). 
MS (ESI): m/z: 710.4 [M + MeOH + Na]+ (cal. 710.3); 1397.1 [2M + 2MeOH + Na]+ (cal. 
1397.6). 
Terephthalic acid-AdGly-Val-Phe-OMe 215: 
The synthesis of terephthalic acid-AdGly-Val-
Phe-OMe 215 was performed with 0.116 g 
(0.236 mmol, 1.0 equiv) hydrochloride, 44.0 mg 
(0.265 mmol, 1.1 equiv) terephthalic acid,  
51.6 mg (0.269 mmol, 1.1 equiv) EDAC, 36.1 mg (0.267 mmol, 1.1 equiv) HOBt, 71.2 µL 
(51.9 mg, 0.513 mmol, 2.2 equiv) TEA, and 3 mL DCM utilizing GP-6. After 25 h the reaction 
mixture was diluted with 30 mL EtOAc. The organic layer was only washed with citric acid 
(0.5 M) (three times 7 mL). After purification via column chromatography (DCM:MeOH 30:1 
to 30:1) 0.054 g (0.089 mmol, 38%) functionalized tripeptides 215 were isolated as colorless 
solid. 
Rf: 0.53 (DCM:MeOH 7:1). 
1H-NMR (600 MHz, CDCl3): δ = 9.36 (bs, 1 H, COOH); 8.04 (d, 2 H, 3J = 8.0 Hz, HAr-COOH); 
7.65 (d, 2 H, 3J = 8.0 Hz, HAr-COOH); 7.27–7.22 (m, 2 H and CHCl3, HPh); 7.21–7.17 (m, 1 H, 
HPh); 7.12–7.08 (m, 2 H, HPh); 7.06 (bs, 1 H, NHCHCH2); 6.97 (d, 1 H, 3J = 8.6 Hz, 
NHCHCH(CH3)2); 5.98 (bs, 1 H, NHAdGly); 4.89–4.85 (m, 1 H, CHCH2); 4.40–4.33 (m, 
CHCH(CH3)2); 3.70 (s, 3 H, OCH3); 3.15 (dd, 1 H, 
2J = 13.9 Hz, 3J = 5.8 Hz, CHCH2); 3.08 
(dd, 1 H, 2J = 13.9 Hz, 3J = 6.6 Hz, CHCH2); 2.27 (bs, 2 H, HAd); 2.25–2.18 (m, 4 H, HAd); 
2.13–2.03 (m, 3 H, HAd and CH(CH3)2); 1.93–1.86 (m, 2 H, HAd); 1.86–1.77 (m, 2 H, HAd); 
1.73 (d, 1 H, J = 11.8 Hz, HAd); 1.68 (d, 1 H, J = 11.6 Hz, HAd); 0.93–0.91 (m, 6 H, CH(CH3)2) 
ppm. 
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13C-NMR (151 MHz, CDCl3): δ = 177.2 (CO); 172.4 (CO); 171.6 (CO); 168.7 (COOH); 166.1 
(CO); 139.9 (Cquart.); 135.7 (Cquart.); 132.6 (Cquart.); 130.3 (CHAr-COOH); 129.3 (CHPh); 128.8 
(CHPh); 127.3 (CHPh); 126.9 (CHAr-COOH); 58.7 (CHCH(CH3)2; 53.6 (CHCH2); 53.1 (Cquart., Ad); 
52.5 (OCH3); 43.0 (Cquart., Ad); 42.5 (CH2,Ad); 40.6 (CH2,Ad); 40.5 (CH2,Ad); 38.7 (CH2,Ad); 38.3 
(CH2,Ad); 37.9 (CHCH2); 35.3 (CH2,Ad); 30.9 (CHCH(CH3)2; 29.4 (CHAd); 29.3 (CHAd); 19.3 
(CH(CH3)2); 18.7 (CH(CH3)2) ppm. 
HR-MS (ESI): m/z: 626.2833 [M + Na]+ (cal. 626.2837). 
MS (ESI): m/z: 602.3 [M – H]– (cal. 602.3). 
9.4.2. SPPS 
Fmoc-deprotection (GP-10):14 
A syringe (reaction vessel) was charged with preloaded N-terminally Fmoc-protected 
polystyrene Wang resin. The deprotection was performed by shaking the solid support two 
times for 30 min in 6 mL (2 mL) piperidine (25% in DMF). Afterwards the resin was washed 
five times each with 6 mL (1.5 mL) DMF, DCM, and DMF. 
Peptide coupling (GP-11):14 
The peptide coupling was performed by shaking the reaction mixture containing N-terminal 
deprotected resin, Fmoc-protected amino acid, HOBt, HBTU, and DiPEA for 1 h in 3.6 mL 
(volume depending on the conc. of the used amino acid) DMF. After filtration of the first 
coupling solution the procedure was repeated. In case of Boc-protected PMH the reaction time 
was prolonged to 2 h. After filtration of the second coupling solution the resin was washed five 
times each with 6 mL (1.5 mL) DMF, DCM, and DMF. 
Both procedures were repeated until the desired oligopeptides were synthesized. The final 
washing step was carried out five times each with 6 mL (1.5 mL) DMF, DCM, and Et2O. 
Peptide cleavage (GP-12):14 
For cleavage of the peptide from the resin the reaction mixture was shaken two times for 2 d in 
6 mL (2 mL) of a TEA-THF-MeOH solation (1:1:9; v/v). After filtration of the second cleavage 
solution the resin was washed four times with 4 mL (0.5 mL) DCM. After removing the solvent 
under reduced pressure and co-evaporating several times with DCM the target compound was 
purified via HPLC. 
 
                                                 
14 Data in brackets belong to the automated peptide synthesis. 
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Boc-PMH-AdGly-Cha-Phe-OMe 1: 
The synthesis of Boc-PMH-AdGly-Cha-Phe-OMe 1 
was performed using GP-10, GP-11, and GP-12. 
0.455 g (0.300 mmol) of preloaded Fmoc-Phe-Wang 
resin 116 were utilized. One coupling step was 
performed with 0.237 g (0.603 mmol, 2.0 equiv) 
Fmoc-Cha-OH or 0.251 g (0.602 mmol, 2.0 equiv) Fmoc-AdGly-OH as well as 0.092 g  
(0.681 mmol, 2.3 equiv) HOBt, 0.228 g (0.600 mmol, 2.0 equiv) HBTU, 0.204 mL (0.151 g, 
1.17 mmol, 3.9 equiv) DiPEA. In case of Boc-PMH-OH 0.122 g (0.451 mmol, 1.5 equiv) were 
used. After purification via HPLC (eluent: TBME/MeOH 93:7; 5 mL min–1; UV detector  
254 nm, column: l = 250 mm, d = 8 mm; LiChrosorb Diol (7 µm, Merck); Rt = 3.6 min)  
0.054 g (0.071 mmol, 24%) tetrapeptide 1 were obtained as colorless solid. 
For analytic data see synthesis of tetrapeptide 1 in solution. 
Boc-PMH-OMe 6: 
During purification of tetrapeptide 1 via HPLC 0.017 g (0.060 mmol, 3%) 
fully protected amino acid 6 were obtained as colorless oil (eluent: 
TBME/MeOH 93:7; 5 mL min–1; UV detector 254 nm, column: l = 250 mm, 
d = 8 mm; LiChrosorb Diol (7 µm, Merck); Rt = 5.9 min). 
1H-NMR (400 MHz, CDCl3): δ = 7.39 (s, 1 H); 6.77 (s, 1 H); 5.25–5.16 (m, 
1 H,); 4.55–4.50 (m, 1 H); 3.73 (s, 3 H); 3.57 (s, 3 H); 3.11 (dd, 1 H, 2J = 15.3 Hz, 3J = 5.7 Hz); 
3.04 (dd, 1 H, 2J = 15.4 Hz, 3J = 6.0 Hz); 1.41 (s, 9 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 171.8; 155.2; 138.5; 128.3; 126.6; 80.4; 53.2; 52.7; 31.5; 
28.4; 27.0 ppm. 
Analytic data are identical to those reported in literature.[22] 
Boc-PMH-AdGly-Cha-Ala-OMe 11: 
The synthesis of Boc-PMH-AdGly-Cha-Ala-OMe 
11 was performed using GP-10, GP-11, and GP-12. 
0.750 g (0.300 mmol) of preloaded Fmoc-Ala-Wang 
resin were utilized. One coupling step was 
performed with 0.237 g (0.603 mmol, 2.0 equiv) 
Fmoc-Cha-OH or 0.251 g (0.602 mmol, 2.0 equiv) Fmoc-AdGly-OH as well as 0.092 g (0.681 
mmol, 2.3 equiv) HOBt, 0.228 g (0.600 mmol, 2.0 equiv) HBTU, 0.204 mL (0.151 g,  
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1.17 mmol, 3.9 equiv) DiPEA. In case of Boc-PMH-OH 0.122 g (0.451 mmol, 1.5 equiv) were 
used. After purification via HPLC (eluent: TBME/MeOH 90:10; 5 mL min–1; UV detector  
254 nm, column: l = 250 mm, d = 8 mm; LiChrosorb Diol (7 µm, Merck); Rt = 8.6 min)  
0.043 g (0.063 mmol, 21%) tetrapeptide 11 were obtained as colorless solid. 
1H-NMR (400 MHz, CDCl3): δ = 7.42 (s, 1 H); 7.07 (d, 1 H, 3J = 7.3 Hz); 6.82 (s, 1 H); 6.29 
(d, 1 H, 3J = 8.0 Hz); 6.23 (s, 1 H); 5.37 (bs, 1 H); 4.53–4.45 (m, 2 H); 4.23 (bs, 1 H); 3.71 (s, 
3 H); 3.57 (s, 3 H); 2.95–2.94 (m, 2 H); 2.16 (bs, 2 H); 1.97–1.89 (m, 4 H); 1.81–1.69 (m, 6 H); 
1.68–1.57 (m, 8 H); 1.39 (s, 9 H); 1.35 (d, 3 H, 3J = 7.2 Hz); 1.26–1.10 (m, 5 H); 0.97–0.75 (m, 
2 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 176.7; 173.2; 172.3; 170.0; 155.5; 138.1; 128.0; 127.5; 80.4; 
54.4; 52.5; 52.4; 50.7; 48.1; 42.6; 42.4; 40.4; 40.2; 39.8; 38.3; 38.2; 35.2; 34.2; 33.6; 32.8; 31.6; 
29.18; 29.16; 28.7; 28.4; 27.1; 26.5; 26.3; 26.2; 18.0 ppm. 
MS (ESI): m/z: 685.4 [M + H]+ (cal. 685.4), 707.4 [M + Na]+ (cal. 707.4). 
HR-MS (ESI): m/z: 354.2123 [M + H + Na]2+ (cal. 354.2088) 685.4289 [M + Na]+ (cal. 
685.4283). 
Boc-Lys(2-Cl-Cbz)-AdGly-Cha-Phe-OMe 120: 
The synthesis of Boc-Lys(2-Cl-Cbz)-AdGly-Cha-
Phe-OMe 120 was performed using GP-10, GP-11, 
and GP-12. 0.155 g (0.102 mmol) of preloaded 
Fmoc-Phe-Wang resin 116 were utilized.  
One coupling step was performed with 0.087 g 
(0.220 mmol, 2.2 equiv) Fmoc-Cha-OH, 0.086 g 
(0.202 mmol, 2.0 equiv) Fmoc-AdGly-OH or 0.091 g (0.219 mmol, 2.2 equiv) Boc-Lys(2-Cl-
Cbz)-OH as well as 0.028 g (0.207 mmol, 2.0 equiv) HOBt, 0.077 g (0.203 mmol, 2.0 equiv) 
HBTU, 0.100 mL (0.076 g, 0.588 mmol, 5.8 equiv) DiPEA. After removing the solvent under 
reduced pressure and high vacuum 0.067 g (0.074 mmol, 74%) tetrapeptide 120 were obtained 
as yellow oil. 
MS (ESI): m/z: 928.5 [M + Na]+ (cal. 928.5). 
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Boc-PMH-AdGly-Lys(Cbz)-Phe-OMe 125: 
The synthesis of Boc-PMH-AdGly-Lys(Cbz)-Phe-
OMe 125 was performed using GP-10, GP-11, and 
GP-12. 0.154 g (0.102 mmol) of preloaded  
Fmoc-Phe-Wang resin 116 were utilized.  
One coupling step was performed with 0.104 g  
(0.206 mmol, 2.0 equiv) Fmoc-Lys(Cbz)-OH, 
0.086 g (0.206 mmol, 2.0 equiv) Fmoc-AdGly-OH 
or 0.058 g (0.215 mmol, 2.1 equiv) Boc-PMH-OH as well as 0.027 g (0.203 mmol, 2.0 equiv) 
HOBt, 0.077 g (0.203 mmol, 2.0 equiv) HBTU, 0.100 mL (0.076 g, 0.588 mmol, 5.8 equiv) 
DiPEA. After removing the solvent under reduced pressure and high vacuum 0.064 g  
(0.074 mmol, 73%) tetrapeptide 125 were obtained as yellow oil. 
MS (ESI): m/z: 870.4 [M + H]+ (cal. 870.5), 892.3 [M + Na]+ (cal. 892.5). 
Boc-AdGly-Dap(Cbz)-Phe-OMe 142: 
The synthesis of Boc-AdGly-Dap(Cbz)-Phe-OMe 142 was 
performed using GP-10, GP-11, and GP-12. 0.539 g  
(0.350 mmol) of preloaded Fmoc-Phe-Wang resin 116 
were utilized. The first coupling step was performed only 
one time with 0.161 g (0.350 mmol, 1.0 equiv)  
Fmoc-Dap(Cbz)-OH 139, 0.142 g (1.05 mmol, 3.0 equiv) HOBt, 0.401 g (1.06 mmol, 3.0 equiv) 
HBTU, 0.183 mL (0.136 g, 1.05 mmol, 3.0 equiv) DiPEA in 3 mL DMF. HOBt and HBTU 
were dissolved in 3 mL DMF. The second coupling step was performed with 0.208 g  
(0.703 mmol, 2.0 equiv) Boc-AdGly-OH, 0.102 g (0.755 mmol, 2.2 equiv) HOBt, 0.270 g 
(0.712 mmol, 2.0 equiv) HBTU, 0.122 mL (0.091 g, 0.700 mmol, 2.0 equiv) DiPEA in 2 mL 
DMF. HOBt and HBTU were dissolved in 2 mL DMF. After purification via column 
chromatography (DCM:MeOH 15:1) 54.4 mg (0.080 mmol, 23%) 142 were isolated as 
colorless solid. 
Rf: 0.65 (DCM:MeOH 7:1). 
1H-NMR (400 MHz, CDCl3):
15 δ = 7.31–7.11 (m, 9 H and CHCl3); 7.03–6.96 (m, 3 H); 5.55–
5.44 (m, 1 H); 5.04 (s, 2 H); 4.80–4.65 (m, 1 H); 4.40–4.30 (m, 2 H); 3.62 (s, 3 H); 3.54–3.36 
                                                 
15 Racemization observable. 
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(m, 2 H); 3.05 (dd, 1 H, 2J = 13.9 Hz, 3J = 5.6 Hz); 2.93 (dd, 1 H, 2J = 14.0 Hz, 3J = 7.1 Hz); 
2.12–2.07 (m, 2 H); 1.91–1.76 (m, 6 H); 1.65–1.50 (m, 6 H); 1.35 (s, 9 H) ppm. 
13C-NMR (101 MHz, CDCl3):
6 δ = 178.1; 171.7; 170.1; 158.2; 154.1; 136.3; 136.0; 129.3; 
128.68; 128.65; 128.3; 128.1; 127.2; 79.0; 67.2; 54.9; 53.5; 52.5; 50.8; 43.0; 42.7; 42.6; 40.8; 
38.04; 37.96; 37.8; 35.3; 29.2; 28.6 ppm. 
MS (ESI): m/z: 699.3 [M + Na]+ (cal. 699.3). 
HR-MS (ESI): m/z: 699.3375 [M + Na]+ (cal. 699.3364). 
9.5. Epoxidation 
mCPBA-based epoxidation (GP-13):  
The alkene was dissolved in DCM and the resulting solution was cooled to 0 °C. At this 
temperature mCPBA (70%) was added portionwise. Performing the epoxidation in a smaller 
scale, the oxidizer was added without using an ice bath. The resulting mixture was stirred at r.t. 
and the reaction progress was monitored via TLC. For removing remaining mCBA the organic 
layer was washed several times with sat. NaHCO3. After combining and drying the organic 
layers over Na2SO4 and MgSO4, resp., the solvent was evaporated. The crude product was 
purified utilizing column chromatography. 
NaOH/H2O2-based epoxidation (GP-14):  
1.0 equiv alkene was dissolved in MeOH or EtOH. The reaction was started via addition of 
NaOHaq and H2O2 (30%) and the resulting mixture was stirred afterwards. The reaction progress 
was monitored via TLC. After diluting the reaction mixture with brine or water the aq layer was 
extracted three times. After drying the organic layer over Na2SO4 the solvent was evaporated 
and the crude product was finally purified. 
trans-2-Hydroxycyclohexyl 3-methyl-2-oxiranecarboxylate 22: (GP-13) 
0.080 g (0.434 mmol, 1.0 equiv) ester 17 were dissolved in 4 mL DCM. 
Afterwards 0.121 g (0.540 mmol, 1.2 equiv) mCPBA were added.  
The resulting mixture was stirred for 20 h. 10 mL brine were added and the 
aq layer was extracted with DCM (three times 10 mL). After purification via 
column chromatography (n-hexane:EtOAc 3:1 to 2:1) 0.053 g (0.265 mmol, 61%) 22 were 
isolated as slightly yellowish oil. Both diastereomers were obtained with a 2:1 ratio. 
Diastereomer 1 (0.017 g):16 
                                                 
16 Minimal traces of mCBA present in the spectrum. 
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Rf: 0.13 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.70–4.64 (m, 1 H); 4.34 (bs, 1 H, OH); 3.65–3.55 (m, 1 H); 
3.32–3.22 (m, 2 H); 2.10–2.00 (m, 2 H, HCy); 1.76–1.68 (m, 2 H, HCy); 1.40 (d, 3 H, 3J = 5.1 
Hz, CH3); 1.36–1.23 (m, 4 H, HCy) ppm. 
13C-NMR (50 MHz, CDCl3): δ = 169.6; 79.4; 72.7; 54.8; 54.3; 33.3; 30.0; 23.9, 23.8; 17.3 ppm. 
Diastereomer 2 (0.036 g):17 
Rf: 0.09 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.68–4.61 (m, 1 H); 3.98 (bs, 1 H, OH); 3.61–3.55 (m, 1 H); 
3.25–3.19 (m, 2 H); 2.09–2.00 (m, 2 H, HCy); 1.74–1.67 (m, 2 H, HCy); 1.38 (d, 3 H, 3J = 5.1 
Hz, CH3); 1.33–1.20 (m, 4 H, HCy) ppm.  
13C-NMR (50 MHz, CDCl3): δ = 169.4; 79.5; 72.4; 54.8; 54.3; 33.1; 30.0; 23.9, 23.9; 17.2 ppm. 
cis-2-Hydroxycyclohexyl 3-methyl-2-oxiranecarboxylate 23:17,18 (GP-13) 
0.108 g (0.586 mmol, 1.0 equiv) ester 18 were dissolved in 4 mL DCM. 
Afterwards 0.160 g (0.649 mmol, 1.1 equiv) mCPBA were added.  
The resulting mixture was stirred for 24 h. 5 mL brine and 10 mL water were 
added and the aq layer was extracted with DCM (three times 10 mL).  
After purification via column chromatography (n-hexane:EtOAc 3:1 to 2:1) 0.084 g  
(0.420 mmol, 72%) 23 were isolated as colorless oil. 
Rf: 0.13 (0.08) (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.98 (dt, 1 H, J = 7.8 Hz, J = 2.4 Hz,); 3.91–3.85 (m, 1 H); 
3.49 (bs, 1 H, OH); 3.25–3.20 (m, 2 H); 1.91–1.83 (m, 1 H, HCy); 1.81–1.72 (m, 1 H, HCy); 
1.70–1.52 (m, 4 H, HCy); 1.38–1.33 (m, 5 H, CH3 and HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 169.1 (169.0); 75.55 (75.59); 68.98 (68.95); 54.8 (54.9); 
54.2 (54.3); 30.3; 26.9 (27.0); 22.0 (21.9); 21.0 (21.1); 17.23 (17.21) ppm. 
trans-2-Hydroxycyclohexyl (3-methyl-2-oxiranyl)acetate 24a: (GP-13) 
0.051 g (0.257 mmol, 1.0 equiv) ester 20a were dissolved in 2 mL DCM. 
Afterwards 0.070 g (0.284 mmol, 1.1 equiv) mCPBA were added.  
The resulting mixture was stirred for 22 h. 8 mL brine and 10 mL water 
were added and the aq layer was extracted with DCM (three times 6 mL). 
                                                 
17 Minimal traces of mCBA present in the spectrum. 
18 Data referring to the second diastereomer are given in brackets. 
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After purification via column chromatography (n-hexane:EtOAc 2:1) 0.038 g (0.177 mmol, 
69%) 24a were isolated as colorless oil. The diastereomers were separated via HPLC. 
Diastereomer 1: 
Rf: 0.10 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.65–4.59 (m, 1 H, CHOC); 3.58–3.52 (m, 1 H, CHOH); 
3.02 (dt, 1 H, 3J = 5.3 Hz, 3J = 2.2 Hz, CH2CH); 2.89 (dq, 1 H, 
3J = 5.2 Hz, 3J = 2.2 Hz, CHCH3); 
2.71 (dd, 1 H, 2J = 15.7 Hz, 3J = 5.0 Hz, CH2CH); 2.59 (dd, 1 H, 
2J = 15.7 Hz, 3J = 5.7 Hz, 
CH2CH); 2.48 (bs, 1 H, OH); 2.08–2.00 (m, 2 H, HCy); 1.74–1.70 (m, 2 H, HCy); 1.39–1.24 (m, 
7 H, CH3 and HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 170.4 (CO); 79.0 (CHOC); 72.8 (CHOH); 55.0 (CH2CH); 
54.7 (CHCH3); 37.6 (CH2CH); 32.9 (CH2CHOH); 30.1 (CH2CHOC); 24.0 (CH2CH2CHOC); 
23.9 (CH2CH2CHOH); 17.4 (CH3) ppm. 
IR (Film): ṽ = 3407 (m); 2938 (m); 1702 (m); 1274 (m); 1182 (m); 857 (vw) cm−1. 
MS (ESI): m/z: 237.1 [M + Na]+ (cal. 237.1); 451.2 [2M + Na]+ (cal. 451.2); 665.3 [3M + Na]+ 
(cal. 665.4). 
Diastereomer 2: 
Rf: 0.10 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.65–4.59 (m, 1 H, CHOC); 3.59–3.53 (m, 1 H, CHOH); 
3.03–3.00 (m, 1 H, CH2CH); 2.87 (dq, 1 H, 3J = 5.2 Hz, 3J = 2.1 Hz, CHCH3); 2.63–3.52 (m, 2 
H, CH2CH); 2.33 (bs, 1 H, OH); 2.10–1.99 (m, 2 H, HCy); 1.78–1.68 (m, 2 H, HCy); 1.40–1.20 
(m, 7 H, CH3 and HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 170.7 (CO); 78.9 (CHOC); 72.7 (CHOH); 55.2 (CH2CH); 
54.8 (CHCH3); 38.1 (CH2CH); 33.1 (CH2CHOH); 30.1 (CH2CHOC); 24.0 (CH2CH2CHOC); 
23.9 (CH2CH2CHOH); 17.5 (CH3) ppm. 
IR (Film): ṽ = 3435 (s); 2939 (vs); 1732 (vs); 1262 (s); 1186 (vs); 864 (m) cm−1. 
MS (ESI): m/z: 237.1 [M + Na]+ (cal. 237.1); 451.3 [2M + Na]+ (cal. 451.2). 
trans-2-Hydroxycyclohexyl 3-(2-oxiranyl)propionate 24b: (GP-13) 
0.216 g (1.09 mmol, 1.0 equiv) alkene 20b were dissolved in 4 mL DCM. 
Afterwards 0.245 g (0.990 mmol, 0.9 equiv) mCPBA were added.  
The resulting mixture was stirred for 24 h. After diluting with 20 mL 
EtOAc the work-up was performed with NaHCO3 (five times 20 mL) and 
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brine (one time 20 mL). After purification via column chromatography (n-hexane:EtOAc 1:2) 
0.126 g (0.588 mmol, 59%) 24b were isolated as colorless oil. 
Rf: 0.08 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.65–4.59 (m, 1 H, CHOC); 3.60–3.52 (m, 1 H, CHOH); 
3.05–2.98 (m, 1 H, CHOCH2); 2.79–2.76 (m, 1 H, CHOCH2); 2.69 (dd, 1 H, 3J = 14.5 Hz, 4J = 
3.4 Hz, CHOH); 2.56–2.52 (m, 1 H, CHOCH2); 2.51–2.42 (m, 2 H, COCH2CH2CH); 2.13–1.96 
(m, 3 H, COCH2CH2CH and HCy); 1.79–1.67 (m, 3 H, COCH2CH2CH and HCy); 1.39–1.19 (m, 
4 H, HCy) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 173.2 and 172.9 (CO); 78.60 and 78.59 (CHOC); 72.85 and 
72.82 (CHOH); 51.74 and 51.68 (CHOCH2); 47.12 and 47.09 (CHOCH2); 33.1 and 33.0 
(CH2CHOH); 31.30 and 31.26 (COCH2CH2CH); 30.2 and 30.1 (CH2CHOC); 28.0 and 27.9 
(COCH2CH2CH); 24.0 (CH2CH2CHOC); 23.9 (CH2CH2CHOH) ppm. 
IR (Film): ṽ = 3453 (m); 2939 (s); 1732 (vs); 1258 (s); 1181 (m); 840 (w) cm−1. 
HR-MS (ESI): m/z: 215.1282 [M + H]+ (cal. 215.1278); m/z: 237.1103 [M + Na]+ (cal. 
237.1097); m/z: 451.2305 [2M + Na]+ (cal. 451.2302). 
cis-2-Hydroxycyclohexyl (3-methyl-2-oxiranyl)acetate 25a: (GP-13) 
0.104 g (0.525 mmol, 1.0 equiv) ester 21a were dissolved in 5 mL DCM. 
Afterwards 0.144 g (0.584 mmol, 1.1 equiv) mCPBA were added.  
The resulting mixture was stirred for 7 h. 4 mL brine were added and  
the aq layer was extracted with DCM (three times 6 mL).  
After purification via column chromatography (n-hexane:EtOAc 1:1) 0.098 g (0.457 mmol, 
87%) 25a were isolated as colorless oil. The diastereomers were separated via HPLC. 
Diastereomer 1: 
Rf: 0.11 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.99–4.97 (m, 1 H, CHOC); 3.84–3.82 (m, 1 H, CHOH); 
3.02 (dt, 1 H, 3J = 5.5 Hz, 3J = 2.2 Hz, CH2CH); 2.86 (dq, 1 H, 
3J = 5.2 Hz, 3J = 2.2 Hz, CHCH3); 
2.68 (dd, 1 H, 2J = 16.0 Hz, 3J = 5.1 Hz, CH2CH); 2.58 (dd, 1 H, 
2J = 16.0 Hz, 3J = 6.0 Hz, 
CH2CH); 2.22 (bs, 1 H, OH); 1.93–1.80 (m, 1 H, HCy); 1.77–1.49 (m, 5 H, HCy); 1.43–1.24 (m, 
5 H, CH3 and HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 170.1 (CO); 74.8 (CHOC); 69.1 (CHOH); 55.1 (CH2CH); 
54.7 (CHCH3); 37.8 (CH2CH); 30.4 (CH2CHOH); 27.2 (CH2CHOC); 21.9 (CH2CH2CHOC); 
21.4 (CH2CH2CHOH); 17.4 (CH3) ppm. 
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IR (Film): ṽ = 3446 (w); 2938 (m); 1733 (m); 1263 (m); 1183 (m); 863 (vw) cm−1. 
HR-MS (ESI): m/z: 237.1101 [M + Na]+ (cal. 237.1097). 
MS (ESI): m/z: 237.1 [M + Na]+ (cal. 237.1); 451.3 [2M + Na]+ (cal. 451.2); 665.3 [3M + Na]+ 
(cal. 665.4). 
Diastereomer 2: 
Rf: 0.11 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.98–4.95 (m, 1 H, CHOC); 3.87–3.84 (m, 1 H, CHOH); 
3.00 (dt, 1 H, 3J = 5.8 Hz, 3J = 2.1 Hz, CH2CH); 2.85 (dq, 1 H, 
3J = 5.2 Hz, 3J = 2.2 Hz, CHCH3); 
2.70–2.51 (m, 2 H, CH2CH); 2.12 (bs, 1 H, OH); 1.92–1.82 (m, 1 H, HCy); 1.79–1.70 (m, 1 H, 
HCy); 1.69–1.52 (m, 4 H, HCy); 1.45–1.28 (m, 5 H, CH3 and HCy) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 170.3 (CO); 74.8 (CHOC); 69.1 (CHOH); 55.1 (CH2CH); 
54.8 (CHCH3); 38.1 (CH2CH); 30.4 (CH2CHOH); 27.1 (CH2CHOC); 22.0 (CH2CH2CHOC); 
21.3 (CH2CH2CHOH); 17.4 (CH3) ppm. 
IR (Film): ṽ = 3433 (m); 2938 (s); 1716 (s); 1271 (m); 1182 (m); 864 (wv) cm−1. 
MS (ESI): m/z: 237.1 [M + Na]+ (cal. 237.1); 451.0 [2M + Na]+ (cal. 451.2); 665.3 [3M + Na]+ 
(cal. 665.4). 
cis-2-Hydroxycyclohexyl 3-(2-oxiranyl)propionate 25b: (GP-13) 
0.210 g (1.06 mmol, 1.0 equiv) alkene 20b were dissolved in 6 mL DCM. 
Afterwards 0.230 g (0.930 mmol, 0.9 equiv) mCPBA were added.  
The resulting mixture was stirred for 24 h. After diluting with 20 mL 
EtOAc the work-up was performed with NaHCO3 (five times 20 mL) and 
brine (one time 20 mL). After purification via column chromatography (n-hexane:EtOAc 1:2) 
0.114 g (0.532 mmol, 57%) 25b were isolated as colorless oil. 
Rf: 0.08 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 4.96–4.94 (m, 1 H, CHOC); 3.92–3.86 (m, 1 H, CHOH); 
3.06–2.98 (m, 1 H, CHOCH2); 2.79–2.77 (m, 1 H, CHOCH2); 2.58–2.44 (m, 3 H, CHOCH2 
and COCH2CH2CH); 2.30 (dd, 1 H, 
3J = 13.0 Hz, 4J = 4.5 Hz, CHOH); 2.13–2.03 (m, 1 H, 
COCH2CH2CH); 1.92–1.82 (m, 1 H, CH2CHOC); 1.80–1.71 (m, 2 H, COCH2CH2CH and 
CH2CHOH); 1.70–1.53 (m, 4 H, HCy); 1.43–1.31 (m, 2 H, HCy) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 172.7 and 172.5 (CO); 74.64 and 74.58 (CHOC); 69.1 
(CHOH); 51.70 and 51.66 (CHOCH2); 47.11 and 47.06 (CHOCH2); 31.3 and 31.2 
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(COCH2CH2CH); 30.5 (CH2CHOH); 28.0 and 27.9 (COCH2CH2CH); 27.1 (CH2CHOC); 22.22 
and 22.17 (CH2CH2CHOC); 21.2 (CH2CH2CHOH) ppm. 
IR (Film): ṽ = 3471 (vw); 2938 (m); 1731 (m); 1259 (w); 1180 (m) cm−1. 
HR-MS (ESI): m/z: 215.1282 [M + H]+ (cal. 215.1278); m/z: 237.1103 [M + Na]+ (cal. 
237.1097); m/z: 451.2304 [2M + Na]+ (cal. 451.2302). 
1-(3-Phenyl-2-oxiranyl)-1-ethanone 28: (GP-14) 
The reaction was performed with 0.700 g (4.79 mmol, 1.0 equiv) enone 30, 
2.93 mL (30%, 28.7 mmol, 6.0 equiv) H2O2, in total 0.201 mL (4/1 m/m,  
1.01 mmol, 0.2 equiv) NaOHaq and 20 mL MeOH for 6 h at r.t.. The reaction 
was started via addition of 0.035 equiv NaOHaq (4/1 m/m) and 1.0 equiv H2O2 
(30% in water). Further 0.035 equiv NaOHaq (4/1 m/m) were added hourly. For the work-up  
30 mL EtOAc and 30 mL brine were used. In the end 0.577 g (3.56 mol, 74%) 28 were isolated 
as yellow oil starting to crystallize after some time. The crude product was utilized without 
further purification. 
1H-NMR (400 MHz, CDCl3): δ = 7.36–7.33 (m, 3 H); 7.28–7.26 (m, 2 H); 4.00 (d, 1 H, 3J = 
1.8 Hz); 3.49 (d, 1 H, 3J = 1.8 Hz); 2.18 (s, 3 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 204.2; 134.9; 128.9; 128.6; 125.6; 63.4; 57.7; 24.7 ppm. 
Analytic data are identical to those reported in literature.[76b] 
Chiral GC analysis: 
Enantiomers of 28 were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 120 °C; Initial time: 30 min. 
Retention times: Rt1 = 24.5 min; Rt1 = 25.2 min. 
trans-2-Acetoxycyclohexyl (3-methyl-2-oxiranyl)acetate 35: (GP-13) 
0.054 g (0.225 mmol, 1.0 equiv) alkene 33 were dissolved in 2 mL DCM. 
Afterwards 0.061 g (0.247 mmol, 1.1 equiv) mCPBA were added.  
The resulting mixture was stirred for 7 h. After diluting with 10 mL DCM 
the work-up was performed with NaHCO3 (three times 10 mL) and DCM 
(two times with 10 mL). After purification via column chromatography (n-hexane:EtOAc 5:1) 
0.050 g (0.195 mmol, 87%) 35 were isolated as colorless oil. 
Rf: 0.28 (n-hexane:EtOAc 2:1). 
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1H-NMR (400 MHz, CDCl3): δ = 4.87–4.77 (m, 2 H, CHCO); 2.98–2.93 (m, 1 H, CH2CH); 
2.80 (dq, 1 H, 3J = 5.2 Hz, 3J = 2.1 Hz, CHCH3); 2.56–2.44 (m, 2 H, CH2CHOCH); 2.09–1.97 
(m, 5 H, CH3 and HCy); 1.74–1.67 (m, 2 H, HCy); 1.43–1.32 (m, 3 H, HCy); 1.32–1.28 (m, 4 H, 
CHCH3 and HCy) ppm.  
13C-NMR (101 MHz, CDCl3):
19,20 δ = 170.6 (CO); 170.0 and 169.9 (CO); 74.32 and 74.29 
(CHO); 73.7 and 73.6 (CHO); 54.95 and 54.92; 54.5; 38.02 and 37.97 (CH2CH); 30.23 and 
30.22 (CH2CH2CHO); 23.5 (CH2CH2CHO); 21.3 (CH3); 17.4 (CHCH3) ppm. 
cis-2-Acetoxycyclohexyl (3-methyl-2-oxiranyl)acetate 36: (GP-13) 
0.043 g (0.179 mmol, 1.0 equiv) alkene 34 were dissolved in 1.5 mL 
DCM. Afterwards 0.051 g (0.207 mmol, 1.2 equiv) mCPBA were added. 
The resulting mixture was stirred for 7.5 h. After diluting with 10 mL 
DCM the work-up was performed with NaHCO3 (three times 10 mL) and 
DCM (two times with 10 mL). After purification via column chromatography (n-hexane:EtOAc 
5:1) 0.041 g (0.160 mmol, 89%) 36 were isolated as colorless oil. 
Rf: 0.30 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3):
19 δ = 5.14–5.07 (m, 1 H, CHCO); 5.04–4.99 (m, 1 H, CHCO); 
3.01–2.97 (m, 1 H, CH2CH); 2.83 (dq, 1 H, 3J = 5.2 Hz, 3J = 2.6 Hz, CHCH3); 2.65–2.47 (m, 2 
H, CH2CHOCH); 2.04 (2.03) (m, 3 H, CH3); 1.92–1.74 (m, 2 H, HCy); 1.69–1.59 (m, 4 H, HCy); 
1.49–1.37 (m, 2 H, HCy); 1.33 (d, 3 H, 3J = 5.2 Hz, CHCH3) ppm.  
13C-NMR (101 MHz, CDCl3):
20 δ = 170.5 (CO); 170.0 and 169.8 (CO); 71.5 and 71.4 (CHO); 
71.1 and 71.0 (CHO); 55.1 and 55.0; 54.53 and 54.51; 38.1 and 38.0 (CH2CH); 27.9 and 27.8; 
27.7 and 27.6; 22.0 and 21.9; 21.7 and 21.5; 21.3; 17.5 ppm. 
1-Phenyl-7-oxabicyclo[4.1.0]heptane 39: (GP-13) 
0.098 mL (0.097 g, 0.613 mmol, 1.0 equiv) alkene 38 were dissolved in 4 mL DCM. 
Afterwards 0.168 g (0.681 mmol, 1.1 equiv) mCPBA were added. The resulting 
mixture was stirred for 4 h. The reaction was quenched with 5 mL NaHCO3.  
The aq layer was extracted with DCM (three times 10 mL). After purification via column 
chromatography (n-hexane:EtOAc 5:1 to 2:1) 0.088 g (0.505 mmol, 82%) 39 were isolated as 
colorless liquid. 
Rf: 0.46 (n-hexane:EtOAc 5:1). 
                                                 
19 Data referring to the second diastereomer are given in brackets. 
20 Without definite allocation of the signals to one diastereomer. 
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1H-NMR (400 MHz, CDCl3): δ = 7.32–7.24 (m, 4 H); 7.21–7.16 (m, 1 H); 3.02–3.00 (m, 1 H); 
2.21 (ddd, 1 H, J = 14.3 Hz, J = 8.6 Hz, J = 5.4 Hz); 2.05 (dt, 1 H, J = 14.8 Hz, J = 5.3 Hz); 
1.95–1.86 (m, 2 H); 1.58–1.46 (m, 2 H); 1.44–1.36 (m, 1 H); 1.30–1.17 (m, 1 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 142.7; 128.4; 127.3; 125.4; 62.1; 60.4; 29.0; 24.9; 20.3; 19.9 
ppm. 
Analytic data are identical to those reported in literature.[175] 
Chiral GC analysis: 
Enantiomers of 39 were separated by chiral GC employing a 30 m FS-Hydrodex β-6-TBDM 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 100 °C; Final temperature:  
152 °C; Rate: 2.00 °C/min. Retention times: Rt1 = 23.7 min; Rt2 = 24.4 min. 
1-Cyclohexyl-7-oxabicyclo[4.1.0]heptane 41: (GP-13) 
0.103 g (0.627 mmol, 1.0 equiv) alkene 40 were dissolved in 6 mL DCM. 
Afterwards 0.174 g (0.706 mmol, 1.1 equiv) mCPBA were added. The resulting 
mixture was stirred for 7 h. The organic layer was washed with sat. NaHCO3  
(five times 20 mL). After purification via column chromatography (n-hexane:EtOAc 20:1) 
0.082 g (0.455 mmol, 73%) 41 were isolated as colorless liquid. 
Rf: 0.38 (n-hexane:EtOAc 20:1). 
1H-NMR (400 MHz, CDCl3): δ = 2.92 (dd, 1 H, 3J = 3.3 Hz, 3J = 1.1 Hz, CHOC); 1.96–1.89 
(m, 1 H, HCy); 1.79–1.72 (m, 6 H, HCy); 1.67–1.63 (m, 2 H, HCy); 1.48–1.34 (m, 2 H, HCy); 
1.25–1.05 (m, 8 H, CH2CHCH2 and HCy) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 63.2 (CHOC); 58.3 (CHOC); 46.0 (CH2CHCH2); 28.1 
(CH2); 27.8 (CH2); 26.6 (CH2); 26.4 (CH2); 26.2 (CH2); 25.3 (CH2); 25.0 (CH2); 20.6 (CH2); 
19.9 (CH2) ppm. 
IR (Film): ṽ = 2928 (vs); 2854 (s); 2669 (vw); 1722 (vw); 1449 (m); 874 (w); 847 (w); 768 (w) 
cm−1. 
HR-MS (EI): m/z: 180.1511 (cal. 180.1514). 
Chiral GC analysis: 
Enantiomers of 41 were separated by chiral GC employing a 30 m FS-Hydrodex β-6-TBDM 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 100 °C; Final temperature:  
150 °C; Rate: 2.00 °C/min. Retention times: Rt1 = 22.6 min; Rt2 = 22.8 min. 
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1-Methyl-7-oxabicyclo[4.1.0]heptane 43: (GP-13) 
6.17 mL (5.00 g, 0.052 mol, 1.0 equiv) alkene 42 were dissolved in 130 mL DCM. 
Afterwards 12.8 g (0.052 mol, 1.0 equiv) mCPBA were added. The resulting 
mixture was stirred for 24 h. After deluting with EtOAc the organic layer washed 
with sat. NaHCO3 (eight times 50 mL). After purification via destillation (123 mbar, 70 to  
75 °C) 1.84 g (0.016 mol, 32%) 43 were isolated as colorless liquid. 
1H-NMR (400 MHz, CDCl3): δ = 2.95 (d, 1 H, J = 3.4 Hz); 1.93–1.79 (m, 3 H); 1.69–1.62 (m, 
1 H); 1.46–1.35 (m, 2 H); 1.29 (m, 3 H); 1.27–1.23 (m, 1 H); 1.22–1.12 (m, 1 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 59.7; 57.7; 30.0; 24.9; 24.1; 20.2; 19.8 ppm. 
Analytic data are identical to those reported in literature.[8] 
Chiral GC analysis: 
Enantiomers of 43 were separated by chiral GC employing a 30 m FS-Hydrodex β-6-TBDM 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 60 °C; Initial time: 20 min. 
Retention times: Rt1 = 14.1 min; Rt2 = 16.0 min. 
2,3-Diphenyloxirane 45: 
Chiral GC analysis: 
Enantiomers of 45 were separated by chiral GC employing a 30 m Chiraldex  
G-TA column (Astech). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 160 °C; Initial time: 24 min. 
Retention times: Rt1 = 21.7 min; Rt2 = 22.1 min. 
1-(2-Oxiranyl)butane 47: (GP-13) 
3.00 mL (2.03 g, 0.024 mol, 1.0 equiv) alkene 46 were dissolved in 35 mL DCM. 
Afterwards 6.45 g (0.026 mol, 1.1 equiv) mCPBA were added. The resulting mixture 
was stirred for 5 h. The organic layer washed with sat. NaHCO3 (230 mL in total).  
After purification via destillation 1.03 g (0.010 mol, 43%) 47 were isolated as colorless liquid. 
1H-NMR (400 MHz, CDCl3): δ = 2.92–2.87 (m, 1 H); 2.73 (dd, 1 H, J = 5.0 Hz, J = 4.0 Hz); 
2.45 (dd, 1 H, J = 5.0 Hz, J = 2.7 Hz); 1.55–1.48 (m, 2 H); 1.47–1.31 (m, 4 H) ; 0.90 (t, 3 H, J 
= 7.1 Hz) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 52.5; 47.2; 32.3; 28.2; 22.6; 14.1 ppm. 
Analytic data are identical to those reported in literature.[8] 
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4-(3,3-Dimethyl-2-oxiranyl)-2-butanone 49: (GP-13) 
2.00 g (0.016 mol, 1.0 equiv) alkene 48 were dissolved in 60 mL DCM. 
Afterwards 3.06 g (0.012 mol, 0.8 equiv) mCPBA were added.  
The resulting mixture was stirred for 5 h. The organic layer washed with 
sat. NaHCO3 (230 mL in total). After purification via column chromatography  
(n-hexane:EtOAc 2:1 to 1:2) 0.034 g (0.239 mmol, 2%[176]) 49 were isolated as colorless liquid. 
Rf: 0.14 (n-hexane:EtOAc 2:1). 
1H-NMR (200 MHz, CDCl3): δ = 2.72 (dd, 1 H, J = 7.9 Hz, J = 4.6 Hz); 2.64–2.57 (m, 2 H) ; 
2.16 (s, 3 H); 1.98–1.83 (m, 1 H); 1.71–1.57 (m, 1 H); 1.29 (s, 3 H); 1.26 (s, 3 H) ppm. 
13C-NMR (50 MHz, CDCl3): δ = 208.0; 63.5; 59.0; 40.4; 30.1; 24.9; 23.1; 18.8 ppm. 
Analytic data are identical to those reported in literature.[177] 
GC analysis: 
Enantiomers of 49 were separated by chiral GC employing a 30 m FS-Hydrodex β-6-TBDM 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 110 °C; Initial time: 8 min. 
Retention times: Rt1 = 6.0 min; Rt2 = 6.2 min. 
(3-Phenyl-2-oxiranyl)methanol 51: (GP-13) 
0.110 g (0.820 mol, 1.0 equiv) alkene 50 were dissolved in 6 mL DCM. 
Afterwards 0.212 g (0.860 mol, 1.0 equiv) mCPBA were added. The resulting 
mixture was stirred for 3 h. The reaction was quenched with 2 mL sat. NaHCO3. 
The organic layer washed with sat. NaHCO3 (three times 10 mL) and brine (three times 10 mL). 
After purification via column chromatography (n-hexane:EtOAc 3:1) 0.051 g (0.349 mmol, 
41%) 51 were isolated as colorless oil. 
Rf: 0.28 (n-hexane:EtOAc 3:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.38–7.26 (m, 5 H); 4.05 (dd, 1 H, J = 12.8 Hz, J = 2.1 Hz); 
3.93 (d, 1 H, J = 2.1 Hz); 3.81 (dd, 1 H, J = 12.8 Hz, J = 3.4 Hz); 3.23 (dt, 1 H, J = 3.8 Hz, J = 
2.3 Hz); 1.96 (bs, 1 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 136.6; 128.5; 128.3; 125.7; 62.4; 61.2; 55.5 ppm. 
Analytic data are identical to those reported in literature.[175] 
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Chiral GC analysis: 
Enantiomers of 51 were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 120 °C; Initial time: 45 min. 
Retention times: Rt1 = 39.6 min; Rt2 = 40.5 min.  
Benzylamino (7-oxabicyclo[4.1.0]hept-1-yl)acetate 53a: (GP-13) 
0.214 g (0.872 mol, 1.0 equiv) alkene 52a were dissolved in 15 mL DCM. 
Afterwards 0.215 g (0.959 mol, 1.1 equiv) mCPBA were added.  
The resulting mixture was stirred for 5.5 h. The organic layer was diluted 
with 90 mL MTBE and washed with sat. NaHCO3 (three times 30 mL). 
After purification via column chromatography (Et2O) 0.180 g (0.689 mmol, 79%) 53a were 
isolated as colorless oil. 
Rf: 0.20 (n-hexane:EtOAc 3:1). 
1H-NMR (200 MHz, CDCl3): δ = 7.41–7.18 (m, 5 H); 5.12 (bs, 1 H); 4.37 (d, 2 H, J = 6.0 Hz); 
4.12 (d, 1 H, J = 11.6 Hz); 3.98 (d, 1 H, J = 11.8 Hz); 3.11 (d, 1 H, J = 2.0 Hz); 2.05–1.62 (m, 
4 H) 1.57–1.10 (m, 4 H) ppm. 
13C-NMR (50 MHz, CDCl3): δ = 156.2; 138.3; 128.6; 127.5; 68.4; 57.9; 56.5; 45.1; 25.2; 24.2; 
19.6; 19.4 ppm. 
Analytic data are identical to those reported in literature.[33a] 
Chiral HPLC analysis: 
Enantiomers of 53a were separated by chiral HPLC employing a 25 cm 
Chiralpak IB column (4.6 mm ID, Daicel) in combination with an UV-detector (220 nm).  
Flow = 1.00 mL/min. Solvent mixture: n-hexane:iso-propanol 90:10. Retention times:  
Rt1 = 10.7 min; Rt2 = 11.9 min. 
6-Methyl-7-oxabicyclo[4.1.0]heptan-2-one 55: (GP-14) 
The reaction was performed with 0.206 mL (0.200 g, 1.82 mmol, 1.0 equiv) enone 
54, 1.10 mL (30%, 10.8 mmol, 5.9 equiv) H2O2, 0.128 mL (4/1 w/w, 0.608 mmol, 
0.3 equiv) NaOHaq, and 10 mL MeOH for 4 h at r.t.. Before deluting the reaction 
mixture a small volume of acetic acid was added. 20 mL Et2O were used for  
work-up. After purification via column chromatography (n-hexane:EtOAc 3:1) 0.049 g  
(0.388 mmol, 21%) 55 were isolated as colorless oil. 
Rf: 0.12 (n-hexane:EtOAc 2:1). 
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1H-NMR (400 MHz, CDCl3): δ = 3.03 (s, 1 H); 2.45 (dt, 1 H, J = 17.6 Hz, J = 4.5 Hz); 2.11–
1.80 (m, 4 H); 1.64–1.57 (m, 1 H); 1.41 (s, 3 H) ppm. 
13C-NMR (101 MHz, CDCl3): 206.8; 62.5; 62.0; 35.8; 28.4; 22.3; 17.2 ppm. 
Analytic data are identical to those reported in literature.[178] 
Chiral GC analysis: 
Enantiomers of 55 were separated by chiral GC employing a 30 m FS-Hydrodex β-6-TBDM 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 100 °C; Final temperature:  
140 °C; Rate: 2.00 °C/min. Retention times: Rt1 = 7.9 min; Rt2 = 8.8 min.  
4,4,6-Trimethyl-7-oxabicyclo[4.1.0]heptan-2-one 57: (GP-14) 
The reaction was performed with 2.00 mL (1.84 g, 13.3 mmol, 1.0 equiv) 
enone 56, 2.30 mL (30%, 22.5 mmol, 1.7 equiv) H2O2, 2.00 mL (9/1 w/w,  
5.00 mmol, 0.4 equiv) NaOHaq, and 20 mL EtOH for 1 h at 35 °C and 30 min 
at r.t.. The solution of NaOHaq and H2O2 was added over 20 min. After diluting 
with 15 mL H2O 25 mL CHCl3 and 20 mL H2O were used for the work-up. After purification 
via column chromatography (n-pentane:EtOAc 9:1) 1.83 g (11.9 mmol, 89%) 57 were isolated 
as colorless liquid. 
Rf: 0.44 (n-pentane:EtOAc 9:1). 
1H-NMR (400 MHz, CDCl3): δ = 3.03 (s, 1 H); 2.59 (d, 1 H, J = 13.3 Hz); 2.06 (d, 1 H, J = 
14.9 Hz); 1.79 (ddd, 1 H, J = 13.3 Hz, J = 2.0 Hz, J = 0.9 Hz); 1.67 (dd, 1 H, J = 14.9 Hz, J = 
2.0 Hz); 1.40 (s, 3 H); 1.00 (s, 3 H); 0.89 (s, 3 H) ppm. 
13C-NMR (101 MHz, CDCl3): 209.0; 64.3; 61.4; 48.0; 42.7; 36.1; 30.8; 27.8; 24.0 ppm. 
Analytic data are identical to those reported in literature.[179] 
Chiral GC analysis: 
Enantiomers of 57 were separated by chiral GC employing a 30 m Chiraldex G-TA column 
(Astech). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. Precolumn pressure = 0.8 
bar. Conditions: Initial temperature: 100 °C; Final temperature: 136 °C; Rate: 2.00 °C/min. 
Retention times: Rt1 = 13.2 min; Rt2 = 15.2 min. 
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6-(Phenylmethyl)-7-oxabicyclo[4.1.0]heptan-2-one 59: (GP-14) 
The reaction was performed with 0.170 g (0.913 mmol, 1.0 equiv) enone 58,  
0.170 mL (30%, 1.66 mmol, 1.8 equiv) H2O2, 0.500 mL (9/1 w/w, 1.25 mmol,  
1.4 equiv) NaOHaq, and 2 mL MeOH for 2 h at r.t.. The solution of NaOHaq and 
H2O2 was added over 20 min. After diluting with 11 mL H2O 20 mL CHCl3 and  
20 mL H2O were used for the work-up. After purification via column chromatography  
(n-pentane:EtOAc:Et2O 4:1:1) 0.070 g (0.346 mmol, 38%) 59 were isolated as colorless oil. 
Rf: 0.42 (n-pentane:EtOAc:Et2O 4:1:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.33–7.23 (m, 3 H); 7.22–7.20 (m, 2 H); 3.11 (s, 1 H); 2.98 
(s, 2 H); 2.48 (dt, 1 H, J = 17.4 Hz, J = 4.5 Hz); 2.11–1.79 (m, 4 H); ; 1.65–1.57 (m, 1 H) ppm. 
13C-NMR (101 MHz, CDCl3): 206.5; 135.4; 129.5; 128.5; 127.0; 65.2; 60.4; 42.2; 35.9; 26.3; 
17.2 ppm. 
Analytic data are identical to those reported in literature.[180] 
Chiral GC analysis: 
Enantiomers of 59 were separated by chiral GC employing a 30 m FS-Hydrodex β-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 100 °C; Final temperature:  
210 °C; Rate: 1.60 °C/min. Retention times: Rt1 = 56.3 min; Rt2 = 56.8 min. 
Phenyl(3-phenyl-2-oxiranyl)formaldehyde 61: (GP-14) 
0.116 g (0.560 mmol, 1.0 equiv) alkene 60 were dissolved in 4 mL MeOH and 
the resulting mixture was cooled to 0 °C. After adding 0.410 mL (0.455 g,  
4.01 mmol, 7.2 equiv) H2O2 (30%) and 0.156 mL (37.4 mg, 0.936 mmol,  
1.7 equiv) NaOH (6 M) the reaction mixture was stirred for 1 h at 0 °C. The reaction was 
quenched with 1 trop glacial acetic acid. After diluting the reaction mixture with 20 mL brine 
Et2O (three times 25 mL) was used for the extraction. After purification via column 
chromatography (n-hexane:EtOAc 4:1) 0.061 g (0.270 mmol, 49%) 61 were isolated as 
colorless solid. 
1H-NMR (400 MHz, CDCl3): δ = 8.04–7.98 (m, 2 H); 7.67–7.58 (m, 1 H); 7.54–7.45 (m, 2 H); 
7.45–7.33 (m, 5 H); 4.31 (d, 1 H, J = 1.9 Hz); 4.08 (d, 1 H, J = 1.8 Hz) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 193.2; 135.6; 135.5; 134.1; 129.2; 129.0; 128.9; 128.5; 
125.9; 61.1; 59.5 ppm. 
Analytic data are identical to those reported in literature.[181] 
193 
 
Chiral HPLC analysis: 
Enantiomers of 61 were separated by chiral HPLC employing a 25 cm 
Chiralpak IC column (4.6 mm ID, Daicel) in combination with an UV-detector (254 nm). Flow 
= 1.00 mL/min. Solvent mixture: n-hexane:iso-propanol 90:10. Retention times: Rt1 = 20.7 min; 
Rt2 = 22.8 min. 
1-(3-(p-Nitrophenyl)-2-oxiranyl)-1-ethanone 63: (GP-14) 
The reaction was performed with 0.120 g (0.628 mmol, 1.0 equiv) 
enone 62, 0.385 mL (30%, 3.77 mmol, 6.0 equiv) H2O2, 9.00 µL  
(4/1 m/m, 0.045 mmol, 0.1 equiv) NaOHaq, and 10 mL MeOH for 1.5 
h at 0 °C. Before deluting with 15 mL brine the reaction was quenched 
with one trop glacial acetic acid. For the work-up 15 mL Et2O were used. After purification via 
column chromatography (n-hexane:EtOAc 3:1) 0.012 g (0.058 mmol, 9%) 63 were isolated as 
slightly yellow solid. 
Rf: 0.23 (n-hexane:EtOAc 3:1). 
1H-NMR (400 MHz, CDCl3): δ = 8.13–8.11 (m, 2 H); 7.41–7.38 (m, 2 H); 4.08 (d, 1 H, 3J = 
1.6 Hz); 3.41 (d, 1 H, 3J = 1.8 Hz); 2.14 (s, 3 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 202.9; 148.0; 142.3; 126.4; 123.7; 63.1; 56.3; 24.7 ppm. 
Analytic data are identical to those reported in literature.[182] 
Chiral GC analysis: 
Enantiomers of 63 were separated by chiral GC employing a 30 m FS-Hydrodex β-6-TBDM 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 200 °C; Initial time: 30 min. 
Retention times: Rt1 = 28.7 min; Rt2 = 29.6 min. 
9.6. Catalytic Epoxidation 
9.6.1. Peracid-Based Epoxidation 
0.250 mmol (1.0 equiv) alkene and 0.013 mmol (0.05 equiv, 5 mol%) cat. were dissolved in 
2.00 mL chloroform. Afterwards 46.5 μL (0.038 g, 0.300 mmol, 1.2 equiv) DIC and  
2 × 51.1 μL (2 × 0.058 g, 2 × 0.500 mmol, 2 × 2.0 equiv) H2O2 (30%) were added. The resulting 
reaction mixture was stirred at r.t.. The second addition was carried out after 1 h. Small samples 
were taken, diluted with DCM, dried over Na2SO4, and analyzed directly via chiral GC. 
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9.6.2. Dioxirane-Based Epoxidation (Oxone®) 
0.050 mmol (0.2 equiv, 20 mol%) TBABr and 0.050 mmol (0.2 equiv, 20 mol%) cat. were 
dissolved in 1.00 mL DCM. Afterwards 0.250 mmol (1.0 equiv) alkene and 1.00 mL H2O were 
added. A mixture of 0.750 mmol (3.0 equiv) Oxone® and 1.15 mmol (4.6 equiv) NaHCO3 (s) 
was prepared beforehand and added portionwise. The resulting biphasic reaction mixture was 
stirred at r.t.. Small samples were taken, diluted with DCM, dried over Na2SO4, and analyzed 
directly via chiral GC. 
9.6.3. Dioxirane-Based Epoxidation (H2O2/MeCN) 
0.1 mol% Na2EDTA, 0.063 mmol (0.1 equiv, 10 mol%) cat., and 1.15 mmol (1.8 equiv) K2CO3 
were dissolved/suspended in 1.92 mL tAmylOH. Afterwards 0.628 mmol (1.0 equiv) alkene, 
1.92 mL H2O, and 5.05 mmol (8.0 equiv) MeCN were added. Every hour 1.26 mmol (2.0 equiv) 
H2O2 (30%) were added (maximal 8.0 equiv in total). The resulting suspension was stirred at 
r.t.. Small samples were taken, diluted with DCM, dried over Na2SO4, and analyzed directly 
via chiral GC. 
9.6.4. PTC-Based Epoxidation 
0.080 mmol (1.0 equiv) enone and 0.008 mmol (0.1 equiv, 10 mol%) cat. were 
dissolved/suspended in 1.00 mL toluene. Afterwards 0.800 mmol (10.0 equiv) H2O2 (30%) and 
0.300 mL NaOH (2% in H2O) were added. The resulting solution was intensively stirred at r.t.. 
Small samples were taken, dried over Na2SO4, and analyzed directly via chiral GC and HPLC, 
resp.. 
9.6.5. Prolinol-Based Epoxidation 
0.022 mmol (0.3 equiv, 25 mol%) cat. were dissolved in 0.435 mL n-hexane.  
Afterwards 0.087 mmol (1.0 equiv) enone and 0.104 mmol (1.2 equiv) TBHP were added. The 
resulting solution was stirred at r.t. and small samples were analyzed directly via chiral HPLC. 
9.7. Michael Addition 
General procedure (GP-15):  
5.0 equiv CuBr•Me2S were suspended in anhyd. Et2O. Under an Ar atmosphere the resulting 
mixture was cooled to 0 °C. At this temperature 10 equiv PhLi (1.8 M solution in dibutylether) 
were added and the resulting mixture was stirred afterwards for 30 min. Before adding the  
α,β-unsaturated ester dissolved in anhyd. Et2O the mixture was cooled to −30 °C. The reaction 
mixture was stirred 2 h at −30 °C and then 2 h at r.t.. The reaction was quenched by adding  
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15 mL sat. NH4Cl. After phase separation the aq layer was extracted with 7 mL Et2O and the 
combined organic layers were dried over Na2SO4. After evaporation of the solvent the crude 
product was purified via column chromatography. 
trans-2-Hydroxycyclohexyl 3-phenylbutyrate 26: (GP-15) 
The reaction was performed with 0.366 g (1.78 mmol, 5.0 equiv) 
CuBr•Me2S dissolved in 7 mL Et2O, 1.96 mL (3.53 mmol, 10 equiv) PhLi, 
and 0.065 g (0.353 mmol, 1.0 equiv) ester 17 dissolved in 2 mL Et2O.  
After purification via column chromatography (n-hexane:EtOAc 8:1 to 2:1) 0.045 g  
(0.170 mmol, 48%) 26 were isolated as slightly yellowish oil.  
Rf: 0.28 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.33–7.29 (m, 2 H); 7.24–7.19 (m, 3 H); 4.50–4.41 (m, 1 H); 
3.46–3.33 (m, 1 H); 3.31–3.22 (m, 1 H); 2.72–2.56 (m, 2 H); 2.00–1.81 (m, 3 H); 1.68–1.58 
(m, 2 H); 1.33–1.08 (m, 8 H) ppm. 
13C-NMR (101 MHz, CDCl3):
21 δ = 172.4 (172.6); 145.6 (145.4); 128.7 (128.8); 126.8 (126.9); 
126.7 (126.8); 78.3; 72.5 (72.6); 43.0 (43.6); 36.7 (37.4); 32.8 (32.7); 29.9 (30.0); 24.0; 23.8; 
22.4 ppm. 
IR (Film): ṽ = 3450 (w); 3028 (vw); 2936 (m); 2863 (w); 1731 (m); 1452 (w); 1268 (m); 1171 
(m); 700 (w) cm−1. 
HR-MS (EI): m/z: 262.1560 (cal. 262.1569). 
Analytic data are identical to those reported in literature.[69] 
cis-2-Hydroxycyclohexyl 3-phenylbutyrate 27: (GP-15) 
The reaction was performed with 0.561 g (2.73 mmol, 5.0 equiv) 
CuBr•Me2S dissolved in 8 mL Et2O, 3.10 mL (5.58 mmol, 10 equiv) PhLi, 
and 0.100 g (0.543 mmol, 1.0 equiv) ester 18 dissolved in 2 mL Et2O.  
After purification via column chromatography (n-hexane:EtOAc 8:1 to 3:1) 13.7 mg (0.052 
mmol, < 10%22) 27 were isolated as colorless oil.  
Rf: 0.22 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3):
22 δ = 7.34–7.30 (m, 2 H); 7.25–7.19 (m, 3 H); 4.83–4.79 (4.84–
4.86) (m, 1 H); 3.62–3.59 (3.72–3.69) (m, 1 H); 3.33–3.22 (m, 1 H); 2.73–2.58 (m, 2 H); 1.77–
1.69 (m, 1 H); 1.66–1.56 (m, 2 H); 1.54–1.41 (m, 3 H); 1.33–1.24 (m, 6 H) ppm.  
                                                 
21 Data referring to the second diastereomer are given in brackets. 
22 Even after performing the column chromatography several time traces of impurities could not be removed. 
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13C-NMR (101 MHz, CDCl3):
23 δ = 172.1 (172.0); 145.5 (145.7); 128.7; 127.0 (126.8); 126.8; 
74.3; 69.0 (69.2); 43.5 (43.1); 37.4 (36.8); 30.4; 26.9; 22.4; 22.2; 21.0 ppm. 
IR (Film): ṽ = 3458 (w); 3062 (vw); 2938 (m); 2866 (m); 1948 (vw); 1731 (m); 1451 (m); 1269 
(m); 1171 (m); 701 (w) cm−1. 
HR-MS (EI): m/z: 262.1552 (cal. 262.1569). 
9.8. Synthesis of Alkenes 
General procedure (GP-16):  
1.0 equiv aldehyde and 20 mol% 29 were dissolved in acetone. The resulting mixture was 
refluxed and the reaction progress was monitored via TLC. The solution was diluted either with 
DCM or EtOAc and was washed afterwards with sat. NaHCO3. After phase separation  
the aq layer was extracted three times with DCM and EtOAc, resp., and the combined organic 
layers were dried over Na2SO4. After evaporation of the solvent the crude product was purified 
via column chromatography if necessary. 
General Procedure (GP-17):  
In an Ar atmosphere the corresponding alcohol was dissolved in anhyd. DCM.  
Afterwards DMAP, isocyanate, and TEA were added and the resulting mixture was stirred for 
24 h at r.t.. At the end of the reaction Et2O was added and the organic layer was washed with 
aq NaHSO4 (10%). The aq layer was extracted with Et2O. After combining the organic layers 
they were washed with sat. NaHCO3 and dried over MgSO4 and Na2SO4, resp..  
After evaporating the solvent the crude product was purified via column chromatography. 
(E)-4-Phenyl-3-buten-2-one 30: (GP-16) 
3.00 g (0.034 mol, 1.0 equiv) morpholine were dissolved in 50 mL Et2O and the 
resulting mixture was cooled to 0 °C. At this temperature a solution of 2.92 mL 
(4.32 g, 0.038 mol, 1.1 equiv) TFA and 25 mL Et2O was added over 10 min.  
The reaction mixture was stirred for 1 h at 0 °C. The formed colorless solid was filtered and 
washed with 50 mL Et2O and n-pentane. After drying over paraffin 6.51 g (0.032 mol, 95%) 29 
were isolated as colorless solid.  
1H-NMR (400 MHz, DMSO-d6): δ = 9.06 (s, 2 H); 3.76 (t, 4 H, 3J = 5.0 Hz); 3.10 (t, 4 H, 3J = 
5.0 Hz) ppm. 
13C-NMR (101 MHz, DMSO-d6): δ = 63.2; 42.7 ppm. 
                                                 
23 Data referring to the second diastereomer are given in brackets. 
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Analytic data are identical to those reported in literature.[76c] 
The reaction mixture containing 1.91 mL (2.01 g, 0.019 mol, 1.0 equiv) 
benzaldehyde, 0.758 g (3.77 mmol, 0.2 equiv, 20 mol%) 29, and 48 mL 
acetone was refluxed for 72 h. For the work-up 50 mL EtOAc and 50 mL 
NaHCO3 were used. After purification via column chromatography  
(n-hexane:EtOAc 6:1) 1.94 g (0.013 mol, 70%) 30 were isolated as yellow oil. 
Rf: 0.21 (n-hexane:EtOAc 6:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.54–7.48 (m, 3 H); 7.40–7.37 (m, 3 H); 6.70 (d, 1 H, 3J = 
16.3 Hz); 2.37 (s, 3 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 198.2; 143.3; 134.2; 130.4; 128.8; 128.1; 127.0; 27.3 ppm. 
Analytic data are identical to those reported in literature.[76c] 
1-Cyclohexylcyclohexene 40:  
A round-bottom flask was charged with 1.51 g (0.062 mol, 1.3 equiv) magnesium 
and 8 mL anhyd. Et2O. A solution of 7.52 mL (10.0 g, 0.061 mol, 1.2 equiv) CyBr 
and 17 mL anhyd. Et2O was added over 45 min. Afterwards the mixture was 
refluxed for 1 h. Before adding a solution of 5.03 mL (4.82 g, 0.049 mol, 1.0 equiv) 
cyclohexyanone and 18 mL anhyd. Et2O carefully over 15 min, the mixture containing the  
in situ formed Grignard species was cooled for several minutes. After refluxing the reaction 
mixture for further 3 h 9 g ice and later sat. NH4Cl and Et2O were added. After phase separation 
the organic layer was washed with sat. NaHSO3 and NaHCO3 and finally with water.  
After drying over Na2SO4 the solvent was removed under reduced pressure. After purification 
via column chromatography (n-hexane:EtOAc 15:1) 2.22 g (0.012 mol, 25%) alcohol 72 were 
isolated as colorless solid. 
Rf: 0.59 (n-hexane:EtOAc 5:1). 
1H-NMR (400 MHz, CDCl3): δ = 1.82–1.77 (m, 4 H); 1.67–1.48 (m, 8 H); 1.43–1.36 (m, 2 H); 
1.28–1.08 (m, 6 H); 1.06–0.96 (m, 2 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 73.1; 48.4; 34.4; 27.0; 26.74; 26.68; 26.1; 22.1 ppm. 
Analytic data are identical to those reported in literature.[183]  
2.22 g (0.012 mol, 1.0 equiv) alcohol 72 were dissolved in 2.20 mL sulfuric acid and 8.40 mL 
acetic acid. The resulting mixture was warmed to 65 °C. After 30 min the black and biphasic 
system was carefully poured on a mixture of Et2O and water. After phase separation the organic 
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layer was washed carefully with sat. NaHCO3 (55 mL in total). After purification via column 
chromatography (n-hexane:EtOAc 20:1) 1.14 g (6.94 mmol, 57%) 40 were isolated as 
yellowish liquid.   
Rf: 0.61 (n-hexane:EtOAc 50:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.45–5.37 (m, 1 H, CH2CCH); 2.00–1.98 (m, 2 H, HCy); 
1.94–1.89 (m, 2 H, HCy); 1.76–1.64 (m, 6 H, CH2CHCH2 and HCy); 1.63–1.51 (m, 4 H, HCy); 
1.31–1.07 (m, 5 H, HCy) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 143.3 (CH2CCH); 118.8 (CH2CCH); 46.0 (2 C, 
CH2CHCH2); 32.1 (2 C, CH2); 27.0 (2 C, CH2); 26.9 (CH2); 26.7 (CH2); 25.4 (CH2); 23.4 (CH2); 
23.0 (CH2) ppm. 
IR (Film): ṽ = 2925 (vs); 2853 (s); 2853 (s); 2667 (vw); 1662 (vw); 1448 (m); 919 (vw); 801 
(vw) cm−1. 
HR-MS (EI): m/z: 164.1566 (cal. 164.1565). 
Cyclohex-1-en-1-ylmethyl benzylcarbamate 52a: 
In an Ar atmosphere 1.62 mL (1.67 g, 11.9 mmol, 1.0 equiv) ester 73 were 
dissolved in 20 mL anhyd. DCM. The reaction mixture was cooled to  
−78 °C and 27.7 mL (29.8 mmol, 2.5 equiv) DiBAL (1.0 M in hexane) 
were added slowly. After stirring the solution for 90 min at −78 °C the 
reaction was quenched with 20 mL of a potassium-sodium-tartrate solution (0.25 M). Then, the 
mixture was allowed to warm-up to r.t. and stirred for further 30 min. Afterwards the solution 
was diluted with 300 mL Et2O, dried over MgSO4, and filtered over a frit containing MgSO4. 
After evaporation of the solvent 1.36 g (11.9 mmol, quant.) of the crude product 74 were 
obtained as colorless liquid, which was used without further purification. 
Rf: 0.20 (toluene:Et2O 9:1).  
1H-NMR (400 MHz, CDCl3): δ = 5.72−5.63 (m, 1 H); 3.97 (s, 2 H); 2.10−1.96 (m, 4 H); 1.34 
(bs, 1 H); 1.72−1.53 (m, 4 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 137.5; 123.0; 67.7; 25.6; 24.9; 22.5; 22.4 ppm. 
For the synthesis of 52a 1.34 g (11.9 mmol, 1.0 equiv) alcohol 74, 0.145 g (1.19 mmol, 
0.1 equiv) DMAP, 1.68 mL (1.81 g, 13.6 mmol, 1.14 equiv) BnNCO 76a, 1.88 mL (1.37 g, 
13.6 mol, 1.14 equiv) TEA, and 26 mL anhyd. DCM were used (GP-17). The reaction mixture 
was diluted with 100 mL Et2O. Afterwards the organic layer was washed with 100 mL NaHSO4 
(10%) and the aq layer was extracted with 100 mL Et2O. After purification via column 
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chromatography (toluene: Et2O 9:1) 2.41 g (9.82 mmol, 83%) carbamate 52a were obtained as 
colorless solid. 
Rf: 0.50 (toluene:Et2O 9:1). 
1H-NMR (200 MHz, CDCl3): δ = 7.40−7.21 (m, 5 H); 5.74 (s, 1 H); 4.99 (s, 1 H); 4.47 (s, 2 
H); 4.38 (d, 2 H, J = 6.0 Hz); 2.10−1.89 (m, 4 H); 1.70−1.51 (m, 4 H) ppm. 
13C-NMR (50 MHz, CDCl3): δ = 156.8; 138.7; 133.5; 128.8; 127.61; 127.55; 126.0; 69.6; 45.2; 
25.9; 25.1; 22.5; 22.3 ppm. 
Analytic data are identical to those reported in literature.[33a] 
Cyclohex-1-en-1-ylmethyl phenylcarbamate 52b: 
For the synthesis of 52b 0.300 g (2.67 mmol, 1.0 equiv) alcohol 74,  
0.033 g (0.267 mmol, 0.1 equiv) DMAP, 0.331 mL (0.363 g, 3.04 mmol, 
1.14 equiv) isocyanate 76b, 0.376 mL (0.405 g, 3.04 mol, 1.14 equiv) 
TEA, and 6 mL anhyd. DCM were used (GP-17). The reaction mixture was diluted with 22 mL 
Et2O and the layers were washed and extracted, resp., with 22 mL NaHSO4 (10%), 22 mL Et2O, 
and 22 mL NaHCO3. After recrystallization (n-hexane) 0.323 g (1.39 mmol, 52%) carbamate 
52b were obtained as colorless solid. 
1H-NMR (200 MHz, CDCl3): δ = 7.37−7.15 (m, 4 H); 7.05−6.90 (m, 1 H); 6.62 (s, 1 H); 
5.78−5.64 (m, 1 H); 4.46 (s, 2 H); 2.06−1.87 (m, 4 H); 1.68−1.43 (m, 4 H) ppm. 
13C-NMR (50 MHz, CDCl3): δ = 153.6; 138.0; 133.1; 129.1; 126.6; 123.4; 118.7; 69.7; 25.9; 
25.0; 22.4; 22.1 ppm. 
HR-MS (EI): m/z: 231.1254 (cal. 231.1259). 
Analytic data are identical to those reported in literature.[33a] 
Cyclohex-1-en-1-ylmethyl ethylcarbamate 52c: 
For the synthesis of 52c 0.300 g (2.67 mmol, 1.0 equiv) alcohol 74,  
0.033 g (0.267 mmol, 0.1 equiv) DMAP, 0.241 mL (0.216 g, 3.04 mmol, 
1.14 equiv) isocyanate 76c, 0.420 mL (0.308 g, 3.04 mol, 1.14 equiv) TEA, 
and 6 mL anhyd. DCM were used (GP-17). The reaction mixture was diluted with 22 mL Et2O 
and the layers were washed and extracted, resp., with 22 mL NaHSO4 (10%), 22 mL Et2O, and 
22 mL NaHCO3. After column chromatography (n-hexane:EtOAc 3:1) 0.345 g (1.90 mmol, 
71%) carbamate 52c were obtained as colorless liquid. 
Rf: 0.33 (n-hexane:EtOAc 3:1). 
200 
 
1H-NMR (600 MHz, CDCl3): δ = 5.73−5.70 (m, 1 H, CH); 4.65 (bs, 1 H, NH); 4.42 (s, 2 H, 
CH2O); 3.24−3.19 (m, 2 H, CH2CH3); 2.05−2.00 (m, 2 H, CH2CCH); 1.99−1.95 (m, 2 H, 
CH2CCH2O); 1.66−1.61 (m, 2 H, CH2CH2CCH2O); 1.60−1.55 (m, 2 H, CH2CH2CCH); 1.13 (t, 
3 H, 3J = 7.3 Hz, CH3) ppm. 
13C-NMR (151 MHz, CDCl3): δ = 156.7 (CO); 133.7 (CCH); 125. 9 (CCH); 69.3 (CH2O); 36.0 
(CH2CH3); 25.9 (CH2CCH2O); 25.1 (CH2CCH); 22.5 (CH2CH2CCH2O); 22.3 (CH2CH2CCH); 
15.4 (CH3) ppm. 
IR (Film): ṽ = 3334 (w); 2931 (m); 1698 (m); 1535 (m); 1252 (m); 1017 (w) cm−1. 
HR-MS (ESI): m/z: 206.1157 [M + Na]+ (cal. 206.1151); m/z: 389.2413 [2M + Na]+ (cal. 
389.2411). 
Cyclohex-1-en-1-ylmethyl isopropylcarbamate 52d: 
For the synthesis of 52d 0.300 g (2.67 mmol, 1.0 equiv) alcohol 74,  
0.033 g (0.267 mmol, 0.1 equiv) DMAP, 0.299 mL (0.259 g, 3.04 mmol, 
1.14 equiv) isocyanate 76d, 0.376 mL (0.405 g, 3.04 mol, 1.14 equiv) 
TEA, and 6 mL anhyd. DCM were used (GP-17). The reaction mixture was diluted with 22 mL 
Et2O and the layers were washed and extracted, resp., with 22 mL NaHSO4 (10%), 22 mL Et2O, 
and 22 mL NaHCO3. After column chromatography (n-hexane:EtOAc 3:1) 0.336 g (1.71 mmol, 
64%) carbamate 52d were obtained as colorless solid. 
Rf: 0.37 (n-hexane:EtOAc 3:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.74−5.68 (m, 1 H, CH); 4.52 (bs, 1 H, NH); 4.40 (s, 2 H, 
CH2O); 3.87−3.74 (m, 1 H, CH(CH3)2); 2.06−2.02 (m, 2 H, CH2CCH); 1.99−1.94 (m, 2 H, 
CH2CCH2O); 1.68−1.61 (m, 2 H, CH2CH2CCH2O); 1.59−1.54 (m, 2 H, CH2CH2CCH); 1.14 
(d, 6 H, 3J = 6.5 Hz, CH(CH3)2) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 155.9 (CO); 133.7 (CCH); 125.9 (CCH); 69.2 (CH2O); 43.1 
(CH(CH3)2); 25.9 (CH2CCH2O); 25.1 (CH2CCH); 23.2 (CH(CH3)2); 22.5 (CH2CH2CCH2O); 
22.3 (CH2CH2CCH) ppm. 
HR-MS (ESI): m/z: 220.1310 [M + Na]+ (cal. 220.1308); m/z: 417.2734 [2M + Na]+ (cal. 
417.2724). 
Cyclohex-1-en-1-ylmethyl tert-butylcarbamate 52e: 
For the synthesis of 52e 0.273 g (2.43 mmol, 1.0 equiv) alcohol 74,  
0.033 g (0.268 mmol, 0.1 equiv) DMAP, 0.317 mL (0.275 g, 2.78 mmol, 
1.14 equiv) isocyanate 76e, 0.390 mL (0.283 g, 2.80 mol, 1.15 equiv) 
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TEA, and 5.5 mL anhyd. DCM were used (GP-17). The reaction mixture was diluted with  
22 mL Et2O and the layers were washed and extracted, resp., with 22 mL NaHSO4 (10%),  
22 mL Et2O, and 22 mL NaHCO3. After column chromatography (n-hexane:EtOAc 5:1)  
71.2 mg (0.337 mmol, 14%) carbamate 52e were obtained as colorless oil. The remaining 
alcohol was reisolated. 
Rf: 0.40 (n-hexane:EtOAc 5:1). 
1H-NMR (400 MHz, CDCl3): δ = 5.74−5.69 (m, 1 H, CH); 4.64 (bs, 1 H, NH); 4.37 (s, 2 H, 
CH2O); 2.07−2.01 (m, 2 H, CH2CCH); 2.00−1.95 (m, 2 H, CH2CCH2O); 1.67−1.61 (m, 2 H, 
CH2CH2CCH2O); 1.60−1.54 (m, 2 H, CH2CH2CCH); 1.31 (s, 9 H, (CH3)3) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 155.2 (CO)24; 133.8 (CCH); 125.8 (CCH); 68.8 (CH2O); 
50.4 (C(CH3)3); 29.1 (C(CH3)3); 26.1 (CH2CCH2O); 25.1 (CH2CCH); 22.5 (CH2CH2CCH2O); 
22.3 (CH2CH2CCH) ppm. 
IR (KBr): ṽ = 3333 (s); 2934 (s); 1697 (vs); 1535 (s); 1274 (vs); 1078 (s) cm−1. 
HR-MS (ES): m/z: 211.1569 (cal. 211.1572). 
Crytal structure: see Chapter 10. 
3-Benzyl-2-cyclohexen-1-one 58:  
In an Ar atmosphere a three-neck round-bottom flask was charged with 43.0 mL 
(43.0 mmol, 2.2 equiv) benzylmagnesium chloride (1.0 M in Et2O). After cooling 
this solution to 0 °C a solution of 2.70 mL (2.78 g, 19.8 mmol, 1.0 equiv)  
3-ethoxy-2-cyclohexen-1-one in 15 mL anhyd. THF was added dropwise and the 
resulting mixture was stirred for 18 h at r.t.. The reaction was quenched carefully with 100 mL 
HCl (1 M) and extracted afterwards with Et2O (five times 25 mL). The organic layer was 
washed with 50 mL sat. NaHCO3, H2O, and brine. After drying over MgSO4 the solvent was 
removed under reduced pressure. After purification via column chromatography  
(n-pentane:EtOAc:Et2O 4:1:1 and n-pentane:Et2O 1:1) 2.28 g (12.2 mol, 62%) 58 were isolated 
as yellowish oil. 
Rf: 0.26 (n-pentane:EtOAc:Et2O 4:1:1) and 0.22 (n-pentane:Et2O 1:1). 
1H-NMR (400 MHz, CDCl3):
25 δ = 7.37–7.22 (m, 3 H); 7.17–7.14 (m, 2 H); 5.86 (s, 1 H); 3.50 
(s, 2 H); 2.36–2.33 (m, 2 H); 2.27 (t, 2 H, J = 6.0 Hz); 1.98–1.92 (m, 2 H) ppm. 
                                                 
24 Can be observed in the HMBC spectra. 
25 Traces of BnOH remained even after two times of purification. 
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13C-NMR (101 MHz, CDCl3):
26 δ = 199.9; 164.7; 136.9; 129.0; 128.6; 126.8; 44.4; 37.2; 29.2; 
22.6 ppm. 
Analytic data are identical to those reported in literature.[184] 
(E)-4-(p-Nitrophenyl)-3-buten-2-one 62: (GP-16) 
The reaction mixture containing 1.00 g (6.62 mmol, 1.0 equiv)  
p-nitrobenzaldehyde, 0.266 g (1.32 mmol, 0.2 equiv, 20 mol%) 29, and 
17 mL acetone was refluxed for 48 h. For work-up 17 mL DCM and 
17 mL sat. NaHCO3 were used. 1.17 g (6.12 mol, 92%) 62 were 
isolated as yellow solid, which was used without further purification. 
1H-NMR (400 MHz, CDCl3): δ = 8.26–8.24 (m, 2 H); 7.70–7.68 (m, 2 H); 7.53 (d, 1 H, 3J = 
16.3 Hz); 6.81 (d, 1 H, 3J = 16.3 Hz); 2.42 (s, 3 H) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 197.5; 148.6; 140.6; 140.0; 130.3; 128.8; 124.2; 28.0 ppm. 
1H-NMR data are identical to those reported in literature.[76c] 
1-(Benzyloxycarbonylamino)-1-cyclohexen-3-one 66:  
0.201 g (1.81 mmol, 1.0 equiv) alkene 64 and 0.575 g (5.43 mmol, 3.0 equiv) 
Na2CO3 were suspended in 12 mL of a solvent mixture (H2O/1,4-dioxane 2/1). 
After cooling the suspension to 0 °C 0.300 mL (0.359 g, 2.10 mmol, 1.2 equiv) 
Cbz-Cl were added. The cooling bath was removed after 30 min and the resulting 
mixture was stirred for 22.5 h at r.t.. Subsequently, the reaction mixture was diluted with H2O, 
the aq layer was extracted with DCM (two times 50 mL), the organic layer was dried over 
Na2SO4, and the solvent was removed under reduced pressure. After purification via column 
chromatography (n-hexane:EtOAc 2:1 to 0:1) 0.137 g (0.559 mol, 31%) 66 were isolated as 
colorless solid. 
Rf: 0.43 (EtOAc). 
1H-NMR (400 MHz, CDCl3): δ = 7.36–7.31 (m, 5 H, HPh); 7.04 (bs, 1 H, NH); 6.40 (s, 1 H, 
CH); 5.15 (s, 2 H, CH2Ph); 2.50 (t, 2 H, J = 6.0 Hz, CH2); 2.32 (t, 2 H, J = 6.5 Hz, CH2); 2.01–
1.95 (m, 2 H, CH2) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 199.6; 156.0; 152.0; 135.4; 128.79; 128.75; 128.6; 110.4; 
67.8; 36.7; 28.3; 21.6 ppm. 
IR (KBr): ṽ = 3445 (vw); 2958 (vw); 1874 (vw); 1750 (w); 1619 (w); 1524 (w); 1219 (w) cm−1. 
                                                 
26 Traces of BnOH remained even after two times of purification. 
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HR-MS (ESI): m/z: 246.1136 [M + H]+ (cal. 246.1125); m/z: 268.0951 [M + Na]+ (cal. 
268.0944); m/z: 491.2185 [2M + H]+ (cal. 491.2177); m/z: 513.2006 [2M + Na]+ (cal. 
513.1996); m/z: 758.3021 [3M + Na]+ (cal. 758.3048). 
Crytal structure: see 10.11. 
9.9. α,β-Unsaturated γ-Hydroxyl Ketones 
General procedure with PhLi (GP-18):  
1.0 equiv epoxide was dissolved in anhyd. Et2O. In an Ar atmosphere this solution was cooled 
to –78 °C. At this temperature firstly 2.0 equiv PhLi (1.8 M in dibutyl ether) and secondly  
1.5 equiv BF3•Et2O were added. After stirring for 2 to 4 h the reaction was quenched by adding 
sat. NaHCO3. After extracting the aq layer three times with Et2O the combined organic layers 
were washed with NaOHaq (9/1 m/m) and brine and finally dried over Na2SO4.  
After evaporation of the solvent the crude product was purified via column chromatography. 
General procedure with Ph2CuLi (GP-19):  
5.0 equiv CuBr•Me2S were suspended in anhyd. Et2O. Under an Ar atmosphere the resulting 
mixture was cooled to 0 °C. At this temperature 10 equiv PhLi (1.8 M solution in dibutyl ether) 
were added and the resulting mixture was stirred afterwards for 10 min. Before adding slowly 
1.0 equiv epoxide dissolved in anhyd. Et2O the mixture was cooled to −30 °C. At this 
temperature the reaction mixture was stirred 2 h. The reaction was quenched by adding  
sat. NH4Cl and the biphasic system was stirred until the copper salts were dissolved. After phase 
separation the aq layer was extracted with Et2O and the combined organic layers were dried 
over Na2SO4. After evaporation of the solvent the crude product was purified via column 
chromatography. 
General procedure with TEA/tBuSH (GP-20):   
A solution consisting of 1.0 equiv tBuSH, 1.0 equiv TEA, and methanol was stirred for 20 min 
at r.t.. After adding 1.0 equiv epoxide dissolved in methanol the resulting mixture was refluxed 
for 2 h. The reaction progress was monitored via TLC. After evaporation of the solvent the 
crude product was purified via column chromatography. 
General procedure with DBU (GP-21):   
1.0 equiv epoxide was dissolved in 5 mL chloroform. After addition of 1.0 equiv DBU the 
mixture was stirred for 1 h at r.t.. After evaporation of the solvent the crude product was purified 
via column chromatography. 
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trans-2-Hydroxycyclohexyl (E)-4-hydroxy-2-pentenoate 31: (GP-21) 
The reaction was performed with 0.100 g (0.467 mmol, 1.0 equiv) epoxide 
24a and 69.8 µL (71.2 mg, 0.468 mmol, 1.0 equiv) DBU.  
After purification via column chromatography (n-hexane:EtOAc 1:7) 
0.085 g (0.397 mmol, 85%) 31 were isolated as colorless oil. 
Rf: 0.38 (n-hexane:EtOAc 1:7). 
1H-NMR (400 MHz, CDCl3): δ = 6.99 (dd, 1 H, 3J = 15.7 Hz, 3J = 4.6 Hz, COCHCH); 6.05 
(dd, 1 H, 3J = 15.7 Hz, 4J = 1.6 Hz, COCHCH); 4.68–4.62 (m, 1 H, CHOC); 4.53–4.47 (m, 1 
H, CHOHCH3); 3.63–3.57 (m, 1 H, CHOH); 2.08–2.02 (m, 2 H, HCy); 1.98 (bs, 2 H, OH); 1.75–
1.71 (m, 2 H, HCy); 1.40–1.24 (m, 7 H, HCy and CH3) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 166.9 (CO); 151.6 (COCHCH); 119.7 (COCHCH); 78.5 
(CHOCO); 73.0 (CHOH); 67.3 (CHOHCH3); 33.1 (CH2CHOH); 30.1 (CH2CHOCO); 24.0 
(CH2CH2CHOCO); 23.9 (CH2CH2CHOH); 22.8 (CH3) ppm. 
IR (Film): ṽ = 3409 (vs); 2939 (vs); 2864 (vs); 1701 (vs); 1273 (vs); 1182 (vs); 857 (m); 597 
(w) cm−1. 
HR-MS (ESI): m/z: 237.1104 [M + Na]+ (cal. 237.1097); 451.2303 [2M + Na]+ (cal. 451.2301). 
cis-2-Hydroxycyclohexyl (E)-4-hydroxy-2-pentenoate 32: (GP-21) 
The reaction was performed with 0.102 g (0.476 mmol, 1.0 equiv) epoxide 
25a and 69.8 µL (71.2 mg, 0.468 mmol, 1.0 equiv) DBU.  
After purification via column chromatography (n-hexane:EtOAc 1:7) 
0.089 g (0.413 mmol, 89%) 32 were isolated as colorless oil. 
Rf: 0.43 (n-hexane:EtOAc 1:7). 
1H-NMR (400 MHz, CDCl3): δ = 6.98 (dd, 1 H, 3J = 15.7 Hz, 3J = 4.6 Hz, COCHCH); 6.06 
(dd, 1 H, 3J = 15.7 Hz, 4J = 1.6 Hz COCHCH); 5.00 (dt, 1 H, 3J = 7.7 Hz, 3J = 2.6 Hz, CHOC); 
4.52–4.46 (m, 1 H, CHOHCH3); 3.90–3.87 (m, 1 H, CHOH); 2.13 (bs, 2 H, OH); 1.93–1.84 
(m, 1 H, HCy); 1.80–1.68 (m, 1 H, HCy); 1.68–1.52 (m, 5 H, HCy); 1.45–1.36 (m, 2 H, HCy); 1.34 
(d, 3 H, 3J = 6.6 Hz, CH3) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 166.4 (CO); 151.6 (COCHCH); 119.7 (COCHCH); 74.4 
(CHOCO); 69.5 (CHOH); 67.3 (CHOHCH3); 30.4 (CH2CHOH); 27.2 (CH2CHOCO); 22.8 
(CH3); 22.0 (CH2CH2CHOCO); 21.3 (CH2CH2CHOH) ppm.
  
IR (Film): ṽ = 3425 (vs); 2939 (vs); 2864 (s); 1715 (vs); 1273 (vs); 1179 (vs); 980 (s); 888 (m); 
595 (w) cm−1. 
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HR-MS (ESI): m/z: 215.1283 [M + H]+ (cal. 215.1278); 237.1104 [M + Na]+ (cal. 237.1097); 
451.2307 [2M + Na]+ (cal. 451.2301). 
Methyl 3-(2-oxiranyl)propionate 37: (GP-20) 
Using the TEA/tBuSH-procedure methyl ester 37 was isolated as  
side-product starting from epoxides 24b and 25b. 
1H-NMR (400 MHz, CDCl3): δ = 3.68 (s, 3 H); 3.00–2.95 (m, 1 H); 2.77–
2.74 (m, 1 H); 2.49 (dd, 1 H, 3J = 4.9 Hz, 3J = 2.7 Hz,); 2.46 (t, 2 H, 3J = 7.4 Hz), 2.01–1.93 
(m, 1 H); 1.80–1.71 (m, 1 H) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 173.3; 51.7; 51.2; 47.0; 30.1; 27.6. ppm.  
HR-MS (ESI): m/z: 153.0519 [M + Na]+ (cal. 153.0522). 
Analytic data are identical to those reported in literature.[185] 
9.10. Synthesis of Carbonate 75 
6-Hydroxy-1,3-dioxaspiro[4.5]decan-2-one 75: 
24.3 mg (0.133 mmol, 1.0 equiv) carbamate 52c were dissolved in 1.33 mL DCM. 
Afterwards 47.7 mg (0.213 mmol, 1.6 equiv) mCPBA were added. After stirring 
the resulting mixture for 24 h at r.t. 3.39 mg (0.007 mmol, 5 mol%) TUC 77 were 
added. After stirring for additional 48 h at r.t. the solvent was evaporated and the 
crude product was purified via column chromatography (Et2O and 0.5% TEA). 
Finally, 17.7 mg (0.103 mmol, 78%) carbonate 75 were obtained as colorless solid. 
Rf: 0.33 (Et2O). 
1H-NMR (400 MHz, CDCl3): δ = 4.60 (d, 1 H, 2J = 8.1 Hz, CH2O); 4.09 (d, 1 H, 2J = 8.1 Hz, 
CH2O); 3.84 (dt, 1 H, 
3J = 10.2 Hz, 3J = 4.1 Hz); 2.71 (d, 1 H, 3J = 3.6 Hz, OH); 2.03−1.96 (m, 
2 H, HCy); 1.82−1.66 (m, 3 H, HCy); 1.42−1.14 (m, 3 H, HCy) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 155.1 (CO); 86.0 (Cquart.); 71.6 (CHOH); 69.0 (CH2O); 34.1; 
30.7; 22.6; 22.2 ppm. 
IR (ATR): ṽ = 3409 (vw); 2935 (vw); 1777 (m); 1396 (w); 1202 (w); 1168 (m); 1065 (s); 727 
(w) cm−1. 
HR-MS (EI): m/z: 173.0808 [M + H]+ (cal. 173.0808). 
Crytal structure: see 10.11. 
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9.11. Synthesis of (Functionalized) Amino Acids 
Boc-Lys(CM)-OMe 137: 
The reaction mixture containing 3.00 mg (0.026 mmol, 3 mol%) DMAP, 
0.402 g (0.969 mmol, 1.0 equiv) Boc-Lys(2-Cl-Cbz)-OH 135, 0.228 g 
(1.19 mmol, 1.2 equiv) EDAC, 0.166 mL (0.121 g, 1.20 mmol, 1.2 equiv) 
TEA, and 6 mL MeOH was stirred for 4 d at r.t. (GP-3). The solvent was 
removed under reduced pressure and the residue was dissolved in DCM 
and H2O. The aq layer was extracted with DCM (three times 15 mL).  
The organic layer was dried over Na2SO4. After purification via column chromatography 
(EtOAc and n-hexane:EtOAc 2:1 to 1:2) 0.114 g (0.266 mmol, 27%) 136 were isolated as 
slightly yellow oil. 
Rf: 0.53 (n-hexane:EtOAc 1:2). 
1H-NMR (400 MHz, CDCl3): δ = 7.43–7.39 (m, 1 H, HAr); 7.38–7.35 (m, 1 H, HAr); 7.28–7.23 
(m, 2 H and CHCl3, HAr); 5.20 (s, 2 H, CH2Ar); 5.08 (d, 1 H, 
3J = 7.2 Hz, NH); 4.89 (bs, 1 H, 
NH); 4.31–4.26 (m, 1 H, CH); 3.73 (s, 3 H, CH3); 3.22–3.17 (m, 2 H, CHCH2) 1.85–1.75 (m, 1 
H, CH2); 1.69–1.59 (m, 1 H, CH2); 1.58–1.48 (m, 2 H, CH2); 1.43 (s, 9 H, C(CH3)3); 1.38–1.30 
(m, 2 H, CH2) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 173.4; 156.4; 155.6; 134.5; 133.7; 129.9; 129.6; 129.5; 
127.0; 80.1; 64.0; 53.3; 52.4; 40.8; 32.5; 29.4; 28.4; 22.5 ppm. 
MS (ESI): m/z: 451.1 [M + Na]+ (cal. 451.2). 
The synthesis of the free amine was performed with 0.100 g (0.233 mmol, 1.0 equiv)  
(2-Cl-Cbz)-protected compound 136, 0.051 g (0.048 mmol, 20 mol%) Pd/C (10%), and 5 mL 
MeOH (GP-7). The reaction mixture was stirred for 23 h. The crude product was utilized 
without further purification. The synthesis of Boc-Lys(CM)-OMe 137 was performed with  
2.20 mg (0.018 mmol, 8 mol%) DMAP, 0.065 g (0.298 mmol, 1.3 equiv) acid para-112,  
0.097 g (0.506 mmol, 2.2 equiv) EDAC, 0.068 mL (0.050 g, 0.490 mmol, 2.1 equiv) TEA, and 
7 mL DCM for 4 d at r.t. (GP-3). The reaction mixture was washed with sat. NaHCO3 (two 
times 15.0 mL). The aq layer was extacted with DCM (three times 10.0 mL). The organic layer 
was dried over Na2SO4. After purification via HPLC (eluent: TBME/MeOH 98:2; 5 mL min
–1; 
UV detector 254 nm, column: l = 250 mm, d = 8 mm; LiChrosorb Amino (7 µm, Merck);  
Rt = 14.1 min) 0.030 g (0.065 mmol, 28%) 137 were isolated as colorless oil. 
1H-NMR (400 MHz, CDCl3): δ = 8.10 (d, 2 H, 3J = 8.0 Hz, CHCCOCF3); 7.94 (d, 2 H, 3J = 
8.5 Hz, NHCOCCH); 6.66 (bs, 1 H, NH); 5.16 (d, 1 H, 3J = 8.0 Hz, NH); 4.34–4.24 (m, 1 H, 
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CH); 3.73 (s, 3 H, CH3); 3.52–3.42 (m, 2 H, CHCH2); 1.88–1.77 (m, 1 H, CH2); 1.73–1.61 (m, 
3 H, CH2); 1.50–1.41 (m, 2 H, CH2); 1.38 (s, 9 H, C(CH3)3) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 180.1 (q, 2JCF = 35.6 Hz, COCF3); 173.3 (CO2CH3); 166.3 
(NHCOCAr); 155.8 (NHCOO); 140.9 (NHCOCAr); 131.9 (CCOCF3); 130.42 (CHCCOCF3); 
130.40 (CHCCOCF3); 127.9 (NHCOCCH); 116.6 (q, 
1JCF = 291.2 Hz, COCF3); 80.1 
(C(CH3)3); 53.1 (CHCH2); 52.5 (CH3); 40.0 (CHCH2); 32.8 (CH2); 28.7 (CH2); 28.4 (C(CH3)3); 
22.7 (CH2) ppm. 
IR (Film): ṽ = 3344 (w); 2935 (w); 1723 (s); 1723 (s); 1695 (s); 1173 (s); 1057 (m); 737 (w) 
cm−1. 
HR-MS (ESI): m/z: 515.1974 [M + MeOH + Na]+ (cal. 515.1976); 1007.4026 [2M + 2MeOH 
+ Na]+ (cal. 1007.4059). 
Fmoc-Dap(Cbz)-OH 139: 
0.200 g (0.613 mmol, 1.0 equiv) Fmoc-Lys(NH2)-OH 138 and 0.198 g  
(1.86 mmol, 3.0 equiv) Na2CO3 were suspended in 2 mL H2O and 1 mL  
1,4-dioxane. After cooling to 0 °C 0.100 mL (0.120 g, 0.701 mmol, 1.1 equiv) 
CbzCl were added. After 15 min the cooling bath was removed and the 
suspension was stirred for 24 h. After 2 h further 2 mL H2O and 1 mL 1,4-dioxane had to be 
added. The reaction mixture was diluted wit 100 mL H2O, extracted with with 20 mL Et2O, and 
acidified with HCl. The aq layer was extracted with EtOAc (three times 27 mL).  
The organic layer was dried over Na2SO4. After purification via column chromatography 
(DCM:MeOH 10:1) 0.193 g (0.419 mmol, 68%) 139 were isolated as colorless solid. 
Rf: 0.50 (DCM:MeOH 7:1). 
1H-NMR and 13C-NMR not meaningful. 
MS (ESI): m/z: 483.1 [M + Na]+ (cal. 483.2); 499.0 [M + K]+ (cal. 499.1). 
Analytic data are reported in literature.[186] 
Benzyl (2S)-4-(N-methylmethoxyamino)-2-((9H-fluoren-9-yl)methoxycarbonylamino)-4-
oxo-butyrate 168: 
The synthesis of Weinreb amide 168 was performed with 1.00 g (2.24 mmol, 
1.0 equiv) 167, 0.250 g (2.56 mmol, 1.1 equiv) N,O-dimethylhydroxylamine 
hydrochloride 148, 0.524 g (2.73 mmol, 1.2 equiv) EDAC, 0.368 g  
(2.72 mmol, 1.2 equiv) HOBt, 0.720 mL (0.525 g, 5.19 mmol, 2.3 equiv) 
TEA, and 20 mL DCM utilizing GP-6. After 21 h the reaction mixture was 
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diluted with EtOAc. For washing a volume of 65 mL was used. After purification via column 
chromatography (n-hexane:EtOAc 1:1 to 1:3) 0.747 g (1.53 mmol, 68%) 168 were isolated as 
colorless foam. 
Rf: 0.21 (n-hexane:EtOAc 1:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.76 (d, 2 H, 3J = 7.5 Hz); 7.60 (d, 2 H, 3J = 7.5 Hz); 7.40 (t, 
2 H, 3J = 7.4 Hz); 7.35–7.27 (m, 7 H); 6.12 (d, 1 H, 3J = 9.0 Hz, NH); 5.24 (d, 1 H, 2J = 12.3 
Hz, CH2Ph); 5.18 (d, 1 H, 
2J = 12.3 Hz, CH2Ph); 4.75–4.72 (m, 1 H, CHCH2CO); 4.43 (dd, 1 
H, 2J = 10.3 Hz, 3J = 7.1 Hz, CHCH2OCO); 4.29 (dd, 1 H, 
2J = 10.3 Hz, 3J = 7.6 Hz, 
CHCH2OCO); 4.21 (t, 1 H, 
3J = 7.3 Hz, CHCH2OCO); 3.63 (s, 3 H, CH3); 3.29 (dd, 1 H, 
2J = 
17.4 Hz, 3J = 3.7 Hz, CHCH2CO); 3.16 (s, 3 H, CH3); 2.97 (dd, 1 H, 
2J = 17.3 Hz, 3J = 3.5 Hz, 
CHCH2CO) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 171.5 (CO); 171.3 (CO); 156.4 (CO); 144.1 (Cquart.); 143.9 
(Cquart.); 141.4 (Cquart.); 141.3 (Cquart.); 135.6 (Cquart.); 128.6; 128.4; 128.2; 127.80; 127.78; 
127.19; 127.18; 125.4; 125.3; 120.1; 67.5 (CH2Ph); 67.4 (CHCH2OCO); 61.3 (CH3); 50.5 
(CHCH2CO); 47.2 (CHCH2OCO); 34.8 (CHCH2CO); 32.0 (CH3) ppm. 
IR (ATR): ṽ = 3326 (vw); 2940 (vw); 1719 (m); 1651 (m); 1500 (m); 1449 (m); 1188 (m); 738 
(s) cm−1. 
HR-MS (ESI): m/z: 511.1846 [M + Na]+ (cal. 511.1840). 
MS (ESI): m/z: 511.3 [M + Na]+ (cal. 511.2); 499.0 [M + K]+ (cal. 499.1). 
9.12. Synthesis of ortho- and meta-Substituted TFMKs 
Methyl (2S)-2-(m-((N-methylmethoxyamino)carbonyl)benzoylamino)-3-phenyl-
propionate 149: 
The synthesis of m-(((1S)-1-methoxycarbonyl-2-phenylethylamino)-
carbonyl)benzoic acid 149 was performed with 0.840 g (3.89 mmol,  
1.0 equiv) ClH3N-Phe-OMe 130, 0.655 g (3.94 mmol, 1.0 equiv) 
isophthalic acid 147, 0.920 g (4.80 mmol, 1.2 equiv) EDAC, 0.655 g 
(4.85 mmol, 1.1 equiv) HOBt, 0.650 mL (0.474 g, 4.68 mmol, 1.2 equiv) 
TEA, and 25 mL DCM utilizing GP-6. After 24 h the reaction mixture 
was diluted with EtOAc. The organic layer was washed with citric acid (0.5 M, in total  
300 mL). As crude product 1.06 g (3.24 mmol, 83%) of the Phe derivative were obtained as a 
colorless solid.  
The synthesis of Weinreb amide 149 was performed with 1.06 g (3.24 mmol, 1.0 equiv) of the 
free carboxylic acid, 0.353 g (3.61 mmol, 1.1 equiv) N,O-dimethylhydroxylamine 
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hydrochloride 148, 0.760 g (3.96 mmol, 1.2 equiv) EDAC, 0.548 g (4.06 mmol, 1.3 equiv) 
HOBt, 1.00 mL (0.729 g, 7.20 mmol, 2.2 equiv) TEA, and 20 mL DCM utilizing GP-6.  
After 24 h the reaction mixture was diluted with 70 mL EtOAc. For washing a volume of  
30 mL was used. After purification via column chromatography (n-hexane:EtOAc 2:1 to 1:5) 
0.369 g (0.996 mmol, 31%) 149 were isolated as colorless oil. 
Rf: 0.36 (n-hexane:EtOAc 1:5). 
1H-NMR (400 MHz, CDCl3): δ = 8.12 (s, 1 H, C(COR)CHC(COR)); 7.92–7.86 (m, 2 H, 
CHCHCH); 7.53–7.49 (m, 1 H, CHCHCH); 7.39–7.30 (m, 3 H, HPh); 7.26–7.24 (m, 2 H, HPh); 
7.14 (bs, 1 H, NH); 5.17–5.12 (m, 1 H, CHCH2); 3.83 (s, 3 H, CH3); 3.59 (s, 3 H, CH3); 3.42 
(s, 3 H, CH3); 3.37 (dd, 1 H, 
2J = 13.9 Hz, 3J = 5.7 Hz, CHCH2); 3.28 (dd, 1 H, 
2J = 13.8 Hz, 
3J = 6.4 Hz, CHCH2) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 172.0 (CO); 168.8 (CO); 166.2 (CO); 136.0 (Cquart.); 134.3 
(Cquart.); 133.7 (Cquart.); 131.3 (CHCHCH); 129.3 (CHPh); 129.2 (CHCHCH and CHPh); 128.5 (2 
C, CHPh); 128.3 (CHCHCH); 127.1 (CHPh); 126.7 (C(COR)CHC(COR)); 61.1 (CH3); 53.7 
(CHCH2); 52.4 (CH3); 37.8 (CHCH2); 33.5 (CH3) ppm. 
IR (Film): ṽ = 3322 (m); 2952 (w); 2236 (vw); 1745 (vs); 1647 (vs); 1213 (vs); 987 (m); 728 
(s) cm−1. 
HR-MS (EI): m/z: 370.1510 (cal. 370.1539). 
2,2,2-Trifluoro-1-(nitrophenyl)-1-ethanone 154: 
After cooling 0.800 mL (0.992 g, 5.70 mmol, 1.0 equiv) trifluoroacetophenone 152 
to 0 °C a mixture of 1.80 mL HNO3 and 1.60 mL H2SO4, which was also cooled to 
0 °C, was added carefully. The resulting mixture was stirred 15 min at 0 °C, 15 min 
at r.t., and 3 h at 50 °C and afterwards poured on 30 mL icy water. The aq layer 
was extracted with 30 mL Et2O. The organic layer was washed with sat. NaHCO3 (totally  
150 mL) as well as 20 mL water and was dried finally over Na2SO4. After purification via 
column chromatography (n-hexane:EtOAc 5:1 to 1:1) 1.21 g (5.52 mmol, 97%) 154 were 
isolated (ortho-154: 0.262 g, 1.20 mmol, 21%, yellowish oil; meta-154: 0.948 g, 4.33 mmol, 
76%, yellowish solid)27. 
ortho-154: 
Rf: 0.33 (n-hexane:EtOAc 2:1). 
                                                 
27 Exact ratio of isomers determined via NMR. 
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1H-NMR (200 MHz, CDCl3): δ = 8.43–8.19 (m, 1 H); 7.99–7.71 (m, 2 H); 7.67–7.43 (m, 1 H) 
ppm.  
13C-NMR (101 MHz, CDCl3): δ = 184.2 (q, 2J = 38.6 Hz, COCF3); 146.3 (CNO2); 135.4; 132.9; 
130.4; 128.7; 124.6; 115.6 (q, 1J = 290.5 Hz, COCF3) ppm. 
meta-154: 
Rf: 0.18 (n-hexane:EtOAc 2:1). 
1H-NMR (400 MHz, CDCl3): δ = 8.90 (s, 1 H, C(COCF3)CHC(NO2)); 8.59–8.56 (m, 1 H, 
CHC(NO2)); 8.43–8.37 (m, 1 H, CHC(COCF3)); 7.82 (t, 1 H, 3J = 8.1 Hz, CHCHCH) ppm.   
13C-NMR (101 MHz, CDCl3): δ = 179.0 (q, 2J = 36.4 Hz, COCF3); 148.8 (CNO2); 135.4 (q, 5J 
= 2.1 Hz, CHC(COCF3)); 131.3 (CCOCF3); 130.8 (CHCHCH); 129.8 (CHC(NO2)); 125.1 (q, 
5J = 2.2 Hz, C(COCF3)CHC(NO2)); 116.4 (q, 
1J = 290.8 Hz, COCF3) ppm. 
IR (Film): ṽ = 3449 (s); 3095 (m); 2876 (w); 1732 (vs); 1535 (vs); 1353 (vs); 1191 (vs); 712 
(vs) cm−1. 
HR-MS (ESI): m/z: 274.0299 [M + MeOH + Na]+ (cal. 274.0298).  
Crytal structure: see Chapter 10. 
9.13. Synthesis of α-Ketoacetale 
3-Ethoxyphthalide 162a: 
0.045 g (0.301 mmol, 1.0 equiv) carboxybenzaldehyde 146 were dissolved in  
2.60 mL EtOAc. Afterwards 1.30 mL diluted hydrochloric acid were added and 
the resulting reaction mixture was stirred for 17.5 h at r.t.. The organic layer was 
diluted with 20 mL EtOAc and washed with 10 mL H2O. Befor drying the organic 
layers over Na2SO4 the aq one was extracted with 10 mL EtOAc. After purification via column 
chromatography (n-hexane:Et2O 1:1 to 0:1) 14.0 mg (0.079 mmol, 26%) 162a were isolated as 
colorless liquid. 
Rf: 0.43 (n-hexane:Et2O 1:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.90–7.88 (m, 1 H); 7.73–7.69 (m, 1 H); 7.59 (t, 2 H, 3J = 
7.6 Hz); 6.37 (s, 1 H); 4.03–3.96 (m, 1 H); 3.91–3.83 (m, 1 H); 1.33 (t, 3 H, 3J = 7.1 Hz) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 168.9; 145.2; 134.5; 130.9; 127.4; 125.6; 123.6; 102.5; 66.1; 
15.3 ppm. 
Analytic data are identical to those reported in literature.[187] 
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3-Phthalideyl acetate 162b: 
0.045 g (0.300 mmol, 1.0 equiv) carboxybenzaldehyde 146 and 0.088 g (0.300 
mmol, 1.0 equiv) amine 165 were dissolved in 4 mL PhMe. The resulting 
reaction mixture was stirred 18 h at r.t.. After addition of 28.4 µL (30.6 mg, 
0.300 mmol, 1.0 equiv) Ac2O stirring was continued for 6 h. The solvent was 
removed under reduced pressure. After purification via column 
chromatography (EtOAc) 0.036 g (0.202 mmol, 67%, 28% ee) 162b were isolated as colorless 
solid.  
Rf: 0.61 (EtOAc). 
1H-NMR (400 MHz, CDCl3): δ = 7.91 (d, 1 H, 3J = 7.6 Hz, H6); 7.74 (td, 1 H, 3J = 7.5 Hz, 4J 
= 1.0 Hz, H5); 7.64 (t, 1 H, 3J = 7.3 Hz, H4); 7.59 (d, 1 H, 3J = 7.6 Hz, H3); 7.41 (s, 1 H, 
CH(OR)2); 2.18 (s, 3 H, CH3) ppm. 
13C-NMR (101 MHz, CDCl3): δ = 169.4 (COCH3); 167.8 (CO lactone); 144.7 (C8); 134.8 (C7); 
131.2 (C6); 126.4 (C5); 125.7 (C4); 123.5 (C3); 92.6 (CH(OR)2); 20.7 (CH3) ppm. 
HR-MS (EI): m/z: 192.0422 (cal. 192.0423). 
Analytic data are identical to those reported in literature.[140c] 
Chiral GC analysis: 
Enantiomers of 162b were separated by chiral GC employing a 30 m FS-Hydrodex β-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 100 °C; Final temperature:  
190 °C; Rate: 2.00 °C/min. Retention zimes: Rt1 = 40.4 min; Rt2 = 40.8 min. 
9.14. Synthesis of Hydroxyl Prolinol Moiety 
((2S,4R)-1-Benzyl-4-hydroxy-2-pyrrolidinyl)diphenylmethanol 188: 
The synthesis of ClH3N-Pro-OMe was performed with 1.00 g (7.63 mmol,  
1.0 equiv) H2N-Pro-OH, 2.16 mL (3.54 g, 29.8 mmol, 3.9 equiv) SOCl2, and 
8 mL MeOH utilizing GP-5. At the beginning the reaction mixture was cooled 
to −20 °C. The reaction mixture was stirred for 4 d. 1.39 g (7.65 mmol, quant.) 
ClH3N-Pro-OMe were obtained as colorless solid. 
1H-NMR (400 MHz, D2O): δ = 4.73–4.68 (m, 2 H); 3.85 (s, 3 H); 3.53 (dd, 1 H, J = 8.9 Hz, J 
= 3.8 Hz); 3.44–3.40 (m, 1 H); 2.53–2.47 (m, 1 H); 2.34–2.27 (m, 1 H) ppm. 
13C-NMR (101 MHz, D2O): δ = 170.2; 69.4; 58.1; 53.8; 53.4; 36.6 ppm. 
MS (ESI): m/z: 146.1 [M + H]+ (cal. 146.1). 
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Analytic data are identical to those reported in literature.[188] 
0.150 g (0.826 mmol, 1.0 equiv) ClH3N-Pro-OMe, 0.108 mL (0.155 g, 0.908 mmol, 1.1 equiv) 
BnBr, and 0.352 mL (0.268 g, 2.07 mmol, 2.5 equiv) DiPEA were dissolved in 5 mL PhMe. 
The resulting reaction mixture was refluxed for 6 h. The biphasic system was diluted with 5 mL 
sat. NaHCO3 and extracted with EtOAc (three times 10 mL). The combined organic layers were 
dried over Na2SO4 and the solvent was removed under reduced pressure. 0.195 g (0.829 mmol, 
quant.) benzyl-protected Pro 187 were obtained as brownish oil. The crude product was used 
without further purification. 
1H-NMR (400 MHz, CDCl3): δ = 7.32–7.26 (m, 5 H); 4.47–4.42 (m, 1 H); 3.91 (d, 1 H, J = 
12.8 Hz); 3.69–3.60 (m, 2 H); 3.65 (s, 3 H); 3.33 (dd, 1 H, J = 10.2 Hz, J = 5.7 Hz); 2.49 (dd, 
1 H, J = 10.2 Hz, J = 3.8 Hz); 2.29–2.22 (m, 1 H); 2.12–2.05 (m, 1 H) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 173.9; 137.8; 129.1; 128.3; 127.3; 70.2; 63.6; 61.1; 58.1; 
51.8; 39.6 ppm. 
Analytic data are identical to those reported in literature.[149b] 
20% of a solution consisting of 0.403 mL (0.601 g, 3.83 mmol, 4.5 equiv) PhBr in 2 mL anhyd. 
Et2O were added to 0.093 g (3.83 mmol, 4.5 equiv) Mg and a little amount of iodine stirred in 
9 mL anhyd. Et2O. The mixture was refluxed and the rest of the bromide solution was added 
once a misting was observable. After the Mg reacted completely 0.200 g (0.850 mmol,  
1.0 equiv) of the Bn-protected Pro 187 dissolved in 5 mL THF was added slowly. After 4 h the 
reaction was quenched with 10 mL sat. NH4Cl and the aq layer was extracted with EtOAc  
(three times 10 mL). The combined organic layers were dried over Na2SO4 and the solvent was 
removed under reduced pressure. After purification via column chromatography (DCM:EtOAc 
3:1) 0.162 g (0.409 mmol, 48%) hydrochloride 188 were isolated as orange oil. 
Rf: 0.06 (DCM:EtOAc 3:1). 
1H-NMR (400 MHz, CDCl3): δ = 7.77 (d, 2 H, J = 8.5 Hz); 7.60–7.58 (m, 2 H); 7.30–7.09 (m, 
9 H); 7.04–7.02 (d, 2 H); 4.95 (s, 1 H); 4.45–4.35 (m, 1 H); 4.28–4.22 (m, 1 H); 3.31 (s, 2 H); 
3.08 (dd, 1 H, J = 11.1 Hz, J = 4.6 Hz); 2.52 (ddd, 1 H, J = 11.2 Hz, J = 4.0 Hz, J = 1.1 Hz); 
1.88 (s, 2 H); 1.56 (s, 1 H) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 147.7; 146.0; 139.5; 128.5; 128.3; 128.2; 128.1; 126.9; 
126.6; 126.4; 125.6; 125.4; 76.8; 70.9; 70.4; 62.1; 61.2; 38.7 ppm. 
MS (ESI): m/z: 360.2 [M + H]+ (cal. 360.2). 
Analytic data are identical to those reported in literature.[149a] 
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9.15. Sulfoxidation 
9.15.1. Racemic Synthesis of Sulfoxides 
General Procedure (GP-22): 
1.0 equiv sulfide was dissolved in 4 mL acetonitrile. 1.0 equiv TMSCl and 1.0 equiv H2O2 
(30%) were added in one portion. The resulting mixture was stirred at r.t. until observing full 
conv. via TLC. The reaction was quenched by adding water and DCM. After phase separation, 
washing with DCM, and drying over Na2SO4 the solvent was evaporated under reduced.  
The crude product was purified via column chromatography. 
1-Methyl-4-(methylsulfinyl)benzene 212a: (GP-22) 
The reaction was performed with 0.097 mL (0.100 g, 0.721 mmol, 1.0 equiv) 
sulfide 211a, 0.092 mL (0.079 g, 0.725 mmol, 1.0 equiv) TMSCl, and  
0.148 mL (0.049 g, 1.24 mmol, 2.0 equiv) H2O2 (30%) for 17 h. For quenching 
10 mL water and 10 mL DCM were used. After purification via column 
chromatography (n-hexane:EtOAc 1:5 to 1:15) 67.8 mg (0.440 mmol, 61%) 212a were isolated 
as colorless oil. 
Rf: 0.10 (n-hexane:EtOAc 1:5). 
1H-NMR (200 MHz, CDCl3): δ = 7.48−7.44 (m, 2 H); 7.27−7.23 (m, 2 H); 2.62 (s, 3 H); 2.33 
(s, 3 H) ppm.  
13C-NMR (50 MHz, CDCl3): δ = 142.4; 141.5; 130.0; 123.5; 44.0; 21.4 ppm. 
Analytic data are identical to those reported in literature.[189] 
Chiral GC analysis: 
Enantiomers of 212a were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 130 °C; Initial time: 40 min. 
Retention times: Rt1 = 33.2 min; Rt2 = 35.0 min. 
1-Methoxy-4-(methylsulfinyl)benzene 212b: (GP-22) 
The reaction was performed with 0.090 mL (0.100 g, 0.648 mmol, 1.0 equiv) 
sulfide 211b, 0.082 mL (0.070 g, 0.646 mmol, 1.0 equiv) TMSCl, and  
0.132 mL (0.044 g, 1.29 mmol, 2.0 equiv) H2O2 (30%) for 7 h. For quenching 
5 mL water and 4 mL DCM were used. After purification via column 
chromatography (n-hexane:EtOAc 2:1 to 1:15) 95.0 mg (0.558 mmol, 86%) 212b were isolated 
as colorless oil. 
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Rf: 0.30 (n-hexane:EtOAc 1:5). 
1H-NMR (400 MHz, CDCl3): δ = 7.52−7.50 (m, 2 H); 6.96−6.94 (m, 2 H); 3.77 (s, 3 H); 2.62 
(s, 3 H) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 161.9; 136.5; 125.4; 114.8; 55.5; 43.9 ppm. 
Analytic data are identical to those reported in literature.[189] 
Chiral GC analysis: 
Enantiomers of 212b were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 170 °C; Initial time: 30 min. 
Retention times: Rt1 = 17.1 min; Rt2 = 17.5 min. 
4-(Methylsulfinyl)benzonitrile 212c: (GP-22) 
The reaction was performed with 0.103 g (0.690 mmol, 1.0 equiv) sulfide 
211c, 0.085 mL (0.073 g, 0.670 mmol, 1.0 equiv) TMSCl, and 0.136 mL 
(0.045 g, 1.33 mmol, 1.9 equiv) H2O2 (30%) for 6.5 h. For quenching 5 mL 
water and 4 mL DCM were used. After purification via column 
chromatography (n-hexane:EtOAc 2:1 to 1:10) 94.0 mg (0.569 mmol, 85%) 212c were isolated 
as colorless solid. 
Rf: 0.33 (n-hexane:EtOAc 1:5). 
1H-NMR (400 MHz, CDCl3): δ = 7.80−7.78 (m, 2 H); 7.74−7.72 (m, 2 H); 2.72 (s, 3 H) ppm.  
13C-NMR (101 MHz, CDCl3): δ = 151.5; 133.0; 124.3; 117.7; 114.7; 43.8 ppm. 
IR (KBr): ṽ = 2992 (w); 2235 (s); 1488 (m); 1082 (vs); 1048 (vs); 832 (s); 553 (s) cm−1. 
HR-MS(EI): m/z = 165.0240 (calc.: m/z = 165.0248). 
Analytic data are identical to those reported in literature.[189] 
Chiral GC analysis: 
Enantiomers of 212c were separated by chiral GC employing a 30 m FS-Hydrodex γ-TBDAc 
column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. 
Precolumn pressure = 0.8 bar. Conditions: Initial temperature: 180 °C; Initial time: 30 min. 
Retention times: Rt1 = 23.9 min; Rt2 = 24.9 min.  
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(Methylsulfinyl)benzene 212d: 
Chiral GC analysis: 
Enantiomers of 212d were separated by chiral GC employing a 30 m FS-Hydrodex 
γ-DiMOM column (Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow 
= 80 mL/min. Precolumn pressure = 0.8 bar. Conditions: Initial temperature:  
100 °C; Final temperature: 170 °C; Rate: 2.00 °C/min. Retention times: Rt1 = 28.2 min;  
Rt2 = 34.2 min. 
9.15.2. Overoxidation to Sulfone 213d 
Methylsulfonyl benzene 213d: 
After dissolving 0.126 g (0.563 mmol, 1.1 equiv) mCPBA in 3.2 mL DCM  
58.6 µL (61.9 mg, 0.499 mmol, 1.0 equiv) sulfide 211d were added.  
Further 0.123 g (0.549 mmol, 1.1 equiv) mCPBA were added after 1 h.  
After an additional hour the reaction mixture was diluted with 22 mL Et2O.  
The organic layer was washed with sat. NaHCO3 (three times 22 mL). The combined aq layers 
were extracted with 22 mL Et2O. After drying the combined organic layers over Na2SO4  
the solvent was removed under reduced pressure. After purifaction via column chromatography 
(Et2O) 66.0 mg (0.422 mmol, 85%) sulfone 213d were isolated as colorless oil. 
Rf: 0.72 (EtOAc). 
1H-NMR (200 MHz, CDCl3): δ = 7.94−7.90 (m, 2 H); 7.69−7.51 (m, 3 H); 3.04 (s, 3 H) ppm.  
13C-NMR (50 MHz, CDCl3): δ = 140.6; 133.8; 129.4; 127.4; 44.5 ppm. 
Analytic data are identical to those reported in literature.[190] 
Chiral GC analysis: 
213d was also injected on the chiral GC employing a 30 m FS-Hydrodex γ-DiMOM column 
(Macherey-Nagel). T (Injector + Detector) = 250 °C. Splitflow = 80 mL/min. Precolumn 
pressure = 0.8 bar. Conditions: Initial temperature: 100 °C; Final temperature: 170 °C; Rate: 
2.00 °C/min. Retention time: Rt = 35.8 min. 
9.16. Catalytic Sulfoxidation 
9.16.1. Dioxirane-Based Sulfoxidation 
Before adding 1.0 equiv sulfide and 5.0 equiv H2O2 (30%) the utilized cat. was dissolved in 
MeCN or a mixture of toluene and MeCN. The resulting reaction mixture was stirred at r.t. and 
small samples were taken and analyzed directly via chiral GC. 
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9.16.2. Peracid-Based Sulfoxidation 
The used cat. was dissolved in the corresponding solvent before adding 1.0 equiv sulfide.  
The reaction was started with the addition of DIC and 5.0 equiv of H2O2 (30%). Afterwards the 
resulting reaction mixture was stirred at r.t. or 0 °C. Small samples were taken and analyzed 
directly via chiral GC.  
9.16.3. Cooperative Catalysis Concept and PTC-Based Sulfoxidation 
1.0 equivalent Oxone® and 0.2 equiv of PTC and/or 0.2 equiv TUC were suspended in 1 mL 
anhyd. solvent or in 2 mL of a 1:1-mixture of distilled solvent and water. If the reaction was 
performed in the absence of water besides anhyd. solvent the reaction vessel was fluted with 
Ar. After adding 1.0 equiv sulfide the reaction mixture was stirred at r.t.. Small samples were 
taken and investigated directly via chiral GC. 
9.16.4. Thiourea-Based Sulfoxidation 
0.1 equiv of the TUC were dissolved in the corresponding anhyd. solvent before adding  
1.0 equiv sulfide. The reaction was started by addition of 1.2 equiv of tert-butyl hydroperoxide 
(5.0-6.0 M in decane). Afterwards the resulting reaction mixture was stirred at r.t..  
Small samples were taken and analyzed directly via chiral GC. 
9.17. Synthesis of PTC 218 
(1S,2S,4S,5R)-1-benzyl-2-((R)-hydroxy(6-methoxyquinolin-4-yl)methyl)-5-
vinylquinuclidin-1-ium bromide 218: 
11.5 g (0.035 mol, 1.0 equiv) tertiary amine 217 were dissolved in  
350 mL THF. Afterwards 4.00 mL (5.75 g, 0.034 mol, 1.0 equiv) BnBr 
were added. The resulting mixture was refluxed for 4.5 h. While pouring 
the solution in 900 mL Et2O a colorless solid formed, which was 
separated via filtration and washed with 200 mL Et2O. The crude product 
was dissolved in 250 mL boiling MeOH. After reaching 40 °C 130 mL Et2O were added and 
the product started to crystallize. The crystals were filtered, washed with Et2O, and dried over 
night in vacuum. The reaction mixture and the mother liquor were concentrated and the formed 
solid was treated in the aforementioned way. 15.1 g (0.030 mol, 90%) bromide 218 were 
obtained as a slightly purple solid. 
m.p.: 167.5−169.1 ° C (lit.: 168−170 °C). 
1H-NMR (400 MHz, DMSO-d6): δ = 8.81 (d, 1 H, J = 4.5 Hz); 8.02 (d, 1 H, J = 9.2 Hz); 7.76 
(d, 1 H, J = 4.5 Hz); 7.74−7.66 (m, 2 H); 7.62−7.54 (m, 3 H); 7.50 (dd, 1 H, J = 9.2 Hz, J = 2.4 
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Hz); 7.40 (d, 1 H, J = 2.2 Hz); 6.71 (d, 1 H, J = 3.8 Hz); 6.63−6.56 (m, 1 H); 5.74 (ddd, 1 H, J 
= 17.3 Hz, J = 10.4 Hz, J = 6.9 Hz); 5.44 (d, 1 H, J = 12.1 Hz); 5.11 (d, 1 H, J = 17.2 Hz); 5.00 
(d, 1 H, J = 10.5 Hz); 4.72 (d, 1 H, J = 12.2 Hz); 4.31−4.19 (m, 1 H); 4.02 (s, 3 H); 3.92−3.83 
(m, 1 H); 3.76−3.65 (m, 1 H); 3.30 (d, 1 H, J = 12.1 Hz); 3.26−3.14 (m, 1 H); 2.75−2.64 (m, 1 
H); 2.23 (dd, 1 H, J = 10.7 Hz, J = 4.0 Hz); 2.14 (dd, 1 H, J = 15.8 Hz, J = 9.6 Hz); 2.04−1.96 
(m, 1 H); 1.83 (t, 1 H, J = 10.2 Hz); 1.45 (t, 1 H, J = 11.8 Hz) ppm.  
13C-NMR (100 MHz, DMSO-d6): δ = 157.4; 147.5; 143.8; 143.7; 138.0; 133.6; 131.5; 130.2; 
129.1; 127.9; 125.4; 121.5; 120.3; 116.6; 102.1; 68.4; 63.6; 63.3; 59.1; 55.6; 50.7; 37.0; 26.0; 
24.2; 20.3 ppm. 
Analytic data are identical to those reported in literature.[146] 
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10. NMR spectra 
1-(o-Fluorophenylmethylthioamino)-1-ethanone 9a: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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1-(o-Chlorophenylmethylthioamino)-1-ethanone 9b: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
220 
 
1-(o-Bromophenylmethylthioamino)-1-ethanone 9c: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Boc-PMH-AdGly-Cha-Ala-OMe 11: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
222 
 
cis-2-Hydroxycyclohexyl crotonate 18: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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trans-2-Hydroxycyclohexyl (E)-3-pentenoate 20a: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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trans-2-Hydroxycyclohexyl 4-pentenoate 20b: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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cis-2-Hydroxycyclohexyl (E)-3-pentenoate 21a: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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cis-2-Hydroxycyclohexyl 4-pentenoate 21b: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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trans-2-Hydroxycyclohexyl 3-methyl-2-oxiranecarboxylate 22:28 (DS1) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (50 MHz, CDCl3) 
 
                                                 
28 Minimal traces of mCBA present in the spectrum. 
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trans-2-Hydroxycyclohexyl 3-methyl-2-oxiranecarboxylate 22:29 (DS2) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (50 MHz, CDCl3) 
 
                                                 
29 Minimal traces of mCBA present in the spectrum. 
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cis-2-Hydroxycyclohexyl 3-methyl-2-oxiranecarboxylate 23:30 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
                                                 
30 Minimal traces of mCBA present in the spectrum. 
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trans-2-Hydroxycyclohexyl (3-methyl-2-oxiranyl)acetate 24a: (DS1) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
231 
 
trans-2-Hydroxycyclohexyl (3-methyl-2-oxiranyl)acetate 24a: (DS2) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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trans-2-Hydroxycyclohexyl 3-(2-oxiranyl)propionate 24b: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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cis-2-Hydroxycyclohexyl (3-methyl-2-oxiranyl)acetate 25a: (DS1) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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cis-2-Hydroxycyclohexyl (3-methyl-2-oxiranyl)acetate 25a: (DS2) 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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cis-2-Hydroxycyclohexyl 3-(2-oxiranyl)propionate 25b: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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cis-2-Hydroxycyclohexyl 3-phenylbutyrate 27: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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trans-2-Hydroxycyclohexyl (E)-4-hydroxy-2-pentenoate 31: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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cis-2-Hydroxycyclohexyl (E)-4-hydroxy-2-pentenoate 32: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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trans-2-Acetoxycyclohexyl (E)-3-pentenoate 33: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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cis-2-Acetoxycyclohexyl (E)-3-pentenoate 34: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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trans-2-Acetoxycyclohexyl (3-methyl-2-oxiranyl)acetate 35: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
242 
 
cis-2-Acetoxycyclohexyl (3-methyl-2-oxiranyl)acetate 36: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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1-Cyclohexylcyclohexene 40: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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1-Cyclohexyl-7-oxabicyclo[4.1.0]heptane 41: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
 
245 
 
Cyclohex-1-en-1-ylmethyl ethylcarbamate 52c: 
1H-NMR (600 MHz, CDCl3) 
 
13C-NMR (151 MHz, CDCl3) 
 
 
246 
 
Cyclohex-1-en-1-ylmethyl isopropylcarbamate 52d: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Cyclohex-1-en-1-ylmethyl tert-butylcarbamate 52e: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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1-(Benzyloxycarbonylamino)-1-cyclohexen-3-one 66: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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6-Hydroxy-1,3-dioxaspiro[4.5]decan-2-one 75: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
250 
 
Boc-Asp(OH)-AdGly-Cha-OMe 96:31 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
                                                 
31 Spektrum contains tBuOH (1.27 ppm) 
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Boc-Phe-AdGly-Asp(OH)-Phe-OMe 100: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
 
252 
 
Boc-Val-Pro-Asp(OH)-OH 102: 
1H-NMR (200 MHz, CDCl3) 
 
13C-NMR (151 MHz, CDCl3) 
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2,2,2-Trifluoro-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-1-ethanone 114: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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2,2,2-Trifluoro-1-(p-((1,2,3,4-tetrahydronaphth-1-ylamino)carbonyl)phenyl)-1-ethanone 
115: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Boc-Lys(CM)-AdGly-Cha-Phe-OMe 122: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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1-(p-(((1S,2S)-2-(p-(2,2,2-Trifluoroacetyl)benzoylamino)cyclohexylamino) 
carbonyl)phenyl)-2,2,2-trifluoro-1-ethanone 128: 
1H-NMR (600 MHz, CDCl3) 
 
13C-NMR (151 MHz, CDCl3) 
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1-(p-(((1R,2R)-2-(p-(2,2,2-Trifluoroacetyl)benzoylamino)cyclohexylamino)carbonyl) 
phenyl)-2,2,2-trifluoro-1-ethanone 129: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Methyl (2S)-3-phenyl-2-(p-(2,2,2-trifluoroacetyl)benzoylamino)propionate 131: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
259 
 
Boc-Lys(CM)-OMe 137: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Boc-AdGly-Dap(Cbz)-Phe-OMe 142: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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Methyl (2S)-2-(m-((N-methylmethoxyamino)carbonyl)benzoylamino)-3-phenyl-
propionate 149: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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2,2,2-Trifluoro-1-(o-nitrophenyl)-1-ethanone ortho-154: 
1H-NMR (200 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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2,2,2-Trifluoro-1-(m-nitrophenyl)-1-ethanone meta-154: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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1-(o-Aminophenyl)-2,2,2-trifluoro-1-ethanol ortho-155: 
1H-NMR (400 MHz, CDCl3 and MeOD-d4) 
 
13C-NMR (101 MHz, CDCl3 and MeOD-d4) 
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1-(m-Aminophenyl)-2,2,2-trifluoro-1-ethanol meta-155: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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(1S)-1-Benzyl-2-oxo-2-(m-(2,2,2-trifluoroacetyl)phenylamino)ethylamino 2,2-
dimethylpropionate meta-161: 
1H-NMR (600 MHz, CDCl3) 
 
13C-NMR (151 MHz, CDCl3) 
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Methyl (2S)-3-cyclohexyl-2-(p-(2,2,2-trifluoroacetyl)benzoylamino)propionate 166: 
1H-NMR (600 MHz, MeOH-d4) 
 
13C-NMR (151 MHz, MeOH-d4) 
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Benzyl (2S)-4-(N-methylmethoxyamino)-2-((9H-fluoren-9-yl)methoxycarbonylamino)-4-
oxo-butyrate 168: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
 
269 
 
Boc-Leu-Phe-((3S)-N-benzylquinuclidinium) bromide 182: 
1H-NMR (400 MHz, MeOD-d4) 
 
13C-NMR (101 MHz, MeOD-d4) 
 
 
270 
 
Boc-Leu-Phe-Thr-((3S)-N-benzylquinuclidinium) bromide 185: 
1H-NMR (400 MHz, MeOD-d4) 
 
13C-NMR (101 MHz, MeOD-d4) 
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Boc-Phe-((2S,4R)-4-oxy-2-pyrrolidinyl)diphenylmethanol 189: 
1H-NMR (400 MHz, CDCl3) 
 
13C-NMR (101 MHz, CDCl3) 
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CM-AdGly-Val-Phe-OMe 214: 
1H-NMR (600 MHz, CDCl3) 
 
13C-NMR (151 MHz, CDCl3) 
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Terephthalic acid-AdGly-Val-Phe-OMe 215: 
1H-NMR (600 MHz, CDCl3) 
 
13C-NMR (151 MHz, CDCl3) 
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11. Crystal Structures 
Cyclohex-1-en-1-ylmethyl tert-butylcarbamate 52e: 
 
Table 48: Crystal data and structure refinement for mo_schr15036_0m_a. 
Identification code  mo_schr15036_0m_a  
Empirical formula  C12 H21 N O2  
Formula weight  211.30  
Temperature  100(2) K  
Wavelength  0.71073 Å  
Crystal system  Orthorhombic  
Space group  Pbca  
Unit cell dimensions a = 9.6757(4) Å = 90°.
 b = 11.4499(5) Å = 90°.
 c = 22.0810(10) Å  = 90°.
Volume 2446.26(18) Å3  
Z 8  
Density (calculated) 1.147 Mg/m3  
Absorption coefficient 0.077 mm-1  
F(000) 928  
Crystal size 0.282 x 0.079 x 0.064 mm3  
Theta range for data collection 2.799 to 25.076°.  
Index ranges 
-11<=h<=11, -13<=k<=13, -
26<=l<=26  
Reflections collected 22049  
Independent reflections 2166 [R(int) = 0.0635]  
Completeness to theta = 
25.242° 
98.1 %  
 
Absorption correction Semi-empirical from equivalents  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 2166 / 0 / 140  
Goodness-of-fit on F2 1.447  
Final R indices [I>2sigma(I)] R1 = 0.1093, wR2 = 0.2796  
R indices (all data) R1 = 0.1223, wR2 = 0.2931  
Extinction coefficient 0.109(12)  
Largest diff. peak and hole 0.652 and -0.663 e.Å-3  
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Table 49: Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for mo_schr15036_0m_a.  
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x Y z U(eq) 
O(001) 868(3) 4463(3) 7301(1) 20(1) 
O(002) 2863(3) 3953(3) 6846(1) 16(1) 
N(003) 2950(4) 5186(3) 7612(2) 17(1) 
C(004) 2113(4) 4539(4) 7268(2) 13(1) 
C(005) 2980(4) 2835(4) 5934(2) 15(1) 
C(006) 3101(5) 1705(4) 5805(2) 19(1) 
C(007) 3696(5) 3758(4) 5568(2) 22(1) 
C(008) 4807(5) 3277(4) 5152(2) 22(1) 
C(009) 2514(5) 5836(4) 8159(2) 17(1) 
C(00A) 2061(5) 3232(4) 6439(2) 20(1) 
C(00B) 3917(6) 1243(4) 5280(2) 29(1) 
C(00C) 1324(6) 6664(5) 8017(2) 32(1) 
C(00D) 4291(6) 2201(5) 4829(2) 28(1) 
C(00E) 3765(6) 6571(6) 8345(3) 39(2) 
C(00F) 2110(7) 4974(5) 8649(2) 40(2) 
 
Table 50: Bond lengths [Å] and angles [°] for mo_schr15036_0m_a. 
O(001)-C(004) 1.210(5) C(009)-C(00C) 1.524(7) 
O(002)-C(004) 1.358(5) C(009)-C(00E) 1.531(7) 
O(002)-C(00A) 1.446(5) C(00A)-H(00E) 0.9900 
N(003)-C(004) 1.335(5) C(00A)-H(00F) 0.9900 
N(003)-C(009) 1.480(5) C(00B)-C(00D) 1.524(7) 
N(003)-H(003) 0.8800 C(00B)-H(00G) 0.9900 
C(005)-C(006) 1.330(7) C(00B)-H(00H) 0.9900 
C(005)-C(00A) 1.498(6) C(00C)-H(00I) 0.9800 
C(005)-C(007) 1.499(6) C(00C)-H(00J) 0.9800 
C(006)-C(00B) 1.498(6) C(00C)-H(00K) 0.9800 
C(006)-H(006) 0.9500 C(00D)-H(00L) 0.9900 
C(007)-C(008) 1.517(7) C(00D)-H(00M) 0.9900 
C(007)-H(00A) 0.9900 C(00E)-H(00N) 0.9800 
C(007)-H(00B) 0.9900 C(00E)-H(00O) 0.9800 
C(008)-C(00D) 1.509(7) C(00E)-H(00P) 0.9800 
C(008)-H(00C) 0.9900 C(00F)-H(00Q) 0.9800 
C(008)-H(00D) 0.9900 C(00F)-H(00R) 0.9800 
C(009)-C(00F) 1.517(7) C(00F)-H(00S) 0.9800 
 
C(004)-O(002)-C(00A) 114.9(3) O(002)-C(00A)-H(00F) 110.0 
C(004)-N(003)-C(009) 124.7(4) C(005)-C(00A)-H(00F) 110.0 
C(004)-N(003)-H(003) 117.6 H(00E)-C(00A)-H(00F) 108.4 
C(009)-N(003)-H(003) 117.6 C(006)-C(00B)-C(00D) 112.1(4) 
O(001)-C(004)-N(003) 127.6(4) C(006)-C(00B)-H(00G) 109.2 
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O(001)-C(004)-O(002) 122.5(4) C(00D)-C(00B)-H(00G) 109.2 
N(003)-C(004)-O(002) 109.9(3) C(006)-C(00B)-H(00H) 109.2 
C(006)-C(005)-C(00A) 120.5(4) C(00D)-C(00B)-H(00H) 109.2 
C(006)-C(005)-C(007) 122.0(4) H(00G)-C(00B)-H(00H) 107.9 
C(00A)-C(005)-C(007) 117.5(4) C(009)-C(00C)-H(00I) 109.5 
C(005)-C(006)-C(00B) 123.7(4) C(009)-C(00C)-H(00J) 109.5 
C(005)-C(006)-H(006) 118.1 H(00I)-C(00C)-H(00J) 109.5 
C(00B)-C(006)-H(006) 118.1 C(009)-C(00C)-H(00K) 109.5 
C(005)-C(007)-C(008) 113.4(4) H(00I)-C(00C)-H(00K) 109.5 
C(005)-C(007)-H(00A) 108.9 H(00J)-C(00C)-H(00K) 109.5 
C(008)-C(007)-H(00A) 108.9 C(008)-C(00D)-C(00B) 111.0(4) 
C(005)-C(007)-H(00B) 108.9 C(008)-C(00D)-H(00L) 109.4 
C(008)-C(007)-H(00B) 108.9 C(00B)-C(00D)-H(00L) 109.4 
H(00A)-C(007)-H(00B) 107.7 C(008)-C(00D)-H(00M) 109.4 
C(00D)-C(008)-C(007) 110.4(4) C(00B)-C(00D)-H(00M) 109.4 
C(00D)-C(008)-H(00C) 109.6 H(00L)-C(00D)-H(00M) 108.0 
C(007)-C(008)-H(00C) 109.6 C(009)-C(00E)-H(00N) 109.5 
C(00D)-C(008)-H(00D) 109.6 C(009)-C(00E)-H(00O) 109.5 
C(007)-C(008)-H(00D) 109.6 H(00N)-C(00E)-H(00O) 109.5 
H(00C)-C(008)-H(00D) 108.1 C(009)-C(00E)-H(00P) 109.5 
N(003)-C(009)-C(00F) 109.2(4) H(00N)-C(00E)-H(00P) 109.5 
N(003)-C(009)-C(00C) 111.2(4) H(00O)-C(00E)-H(00P) 109.5 
C(00F)-C(009)-C(00C) 110.9(4) C(009)-C(00F)-H(00Q) 109.5 
N(003)-C(009)-C(00E) 105.7(4) C(009)-C(00F)-H(00R) 109.5 
C(00F)-C(009)-C(00E) 111.6(5) H(00Q)-C(00F)-H(00R) 109.5 
C(00C)-C(009)-C(00E) 108.1(4) C(009)-C(00F)-H(00S) 109.5 
O(002)-C(00A)-C(005) 108.6(4) H(00Q)-C(00F)-H(00S) 109.5 
O(002)-C(00A)-H(00E) 110.0 H(00R)-C(00F)-H(00S) 109.5 
C(005)-C(00A)-H(00E) 110.0   
 
Table 51: Anisotropic displacement parameters (Å2x 103) for mo_schr15036_0m_a. The anisotropic displacement factor 
exponent takes the form: -2p2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 U11 U22 U33 U23 U13 U12 
O(001) 7(2) 26(2) 26(2) -12(1) 1(1) 0(1) 
O(002) 7(2) 24(2) 17(2) -11(1) 0(1) -1(1) 
N(003) 7(2) 25(2) 19(2) -10(2) 1(1) 1(2) 
C(004) 15(2) 12(2) 12(2) -1(2) -1(2) 2(2) 
C(005) 10(2) 20(2) 13(2) -3(2) -3(2) 1(2) 
C(006) 20(2) 18(2) 20(2) -3(2) 6(2) -7(2) 
C(007) 32(3) 14(2) 20(2) 0(2) 0(2) 4(2) 
C(008) 30(3) 18(2) 19(2) 3(2) 6(2) -2(2) 
C(009) 15(2) 19(2) 16(2) -9(2) 0(2) 1(2) 
C(00A) 16(2) 25(3) 20(2) -11(2) -4(2) -3(2) 
C(00B) 33(3) 20(3) 33(3) -14(2) 10(2) -6(2) 
C(00C) 37(3) 28(3) 29(3) -15(2) -7(2) 10(2) 
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C(00D) 31(3) 32(3) 20(2) -6(2) 10(2) -5(2) 
C(00E) 22(3) 54(4) 42(3) -36(3) -2(2) 2(3) 
C(00F) 76(5) 29(3) 16(2) -1(2) 5(3) 3(3) 
 
Table 52: Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for mo_schr15036_0m_a. 
 x Y z U(eq) 
H(003) 3826 5229 7506 20 
H(006) 2645 1159 6060 23 
H(00A) 4120 4331 5847 27 
H(00B) 3000 4176 5321 27 
H(00C) 5068 3879 4851 27 
H(00D) 5639 3080 5392 27 
H(00E) 1274 3684 6275 24 
H(00F) 1689 2548 6659 24 
H(00G) 3371 634 5070 34 
H(00H) 4775 876 5432 34 
H(00I) 1561 7141 7663 48 
H(00J) 1159 7175 8366 48 
H(00K) 488 6211 7931 48 
H(00L) 5016 1912 4551 33 
H(00M) 3468 2403 4585 33 
H(00N) 4558 6057 8417 59 
H(00O) 3549 7001 8717 59 
H(00P) 3988 7124 8021 59 
H(00Q) 1332 4498 8508 60 
H(00R) 1839 5401 9015 60 
H(00S) 2898 4467 8741 60 
 
1-(Benzyloxycarbonylamino)-1-cyclohexen-3-one 66: 
 
Table 53: Crystal data and structure refinement for schr15033. 
Identification code  schr15033  
Empirical formula  C14 H15 N O3  
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Formula weight  245.27  
Temperature  99(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  P21/n  
Unit cell dimensions a = 7.1379(4) Å = 90°.
 b = 17.4393(10) Å = 106.555(2)°.
 c = 10.4161(5) Å  = 90°.
Volume 1242.85(12) Å3  
Z 4  
Density (calculated) 1.311 Mg/m3  
Absorption coefficient 0.093 mm-1  
F(000) 520  
Crystal size 0.559 x 0.325 x 0.198 mm3  
Theta range for data collection 3.093 to 25.064°.  
Index ranges -8<=h<=8, -20<=k<=20, -12<=l<=12  
Reflections collected 32806  
Independent reflections 2214 [R(int) = 0.0908]  
Completeness to theta = 25.064° 99.9 %   
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.7425 and 0.7053  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 2214 / 0 / 167  
Goodness-of-fit on F2 1.090  
Final R indices [I>2sigma(I)] R1 = 0.0398, wR2 = 0.0922  
R indices (all data) R1 = 0.0501, wR2 = 0.0963  
Extinction coefficient n/a  
Largest diff. peak and hole 0.171 and -0.281 e.Å-3  
 
Table 54: Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for schr15033. U(eq) is 
defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
O(1) 11408(2) 7265(1) 3786(1) 31(1) 
N(1) 6956(2) 7104(1) 6402(1) 16(1) 
C(1) 10798(2) 7518(1) 4704(2) 22(1) 
O(2) 5988(2) 6116(1) 4888(1) 22(1) 
C(2) 11852(3) 8160(1) 5588(2) 31(1) 
C(3) 10514(2) 8612(1) 6216(2) 27(1) 
O(3) 4662(2) 6303(1) 6595(1) 18(1) 
C(4) 9434(2) 8076(1) 6906(2) 22(1) 
C(5) 8473(2) 7427(1) 6017(1) 15(1) 
C(6) 9100(2) 7186(1) 4973(1) 17(1) 
C(7) 5882(2) 6469(1) 5860(1) 15(1) 
C(9) 1990(2) 5575(1) 6938(1) 17(1) 
C(8) 3384(2) 5658(1) 6108(2) 25(1) 
C(10) 815(2) 4921(1) 6751(2) 21(1) 
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C(11) -539(2) 4823(1) 7458(2) 26(1) 
C(12) -744(2) 5373(1) 8366(2) 27(1) 
C(13) 419(2) 6021(1) 8555(2) 29(1) 
C(14) 1776(2) 6122(1) 7847(2) 22(1) 
 
Table 55: Bond lengths [Å] and angles [°] for schr15033. 
O(1)-C(1) 1.2389(18) C(3)-C(4) 1.517(2) C(9)-C(14) 1.383(2) C(12)-H(12) 0.9500 
N(1)-C(7) 1.3725(19) C(3)-H(3A) 0.9900 C(9)-C(10) 1.395(2) C(13)-C(14) 1.386(2) 
N(1)-C(5) 1.3784(18) C(3)-H(3B) 0.9900 C(9)-C(8) 1.500(2) C(13)-H(13) 0.9500 
N(1)-H(1) 0.862(18) O(3)-C(7) 1.3454(17) C(8)-H(8A) 0.9900 C(14)-H(14) 0.9500 
C(1)-C(6) 1.440(2) O(3)-C(8) 1.4461(17) C(8)-H(8B) 0.9900   
C(1)-C(2) 1.508(2) C(4)-C(5) 1.499(2) C(10)-C(11) 1.383(2)   
O(2)-C(7) 1.2056(17) C(4)-H(4A) 0.9900 C(10)-H(10) 0.9500   
C(2)-C(3) 1.522(2) C(4)-H(4B) 0.9900 C(11)-C(12) 1.384(2)   
C(2)-H(2A) 0.9900 C(5)-C(6) 1.3550(19) C(11)-H(11) 0.9500   
C(2)-H(2B) 0.9900 C(6)-H(6) 0.9500 C(12)-C(13) 1.383(2)   
 
C(7)-N(1)-C(5) 127.08(12) C(5)-C(4)-H(4A) 109.2 O(3)-C(8)-H(8B) 109.8 
C(7)-N(1)-H(1) 115.7(12) C(3)-C(4)-H(4A) 109.2 C(9)-C(8)-H(8B) 109.8 
C(5)-N(1)-H(1) 116.8(12) C(5)-C(4)-H(4B) 109.2 H(8A)-C(8)-H(8B) 108.3 
O(1)-C(1)-C(6) 120.46(15) C(3)-C(4)-H(4B) 109.2 C(11)-C(10)-C(9) 120.67(15) 
O(1)-C(1)-C(2) 120.80(15) H(4A)-C(4)-H(4B) 107.9 C(11)-C(10)-H(10) 119.7 
C(6)-C(1)-C(2) 118.71(13) C(6)-C(5)-N(1) 124.99(14) C(9)-C(10)-H(10) 119.7 
C(1)-C(2)-C(3) 112.46(13) C(6)-C(5)-C(4) 122.15(13) C(10)-C(11)-C(12) 120.26(15) 
C(1)-C(2)-H(2A) 109.1 N(1)-C(5)-C(4) 112.84(12) C(10)-C(11)-H(11) 119.9 
C(3)-C(2)-H(2A) 109.1 C(5)-C(6)-C(1) 121.35(14) C(12)-C(11)-H(11) 119.9 
C(1)-C(2)-H(2B) 109.1 C(5)-C(6)-H(6) 119.3 C(13)-C(12)-C(11) 119.25(15) 
C(3)-C(2)-H(2B) 109.1 C(1)-C(6)-H(6) 119.3 C(13)-C(12)-H(12) 120.4 
H(2A)-C(2)-H(2B) 107.8 O(2)-C(7)-O(3) 124.98(13) C(11)-C(12)-H(12) 120.4 
C(4)-C(3)-C(2) 110.50(13) O(2)-C(7)-N(1) 126.63(13) C(12)-C(13)-C(14) 120.65(16) 
C(4)-C(3)-H(3A) 109.6 O(3)-C(7)-N(1) 108.39(11) C(12)-C(13)-H(13) 119.7 
C(2)-C(3)-H(3A) 109.6 C(14)-C(9)-C(10) 118.69(14) C(14)-C(13)-H(13) 119.7 
C(4)-C(3)-H(3B) 109.6 C(14)-C(9)-C(8) 123.29(13) C(9)-C(14)-C(13) 120.48(14) 
C(2)-C(3)-H(3B) 109.6 C(10)-C(9)-C(8) 118.00(13) C(9)-C(14)-H(14) 119.8 
H(3A)-C(3)-H(3B) 108.1 O(3)-C(8)-C(9) 109.19(12) C(13)-C(14)-H(14) 119.8 
C(7)-O(3)-C(8) 114.44(11) O(3)-C(8)-H(8A) 109.8   
C(5)-C(4)-C(3) 112.16(12) C(9)-C(8)-H(8A) 109.8   
 
Table 56: Anisotropic displacement parameters (Å2x 103) for schr15033. The anisotropic displacement factor exponent takes 
the form: -2p2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 U11 U22 U33 U23 U13 U12 
O(1) 44(1) 30(1) 32(1) 9(1) 31(1) 12(1) 
N(1) 17(1) 21(1) 14(1) -5(1) 9(1) -4(1) 
C(1) 27(1) 22(1) 24(1) 10(1) 16(1) 10(1) 
O(2) 30(1) 20(1) 18(1) -5(1) 11(1) -5(1) 
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C(2) 25(1) 32(1) 46(1) 2(1) 24(1) -6(1) 
C(3) 26(1) 25(1) 35(1) -7(1) 16(1) -9(1) 
O(3) 17(1) 20(1) 20(1) -5(1) 9(1) -7(1) 
C(4) 18(1) 28(1) 23(1) -8(1) 12(1) -6(1) 
C(5) 12(1) 19(1) 15(1) 2(1) 6(1) 2(1) 
C(6) 20(1) 17(1) 15(1) 2(1) 8(1) 2(1) 
C(7) 15(1) 16(1) 14(1) 1(1) 4(1) 2(1) 
C(9) 15(1) 18(1) 18(1) 4(1) 3(1) 1(1) 
C(8) 27(1) 22(1) 30(1) -9(1) 14(1) -11(1) 
C(10) 21(1) 18(1) 22(1) 3(1) 4(1) -2(1) 
C(11) 21(1) 26(1) 28(1) 9(1) 3(1) -8(1) 
C(12) 19(1) 39(1) 25(1) 8(1) 10(1) -2(1) 
C(13) 27(1) 34(1) 29(1) -4(1) 14(1) -3(1) 
C(14) 21(1) 21(1) 26(1) -2(1) 9(1) -4(1) 
 
Table 57: Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for schr15033. 
 x y z U(eq) 
H(1) 6730(30) 7286(10) 7114(17) 24(4) 
H(2A) 12415 8512 5051 38 
H(2B) 12944 7943 6308 38 
H(3A) 11298 8981 6875 33 
H(3B) 9559 8906 5512 33 
H(4A) 10367 7865 7723 26 
H(4B) 8427 8370 7183 26 
H(6) 8406 6791 4407 20 
H(8A) 4166 5184 6166 30 
H(8B) 2647 5741 5158 30 
H(10) 947 4540 6131 25 
H(11) -1332 4376 7320 31 
H(12) -1673 5307 8853 33 
H(13) 286 6401 9177 34 
H(14) 2564 6570 7987 26 
 
6-Hydroxy-1,3-dioxaspiro[4.5]decan-2-one 75: 
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Table 58: Crystal data and structure refinement for schreiner14003. 
Identification code  schreiner14003  
Empirical formula  C8 H12 O4  
Formula weight  172.18  
Temperature  150(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  P 21/c  
Unit cell dimensions a = 7.4670(15) Å = 90°.
 b = 5.4625(11) Å = 95.16(3)°.
 c = 19.454(4) Å  = 90°.
Volume 790.3(3) Å3  
Z 4  
Density (calculated) 1.447 Mg/m3  
Absorption coefficient 0.116 mm-1  
F(000) 368  
Crystal size 0.380 x 0.290 x 0.200 mm3  
Theta range for data collection 2.102 to 27.510°.  
Index ranges 
-8<=h<=9, -7<=k<=6, -
24<=l<=24  
Reflections collected 9267  
Independent reflections 1792 [R(int) = 0.1243]  
Completeness to theta = 
25.242° 
99.9 %  
 
Absorption correction Empirical  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 1792 / 0 / 110  
Goodness-of-fit on F2 0.933  
Final R indices [I>2sigma(I)] R1 = 0.0455, wR2 = 0.0927  
R indices (all data) R1 = 0.0913, wR2 = 0.1073  
Extinction coefficient n/a  
Largest diff. peak and hole 0.202 and -0.261 e.Å-3  
 
Table 59: Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for schreiner14003. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
C(1) 2056(2) 6825(3) 3839(1) 22(1) 
O(1) 589(2) 7330(2) 2681(1) 38(1) 
C(2) 2290(2) 7134(3) 3076(1) 26(1) 
O(2) 1093(2) 4529(2) 3914(1) 28(1) 
C(3) 3391(3) 9407(3) 2955(1) 32(1) 
O(3) -776(2) 7307(2) 4262(1) 36(1) 
C(4) 5194(3) 9392(4) 3385(1) 33(1) 
O(4) -1626(2) 3394(2) 4207(1) 42(1) 
C(5) 4938(3) 9033(4) 4142(1) 31(1) 
C(6) 3864(2) 6711(3) 4254(1) 28(1) 
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C(7) 772(2) 8698(3) 4113(1) 29(1) 
C(8) -532(3) 4945(3) 4132(1) 29(1) 
 
Table 60: Bond lengths [Å] and angles [°] for schreiner14003. 
C(1)-O(2) 1.460(2) C(3)-C(4) 1.520(3) 
C(1)-C(6) 1.510(3) O(3)-C(8) 1.330(2) 
C(1)-C(2) 1.520(3) O(3)-C(7) 1.434(2) 
C(1)-C(7) 1.531(2) C(4)-C(5) 1.514(3) 
O(1)-C(2) 1.428(2) O(4)-C(8) 1.195(2) 
C(2)-C(3) 1.519(3) C(5)-C(6) 1.527(3) 
O(2)-C(8) 1.340(2)   
 
O(2)-C(1)-C(6) 109.62(14) O(1)-C(2)-C(1) 110.99(15) C(4)-C(5)-C(6) 111.10(17) 
O(2)-C(1)-C(2) 107.15(15) C(3)-C(2)-C(1) 110.68(16) C(1)-C(6)-C(5) 110.22(16) 
C(6)-C(1)-C(2) 110.52(15) C(8)-O(2)-C(1) 110.76(13) O(3)-C(7)-C(1) 104.92(13) 
O(2)-C(1)-C(7) 102.10(13) C(2)-C(3)-C(4) 112.04(17) O(4)-C(8)-O(3) 123.92(16) 
C(6)-C(1)-C(7) 113.52(16) C(8)-O(3)-C(7) 110.44(13) O(4)-C(8)-O(2) 124.51(16) 
C(2)-C(1)-C(7) 113.38(16) C(5)-C(4)-C(3) 110.64(15) O(3)-C(8)-O(2) 111.56(15) 
O(1)-C(2)-C(3) 108.86(16)     
 
Table 61: Anisotropic displacement parameters (Å2x 103) for schreiner14003. The anisotropic displacement factor exponent 
takes the form: -2p2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 U11 U22 U33 U23 U13 U12 
C(1) 24(1) 19(1) 25(1) 0(1) 2(1) 0(1) 
O(1) 42(1) 33(1) 36(1) 2(1) -16(1) -5(1) 
C(2) 28(1) 26(1) 24(1) 1(1) -1(1) 0(1) 
O(2) 26(1) 21(1) 37(1) 1(1) 10(1) -1(1) 
C(3) 40(1) 31(1) 27(1) 2(1) 4(1) -6(1) 
O(3) 25(1) 28(1) 56(1) -9(1) 12(1) -2(1) 
C(4) 30(1) 34(1) 37(1) -6(1) 10(1) -7(1) 
O(4) 31(1) 35(1) 61(1) -2(1) 14(1) -6(1) 
C(5) 21(1) 39(1) 33(1) -8(1) 2(1) -3(1) 
C(6) 25(1) 34(1) 24(1) 2(1) 0(1) 5(1) 
C(7) 23(1) 25(1) 40(1) -3(1) 5(1) -1(1) 
C(8) 24(1) 29(1) 34(1) 0(1) 4(1) 0(1) 
 
Table 62: Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for schreiner14003. 
 x y z U(eq) 
H(1) 195 5924 2580 46 
H(2) 2937 5671 2913 31 
H(3A) 2705 10877 3073 39 
H(3B) 3595 9509 2460 39 
H(4A) 5951 8054 3226 40 
H(4B) 5823 10961 3323 40 
H(5A) 4298 10465 4313 37 
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H(5B) 6128 8922 4409 37 
H(6A) 4538 5265 4111 34 
H(6B) 3690 6536 4750 34 
H(7A) 1331 9501 4536 35 
H(7B) 439 9970 3762 35 
 
2,2,2-Trifluoro-1-(m-nitrophenyl)-1-ethanone meta-154: 
 
Table 63: Crystal data and structure refinement for schreiner12022. 
Identification code  schreiner12022  
Empirical formula  C8 H4 F3 N O3  
Formula weight  219.12  
Temperature  190(2) K  
Wavelength  0.71073 A  
Crystal system  Orthorombic  
Space group  Pnma  
Unit cell dimensions a = 11.804(2) Å = 90°.
 b = 6.7160(13) Å = 90°.
 c = 10.677(2) Å  = 90°.
Volume 846.4(3) Å3  
Z 4  
Density (calculated) 1.720 Mg/m3  
Absorption coefficient 0.173 mm-1  
F(000) 440  
Crystal size 0.85 x 0.40 x 0.05 mm3  
Theta range for data collection 2.57 to 27.51°.  
Index ranges 
-12<=h<=15, -8<=k<=8, -
13<=l<=13  
Reflections collected 5643  
Independent reflections 1057 [R(int) = 0.0495]  
Completeness to theta = 27.51° 99.6 %   
Absorption correction Empirical  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 1057 / 0 / 100  
Goodness-of-fit on F2 1.047  
Final R indices [I>2sigma(I)] R1 = 0.0382, wR2 = 0.1029  
R indices (all data) R1 = 0.0534, wR2 = 0.1118  
Largest diff. peak and hole 0.243 and -0.240 e.Å-3  
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Table 64: Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for schreiner12022. U(eq) 
is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
F(1) -9072(1) 2500 4794(1) 64(1) 
F(2) -10215(1) 4096(1) 3598(1) 53(1) 
O(1) -7671(1) 2500 2965(2) 65(1) 
O(2) -6602(2) 2500 -1446(2) 66(1) 
O(3) -7869(2) 2500 -2873(2) 85(1) 
N(1) -7584(2) 2500 -1787(2) 47(1) 
C(1) -9010(2) 2500 1318(2) 31(1) 
C(2) -10143(2) 2500 952(2) 31(1) 
C(3) -10430(2) 2500 -306(2) 33(1) 
C(4) -9596(2) 2500 -1209(2) 33(1) 
C(5) -8477(2) 2500 -825(2) 34(1) 
C(6) -8157(2) 2500 411(2) 34(1) 
C(7) -8647(2) 2500 2643(2) 38(1) 
C(8) -9548(2) 2500 3683(2) 41(1) 
 
Table 65: Bond lengths [Å] and angles [°] for schreiner12022. 
O(2)-N(1) 1.214(3) C(4)-C(5) 1.383(3) 
O(3)-N(1) 1.208(3) C(4)-H(7) 0.91(2) 
N(1)-C(5) 1.472(3) C(5)-C(6) 1.372(3) 
C(1)-C(2) 1.394(3) C(6)-H(8) 0.96(2) 
C(1)-C(6) 1.397(3) C(7)-C(8) 1.539(3) 
C(1)-C(7) 1.478(3) C(8)-F(2)#1 1.3330(15) 
C(2)-C(3) 1.386(3)   
 
O(3)-N(1)-O(2) 123.65(19) C(4)-C(3)-H(6) 117.8(12) C(1)-C(6)-H(8) 119.6(13) 
O(3)-N(1)-C(5) 118.07(19) C(2)-C(3)-H(6) 122.0(12) O(1)-C(7)-C(1) 123.48(19) 
O(2)-N(1)-C(5) 118.29(18) C(3)-C(4)-C(5) 118.38(18) O(1)-C(7)-C(8) 117.15(19) 
C(2)-C(1)-C(6) 119.85(18) C(3)-C(4)-H(7) 121.9(15) C(1)-C(7)-C(8) 119.37(17) 
C(2)-C(1)-C(7) 123.12(17) C(5)-C(4)-H(7) 119.7(15) F(1)-C(8)-F(2) 108.35(11) 
C(6)-C(1)-C(7) 117.03(17) C(6)-C(5)-C(4) 123.21(17) F(1)-C(8)-F(2)#1 108.35(11) 
C(3)-C(2)-C(1) 120.40(17) C(6)-C(5)-N(1) 118.30(17) F(2)-C(8)-F(2)#1 107.05(17) 
C(3)-C(2)-H(5) 120.2(13) C(4)-C(5)-N(1) 118.49(17) F(1)-C(8)-C(7) 110.84(18) 
C(1)-C(2)-H(5) 119.4(13) C(5)-C(6)-C(1) 117.91(18) F(2)-C(8)-C(7) 111.06(11) 
C(4)-C(3)-C(2) 120.24(18) C(5)-C(6)-H(8) 122.5(13) F(2)#1-C(8)-C(7) 111.06(11) 
 
Table 66: Anisotropic displacement parameters (Å2x 103) for schreiner12022. The anisotropic displacement factor exponent 
takes the form: -2p2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
 U11 U22 U33 U23 U13 U12 
F(1) 65(1) 98(1) 28(1) 0 -5(1) 0 
F(2) 55(1) 55(1) 48(1) -7(1) 9(1) 10(1) 
O(1) 31(1) 123(2) 42(1) 0 -10(1) 0 
O(2) 34(1) 115(2) 49(1) 0 10(1) 0 
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O(3) 59(1) 166(2) 31(1) 0 9(1) 0 
N(1) 39(1) 62(1) 38(1) 0 7(1) 0 
C(1) 26(1) 35(1) 32(1) 0 0(1) 0 
C(2) 24(1) 34(1) 35(1) 0 2(1) 0 
C(3) 26(1) 34(1) 39(1) 0 -5(1) 0 
C(4) 34(1) 34(1) 32(1) 0 -6(1) 0 
C(5) 30(1) 39(1) 31(1) 0 4(1) 0 
C(6) 24(1) 43(1) 34(1) 0 0(1) 0 
C(7) 31(1) 50(1) 34(1) 0 -3(1) 0 
C(8) 41(1) 53(1) 30(1) 0 -2(1) 0 
 
Table 67: Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for schreiner12022. 
 x y z U(eq) 
H(5) -10709(19) 2500 1560(20) 32(5) 
H(6) -11202(19) 2500 -581(19) 33(5) 
H(7) -9760(20) 2500 -2040(20) 44(6) 
H(8) -7381(19) 2500 670(20) 38(6) 
 
Table 68: Torsion angles [°] for schreiner12022. 
C(6)-C(1)-C(2)-C(3) 0.0 O(3)-N(1)-C(5)-C(4) 0.0 C(2)-C(1)-C(7)-C(8) 0.0 
C(7)-C(1)-C(2)-C(3) 180.0 O(2)-N(1)-C(5)-C(4) 180.0 C(6)-C(1)-C(7)-C(8) 180.0 
C(1)-C(2)-C(3)-C(4) 0.0 C(4)-C(5)-C(6)-C(1) 0.0 O(1)-C(7)-C(8)-F(1) 0.0 
C(2)-C(3)-C(4)-C(5) 0.0 N(1)-C(5)-C(6)-C(1) 180.0 C(1)-C(7)-C(8)-F(1) 180.0 
C(3)-C(4)-C(5)-C(6) 0.0 C(2)-C(1)-C(6)-C(5) 0.0 O(1)-C(7)-C(8)-F(2) 120.50(12) 
C(3)-C(4)-C(5)-N(1) 180.0 C(7)-C(1)-C(6)-C(5) 180.0 C(1)-C(7)-C(8)-F(2) -59.50(12) 
O(3)-N(1)-C(5)-C(6) 180.0 C(2)-C(1)-C(7)-O(1) 180.0 O(1)-C(7)-C(8)-F(2)#1 -120.50(12) 
O(2)-N(1)-C(5)-C(6) 0.0 C(6)-C(1)-C(7)-O(1) 0.0 C(1)-C(7)-C(8)-F(2)#1 59.50(12) 
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